CD009027 Counter({'Seizures': 5, 'Brain Lesion': 3, 'Antiepileptics': 3, 'Appearance of lesion on brain imaging': 3, 'No available term': 2, 'Finding Related To Ability To Perform Activities Of Everyday Life': 2, 'Carer Able To Cope': 2, 'Asthma Finding': 2, 'Depression': 2, 'Tinnitus': 2, 'Quality of Life': 2, 'Adverse Event': 2, 'Cognitive Function Finding': 2, 'Finding Relating To Institutionalization': 2, 'Ct Scan': 2, 'Nicotine Dependence': 2, 'Behavior Finding': 2})
NULL Counter({"Dementia Due To Alzheimer's Disease": 91, 'Dementia': 38, 'Donepezil': 26, 'Haloperidol': 18, 'Type 2 Diabetes Mellitus': 15, 'Healthy': 15, 'adverse events': 15, 'Memantine': 15, 'Agitation': 14, '': 13, 'Smoker': 13, 'Tinnitus': 12, 'Adverse events': 12, 'Hip Fracture': 12, 'Asthma': 11, "Alzheimer's Disease": 11, 'Stroke': 11, 'Vascular Dementia': 9, 'Counseling': 9, 'Mood': 9, 'No available term': 9, 'Dexmedetomidine': 9, 'Caregiver': 9, 'Delirium': 9, 'Palliative Care': 9, 'Risperidone': 9, 'Old-age': 9, 'Metrifonate': 9, 'Music Therapy': 9, 'Surgery': 9, 'Atorvastatin': 9, 'Rivastigmine': 9, 'Simvastatin': 9, 'Fatigue': 8, 'Behavioural And Psychiatric Symptoms Of Dementia': 8, 'Transcranial Magnetic Stimulation': 6, 'Glucose': 6, 'Depression': 6, 'Psychosis': 6, 'Placebo': 6, 'Quality of life': 6, 'Midazolam': 6, 'Traumatic Brain Injury': 6, 'Cognitive - Behavior Therapy': 6, 'depression': 6, 'Postpartum Depression': 6, 'Fluoxetine': 6, 'Multiple Sclerosis': 6, 'Cancer': 6, 'safety': 6, 'tolerability': 6, 'Pregnant': 6, 'Elderly': 6, 'Blood pressure': 6, 'Cognitive function': 6, 'Cardiovascular Event Risk': 6, 'Global function': 6, 'Cognition: MMSE': 6, 'delirium symptoms': 6, 'Functional Rehabilitation': 6, 'Memory Skills Training': 6, 'Treatment-emergent adverse events': 6, 'Activities of daily living': 6, 'Any adverse event(s)': 6, 'Side effects (unspecified)': 6, 'Melatonin': 6, 'Functional Linguistic Communication Inventory (FLCI) score': 6, 'mood': 6, 'Chronic Obstructive Pulmonary Disease': 6, 'cognition': 6, 'Rheumatoid Arthritis': 5, 'Cognitive function finding': 5, 'Pregnancy': 5, 'Intensive Care': 5, 'Any adverse event': 5, 'Death': 5, 'Hiv Positive': 5, 'Living In Residential Institution': 4, 'Aromatherapy': 3, 'Aspirin': 3, 'Lemon Balm Oil': 3, 'Finding Related To Ability To Perform Activities Of Everyday Life': 3, 'Carer Able To Cope': 3, 'Asthma Finding': 3, 'Quality of Life': 3, 'Cognitive Function Finding': 3, 'Finding Relating To Institutionalization': 3, 'Nicotine Dependence': 3, 'Behavior Finding': 3, 'time to relapse': 3, 'Portal Vein Thrombosis': 3, 'Chronic Liver Disease': 3, 'Antithrombin Iii': 3, 'Adverse events and adverse drug reactions.': 3, 'Efficacy was evaluated by contrast enhanced computed tomography using a five-grade scale (complete response, partial response, slight response, no response, and progression).': 3, 'Not reported': 3, 'Sleep': 3, 'Stress': 3, 'Depression/anxiety': 3, 'Spirituality': 3, 'Anal Fissure': 3, 'Lateral Sphincterotomy': 3, 'improvement of symptoms': 3, 'Grape Juice': 3, 'episodic memory': 3, 'working memory': 3, 'attention': 3, 'Endoscopy': 3, 'Ketamine': 3, 'effectiveness of the sedation': 3, 'complications during the procedure and recovery period': 3, 'functional outcome at 6 and 12 months': 3, 'Return to work at 6 and 12 months past trauma': 3, 'post-Traumatic complaints': 3, 'anxiety': 3, 'Opioid Dependence': 3, 'regular opiate use': 3, 'increased readiness to reduce opiate use': 3, 'reduced severity of opiate dependence': 3, 'Colistin': 3, 'Plasma levels of F1+2 prothrombin fragments, thrombin-antithrombin complexes (TAT)': 3, 'plasminogen activator inhibitor-1 (PAI-1)': 3, 'plasmin-antiplasmin complexes (PAP)': 3, 'von Willebrand factor antigen levels (vWF)': 3, 'E-selectin': 3, 'tissue-type plasminogen activator (t-PA) antigen and activity': 3, 'Fibromyalgia': 3, 'Bathing Procedures': 3, 'fibromyalgia impact questioning': 3, 'modified fatigue impact scale': 3, 'tender point count': 3, 'visual analogue scale': 3, 'Dapagliflozin': 3, 'quantify fat distribution using MRI': 3, 'changes in energy intake': 3, 'eating behaviour': 3, 'quantify liver fat using proton magnetic resonance spectroscopy (1H-MRS)': 3, 'Changes in central nervous system (CNS) responses to food images using blood oxygen level dependent (BOLD) functional MRI (fMRI)': 3, 'energy expenditure': 3, 'Anterior Epistaxis': 3, 'Cauterization': 3, 'infection': 3, 'efficacy (no re-bleed)': 3, 'post-operative pain': 3, 'septal perforation': 3, 'Hamilton Depression Rating Scale (HDRS 17-item)': 3, 'Postoperative Pain': 3, 'Nalbuphine': 3, 'Pain management': 3, 'Hydration Care': 3, 'intraoperative haemodynamics': 3, 'donor subclinical acute kidney injury (defined as plasma NGAL, &amp;gt;153 ng/ml) on day 1 postoperatively': 3, 'donor sleep quality': 3, 'recipient subclinical acute kidney injury': 3, 'perioperative complications': 3, 'Preterm Infant (Less than 37 weeks)': 3, 'Sucrose': 3, 'Premature Infant Pain Profile (PIPP)': 3, 'Sound': 3, 'residual inhibition (RI)': 3, 'Beck Anxiety Inventory (BAI)': 3, 'Tinnitus Handicap Inventory (THI)': 3, 'minimum masking levels (MML)': 3, 'Tinnitus loudness (scored 0-10)': 3, 'Gastric Spasm': 3, 'Hyoscine butylbromide': 3, 'difference in pain intensity (PID) from the pre-dose baseline at 20 min after the first injection': 3, 'Focal Epilepsy': 3, 'Levetiracetam': 3, 'Twenty-four-week and 48-week seizure freedom rates': 3, 'Iga Nephropathy': 3, 'Prednisolone': 3, 'Methylprednisolone Pulse Therapy': 3, 'Decrease in estimated glomerular filtration rate': 3, 'Reduction of proteinuria': 3, 'Increased serum creatinine': 3, 'Rme - Rapid Maxillary Expansion Appliance': 3, 'upper intermolar widths': 3, 'upper intercanine widths': 3, 'permanent molar angulation': 3, 'upper intermolar distance': 3, 'increases of angulation of upper and lower permanent molars': 3, 'Upper intercanine distance': 3, 'Uterine Fibroids': 3, 'Vasopressins': 3, 'estimated blood loss': 3, 'Behavioural Disorder': 3, 'Exercises': 3, 'self-regulation': 3, 'learning inhibiting disciplinary time out of class': 3, 'Deafness': 3, "surgeons' satisfaction score": 3, 'intraoperative fentanyl and propofol consumption': 3, 'incidence of complications': 3, 'mean arterial pressure (MAP)': 3, 'incidences of emergence delirium': 3, 'Heart rate (HR)': 3, 'Aerobic Exercises': 3, 'societal participation': 3, 'perceived fatigue (Checklist Individual Strength (CIS20r) fatigue subscale)': 3, 'Periprosthetic Osteolysis': 3, 'Denosumab Injectable Solution': 3, 'bone mineral density of the lumbar spine': 3, 'change in volume of the osteolytic lesion at 3 years measured with three-dimensional computed tomography (3D-CT)': 3, 'serological markers of bone turnover': 3, 'functional outcome scores': 3, 'Plane Wart': 3, 'Methylene Blue': 3, 'Photodynamic Therapy': 3, 'dermoscope picture': 3, 'change of the number of warts': 3, 'Panax Ginseng Whole Extract': 3, 'Function': 3, 'Saffron Extract': 3, 'Beck Depression Inventory-Second Edition (BDI-II)': 3, 'Renal Transplant': 3, 'Recipient Of Transplantation': 3, 'Paricalcitol': 3, 'glomerular filtration rate (GFR)': 3, 'change in spot urine albumin/creatinine ratio': 3, 'effects on gene expression.': 3, 'endothelial function measured by peripheral arterial tonometry as reactive hyperemia index (RHI)': 3, 'pulse wave velocity (PWV)': 3, 'Epilepsy': 3, 'Carbamazepine': 3, 'plasma carbamazepine (CBZ) concentrations': 3, 'seizure control': 3, 'O/e - Hernia': 3, 'Hydrocele': 3, 'Bupivacaine': 3, 'Successful anaethesia': 3, 'Radical Mastectomy': 3, 'Hemodynamic changes': 3, 'Recovery time': 3, 'Bleeding at the surgical field': 3, 'Requirement of isoflurane': 3, 'Intraoperative fentanyl consumption': 3, 'Dysphagia': 3, 'Transcranial Electrical Stimulation': 3, 'Usual Care': 3, 'Swallowing function': 3, 'Lactobacillus Rhamnosus Gg': 3, 'gestational diabetes mellitus': 3, 'preconception lifestyle': 3, 'Healthcare Professional': 3, 'Outpatient Care Management': 3, 'Knowledge about dementia': 3, 'perception of quality of dementia care in their practice setting': 3, 'attitudes about dementia': 3, 'Tumor Surgically Unresectable': 3, 'Gastric Cancer': 3, 'Lansoprazole': 3, 'overall survival': 3, 'occurrence of tumor bleeding': 3, 'transfusion requirement': 3, 'Vibration - Treatment': 3, 'Physical Therapy Procedure': 3, 'functional ambulation': 3, 'Balance: Berg balance scale': 3, 'Functional improvement': 3, 'Thiopentone': 3, 'heart rate': 3, 'post-ECT agitation score': 3, 'mean arterial blood pressure': 3, 'time to spontaneous respiration': 3, 'Motor seizure duration,': 3, 'obeying verbal commands': 3, 'Cranberry Preparation Oral Capsule': 3, 'Presence of bacteriuria': 3, 'Total antimicrobial administration': 3, 'Urinary tract infection': 3, 'Pyuria': 3, 'antibiotic-resistant organisms': 3, 'All-cause hospitalisation': 3, 'All-cause mortality': 3, 'Antibiotics administered for suspected UTIs': 3, 'General Health Good': 3, 'Group Cognitive Behavioural Therapy': 3, 'educational attainment': 3, 'Self-report psychological outcomes': 3, 'Concussion': 3, 'Aromatherapy Massage': 3, 'Physiological parameters': 3, 'Awareness: Nonresponse overview scale (FOUR)': 3, 'Pulse rate': 3, 'Arterial blood oxygen saturation': 3, 'Respiration rate': 3, 'Rheum': 3, 'Methotrexate': 3, 'Leflunomide': 3, 'levels of serum rheumatoid factor (RF)': 3, 'anti-cyclic citrullinated protein antibodies (CCP-Ab)': 3, 'visual analogue score for pain (VAS)': 3, 'tenderness score': 3, 'health assessment questionnaire (HAQ) score for quality of life': 3, 'erythrocyte sedimentation rate (ESR)': 3, 'number of swollen joints': 3, 'C reactive protein (CRP)': 3, 'number of painful joints': 3, 'objective pain score': 3, 'Lung Cancer': 3, 'Radiation Therapy': 3, 'Esophageal Cancer': 3, 'Esophagitis': 3, 'Chinese Herbal Medicine': 3, 'Incidence of esophagitis': 3, 'Duration of esophagitis': 3, 'Change of CM symptoms': 3, 'Blood routine examination': 3, 'Grade of esophagitis': 3, 'Body weight': 3, 'Time of occurence of esophagitis': 3, 'Karnofsky performance status (KPS) scale': 3, 'Hepatorenal function': 3, 'Side-effects': 3, 'Varenicline': 3, 'Asthma symptom score': 3, 'Smoking status': 3, 'Methacholine challenge': 3, 'General health quality score': 3, 'Relapse rate': 3, 'Airway hyperresponsiveness (AHR)': 3, 'Galantamine': 3, "Clinical finding: Clinician's Interview-Based Impression of Change plus Caregiver Input (CIBIC-plus)": 3, 'Cognitive function: 11- item AD Assessment Scale cognitive subscale (ADAS-cog/11)': 3, 'Disability Assessment for Dementia (DAD)': 3, 'Smoking Cessation Therapy': 3, 'self-reported abstinence, with biochemical verification at 6 months': 3, 'Mean number of cigarettes smoked per day': 3, 'Self reported attempts to quit smoking': 3, 'Stage of change at 6 months': 3, 'Adolescence': 3, 'Tobacco Abuse Prevention Education': 3, 'Nicotine dependence': 3, 'Consumption of cigarettes': 3, 'CO ppm levels': 3, 'Electrical Nerve Stimulation Procedure': 3, 'Transcutaneous Electrical Nerve Stimulation': 3, 'Behaviour finding': 3, 'Behaviour': 3, 'Caregiver role strain': 3, 'Patient satisfaction': 3, 'Caregiver burden': 3, 'Antipsychotics': 3, 'Recommendation To Discontinue A Therapy': 3, 'Severe Impairment Battery (SIB) score': 3, 'Neuropsychiatric Inventory (NPI)': 3, 'Rofecoxib': 3, "Clinician's Interview Based Impression of Change with caregiver input (CIBIC+)": 3, 'cognitive subscale of the AD Assessment Scale (ADAS-cog)': 3, 'Community Health Procedure': 3, 'Education About Cardiovascular Disease': 3, 'Health Promotion': 3, 'Smoking Cessation Education': 3, 'Average cigarettes smoked per day': 3, 'Systolic blood pressure': 3, 'Fasting blood glucose': 3, "Clinician's Interview-Based Impression of Change-Plus": 3, 'Sum of the Boxes of the Clinical Dementia Rating': 3, "Cognition: Alzheimer's Disease Assessment Scale-cognitive subscale": 3, 'progression of disability': 3, 'formal care costs': 3, 'behavioural and psychological symptoms': 3, 'carer psychopathology': 3, 'unpaid caregiver time': 3, 'Bristol activities of daily living scale (BADLS)': 3, 'deaths': 3, 'entering institutional care': 3, 'Systolic Hypertension': 3, 'Ischaemic Stroke': 3, 'Haemorrhagic Stroke': 3, 'Glyceryl Trinitrate': 3, 'Nitric Oxide': 3, 'Safety': 3, 'Function: modified Rankin Scale': 3, 'need for midazolam rescue': 3, 'Delirium management': 3, 'Assessment Of Risk For Hospital Acquired Complication': 3, 'Staff Education': 3, 'Development Of Individualized Plan Of Care': 3, 'Postoperative complications of treatment - urinary tract infections': 3, 'Postoperative complications of treatment - postoperative delirium': 3, 'Postoperative complications of treatment - falls': 3, 'Functional recovery - Regain of activities of daily living performance level before the fracture': 3, 'Functional recovery - Regain of previous independent indoor walking ability performance': 3, 'Postoperative complications of treatment - nutritional problems': 3, 'Blood Sugar Management': 3, 'Digit Symbol Substitution Test (DSST) score': 3, 'Total brain volume': 3, 'increased mortality': 3, 'Cognitive Skills Training': 3, 'behavioural': 3, 'Cognitive': 3, 'functional assessment': 3, 'Well Elder': 3, 'Token Economy Therapy': 3, 'Skills Training': 3, 'free recall performance': 3, 'word recall performanc': 3, 'midazolam rescue': 3, 'Sertraline': 3, 'remission of depression': 3, 'Cornell scale for Depression in Dementia': 3, "modified Alzheimer's Disease Cooperative Study Clinical Global Impression of Change": 3, 'Cognitive Impairment': 3, 'Readmission to hospital up to 24 months following discharge': 3, 'One or more fall up to 24 months following discharge': 3, 'walking ability': 3, 'One or more emergency room visits up to 24 months following discharge': 3, 'activities of daily life': 3, 'Perindopril': 3, 'gliclazide': 3, 'Indapamide': 3, 'diabetic eye disease': 3, 'nephropathy': 3, 'all-cause mortality': 3, 'cardiovascular death': 3, 'cause-specific cardiovascular end-points': 3, 'non-fatal myocardial infarction': 3, 'non-fatal stroke': 3, 'dementia': 3, 'Centroparietal alpha absolute power (measured using Polysomnography with REM sleep EEG spectral analysis)': 3, 'Polysomnography with REM sleep EEG spectral analysis': 3, 'cognitive evaluation using the Alzheimer Disease Assessment Scale, cognitive subscal': 3, 'Frontal alpha abolute power (measured using Polysomnography with REM sleep EEG spectral analysis)': 3, 'Frontal theta absolute power during REM sleep (measured using Polysomnography with REM sleep EEG spectral analysis)': 3, 'REM sleep duration (measured using polysomnography with REM sleep EEC spectral analysis)': 3, 'Occipital slowing ratio (measured using Polysomnography with REM sleep EEG spectral analysis)': 3, 'Frontal delta absolute power during REM sleep (measured using Polysomnography with REM sleep EEG spectral analysis)': 3, 'Overall theta absolute power during REM sleep (measured using Polysomnography with REM sleep EEG spectral analysis)': 3, 'caregiver-rated modified Crichton scale': 3, "Japanese version of the Alzheimer's Disease Assessment Scale - cognitive subscale": 3, 'Sum of the Boxes of the Clinical Dementia Rating (CDR-SB)': 3, 'Japanese version of the Clinical Global Impression of Change': 3, 'Mental Function Impairment Scale': 3, 'Attention Training': 3, 'Relaxation Exercise': 3, 'Memory: recall': 3, "Clinician's Interview Based Impression of Severity with Caregiver Input (CIBIS-Plus)": 3, "Clinician's Interview Based Impression of Change with Caregiver Input (CIBIC-Plus)": 3, "Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-Cog) score": 3, "Alzheimer's Disease Assessment Scale, Noncognitive Subscale (ADAS-Noncog) score": 3, 'Electrocardiographic examination findings': 3, 'Mini-Mental State Examination (MMSE) score': 3, 'Vital signs (unspecified)': 3, 'Neurologic examination findings': 3, 'Premature study termination': 3, 'Abnormalities on laboratory tests': 3, 'Psychiatric and behavioral disturbances': 3, 'Global state': 3, 'Cognitive performance': 3, "Mood (measured using professional caregivers' judgments)": 3, 'Facial expressions (measured using short, filmed interviews)': 3, 'Valence of discourse (measured using short, filmed interviews)': 3, 'Agitation (measured using the Cohen-Mansfield Agitation Inventory)': 3, 'Anxiety (measured using the Rating of Anxiety in Dementia scale)': 3, 'Severe adverse event(s)': 3, 'Mean erythrocyte acetylcholinesterase inhibition': 3, 'Heart rate (measured using electrocardiogram)': 3, 'Nausea': 3, 'Laboratory abnormalities': 3, 'Accidental injury': 3, 'Muscle weakness': 3, 'Diarrhea': 3, 'Leg cramps': 3, 'Delirium severity (measured using the Memorial Delirium Assessment Scale (MDAS))': 3, 'Delirium presence (measured using the Confusion Assessment Method (CAM))': 3, 'Clinical Global Impression of Change (CGI-C) score': 3, "Behavioural Rating Scale for Geriatric Patients (BGP), 'care dependence' subscore": 3, 'Modified D-Scale (Arnold/Ferm) score': 3, 'Elective Surgery': 3, 'Orthopaedic Procedure': 3, 'Presence of postoperative delirium (measure not specified)': 3, 'Persistence of postoperative delirium (measure not specified)': 3, 'Severity of postoperative delirium (measure not specified)': 3, 'Lecithin': 3, 'Wepman Aphasia Screen': 3, 'Verbal Selective Reminding Test score': 3, 'Spatial Memory Test score': 3, 'Mini Mental State Examination (MMSE) score': 3, 'Lawton Instrumental Activities of Daily Living (ADL) scale': 3, 'Verbal Fluency Test score': 3, 'Clinical Dementia Rating (CDR) Scale': 3, 'Light Therapy': 3, 'Nocturnal activity (minutes, measured using an activity/lux monitoring device)': 3, 'Timing of main sleep episode (measure not specified)': 3, 'Amplitude characteristics of the rest-activity cycle (measured using an activity/lux monitoring device)': 3, 'Circadian stability (measured using an activity/lux monitoring device)': 3, 'Sleep duration (minutes, measured using an activity/lux monitoring device)': 3, 'Nocturnal immobility (minutes, measured using an activity/lux monitoring device)': 3, 'Sleep latency (minutes, measured using an activity/lux monitoring device)': 3, 'Nighttime light exposure (minutes, measured using an activity/lux monitoring device)': 3, 'Clinical status (measure not specified)': 3, 'Cognitive status (measure not specified)': 3, 'Mortality (at 3 months)': 3, 'Delirium (measure not specified)': 3, 'Duration of delirium (metric not specified)': 3, 'Physostigmine': 3, 'Nausea and vomiting': 3, 'Clinical Global Impression of Change (CGIC)': 3, "Alzheimer's Disease Assessment Scale, Cognitive subscale (ADAS-Cog) score": 3, "Clinician's Interview-Based Impression of Change With Caregiver Input (CIBIC-Plus)": 3, 'Sleep Disturbance': 3, 'Trazodone': 3, 'Cognitive function (measured using the Mini-Mental Health Examination (MMSE) score)': 3, 'Severity of adverse events': 3, 'Sleep duration (minutes per night, measured using actigraphy)': 3, 'Nighttime percent sleep (measured using actigraphy)': 3, 'Cognitive function (measured using the forward/backward digit span task)': 3, 'Daytime sleepiness (measured using actigraphy)': 3, 'Cognitive function (measured using a letter-number sequencing task)': 3, 'Cognitive function (measured using a digit symbol-coding task)': 3, 'Daytime naps (measured using actigraphy)': 3, 'Functionality (measured using the Katz Index)': 3, 'Cognitive function (measured using a symbol search task)': 3, 'Cognitive function (measured using an arithmetic task)': 3, 'Atomoxetine': 3, 'improved attention impairment': 3, 'Clinical Global Impression of Change (CGI-C)': 3, 'Severe Impairment Battery': 3, 'Neuropsychiatric symptoms (measured using the Neuropsychological Inventory (NPI))': 3, 'Standardised Mini Mental State Examination score': 3, 'Agitation (measured using the Cohen-Mansfield Agitation Inventory (CMAI))': 3, 'sleep, as assessed by the Pittsburgh Sleep Quality Index (PSQI)': 3, 'Instrumental Activities of Daily Living (IADL)': 3, 'Mini-Mental State Examination (MMSE)': 3, 'safety parameters': 3, 'daily sleep diary': 3, 'AD Assessment Scale-Cognition (ADAS-Cog)': 3, 'Cognition: SMMSE': 3, 'Systolic Dysfunction': 3, 'Chlorthalidone': 3, 'stroke and cardiovascular death': 3, 'Combined score on the Social Communication and Communication of Basic Needs subscales of the American Speech-Language-Hearing Association Functional Assessment Communication Skills for Adults (ASHA FACS)': 3, 'Treatment-emergent adverse event': 3, 'Combined score on the Social Communication and Communication of Basic Needs subscales of the ASHA-FACS scale': 3, 'Family Support': 3, 'Reminiscence Therapy': 3, 'Health-related quality of life (SF-12)': 3, 'Quality of life (QoL-AD)': 3, 'caregiver burden': 3, 'neuropsychological tests': 3, 'quality of life': 3, 'Interferon beta': 3, 'Expanded disability status scale': 3, 'MRI': 3, 'Brain volume': 3, 'Rao battery': 3, 'Multiple sclerosis functional composite Score': 3, 'disease activity and progression': 3, 'relapse rate': 3, 'Support': 3, 'Education': 3, 'proxy rated European quality of life visual analogue scale (EQ-VAS) score': 3, 'Geriatric depression scale': 3, 'mini mental state examination (MMSE) score': 3, 'Depression: Cornell Depression Scale': 3, 'Neuromuscular Stimulation': 3, 'Muscle strength': 3, 'Multisensory Play': 3, 'Sensory Stimulation': 3, 'talked more spontaneously': 3, 'related better to others': 3, 'active': 3, 'speech skills': 3, 'behaviour,': 3, 'alert': 3, 'less bored/inactive': 3, 'happy': 3, 'did more from their own initiative': 3, 'memory': 3, 'activities of daily living': 3, 'global functioning': 3, 'Transdermal Patch': 3, 'Mental Function Impairment Scale, MENFIS': 3, 'Behavioral Pathology in AD, BEHAVE-AD': 3, "Clinician's Interview- Based Impression of Change plus Caregiver Input (CIBIC plus-J)": 3, 'Disability Assessment for Dementia, DAD': 3, 'Cognition: ADAS-J Cog': 3, 'Monoamine oxidase inhibitor': 3, 'Performance on a continuous performance task (measure not specified)': 3, 'Intrusions (measure not specified)': 3, 'Recognition (measure not specified)': 3, 'Episodic learning and memory (measure not specified)': 3, 'Knowledge memory (measure not specified)': 3, 'Attention (measure not specified)': 3, 'Quetiapine': 3, 'Agitation (measured using the Cohen-Mansfield agitation inventory)': 3, 'Cognition (measured using the Severe Impairment Battery)': 3, 'Global function (measured using the Alzheimer’s Disease Cooperative Study – Clinical Global Impression of Change (ADCS-CGIC) score)': 3, 'Neuropsychiatric symptoms (measured using the Neuropsychiatric Inventory (NPI))': 3, 'Global staging (measured using the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score)': 3, 'Hippocampal volume (measured using MRI scan)': 3, "Function (measured using the Alzheimer's Disease Functional Assessment and Change Scale (ADFACS))": 3, 'Whole brain volume (measured using MRI scan)': 3, "Cognitive function: Alzheimer's Disease Assessment Scale-cognitive (ADAS-cog) score": 3, 'resource use': 3, 'activities of daily living (ADLs)': 3, 'Cognitive function: Mini-Mental State Examination': 3, 'ADCS Clinical Global Impression of Change': 3, 'quality of life (QOL) measures': 3, 'Monitoring Drug Withdrawal': 3, 'sleep/wake activity, behavioural and psychological symptoms': 3, 'Diabetes Mellitus': 3, 'Cardiovascular Disorder': 3, 'development of vascular disease': 3, 'Diabetes': 3, 'major coronary events': 3, 'major vascular events': 3, 'Cognition': 3, 'Indacaterol': 3, 'Glycopyrronium Bromide': 3, 'Trough forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Obstructive Sleep Apnea Syndrome': 3, 'Extension Of Mandibular Ridge': 3, 'snoring': 3, 'apnoea-hypopnoea': 3, 'compliance': 3, 'sleep quality': 3, 'Asthma Education': 3, 'Team Games For Therapy': 3, 'Asthma functional severity (measure(s) not specified)': 3, 'Adherence to inhaled corticosteroids (ICS) (measured using an integrated MDILog-II device)': 3, 'Spirometry values (unspecified)': 3, 'Parent-adolescent conflict (measured using an unspecified parent-reported measure)': 3, 'Vilanterol': 3, 'Fluticasone Furoate (GW685698X)': 3, 'Serious adverse event(s)': 3, '12-lead electrocardiogram (ECG) parameters (unspecified, measured using electrocardiogram (ECG))': 3, 'Drug-related adverse event(s) - oropharyngeal pain': 3, 'Laboratory evaluations (unspecified)': 3, 'Withdrawal from study due to serious adverse event(s)': 3, 'Any drug-related adverse event(s)': 3, 'Vital signs': 3, 'Lung function - Evening peak expiratory flow (PEF) (measured using spirometry)': 3, 'Postpartum Hemorrhage': 3, 'Tranexamic Acid': 3, 'Change in ETP': 3, "Dupuytren's Disease": 3, 'Adalimumab': 3, 'cost-effectiveness': 3, 'Cryptococcal Meningitis': 3, 'Hiv Negative': 3, 'Amphotericin B': 3, 'Fluconazole': 3, 'Tamoxifen': 3, 'QT prolongation': 3, 'Early Fungicidal Activity': 3, 'Meningitis': 3, 'Dexamethasone': 3, 'death': 3, 'new neurological event': 3, 'Tuberculous meningitis': 3, 'Rifampicin': 3, 'incidence of immune reconstitution inflammatory syndrome': 3, 'survival time': 3, 'neurological outcomes': 3, 'pharmacokinetic parameters in plasma and CSF': 3, 'Asthma Management': 2, 'Glycemic control': 2, 'Spinal Cord Injury': 2, 'Finding Related To Ability To Perform Gross Motor Function': 2, 'Leptin': 2, 'Fat mass': 2, 'Lean mass': 2, 'Maximum oxygen uptake': 2, 'Insulin sensitivity (HOMA-IR)': 2, 'Sedentary': 2, 'Group Exercise': 2, 'Walking Practice': 2, 'In Vitro Fertilization': 2, 'Live births': 2, 'Pregnancy rates': 2, 'Adhd': 2, 'activity level using the QbTest': 2, 'cognitive performance': 2, 'Childhood Obesity': 2, 'child health-related quality of life measured by the Pediatric Quality of Life 4.0': 2, 'parental resource empowerment': 2, 'One-year changes in age- and sex-specific BMI z score': 2, 'total cholesterol (TC)': 2, 'HDL-cholesterol (HDL)': 2, 'triglyceride (TG)': 2, 'LDL-cholesterol (LDL)': 2, 'decline in the sum of swollen joints': 2, 'decline in the sum of tender joints': 2, 'Plasma concentrations of n-6 PUFA linoleic acid and arachidonic acid (AA) in erythrocyte lipids': 2, 'Smoking': 2, 'six-year prolonged abstinence': 2, 'Dry Skin': 2, 'Atopic Eczema': 2, 'Skin hydration': 2, 'clinical events': 2, 'safety climate': 2, 'adherence to care processes': 2, 'in-hospital mortality': 2, 'Living In Nursing Home': 2, 'Brief Psychiatric Rating Scale Agitation Score': 2, 'Tobacco Use': 2, 'Nicotine Replacement Therapy Provided Free': 2, 'Smoking Cessation Assistance': 2, 'Nightmare': 2, 'Mildly severe adverse events': 2, 'Hyperkalemia': 2, 'Serious adverse events': 2, 'Abdominal distension': 2, 'Moderately severe adverse events': 2, 'Fall': 2, 'Dizziness': 2, 'Depression (measure not specified)': 2, 'Communication (measure not specified)': 2, 'Positive mood (measure not specified)': 2, 'Cognition (measure not specified)': 2, 'neuropsychological evaluations': 2, 'significant side effects': 2, 'serious adverse events': 2, 'clinical evaluations': 2, 'Opium Dependence': 1})
CD003150 Counter({'Agitation': 8, 'Aromatherapy': 8, 'Dementia': 5, 'Donepezil': 5, 'Lavender Oil': 3, 'affect': 3, 'target behaviours': 3, 'agitated': 3, 'Behavioural And Psychiatric Symptoms Of Dementia': 3, "Dementia Due To Alzheimer's Disease": 3, 'Melissa Officinalis Leaf Oil': 3, 'Therapeutic Touch': 3, 'Pittsburgh Agitation Scale (PAS)': 3, 'Neuropsychiatric Inventory': 3, 'Transcranial Magnetic Stimulation': 2, 'Glucose': 2, 'Lemon Balm Oil': 2, 'Haloperidol': 2})
CD007220 Counter({'Old-age': 2, 'Glucose': 2})
CD009196 Counter({'Febrile Seizure': 3, 'Ibuprofen': 3, 'Acetaminophen': 3, 'Diclofenac': 3, 'Recurrence of febrile seizure': 3})
CD011125 Counter({'Smoker': 3, 'Tuberculosis': 3, 'Support': 3, 'Bupropion': 3, 'abstinence': 3})
CD009258 Counter({'No available term': 3, 'Clobazam': 3, 'Epileptic Seizure': 3, 'Finding Of Functional Performance And Activity': 3, 'Treatment Withdrawal': 3, 'Drug Side Effect': 3})
CD012197 Counter({"Dementia Due To Alzheimer's Disease": 72, 'Behavioural And Psychiatric Symptoms Of Dementia': 47, 'Agitation': 28, 'Dementia': 23, "Alzheimer's Disease": 21, 'Donepezil': 21, 'Psychosis': 18, 'Aggression': 17, 'Depression': 15, 'Living In Residential Institution': 14, 'Mini-Mental State Examination': 12, 'Risperidone': 12, 'Sertraline': 12, 'Neuropsychiatric Inventory': 12, 'Extrapyramidal symptoms': 9, 'Valproate': 9, 'Methylphenidate': 9, 'Cohen-Mansfield Agitation Inventory': 7, 'Monitoring Drug Withdrawal': 6, 'agitation': 6, 'adverse events': 6, 'Neuropsychiatric Inventory (NPI)': 6, 'Vital signs': 6, 'Antipsychotics': 6, 'Behaviour': 6, 'aggression': 6, 'Adverse events (unspecified)': 6, 'cognition': 6, 'Disability Assessment for Dementia': 6, 'Severe Impairment Battery': 6, 'Indifference/Apathy': 6, 'Olanzapine': 6, 'Behavioral And Psychiatric Symptoms Of Dementia': 5, 'Cornell Scale for Depression in Dementia': 5, 'Mental Disorder': 3, 'Placebo': 3, 'Brief Psychiatric Rating Scale (BPRS) psychosis and hostile suspiciousness factor scores': 3, 'Clinical symptoms': 3, 'Clinical symptoms: Clinical Global Impression-Change (CGI-C)': 3, 'psychosis': 3, 'Aripiprazole': 3, 'Body weight': 3, 'Neuropsychiatric Inventory (NPI) Psychosis subscale and Brief Psychiatric Rating Scale (BPRS)': 3, 'Adverse events': 3, 'Cognition: Mini Mental State Examination': 3, 'Apathy Scale': 3, 'Patient Global Assessment Scale': 3, 'Clinical Dementia Rating Scale-Sum of the Boxes': 3, 'Cognitition: ADASCog': 3, 'Cognition: Computerized Memory Battery Test': 3, 'Serious - unspecified': 3, 'Alzheimer Disease Assessment Scale-cognitive subscale': 3, 'Computerized Memory Battery Test': 3, 'Clinical Dementia Rating Scale': 3, 'Affectionate Charactegi': 3, 'Any adverse event': 3, 'Agitation: Cohen-Mansfield Agitation Inventory': 3, 'Tolerability': 3, 'Neuropsychiatric inventory (NPI)': 3, 'Cognitive function: Mini Mental State Examination': 3, 'Aggression: Neuropsychiatric Inventory (NPI)': 3, 'Agitation: Neuropsychiatric Inventory (NPI)': 3, 'Living In Nursing Home': 3, 'Mini Mental State Examination': 3, 'Clinical Dementia Rating (Nursing Home Version)': 3, 'Neuropsychiatric Inventory-Nursing Home Version (NPI-NH)': 3, 'Clinical Dementia Rating (Nursing Home Version)-Sum of the Boxes (CDR-SB)': 3, 'Clinical Dementia Rating (Nursing Home Version)-Sum of the Boxes': 3, 'Electrocardiogram': 3, 'Clinical laboratory tests': 3, 'clinical laboratory tests': 3, 'physical examinations': 3, 'Neuropsychiatric Inventory-Nursing Home Version': 3, 'Clinical Dementia Rating Sum of the Boxes (CDR-SB)': 3, 'Physical examination': 3, 'Treatment-emergent adverse events': 3, 'treatment-emergent adverse events (AEs)': 3, 'Withdrawal due to adverse events': 3, 'Mini Mental State Examination (MMSE)': 3, 'Treatment-emergent adverse events (AEs)': 3, 'Physical Self-Maintenance Scale (PSMS)': 3, 'Physical examinations': 3, 'Electrocardiograms (ECGs)': 3, 'Laboratory tests': 3, "Behavioral Pathology in Alzheimer's Disease (BEHAVE-AD)": 3, 'Clinical Global Impression of Change (CGI-C)': 3, 'Cohen-Mansfield Agitation Inventory (CMAI)': 3, 'Clinical Global Impression of Severity (CGI-S)': 3, 'Recommendation To Continue With Drug Treatment': 3, 'Behavioural problems': 3, 'Cognitive function': 3, 'Apathy': 3, 'severity of psychosis': 3, 'Severity of agitation': 3, 'extrapyramidal signs': 3, 'Haloperidol': 3, 'Hospitalization': 3, 'Social Dysfunction and Aggression scale-9 (SDAS-9)': 3, 'Dependent behaviour (measured using the Social Dysfunction and Aggression Scale (SDAS-9))': 3, 'Clinical Global Impression scale': 3, 'Suspicious behaviour (measured using the Social Dysfunction and Aggression Scale (SDAS-9))': 3, 'Restless behaviour (measured using the Social Dysfunction and Aggression Scale (SDAS-9))': 3, 'Restless, melancholic and anxious behavior': 3, 'Suspicious and dependent behavior': 3, 'Psychosocial': 3, 'Anxious behaviour (measured using the Social Dysfunction and Aggression Scale (SDAS-9))': 3, 'Social Dysfunction and Aggression scale-9': 3, 'Clinical Global Impression scale (CGI) score': 3, 'Social Dysfunction and Aggression Scale (SDAS-9) score': 3, 'Clinical Global Impression scale (CGI)': 3, 'Imipramine': 3, 'Hamilton Rating Scale for Depression': 3, 'cognitive function': 3, 'Venlafaxine': 3, 'Montgomery-Asberg Depression Rating scale': 3, 'DSM-IV for depression and dementia': 3, 'Cornell Scale for depression in dementia': 3, 'Clinical Global Impressions': 3, 'Mirtazapine': 3, 'Death': 3, 'adverse reactions': 3, 'reduction in depression (CSDD score)': 3, 'Major Depression': 3, 'Moclobemide Oral Tablet': 3, 'ECG': 3, '24-item Hamilton Depression Scale score': 3, 'Side-effects - unspecified': 3, 'Tyramine reaction': 3, 'Premature discontinuation  of treatment': 3, 'Dietary restrictions': 3, 'Laboratory findings - unspecified': 3, 'Vital signs - unspecified': 3, '17-item Hamilton Depression Scale score': 3, 'Cognitive function (measured by the SCAG Factor 1)': 3, 'Clinical global assessment of tolerance': 3, 'Unspecified': 3, 'Caregiver distress (measured by the Neuropsychiatric Inventory)': 3, 'Patient behavior disturbance (measured by the Neuropsychiatric Inventory)': 3, 'Hamilton Depression Rating Scale': 3, 'Psychogeriatric Depression Rating Scale-activities of daily living subscale': 3, 'Clinical response': 3, 'patient rated quality of life assessment': 3, 'modified Interview for Deterioration in Daily living activities in Dementia (IDDD)': 3, "global evaluation, the Clinician's Interview-Based Impression of Change with caregiver input (CIBIC plus)": 3, 'Sum of the Boxes of the Clinical Dementia Rating Scale (CDR-SB)': 3, "cognitive performance test: the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog)": 3, 'Psychosocial Intervention Strategy': 3, 'Citalopram': 3, 'Ability to complete activities of daily living (ADLs)': 3, 'Neuropsychiatric Inventory (NPI) score': 3, 'Caregiver distress (measure not specified)': 3, 'Modified Alzheimer Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGIC) score': 3, '18-point Neurobehavioral Rating Scale agitation subscale (NBRS-A) score': 3, 'Use of rescue Lorazepam': 3, 'Cognitive safety (measured using the 30-point Mini Mental State Examination (MMSE) score)': 3, 'Caregiver distress': 3, 'Use of rescue lorazepam': 3, 'Cognitive safety (measured using scores from the 30-point Mini Mental State Examination (MMSE))': 3, 'Cardiac adverse effects': 3, 'Cognitive adverse effects': 3, 'Cohen-Mansfield Agitation Inventory (CMAI) score': 3, 'Ability to complete activities of daily living (ADLs) (measure not specified)': 3, "Depressed Mood In Alzheimer's Disease": 3, 'Gastrointestinal adverse events': 3, 'Cornell Scale for Depression in Dementia (CSDD) scores': 3, 'Respiratory adverse events': 3, "Remission (measured using both the Modified Alzheimer's Disease Cooperative Study-Clinical Impression of Change score and the Cornell Scale for Depression in Dementia score) at 12 week follow-up.": 3, "modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGIC)": 3, 'Other adverse events - type(s) not specified': 3, 'Carer distress': 3, 'clinical benefit': 3, 'behaviour': 3, 'ADL: Activities of daily living': 3, 'Fluoxetine': 3, 'mood improvement': 3, 'Side effects - unspecified': 3, 'Mini-Mental State Exam': 3, 'Hamilton Rating Scale For Anxiety': 3, 'Hamilton Depression Scale': 3, 'Functional Independence Measure': 3, 'Clinical global impression': 3, 'irritability': 3, 'fenfluramine challenge to evaluate central serotonergic tone': 3, 'aberrant motor behavior': 3, "Clinician's Interview-Based Impression of Change with caregiver input (CIBIC+)": 3, 'Cognition: standardized Mini-Mental State Examination': 3, 'Functional Rating Scale': 3, 'instrumental activities of daily living': 3, 'Clinical Global Impressions Scale [CGI])': 3, 'Depression: Cornell Scale for Depression in Dementia': 3, 'Cognition: modified Mini-Mental State Examination': 3, 'Apathy Evaluation Scale-Clinician': 3, 'Cognition: Mini-Mental State Examination': 3, 'caregiver burden (Zarit Burden Scale)': 3, 'activities of daily living': 3, 'Quetiapine': 3, 'Brief Psychiatric Rating Scale (BPRS)': 3, 'care needs': 3, 'Clinical Global Impression of Changes': 3, 'functioning': 3, 'Psychiatric and behavioral symptoms': 3, 'quality of life': 3, 'Modafinil': 3, 'Anticholinesterases': 3, 'Activities of daily living (ADL) performance (measured using direct assessment)': 3, 'Apathy (measured using family report on the Frontal Systems Behavior Scale)': 3, 'caregiver burden': 3, 'Activities of daily living (ADL) performance (measured using family report)': 3, 'No available term': 3, 'Apathy Evaluation Scale': 3, 'adverse event': 3, 'Metrifonate': 3, 'Global Deterioration Scale (GDS)': 3, "Clinician's Interview-Based Impression of Severity with Caregiver Input (CIBIS-plus)": 3, 'Mini-Mental State Examination (MMSE)': 3, "Clinician's Interview-Based Impression of Change with Caregiver Input (CIBIC-plus)": 3, 'ADAS-Noncognitive subscale (ADAS-Noncog)': 3, "Cognition: Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)": 3, 'Disability Assessment in Dementia': 3, 'Cognition: Mini-Mental State Examination (MMSE) score': 3, "modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGI-C)": 3, 'Neuropsychiatric Inventory (NPI) apathy score': 3, 'Apathy Evaluation Scale (AES)': 3, 'Time to emergence of clinically significant agitation or psychosis': 3, 'gait disturbance': 3, 'weakness.': 3, 'somnolence': 3, 'diarrhea': 3, 'tremor': 3, 'magnetic resonance imaging scans': 3, "Clinician's Interview-Based Impression of Change (CIBIC-plus)": 3, 'Standardized Mini-Mental State Examination (SMMSE)': 3, 'Laboratory measures': 3, 'Any adverse event(s)': 3, 'Anorexia': 3, 'Urinary incontinence': 3, 'Weight': 3, 'NPI/NH Psychosis total score': 3, 'Clinical Global Impression scale, Item C (CGI-C) score': 3, 'Episodes of physically aggressive behavior (PAB)': 3, 'Withdrawal due to unacceptable levels of agitation': 3, 'Completion of the 4 weeks of double-blind medication': 3, 'Physically aggressive behaviour': 3, 'Quality of life': 3, 'Problem Behavior': 2, 'Brief Psychiatric Rating Scale': 2, 'Behavioral and psychological symptoms (measured using the Neuropsychiatric Inventory (NPI))': 2, 'efficacy': 2, 'safety': 2, 'tolerability': 2, "clinician's global impression of change (CGI-C) scale": 2, 'electrocardiograms': 2, 'Frontal Systems Behavior Inventory (FrSBe)': 2, 'Adverse events (AEs)': 2, '4-domain A/A subscale of the Neuropsychiatric Inventory (NPI-4-A/A)': 2, 'vital signs': 2, 'laboratory assessments': 2, "Cognition: Alzheimer's Disease Assessment Scale-Cognitive": 2, 'Levels of albumin': 2, 'Levels of monocytes': 2, 'Levels of total protein': 2, 'skin cancers': 2, 'serious adverse events': 2, 'Levels of lymphocytes': 2, 'treatment discontinuations due to adverse events': 2, 'Weight loss': 2, 'Levels of eosinophils': 2, 'cholesterol Levels': 2, "cognitive subscale of the Alzheimer's Disease Assessment Scale for cognition (ADAS-cog)": 2, 'Levels of T cells': 2, 'Levels of immunoglobulins': 2, "Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale": 2, 'Levels of uric acid': 2, 'infections': 2, 'urine pH': 2})
CD010821 Counter({'Chronic Obstructive Pulmonary Disease': 15, 'Neuromuscular Stimulation': 9, 'Therapeutic Exercise': 3, "Quality of life (measured using the St George's Respiratory Questionnaire (SGRQ))": 3, 'Hospital Anxiety and Depression Scale (HADS)': 3, 'Exercise capacity - 6-minute walk distance (metres, measured using the six-minute walk test (6MWT))': 3, 'London Chest Activity of Daily Living Scale (LCADL)': 3, 'Respiratory Therapy': 3, 'Exercises': 3, '6-minute walk distance (metres, measured using the six-minute walk test (6MWT))': 3, 'Pulmonary function - Forced expiratory volume in one second/ Forced vital capacity (FEV1/FVC) (measured using spirometry)': 3, 'Free fat mass': 3, 'Beta-endorphin level': 3, 'Pulmonary function - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Tumor necrosis factor (TNF-alpha) level': 3, 'Dyspnea (measured using the Borg Dyspnea Scale score)': 3, 'Exercise tolerance - Time to the limit of exercise tolerance (Tlim)': 3, "Quality of life (measured using the St George's Respiratory Questionnaire (SGRQ) total score)": 3, 'Leg fatigue (measured using the Borg Leg Fatigue scale score)': 3, 'Physical Deconditioning': 3, 'Body Mass Index Low': 3, 'Therapeutic Electrical Stimulation': 3, 'quadriceps strength': 3, 'daily tasks': 3, 'walking distance': 3, 'quality of life': 3, 'dyspnea': 3, 'Dyspnea': 3, 'Quadriceps Weakness': 3, 'Exercise Promotion: Strength Training': 3, 'exercise performance': 3, 'quadriceps muscle strength and endurance': 3, 'lower-limb fat-free mass,': 3, 'exercise-induced symptoms of dyspnoea and fatigue': 3, 'Transcutaneous Electrical Nerve Stimulation': 3, 'Shuttle walk test': 3, 'Lung function test': 3, 'Peak workload': 3, 'Quadricep and hamstring muscle strength': 3, 'Peak oxygen uptake': 3, 'Withdrawal due to adverse events': 3, 'Exercise capacity': 3, 'Epilepsy': 2, 'Partial Seizures': 2, 'Fev 1': 2})
CD000215 Counter({'Seizures': 6, 'Albendazole': 6, 'Finding Of Number Of Lesions': 3, 'Neurocysticercosis': 3, 'Seizure': 3, 'Antiepileptics': 3, 'Dexamethasone': 3, 'resolution of lesions on follow-up CT': 3, 'death': 3, 'need for subsequent hospital admission': 3, 'recurrence of seizures': 3, 'encephalopathy (headache/vomiting/altered sensorium)': 3})
CD008345 Counter({'Caregiver': 17, 'Dementia': 17, 'Case Management': 9, 'Caregiver burden': 8, 'Caregiver quality of life': 8, 'Cornell Scale for Depression in Dementia (CSDD)': 6, "Dementia Due To Alzheimer's Disease": 5, 'Dementia symptoms': 5, 'Development Of Care Plan': 3, 'behavioural difficulties': 3, 'Patient quality of life': 3, 'Primary caregiver sense of competence': 3, 'Caregiver depressive symptoms': 3, 'Activities of Daily Living': 3, 'Resource use': 3, 'Neuropsychiatric inventory (NPI)': 3, "Caregiver's depression severity": 3, 'Cognitive function finding': 3, 'Coordination Of Care Plan': 3, 'Rate of institutionalization': 3, 'Time to institutionalization': 3, 'Personal Well-Being Index for Adult (PWI-A) of the family caregivers': 3, 'Mini-Mental State Examination (MMSE)': 3, 'Zarit Burden Scale (ZBI)': 3, 'General Health Questionnaire (GHQ)': 3, 'Neuropsychiatric Inventory (NPI)': 3, 'Personal Well-Being Index for Intellectually Disabled (PWI-ID) of the demented subjects': 3, 'Caregiver Support': 3, 'Institionalization': 3, 'Social support': 3, 'decrease service utilization': 2, 'decrease caregiver depression': 2, 'decrease caregiver care-related strain': 2, 'increase satisfaction with managed care': 2, 'Institutionalization rates': 2})
CD008286 Counter({'Smoker': 15, 'Nicotine Replacement Therapy Using Nicotine Patch': 12, 'Smoking Cessation Assistance': 6, 'Smoking cessation': 6, 'Motivational Interviewing Technique': 6, 'Bipolar Disorder': 3, 'Schizophrenia': 3, 'Group Exercise': 3, 'Smoking Cessation Therapy': 3, 'Seizures': 3, 'Drug Toxicity': 3, 'Cessation Of Smoking': 3, 'Carbon Monoxide': 3, 'Surgery': 3, 'Provision Of Written Information About Smoking Cessation': 3, 'Brief Intervention For Smoking Cessation': 3, 'Mental Health Problem': 3, 'Motivation Technique': 3, 'Biochemical confirmation of smoking abstinence': 3, 'Smoking abstinence': 3, 'Cancer': 3, 'Counseling': 3, 'Treatment satisfaction': 3, 'Smoking status - self-report': 3, 'Smoking status - urinary cotinine assessment': 3, 'Tobacco Use': 3, 'Telephone Follow-up': 3, 'Provision Of Written Information': 3, 'Referral To Service': 3, 'Nicotine Replacement Therapy Using Nicotine Gum': 3, 'Quitline use': 3})
CD011683 Counter({'At Risk From Passive Smoking': 3, 'Asthma': 3, 'Behavioral Therapy': 3, 'number of household cigarettes smoked': 3, "parental reports of child's hours of SHS exposure": 3, 'urine cotinine': 3, "child's urine cotinine": 3, 'Smoker': 3, 'Computerized Cognitive Behavioral Therapy': 3, 'Smoking Cessation Therapy': 3, 'Completion of course': 3, 'Smoking cessation': 3})
CD006370 Counter({'No available term': 3, 'Cognitive - Behavior Therapy': 3, 'psychosocial functioning': 3, 'seizure frequency at end of treatment and at 6-month follow-up': 3, '3 months of seizure freedom at 6-month follow-up': 3, 'health service use': 3, 'employment': 3})
CD008900 Counter({'Vascular Dementia': 4, 'Cognition': 2, 'Activities of Daily Living': 2, 'Cognitive Function finding: Trail making test': 2, 'Nuremberg Activities Inventory': 2, 'Sandoz Clinical Assessment Geriatric': 2, 'Depression: Hamilton Depression Scale': 2, 'Clinical Global Impression': 2, 'Cognitive function finding: Mini-Mental State Examination': 2})
CD005399 Counter({'Lennox-gastaut Syndrome': 6, 'Felbamate': 3, 'total seizure frequency': 3, 'lenno': 3, 'Clobazam': 3, 'Global assessments': 3, 'Decrease in mean drop seizure rates': 3, 'Decrease in other seizure types': 3})
CD006378 Counter({"Dementia Due To Alzheimer's Disease": 21, 'Indomethacin': 6, 'Activities of Daily Living': 6, 'Neuropsychiatric Inventory': 6, 'Cognition: battery of cognitive tests': 3, 'Misoprostol': 3, 'Diclofenac': 3, 'Clinical finding: Global Deterioration Scale': 3, 'Withdrawal rates': 3, 'Clinical finding: Clinical Global Impression of Change': 3, "Cognitive function finding: Alzheimer's Disease Assessment Scale cognitive and noncognitive subsections": 3, 'Independence: Physical Self-Maintenance Scale': 3, 'Drug-related adverse events': 3, 'Caregiver-rated Global Impression of Change': 3, 'Cognitive function finding: Mini-Mental State Examination': 3, 'Celecoxib': 3, "Alzheimer's Disease Assessment Scale-Cognitive Behavior (ADAS-cog)": 3, "Clinician's Interview-Based Impression of Change Plus (CIBIC+)": 3, 'Omeprazole': 3, 'Mini-Mental State Examination': 3, 'Interview for Deterioration in Daily life in Dementia.': 3, "Clinician's Interview Based Impression of Change with caregiver input": 3, 'AD Assessment Scale (ADAS-cog)': 3, 'the noncognitive subscale of the ADAS': 3, 'Nimesulide': 3, 'affect': 3, 'clinical status': 3, 'behavior': 3, 'activities of daily living': 3, 'cognition': 3, 'Ibuprofen': 3, 'Esomeprazole': 3, 'Mini Mental State Examination': 3, 'Clinical Dementia Rating': 3, 'Alzheimer Disease Assessment Scale- Cognitive (ADAS-Cog) subscale score': 3, 'Prednisone': 3, 'Cognitive function finding: ADAScog': 3, 'Behaviour': 3, 'Healthy': 2, 'Well-being': 2, 'salivary cortisol': 2, 'Cognition was assessed with tests of speed, attention and episodic memory': 2, 'perceived health': 2, 'mood': 2})
CD009444 Counter({'Multiple Sclerosis': 12, 'Donepezil': 12, 'Rivastigmine': 9, 'Cognitive Impairment': 9, 'Cognitive function finding': 9, "Huntington's Disease": 6, 'Cognition:': 3, 'Verbal learning': 3, 'Verbal memory': 3, 'Memory finding': 3, 'cadasil': 3, 'Dementia rating scale': 3, 'Quality of Life': 3, 'Adverse events': 3, 'Chorea': 3, 'Cognitive function': 3, 'Memory': 3, 'Progressive Aphasia': 3, 'Frontotemporal Dementia': 3, 'Galantamine': 3, 'Clinical Global Impression of Severity': 3, 'Aphasia quotient of Western Aphasia Battery': 3, 'Clinical Global Impression of Improvement': 3, 'Frontal behavioral inventory': 3, 'memory': 3, 'Safety': 3, 'Total recall score': 3})
CD010274 Counter({'Smoker': 3, 'Alcohol Dependence': 3, 'Smoking Cessation Therapy': 3, 'Smoking abstinence': 3})
CD007078 Counter({'Smoker': 28, 'Smoking Cessation Therapy': 12, 'Smoking Cessation Assistance': 9, 'Smoking cessation': 9, 'Healthy': 9, 'Physical activity': 6, 'Tobacco Abuse Prevention Education': 6, 'self-reported 7-day point prevalence abstinence rates at 3 months and 12 months': 3, 'Intervention reach': 3, 'Cost-effectiveness': 3, 'Sustained abstinence from smoking.': 3, 'Hiv Infection': 3, 'Health Promotion': 3, 'Healthy eating': 3, 'Intention to be healthier': 3, 'Attitude': 3, 'Perceived behaviour control': 3, 'Ready To Stop Smoking': 3, 'Computerized Cognitive Behavioral Therapy': 3, 'Abstinence of smoking': 3, '6 month sustained biochemically verified abstinence': 3, 'Planning Structured Activities': 3, 'Point prevalence abstinence': 3, 'Continued abstinence': 3, 'Negotiation Of Date For Cessation Of Smoking': 3, 'Provision Of Written Information About Smoking Cessation': 3, 'Nicotine Replacement Therapy Using Nicotine Patch': 3, 'smoking abstinence': 3, 'Counseling': 3, 'Smoking prevalence': 3, 'Health Promotion Education': 3, 'Smoking status': 3, 'Portions of fruit and vegetables consumed': 3, 'Units of alcohol consumed': 3, 'Reduction in cigarettes smoked': 3, 'Commitment to abstinence': 3, '24hr quit attempts': 3, 'Smoking abstinence': 3, 'Resistance to quitting': 3, 'Cigarette use': 3, 'Resistance to smoking': 3, 'Behavioural intentions to smoke': 3, 'Depressive Symptom': 3, 'Tobacco Use': 3, 'Acceptance And Commitment Therapy': 3, 'Acceptance of internal cues': 3, 'Satisfaction with program': 3, 'Engagement with program': 3, 'Acceptance of physical cravings': 3, 'Depressive symptoms (measure not specified)': 3, 'Time on site': 3})
CD003031 Counter({'Febrile Seizure': 21, 'Diazepam': 9, 'Phenobarbital': 9, 'Recurrence of febrile seizure': 6, 'Midazolam': 3, 'Control of seizures': 3, 'Fever': 3, 'Other moderate side effects': 3, 'Irritability': 3, 'Lethargy': 3, 'Reduction in febrile seizures': 3, 'Ataxia': 3, 'lengthy awakenings': 3, 'night awakenings': 3, 'Total sleep time': 3, 'Academic achievement': 3, 'Motor development': 3, 'Cognitive development': 3, 'Intellectual development': 3, 'Epilepsy': 3, 'side effects': 3, 'recurrence of convulsions': 3})
CD001837 Counter({'Cardiovascular Morbidity': 3, 'Smoker': 3, 'Smoking Cessation Therapy': 3, '': 3, 'Cost': 3, 'self-reported quit rates': 3})
CD005502 Counter({'Epilepsy': 3, 'Progressive Muscle Relaxation': 3, 'Seizure frequency': 3})
CD012615 Counter({'Bladder Muscle Dysfunction - Overactive': 3, 'Silodosin': 3, 'voiding functions measured by uroflowmetry': 3, 'OABSS (Overactive Bladder Symptom Score)': 3, 'I-PSS (International Prostate Symptom Score)': 3, 'I-PSS quality of life': 3})
CD010078 Counter({'Pregnancy': 5, 'Smoker': 5, 'Smoking Cessation Therapy': 3, 'Nicotine Replacement Therapy Using Nicotine Patch': 3, 'cost': 3, 'Bupropion': 2})
CD004032 Counter({"Dementia Due To Alzheimer's Disease": 20, 'Transcutaneous Electrical Nerve Stimulation': 9, 'Transcranial Electrical Stimulation': 6, 'Affect': 6, 'Salivary cortisol levels': 5, 'Nocturnal restlessness': 5, 'affective behavior': 3, 'Cognitive function': 3, 'cognition': 3, 'Cognition: verbal fluency': 3, 'Cognition: visual memory': 3, 'Cognition: face recognition': 3, 'Neuropsychological tests': 3, 'Cranial Nerve Neurostimulator Electrode Procedures': 3, 'Rest-activity rhythm': 3, 'Salivary cortisol': 3, 'Cognitive function finding': 3, 'Affective behaviour (measure(s) not specified)': 3, 'Cognition (measure(s) not specified)': 3, 'rest-activity rhythm': 3, 'Rest activity rhythm': 3, 'Cognition': 3})
CD005465 Counter({"Dementia Due To Alzheimer's Disease": 6, 'Agitation': 3, 'Divalproex Sodium': 3, 'tolerability': 3, 'change from baseline on the Brief Psychiatric Rating Scale (BPRS) Agitation factor': 3, 'safety': 3, 'Psychiatric Rating Scale (BPRS) Agitation factor': 3, 'safety and tolerability': 3, 'Clinical Global Impression of Change': 3, 'Cohen-Mansfield Agitation Inventory score': 3, 'Total Brief Psychiatric Rating Scale (BPRS).': 3, 'Memantine': 3, "Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale (ADCS-ADL19)": 3, 'Severe Impairment Battery (SIB)': 3, "Clinician's Interview-Based Impression of Change plus Caregiver Input (CIBIC-Plus)": 3})
CD003289 Counter({'Smoker': 14, 'Smoking cessation': 6, 'Smoking Cessation Education': 3, 'Intention to quit smoking': 3, 'Nicotine dependence scores': 3, 'Quit rate': 3, 'Smoking Cessation Therapy': 3, 'smoking cessation': 3, 'intervention receptivity': 3, 'intervention engagement': 3, 'Cognitive - Behavior Therapy': 3, 'Healthy': 3, 'Tobacco Abuse Prevention Education': 3, 'Smoking behaviour': 3, 'Smoking intentions': 3, 'Disapproval of parental smoking': 3, 'Prevalence of smoking': 3, 'Knowledge about smoking': 3, 'Smoking Cessation Assistance': 3, 'Readiness to stop smoking': 3, 'number of cigarettes smoked in the past 30 days': 2, 'increased intentions not to smoke in the future': 2})
CD009670 Counter({'Smoking Cessation Therapy': 6, 'Smoker': 3, 'smoking abstinence': 3, 'Tobacco Use': 3, 'Provision Of Written Information About Smoking Cessation': 3, 'Nicotine Replacement Therapy Using Nicotine Lozenge': 3, 'Self-reported tobacco abstinence': 3, 'Psychiatric Disorders': 3, 'self-reported smoking cessation': 3, 'motivation to quit (MTQ)': 3, 'number of cigarettes smoked': 3, 'Fagerstrom test of nicotine dependence': 3, 'carbon monoxide-verified smoking cessation': 3})
CD004125 Counter({'Dexamethasone': 6, 'vomiting': 6, 'Epilepsy': 3, 'Nausea': 3, 'Headache': 3, 'Meningism': 3, 'Fever': 3, 'Sleep Hypoventilation Due To Lower Airway Obstruction': 3, 'Airways Obstruction': 3, 'Tonsil And/or Adenoid Hypertrophy': 3, 'Tonsillitis': 3, 'complications': 3, 'pain': 3, 'emergency room visits': 3, 'temperature': 3, 'postoperative oral intake': 3})
CD001909 Counter({'Lamotrigine': 6, 'Partial Seizures': 3, 'total numbers of all seizures types': 3, 'reduction in seizure counts': 3, 'Partial Seizure': 3, 'Physical examination': 3, 'Neurological examination': 3, 'Body weight': 3, 'Electrocardiogram': 3, 'Adverse effects': 3, 'Vital signs': 3, 'Laboratory tests': 3})
CD005003 Counter({'Epilepsy': 5, 'Recommendation To Stop Treatment': 3, 'Seizure control': 3, 'Seizure recurrence': 2})
CD011412 Counter({'Epilepsy': 10, 'Adverse events': 7, 'Phenobarbital': 6, 'Seizure control': 4, 'Tonic-clonic Seizure': 3, 'Partial Seizures': 3, 'Oxcarbazepine': 3, 'Seizures': 3, 'Tolerability': 3, 'Lamotrigine': 3, 'Number of seizures': 3, 'Side effects': 3, 'Laboratory tests': 3, 'Tonic-clonic Epilepsy': 3, 'Behaviour': 3, 'Time to first seizure': 3, 'Behavioural problems': 3, 'Occurence of seizures': 3, 'Partial Seizure': 3, 'Valproate': 3, 'tremor': 3, 'occurence of seizure': 3, 'weight gain': 3, 'withdrawals from study': 2, 'Skin rashes': 2, 'Toxicity': 2})
CD006219 Counter({'Smoker': 15, 'Varenicline': 6, 'Nicotine Replacement Therapy Using Nicotine Patch': 6, 'Skin irritation': 6, 'Smoking abstinence': 6, 'Counseling': 3, 'Clinical finding: other laboratory measures': 3, 'Clinical finding: vital signs': 3, 'Adverse events': 3, 'Smoking status': 3, 'Reduce cigarette consumption': 3, 'Serious adverse events': 3, 'Carbon monoxide confirmed self-reported abstinence': 3, 'Healthy': 3, 'Medication Dosage Tapering': 3, 'Smoking cessation - determined by serum cotinine level of 15 ng/mL (after week 18)': 3, 'Smoking cessation - determined by CO level of 9ppm or less': 3, 'Percentage of patients not smoking': 3, 'Smoking Cessation Assistance': 3, 'Provision Of Written Information About Smoking Cessation': 3, 'Smoking cessation': 3, 'Exhaled carbon monoxide': 3, 'Stopped Smoking': 3, 'Bupropion': 3, 'Nicotine Replacement Therapy Using Nicotine Gum': 3, 'Smoking Cessation Therapy': 3, 'Relapse from smoking abstinence': 3})
CD006504 Counter({'Rivastigmine': 9, "Dementia Due To Parkinson's Disease": 6, 'Cognitive function finding': 6, 'Donepezil': 3, "Unified Parkinson's Disease Rating Scale.": 3, 'Clinical Global Impression of Change (CGI)': 3, 'Tolerability and adverse events': 3, 'Brief Psychiatric Rating Scale': 3, 'Dementia With Lewy Bodies': 3, 'Neuropsychological tests': 3, 'Neuropsychiatric inventory': 3, '10-item Neuropsychiatric Inventory': 3, 'Cognitive Drug Research power of attention tests': 3, 'Ten Point Clock-Drawing test': 3, "Alzheimer's Disease Assessment Scale (ADAS-cog)": 3, "lzheimer's Disease Cooperative Study-Clinician's Global Impression of Change (ADCS-CGIC)": 3, "Alzheimer's Disease Cooperative Study-Activities of Daily Living": 3, 'Verbal Fluency test': 3, 'Mini-Mental State Examination': 3, "Dementia Associated With Parkinson's Disease": 3, "Parkinson's Disease": 3, 'Cognitive function: Mattis dementia rating scale': 3, 'Initiation': 3, 'behavioural disturbance': 3, 'Attention': 3, 'activities of daily living': 3})
CD001292 Counter({'Smoker': 6, 'Smoking Cessation Therapy': 6, 'Nicotine Replacement Therapy Using Nicotine Patch': 3, 'Smoking cessation': 3, 'Criminal Behavior': 3, 'Bupropion': 3, 'Brief Intervention For Smoking Cessation': 3, 'Smoking abstinence': 3})
CD012494 Counter({'Joint Replacement': 3, 'Elective Surgery': 3, 'Old-age': 3, 'Donepezil': 3, 'Postoperative delirium (measured using daily medical records)': 3, 'Subsyndromal delirium (measure not specified)': 3, 'Postoperative delirium (measured using DSM-IV diagnostic criteria for delirium)': 3, 'Postoperative delirium (measured using the Confusion Assessment Method)': 3, 'Postoperative delirium (measured using the Delirium Symptom Interview)': 3, 'Postoperative delirium': 3, 'Disposition to home or to another facility (measure not specified)': 3, 'Postoperative delirium (measured using nurse observation reviews)': 3, 'Cognitive Impairment': 3, 'Traumatic Brain Injury': 3, 'Rivastigmine': 3, "Cambridge Neuropsychological Test Automated Battery (CANTAB) Rapid Visual Information Processing (RVIP) A' subtest score": 3, 'Hopkins Verbal Learning Test (HVLT)': 3, "1.0 SD or greater improvement from baseline at week 12 on either the Cambridge Neuropsychological Test Automated Battery (CANTAB) Rapid Visual Information Processing (RVIP) A' subtest; and the Hopkins verbal Learning Test (HVLT)": 3})
CD003158 Counter({'Acetylcarnitine': 6, "Dementia Due To Alzheimer's Disease": 5, 'Dementia': 5, 'Selective attention': 3, 'Verbal critical abilities': 3, 'Long term verbal memory': 3, 'Blessed Dementia Scale': 3, 'Buccofacial apraxia': 3, 'Logical Intelligence': 3, 'Ideomotor': 3, 'Clinical ratings scales': 3, 'Psychometric tests': 3, 'Cognitive function finding': 2, 'Biomarkers': 2})
CD004748 Counter({"Dementia Due To Alzheimer's Disease": 9, 'Anticholinesterases': 3, 'adverse events': 3, "Cognitive function: cognitive subscale of the Alzheimer's Disease Assessment Scale [ADAScog]": 2, 'Clinical symptoms: Clinical Global Improvement scale': 2, 'Cognitive function finding: ADAScog': 2, 'Adverse events': 2, 'Adverse events:': 2, 'Clinical finding: Clinical Global Improvement scale': 2, 'Cognition': 2, "Cognition: cognitive subscale of the alzheimer's disease assessment scale (ADAS)": 2, 'Biomarkers: liver transaminase levels': 2, "Clinical symptoms: physician's clinical global impression of change": 2, 'Clinical global impression of change': 2, 'Caregiver rating scales': 2, 'Cognitive function': 2, "Clinical symptoms: Alzheimer's Disease Assessment Scale": 2, 'Clinical symptoms: Clinical Global Impression of Change scale': 2, 'memory': 2})
CD001417 Counter({'Refractory Epilepsy': 6, 'Topiramate Oral Tablet': 6, '': 6, 'Seizure frequency': 3, 'Partial Seizure': 3, 'Topiramate': 3, 'Cognition: forgetfulness or impaired memory': 3, 'Therapeutic response': 3, 'Cognition: concentration or attention difficulties': 3, 'Adverse events': 3, 'Seizure rate': 3, 'Emotional lability': 3, 'Seizure severity': 3, 'Partial Epilepsy': 3, 'Epilepsy': 3, '≥ 50% reduction in complex partial seizures': 3})
CD007302 Counter({'Focal Epilepsy': 6, 'Complex Partial Epileptic Seizure': 6, 'Vigabatrin': 6, 'Seizure frequency': 3, 'Clinical finding: Laboratory tests': 3, 'Seizure-free days': 3, 'Clinical finding: MRI changes': 3, 'Usual Care': 3, 'Cognitive function finding': 3, 'Mood finding': 3, 'Adjustment': 3, 'Seizure control': 3})
CD011851 Counter({'Coronary Heart Disease': 3, 'Health Promotion': 3, 'Encounter By Short Message Service Text Messaging': 3, 'low-density lipoprotein cholesterol (LDL-C) level': 3, 'Smoking status': 3, 'body mass index (BMI)': 3, 'Physical activity': 3, 'systolic blood pressure': 3})
CD002152 Counter({'Cerebral Malaria': 3, 'Phenobarbital': 3, 'Seizure frequency': 3, 'Respiratory arrest': 3, 'Mortality': 3})
CD009132 Counter({'Mild Cognitive Impairment': 12, 'Rivastigmine': 6, 'Galantamine': 6, 'Cognitive function finding': 3, 'Disease progression: progressed to AD': 3, 'Serious adverse events': 3, 'Adverse events': 3, 'Global function': 3, 'Executive function': 3, 'Memory': 3, 'Donepezil': 3, '': 3, 'New York University (NYU) Paragraph Delayed Recall test': 3, 'neuropsychologic measures': 3, 'modified AD Assessment Scale-cognitive subscale (ADAS-cog)': 3, 'Patient Global Assessment (PGA)': 3, "Alzheimer disease (AD) Cooperative Study Clinician's Global Impression of Change for MCI (ADCS CGIC-MCI)": 3, 'Cognition: AD Assessment Scale-cognitive subscale (ADAS-cog': 3, 'Cognitive Impairment': 3, 'Ischaemic Stroke': 3, 'Stroke': 3, 'Cerebrovascular Disease': 3, 'Cognitive function finding: Ten-Point Clock Drawing and Color Trails 1 and 2': 3, 'Cognitive function': 3, 'Verbal fluency': 3, 'CDR memory score': 3, 'adverse event': 3, 'igit Symbol Substitution Test': 3, 'Mortality at 24 months': 3, 'Conversion from MCI to dementia': 3, 'Clinical Dementia Rating (CDR)': 3})
CD010269 Counter({'Intensive Care': 3, 'Sedation': 3, 'Mechanical Ventilation': 3, 'Dexmedetomidine': 3, 'Attention:  post-ICU neuropsychological testing': 3, 'Cognitive function finding:  post-ICU neuropsychological testing': 3, 'Motor speed:  post-ICU neuropsychological testing': 3, 'Mortality': 3, 'Delirium': 3, 'Agitation: RASS scale': 3, 'Coma': 3})
CD004492 Counter({'Smoker': 8, 'Smoking cessation': 8, 'Hypercholesterolemia': 3, 'Hypertensive': 3, 'Counseling': 3, 'Carbon monoxide testing': 3, 'Provision Of Written Information About Smoking Cessation': 3, 'Smoking Cessation Therapy': 3})
CD006103 Counter({'Smoker': 12, 'Varenicline': 12, 'Smoking cessation': 6, 'Acute Coronary Syndrome': 6, 'Asthma': 3, 'Smoking Cessation Therapy': 3, 'Asthma symptom score': 3, 'CO measurement': 3, 'Smoking status': 3, 'Methacholine challenge': 3, 'General health quality score (15D)': 3, 'Continuous abstinence': 3, 'Smoking enjoyment': 3, 'Withdrawal symptoms': 3, 'exhaled carbon monoxide': 3, 'adverse events': 3, 'self reported smoking': 3, 'Tobacco Use': 3, 'Supportive Counseling': 3, 'Daily cigarette consumption (number of cigarettes)': 3, 'Major cardiovascular events': 3, 'Serious adverse events (unspecified)': 3})
CD005381 Counter({'Aerobic Exercises': 9, 'Elderly': 6, 'Healthy': 6, 'Exercises': 3, 'finger-movement tracking test': 3, 'submaximal graded exercise tolerance step test': 3, 'Estimated VO2 Max': 3, 'Reaction time': 3, 'Yoga': 3, 'Cognitive measures: alertness': 3, 'quantitative electroencephalogram (EEG) measure of alertness': 3, 'Profile of Mood States': 3, 'Multi-Dimensional Fatigue Inventory': 3, 'Stroop test': 3, 'Cognitive measures: attention': 3, 'SF-36 health-related quality of life': 3, 'physical measures related to the interventions': 3, 'Cognitive Stimulation': 3, 'Cognitive function': 3})
CD005222 Counter({'Neurocysticercosis': 3, 'Antiepileptics': 3, 'Albendazole': 3, 'Dexamethasone': 3, 'Recurrence of seizures': 3, 'Lesion resolution': 3})
CD012081 Counter({'Epilepsy': 4, 'Quality of Life: SF-36 scale': 2, 'Epilepsy-related fears scale': 2, 'Seizure frequency': 2, 'Side effects': 2, 'Depression: von Zerssen Depression Scale': 2, 'Satisfied with the drug therapy': 2, 'Epilepsy: restrictions in daily life scale': 2, 'Coping with Epilepsy and Adaptation': 2, 'Self esteem: Rosenberg self-esteem scale': 2, 'Medication adherence': 2, 'Awareness, knowledge and attitude about epilepsy': 2, 'Clinic attendance': 2})
CD009149 Counter({'Caregiver': 3, 'Dementia': 3, 'Home Care Of Patient': 3, 'Activities of daily living in dementia patient': 3, 'caregiver burden': 3, 'Behavioural problems associated with dementia': 3, "Caregiver distress due to dependent's behavioural disturbance": 3, 'Caregiver mental health': 3, "Dementia Due To Alzheimer's Disease": 3, 'Donepezil': 3, 'Caregiver time spent providing care annually (hours)': 3, 'Average (mean) annual total costs, incorporating health care costs and caregiver time spent providing care (SEK and USD)': 3, 'Instrumental Activities of Daily Living scale': 3, 'Average (mean) annual health care costs (SEK and USD)': 3, 'Progressive Deterioration Scale': 3})
CD011768 Counter({'Nulliparous': 3, 'Pregnancy': 3, 'Family Support': 3, 'Usual Care': 3, 'Infant: birthweight': 3, 'biomarker-calibrated self-reported tobacco use': 3, 'proportion of women with a second pregnancy within 24 months post-partum': 3, 'Infant: emergency admissions': 3, 'adverse events': 3, 'Infant: hospital admissions': 3})
CD011677 Counter({'Healthy': 3, 'Health Promotion Education': 3, 'School: adoption of healthy lifestyle policies': 3, 'Children: proportion consuming fruits and vegetables': 3, 'Children: attendance at physical training classes': 3, 'Children: knowledge of healthy lifestyle': 3})
CD006887 Counter({'Cardiovascular Event Risk': 3, 'Health Promotion': 3, 'Prescription of lipid lowering drugs': 3, 'LDL cholesterol': 3})
CD013102 Counter({'Asthma': 5, 'Cardiovascular Event Risk': 3, 'Medication Monitoring Assessment': 3, 'Cardiovascular Education': 3, 'Assessment For Risk Of Cardiovascular Disease': 3, 'smoking cessation': 3, 'glycosylated hemoglobin': 3, 'Systolic blood pressure': 3, 'LDL cholesterol': 3, 'Referral To Pharmacist': 3, 'Asthma Education': 3, 'Asthma Monitoring': 3, 'Education About Asthma Self Management': 3, 'Paediatric asthma quality of life questionnaire (PAQLQ), Symptoms subdomain score': 3, 'emotions': 3, 'Paediatric asthma quality of life questionnaire (PAQLQ), Activities subdomain score': 3, 'Spirometric values (unspecified, measured using spirometry)': 3, 'Paediatric asthma quality of life questionnaire (PAQLQ), Emotions subdomain score': 3, 'quality of life questionnaire': 3, 'symptoms': 3, 'Beta-agonists usage': 3, 'activities': 3, 'spirometry': 3, '': 2})
CD007204 Counter({"Dementia Due To Alzheimer's Disease": 3, 'Dronabinol': 3, 'Body weight': 3, 'Behavioural disturbance of dementia': 3, 'Adverse events': 3})
CD005315 Counter({'Dementia': 6, 'Aromatherapy': 3, 'Lavender Oil': 3, 'Agitation': 3, "Dementia Due To Alzheimer's Disease": 3, 'Music Therapy': 3, 'Number of hitting behaviours (measured using observation of participants during bathing episodes)': 3, 'Number of aggressive behaviours (measured using observation of participants during bathing episodes)': 3, 'Total number of aggressive behaviours (measured using observation of participants during bathing episodes)': 3})
CD007144 Counter({'Seizure': 8, 'Usual Care': 3, 'Carbamazepine': 3, 'Side effects': 3, 'Recurrence of seizures': 3, 'Antiepileptics': 3, 'Recurrence of seizure': 3, 'Therapeutic response to treatment': 2})
CD002750 Counter({'Refractory Epilepsy': 3, 'Seizure': 3, 'Flunarizine': 3, 'Seizure control': 3})
CD011244 Counter({'Smoker': 2, 'Perception of health warning': 2, 'Cigarette taste': 2, 'Change in smoking behaviour': 2, 'Experience of smoking': 2, 'number of cigarettes smoked': 2, 'Volume of smoke inhaled': 2, 'Self-reported motivation to quit': 2, 'Nonsmoker': 1})
CD001055 Counter({'Pregnancy': 6, 'Smoker': 6, 'Low Income': 3, 'Pregnancy Smoking Education': 3, 'Abstinence per self-report confirmed with carbon monoxide breath testing': 3, 'Second Trimester Pregnancy': 3, 'First Trimester Pregnancy': 3, 'Smoking Cessation Therapy': 3, 'Physical Exercises': 3, 'Smoking abstinence validated by salivary cotinine levels': 3, 'Smoking abstinence validated by exhaled carbon monoxide': 3})
CD004816 Counter({'Cardiovascular Event Risk': 3, 'Elevated Cholesterol': 3, 'Health Promotion Education': 3, 'cholesterol levels': 3, 'Improvement in lifestyle': 3, 'Improvement on risk factors': 3, 'Improved diet': 3, 'Vascular Disorders': 3, 'Old-age': 3, 'Pravastatin': 3, 'Coronary heart disease death': 3, 'Mortality from coronary disease': 3, 'Composite of coronary death, non-fatal myocardial infarction, and fatal or non-fatal stroke': 3, 'Stroke': 3, 'Cognitive function (measure(s) not specified)': 3, 'Non-fatal myocardial infarction': 3, 'New cancer diagnosis': 3, 'Disability (measure(s) not specified)': 3, 'Transient ischaemic attack': 3})
CD001416 Counter({'Refractory Epilepsy': 3, 'Zonisamide': 3, 'Usual Care': 3, 'adverse effects': 3, 'seizure control': 3})
CD004306 Counter({'Tobacco Use': 6, 'Smoker': 3, 'Tobacco Use Cessation Education': 3, 'Abstinence from tobacco use': 3, 'Reduction in tobacco use': 3, 'Smoking Cessation Education': 3, 'Smoking Cessation Therapy': 3, 'abstinence from tobacco use': 3})
CD010216 Counter({'Smoker': 2, 'Saliva cotinine': 2, 'Smoking cessation': 2, 'Body weight': 2, 'Appetite': 2})
CD000173 Counter({'Head Injury': 3, 'Phenytoin': 3, 'Incidence of seizures': 3})
CD007825 Counter({'Caregiver': 3, 'Dementia': 3, 'Caregiver Support': 3, 'Cost of services': 3, 'Use of services': 3, 'Institutionalisation': 3})
CD006341 Counter({'Donepezil': 6, 'Dementia': 3, 'Transcutaneous Electrical Nerve Stimulation': 3, 'Nocturnal delirium': 3, 'Behaviour disorders': 3, 'Sleep quality (night)': 3, 'sleep': 3, 'Wandering': 3, 'Decreased motivation during the daytime': 3, 'Motivation': 3, "Dementia Due To Alzheimer's Disease": 3, 'Caregiver': 3, 'Activities of Daily Living (measured using the the modified instrumental activities of daily living (IADL) scale (IADL+))': 3, 'Activities of Daily Living (measured using the Disability Assessment for Dementia (DAD))': 3, "Patients' social behaviour (evaluated through the use of a caregiver diary that captured observations of patients' motivation, interactions, and engagement)": 3, 'Caregiver Stress Scale (CSS)': 3, 'Caregiver stress (measured using a modified, multiple-item Caregiver Stress Scale (CSS))': 3, 'Caregiver time spent assisting patients with basic and instrumental activities of daily living (measured as part of the IADL+ and PSMS+ scales)': 3, 'Activities of Daily Living (measured using the Modified Physical Self Maintenance Scale (PSMS+))': 3, "Alzheimer's Disease": 3, 'Cognitive Stimulation': 3, 'overall global function': 3, 'relevance of discourse': 3, 'performance of functional abilities': 3, 'irritability': 3, 'apathy': 3, 'Caregiver report': 3, 'emotional symptoms,': 3, 'Participant report': 3, 'quality of life': 3})
CD003277 Counter({'Lennox-gastaut Syndrome': 3, 'Felbamate': 3, 'Number of atonic seizures': 3, 'Seizure frequency': 3, 'Carer evaluation of Quality of Life': 3})
CD003723 Counter({'Status Epilepticus': 11, 'Seizure': 9, 'Levetiracetam': 3, 'Clinical seizure cessation': 3, 'Hospital mortality': 3, 'Adverse events': 3, '24hr freedom from seizure': 3, 'Lorazepam': 3, 'Respiratory depression': 3, 'Intensive care admission': 3, 'Prescription of additional anticonvulsants': 3, 'Seizure control': 3, 'Midazolam': 3, 'seizure control': 3, 'Valproate': 3, 'Phenytoin': 3, 'in-hospital complications': 3, 'adverse events': 3, 'Neurological outcome at discharge': 3, 'Seizure control: Treatment was considered successful when all motor or EEG seizure activity ceased within 20 min after the beginning of the drug infusion and no return of seizure activity during the next 12h': 3, 'Hypotension': 2, 'Requirement for ventilation': 2, 'Liver function': 2, 'Median time to control seizure': 2})
CD008497 Counter({'Epilepsy': 10, 'Adverse effects': 4, 'Cortical Stimulation': 3, 'Mood': 3, 'Neuropsychological function': 3, 'Unspecified': 3, 'Percent change in seizures': 3, 'Stimulation': 3, 'Seizures (number)': 3, 'Seizure control': 2, 'Temporal Lobe Epilepsy': 2, 'Cognitive function finding': 2, 'Attention and concentration': 2, 'Monthly seizure frequency': 2, 'Seizure': 2, 'Seizure free for 6 months': 2, 'quality of life measures (QOLIE-31)': 2, 'Number of seizures': 2, 'Liverpool seizure severity scale': 2, 'Intracranial haemorrhage': 2})
CD001188 Counter({'Open Heart Surgery': 3, 'Smoking Cessation Education': 3, 'Diet Education': 3, 'Exercise Education': 3, 'Lifestyle Education': 3, 'Dietary habits': 3, 'Physical activity': 3, 'Smoking cessation': 3, 'Cardiovascular disease': 3, 'Death': 3})
CD001908 Counter({'Partial Epilepsy': 2, 'Cognitive function finding': 2, 'Change to EEG': 2, 'Complex Partial Epileptic Seizure': 2, 'seizure frequency': 2, 'adverse events': 2})
CD004304 Counter({'Folic Acid': 6, 'Folate Deficiency': 3, 'Behaviour': 3, 'Frequency of fits': 3, 'Gingival conditions': 3, 'EEG': 3, 'Blood folate levels': 3, 'Hyperplasia Of Gingiva': 3, 'Seizure control': 3, 'Gingival hyperplasia': 3, 'Epilepsy': 3, 'Thiamine': 3, 'Folate': 3, 'neuropsychological functions in both verbal and non-verbal IQ testing': 3})
CD009900 Counter({'Phenytoin': 9, 'Head Injury': 6, 'Traumatic Brain Injury': 3, 'Subarachnoid Haemorrhage': 3, 'Levetiracetam': 3, 'Disability Rating Scale (DRS)': 3, 'EEG': 3, 'Glasgow Outcomes Scale Extended (GOS-E)': 3, 'Trauma': 3, 'Neurobehavioural assessments': 3, 'Prevention of posttraumatic seizures': 3, 'Neurologic outcome at 30 days': 3, 'Survival': 3, 'Posttraumatic seizures in first 48 hrs': 3, 'Seizure occurence': 3, 'Brain Injury': 3, 'Carbamazepine': 3, 'occurence of post-traumatic seizures': 3})
CD004990 Counter({'Frontotemporal Dementia': 3, 'Trazodone': 3, 'agitation': 3, 'irritability': 3, 'Neuropsychiatry Inventory (NPI)': 3, 'eating disorders': 3, 'Neuropsychiatric Inventory Score': 3, 'cognitive function finding: MMSE': 3, 'depressive symptoms': 3})
CD001415 Counter({'Refractory Epilepsy': 6, 'Gabapentin': 6, 'Temper': 3, 'Fatigue': 3, 'Cognition': 3, 'Psychomotor testing': 3, 'Dysphoria': 3, 'Side effects': 3, 'Worry': 3, 'Drowsiness': 3, 'Memory testing': 3, 'Seizure frequency': 3, 'Patient well being': 3})
CD008781 Counter({'Partial Seizure': 5, 'Focal Epilepsy': 3, 'Vigabatrin': 3, 'Seizures': 3, 'Unspecified': 3, 'Epilepsy': 3, 'Tonic-clonic Seizure': 3, 'Vigabatrin Oral Tablet': 3, 'Visual evoked potential recordings and neuropsychological evaluation': 3, 'Drug success rate': 3, 'Tolerability': 2, 'Efficacy': 2})
CD001905 Counter({'Status Epilepticus': 3, 'Lorazepam': 3, 'Fosphenytoin': 3, 'Time to cessation of status epilepticus': 3, 'Requirement for sedation': 3, 'Rate of seizure recurrence': 3, 'Assisted ventilation': 3, 'Return to baseline mental status': 3})
CD011120 Counter({'Hiv Infection': 6, 'Smoker': 6, 'Aids': 3, 'Smoking Cessation Assistance': 3, 'Depression': 3, 'Self-efficacy change score': 3, 'Anxiety': 3, 'Quit motivation': 3, 'Social support': 3, 'Smoking abstinence at 3 months': 3, 'Provision Of Written Information About Smoking Cessation': 3, 'Nicotine Replacement Therapy Using Nicotine Patch': 3, 'Percentage of smoking days': 3, 'Number of cigarettes smoked': 3, 'Biochemically verified smoking abstinence': 3})
CD001903 Counter({'Epilepsy': 8, 'Dietary Regime': 3, 'Serum beta-hydroxybutyrate': 3, 'Serum acetoacetate': 3, 'Lack of energy': 3, 'Seizure frequency': 3, 'Vomiting': 3, 'Blood ketone levels': 3, 'Low Carbohydrate Food': 3, 'ketosis': 3, 'seizure frequency': 3, 'tolerability': 3, 'Reduction in seizures': 2})
CD005062 Counter({'Epilepsy': 2, 'Epilepsy score': 2, 'Attack frequency': 2})
CD009921 Counter({'Smoker': 6, 'Nicotine Replacement Therapy Provided Free': 6, 'Low Income': 3, 'Smoking Cessation Therapy': 3, 'Self-reported past-7-day tobacco abstinence at 9 months': 3, 'Respiratory Morbidity': 3, 'Provision Of Written Information About Smoking Cessation': 3, 'Brief Intervention For Smoking Cessation': 3, 'smoking status at 26 and 52 weeks': 3})
CD004705 Counter({'Smoker': 9, 'Smoking cessation': 6, 'Smoking Cessation Education': 3, 'Nicotine dependence': 3, 'Smoking abstinence self-efficacy': 3, 'Behavioural change': 3, 'Smoking cessation rates': 3, 'Renal Transplant': 3, 'Carbon Monoxide Breath Analyzer (physical Object)': 3, 'Brief Intervention For Smoking Cessation': 3, 'reduction in the number of cigarettes smoked per day': 3, 'Increase in motivation to stop smoking': 3, 'Tobacco Use': 3, 'Spirometry': 3, 'Quit success': 3})
CD009338 Counter({'Pregnancy': 3, 'Smoker': 3, 'Pregnancy Smoking Education': 3, 'Smoking status using urine cotinine': 3, 'Smoking status using breath carbon monoxoide': 3})
CD004493 Counter({'Prevention': 3, 'Adolescence': 3, 'Drug Abuse Prevention Education': 3, 'Cigarette use': 3, 'Alcohol misuse': 3, 'Marijuana use': 3})
CD003698 Counter({'Smoker': 3, 'Bupropion': 3, 'Nicotine Replacement Therapy Using Nicotine Patch': 3, 'Brief Intervention For Smoking Cessation': 3, 'Self-reported abstinence': 3, 'Biochemically confirmed abstinence': 3})
CD005593 Counter({"Dementia Due To Alzheimer's Disease": 9, 'Rivastigmine': 6, 'Activities of daily living': 6, 'Cognitive function finding': 6, 'Donepezil': 6, 'activities of Daily Living (PDS)': 3, 'progressive Detrioration Scale (PDS) At 26 weeks': 3, "Clinician's Interview Based Impression of Change-Plus (CIBIC-Plus)": 3, 'Clinical symptoms': 3, 'Global Deterioration Scale': 3, "Alzheimer's Disease Assessmant Scale-Cognitive subscale (ADAS-Cog)": 3, 'Global deterioration': 3, 'Mini-Mental State Examination': 3, 'Global functioning': 3, 'Behavioural symptoms': 3, "Alzheimer's Disease": 3, 'Functional brain activity - average glucose metabolism in an axial brain slice (measured by positron emission tomography)': 3, 'Functional brain activity - regional brain glucose metabolism (measured by positron emission tomography)': 3, 'right, left, and total hippocampal volumes': 3, "Alzheimer's Disease Assessment Scale cognitive subscale": 3, 'brain concentrations of N-acetylaspartate': 3})
CD011014 Counter({'Refractory Epilepsy': 6, 'Polyunsaturated Fatty Acid Supplementation': 6, 'Seizure frequency': 6})
CD009187 Counter({'No available term': 3, 'Physician Status Report Management': 3, 'Referrals': 3, 'Estimated number of smokers who quit': 3})
CD009927 Counter({'High Risk Sexual Behavior': 2, 'Smoker': 2, 'Smoking cessation': 2, 'Condom use': 2, 'Smoking prevention': 2})
CD011682 Counter({'Chronic Obstructive Pulmonary Disease': 31, 'COPD Exacerbation': 7, 'Telephone Encounter': 6, 'Self-care Patient Education': 6, 'Health-related quality of life (measured using the 36-Item Short Form Health Survey questionnaire (SF-36))': 6, 'Palliative Care': 6, 'Hospitalization': 5, 'Inhaler Technique Shown': 3, 'Depression Screening': 3, 'Smoking Cessation Therapy': 3, 'Assessment Of Anxiety': 3, 'Gastroesophageal Reflux Study': 3, 'Hospitalisation for acute exacerbations of COPD (AECOPD)': 3, 'Emergency department visits for  for acute exacerbations of COPD (AECOPD)': 3, '90 day admission rate': 3, '30 day admission rate': 3, 'Dyspnea': 3, 'Exercises': 3, 'Walking Practice': 3, 'Health-related quality of life - Vitality (measured using the 36-Item Short Form Health Survey questionnaire (SF-36), Vitality domain)': 3, 'Dyspnea during exercise (measured using the Chronic Respiratory Questionnaire (CRQ), the Shortness of Breath Questionnaire, and Baseline/Transitional Dyspnea Index)': 3, 'Health-related quality of life (measured using the 36-Item Short Form Health Survey (SF-36))': 3, 'Health-related quality of life, Vitality (measured using the 36-Item Short Form Health Survey (SF-36), Vitality subdomain)': 3, 'Chronic Respiratory Questionnaire (CRQ), Mastery subdomain score': 3, 'Dyspnea during activities of daily living (measured using the Chronic Respiratory Questionnaire (CRQ) score)': 3, 'Exercise performance (measured using an incremental treadmill test (ITT))': 3, 'Exercise performance (measured using an endurance treadmill tests (ETT))': 3, 'Baseline/Transitional Dyspnea Index score': 3, 'Exercise performance (6-minute walk distance, metres, measured using the six-minute walk test (6MWT))': 3, 'Chronic Respiratory Questionnaire (CRQ), Mastery domain score': 3, 'Dyspnea (measured using the Shortness of Breath Questionnaire)': 3, 'Dyspnea with activities of daily living (measured using the Chronic Respiratory Questionnaire (CRQ), the Shortness of Breath Questionnaire, and Baseline/Transitional Dyspnea Index)': 3, '6-minute walk test (6MWT)': 3, 'Exercise performance (measured using incremental treadmill tests (ITTs) and endurance treadmill tests (ETTs))': 3, 'Dyspnea during laboratory exercise (measured using the Chronic Respiratory Questionnaire (CRQ) during an incremental treadmill test (ITT))': 3, 'Diabetes Mellitus': 3, 'Diabetes': 3, 'Irritable Bowel Syndrome': 3, 'Symptom Management': 3, 'Health-related quality of life (measure(s) not specified)': 3, 'shared decision making': 3, 'patients attending trained practices and those attending control practices': 3, 'generic health related quality of life measured at 12 months': 3, 'Self-efficacy (measure(s) not specified)': 3, 'Shared decision making (measure(s) not specified)': 3, 'COPD Action Plan': 3, 'Home Visit': 3, 'Telephone Follow-up': 3, 'Pulmonary Rehabilitation': 3, 'Home Care By Visiting Nurse': 3, 'Intermediate Nursing Care': 3, 'Death - Due to COPD': 3, 'Unscheduled primary care (GP) consultation(s)': 3, 'Death - All cause': 3, 'Hospital readmission(s)': 3, 'Hospital readmission (at 2 years)': 3, 'Quality of life (measure(s) not specified)': 3, 'Unscheduled primary care consultations (at 2 years)': 3, 'Quality of life (measure not specified)': 3, 'Death': 3, 'Death as a result of COPD': 3, 'COPD exacerbation(s)': 3, 'Lifestyle Education': 3, 'Severity of COPD symptoms - Mental state (measured using the Clinical COPD Questionnaire (CCQ), Mental state domain score)': 3, 'Severity of COPD symptoms - Overall symptoms (measured using the Clinical COPD Questionnaire (CCQ), Total score)': 3, 'Severity of COPD symptoms - Symptoms (measured using the Clinical COPD Questionnaire (CCQ), Symptoms domain score)': 3, 'Severity of COPD symptoms - Functional state (measured using the Clinical COPD Questionnaire (CCQ), Functional state domain score)': 3, 'Moderate Chronic Obstructive Pulmonary Disease': 3, 'Mild Chronic Obstructive Pulmonary Disease': 3, 'Consultation': 3, 'Education': 3, 'utilization of rescue medication': 3, 'Doctor visits': 3, 'travel costs': 3, 'educational and time costs': 3, 'hospital admissions': 3, 'days off work': 3, 'patient satisfaction': 3, 'Patient Education': 3, '': 3, 'Emergency Care': 3, 'Hospital Based Outpatient Care': 3, "Quality of life - Impact (measured using the St George's Respiratory Questionnaire (SGRQ) impact domain score)": 3, 'Oxygen saturation (measure not specified)': 3, "Quality of life - Symptoms (measured using the St George's Respiratory Questionnaire (SGRQ) symptoms domain score)": 3, 'Spirometry (outcome(s) not specified)': 3, "Quality of life - Overall (measured using the St George's Respiratory Questionnaire (SGRQ) total score)": 3, 'Chronic Heart Failure': 3, 'Case Management': 3, 'Nursing Care Coordination': 3, 'Physical functioning (measured using the 36-Item Short Form Health Survey questionnaire (SF-36), Physical functioning score)': 3, 'Physical role functioning (measured using the 36-Item Short Form Health Survey questionnaire (SF-36), Physical role functioning score)': 3, 'Emotional role functioning (measured using the 36-Item Short Form Health Survey questionnaire (SF-36), Vitality score)': 3, 'Emergency care visit(s)': 3, 'Mental health (measured using the 36-Item Short Form Health Survey questionnaire (SF-36), Mental health score)': 3, 'Bodily pain (measured using the 36-Item Short Form Health Survey questionnaire (SF-36), Bodily pain score)': 3, 'General health perceptions (measured using the 36-Item Short Form Health Survey questionnaire (SF-36), General health perceptions score)': 3, 'Self-management of illness (patient-reported, measure not specified)': 3, 'Awareness of illness-related resources (patient-reported, measure not specified)': 3, 'Social role functioning (measured using the 36-Item Short Form Health Survey questionnaire (SF-36), Emotional role functioning score)': 3, 'Legal preparation for end of life (patient-reported)': 3, 'Vitality (measured using the 36-Item Short Form Health Survey questionnaire (SF-36), Vitality score)': 3, 'Self-care Interventions': 3, 'self-care adherence': 3, "Saint George's Respiratory Questionnaire (SGRQ)": 3, '6-minute walking distance test': 3, 'health-related quality of life (HRQoL)': 3, 'peak expiratory flow rate': 3, 'Not reported': 3, 'Telemedicine': 3, 'discharge to hospital': 3, 'Medical Outcome Study 36-item short form [SF-36], illness intrusiveness': 2, 'Chronic Disease': 2, 'improved health status': 2, 'Health care costs': 2, 'Quality of life': 2, 'Chronic Obstructive Pulmonary Disease Self-management Plan Given': 2, 'Wound - In Medical Care': 1, 'Congestive Heart Failure Stage C': 1})
CD003020 Counter({'Healthy': 3, 'Life Skills Training': 3, 'Drug use': 3, 'Development of decision making skills': 3, 'Development of refusal skill': 3, 'Attitude to drugs': 3, 'Tobacco use': 3, 'Knowledge of drugs': 3, 'Development of problem solving skills': 3})
CD012330 Counter({'Asthma': 10, 'Asthma Self Management': 5, 'Epilepsy': 3, 'Education About Asthma Self Management': 3, 'school absenteeism': 3, 'knowledge about condition': 3, 'attitude to condition': 3, 'hospital visits': 3, 'beliefs about condition': 3, 'behaviour': 3, 'hospitalisation': 3, 'Educational Session With Patient': 3, 'ED reatendance': 3, 'Childhood Asthma': 3, 'Health-related Quality of Life': 3, 'Emergency Care': 2, 'Exacerbation Of Asthma': 2, 'Quality of life (measure(s) not specified)': 2, 'Use of controller-medication (unspecified)': 2, 'Emergency department visit(s) for asthma': 2, 'Shared Decision Making': 2, 'adherence to asthma pharmacotherapy': 2, 'asthma-related quality of life': 2, 'cumulative dose of asthma medication': 2, 'asthma control and lung function': 2, 'health care use': 2})
CD010925 Counter({"Dementia Due To Parkinson's Disease": 3, 'Donepezil': 3, 'Activities of daily living': 3, 'neuropsychological battery': 3, 'memory': 3, 'attention': 3, 'global cognitive status': 3, 'Psychiatric symptoms': 3, 'psychomotor speed': 3})
CD011425 Counter({'Chronic Obstructive Pulmonary Disease': 3, 'Identifying Personal Goals': 3, 'Provision Of Pedometer': 3, 'Physical Exercises': 3, 'Dsypnea': 3, 'daily step counts': 3, 'Copd': 2, 'Physical Activity': 2, 'Smoking cessation': 2})
CD006886 Counter({'Smoker': 6, 'Smoking Cessation Education': 3, 'Reported smoking cessation': 3, 'Spirometry': 3, 'Carbon Monoxide Breath Analyzer (physical Object)': 3, 'Smoking Cessation Therapy': 3, 'Quit rate': 3})
CD001770 Counter({'Spasms': 3, 'Flunarizine': 3, 'Bayley Scales of Infant Development (BSID)': 3, 'Vineland Adaptive Behavior Scale (VABS)': 3, 'No available term': 2, 'Spasm cessation': 2, 'Unspecified': 2})
CD009905 Counter({'Asthma': 5, 'Referral To Health Worker': 3, 'Trough (pre-dose) forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Behaviours related to reducing indoor environmental triggers (unspecified, measure(s) not specified)': 3, 'Lung function - Trough (pre-dose) peak expiratory flow (PEF) (measured using spirometry)': 3, 'Asthma symptoms - Cough that won’t go away (child reported, measure not specified)': 3, 'Depressive symptoms (caregiver report, measure not specified)': 3, 'Asthma symptoms - Coughing with exercise (child reported, measure not specified)': 3, 'Unscheduled medical visit(s)': 3, 'Inadequate use of asthma controller medication (child reported, measure not specified)': 3, 'Concentration of dog allergen in household dust (measure not specified)': 3, 'Housing Related Procedures': 2, 'Allergic Reaction Control Education': 2, 'Allergic Reaction Control Assessment': 2, 'Allergic Reaction Control Management': 2, 'Control Of Rodents': 2, 'Community Health Procedure': 2})
CD007176 Counter({"Dementia Due To Alzheimer's Disease": 3, 'Selegiline': 3, 'D-alpha-tocopherol': 3, 'Activities of daily living': 3, 'Death': 3, 'Institutionalization': 3, 'Clinical dementia rating (CDR)': 3})
CD011905 Counter({'Administration Of Vitamin B12': 6, 'Vitamins': 6, 'Folic Acid': 6, 'Cognition': 6, 'Healthy': 3, 'Vitamin B6': 3, 'Folate': 3, 'Cognitive function finding': 3, 'Mood finding': 3, 'Mood': 3, 'Amnestic Symptoms': 3, 'Mild Cognitive Impairment': 3, 'Donepezil': 3, 'Vitamin E': 3, '': 3, 'Function': 3, "progression from mild cognitive impairment to Alzheimer's disease": 3, "disease progression to Alzheimer's disease": 3, 'function': 3, 'cognition': 3, 'Vitamin B Deficiency': 3, 'red blood cell folate concentrations': 3, 'Cognition - memory function': 3, 'Vitamin B-12 status': 3, 'tHcy concentrations': 3, 'Vitamin B12 Deficiency (non Anemic)': 3, 'Cognitive function (measured by a 12-words learning test score)': 3, 'Cognitive function (measured by the Cambridge Cognitive Examination (CAMCOG))': 3, 'Cognitive function (measured by the Mini-Mental State Examination (MMSE) score)': 3, 'Symptoms of depression (measured using the Major Depression Inventory score)': 3})
CD011025 Counter({'Drug Resistant Epilepsy': 2, 'Epilepsy': 2, 'Seizure frequency': 2})
CD010541 Counter({'Temporal Lobe Epilepsy': 2, 'seizure freedom Engel class I': 2})
CD007124 Counter({'Epilepsy': 3, 'Carbamazepine': 3, 'fluctuation in serum CBZ concentrations': 3})
CD003724 Counter({'Narcolepsy': 2, 'Daytime sleepiness': 2, 'Amount of non-REM slow wave sleep': 2, 'Reduced wakefulness after sleep onset': 2, 'Feeling of being refreshed': 2})
CD006470 Counter({'Living In Residential Institution': 2, 'Dementia': 2, 'Functional Assessment Staging': 2, 'Quality of Life': 2, "Pleasant Events Scale-Alzheimer's disease,": 2, 'Cohen-Mansfield Agitation Inventory': 2, 'Multidimensional Observation Scale of Elderly Subjects': 2, 'Brief Cognitive Rating Scale': 2, 'activities of daily living': 2, 'Apparent Affect Rating Scale': 2})
CD011823 Counter({'Smoker': 9, 'Nicotine Replacement Therapy Using Nicotine Patch': 6, 'Selegiline': 3, 'post-quit craving': 3, 'depressive symptom': 3, 'Biochemically verified sustained abstinence from cigarette smoking': 3, 'Tobacco Use': 3, 'Behavioral Therapy': 3, 'Varenicline': 3, 'Counseling': 3, 'smoking cessation': 3, 'smoking quit rates while minimising side-effects': 3})
CD010062 Counter({'Benign Rolandic Epilepsy': 3, 'Epilepsy': 3, 'Sulthiame': 3, 'termination of trial': 3, 'early seizure recurrence': 3, 'Tolerability': 3})
CD008191 Counter({'Agitation': 19, "Dementia Due To Alzheimer's Disease": 9, 'Behavioural And Psychiatric Symptoms Of Dementia': 6, 'Haloperidol': 6, 'Trazodone': 6, 'Dementia': 6, "Alzheimer's Disease": 3, 'Caregiver': 3, 'Behavior Management': 3, 'agitation': 3, 'caregiver burden': 3, 'Cognition': 3, 'patient agitation': 3, 'Cognitive function': 3, "Alzheimer's Disease Cooperative Study Clinical Global Impression of Change": 3, 'Clinical Global Impression of Change': 3, 'function': 3, 'Caregiver burden': 3, 'cognition': 3, 'Oppositional behaviour': 3, 'Repetitive behaviour': 3, 'adverse effects': 3, 'Unwarranted accusations': 3, 'Excessive motor activity': 3, 'Verbally agressive behaviour': 3, 'Psychosis': 3, 'Risperidone': 3, 'Acute physical illness': 3, 'Extrapyramidal symptoms': 3, 'Neuropsychiatric Inventory score': 3, 'Multi Infarct Dementia, Uncomplicated': 3, 'Primary Degenerative Dementia': 3, 'Fluvoxamine': 3, 'neuropsychological tests (picture recall and recognition, trail making and finger tapping)': 3, 'GBS scale scores (degrees of dementia)': 3, 'irritability, anxiety, fear-panic, mood level and restlessnes': 3, 'GBS subscale score (clinical profiles, including symptoms common in dementia, motor, emotional and intellectual functioning)': 3, 'Fluoxetine': 3, 'Toxicity': 3, 'Therapeutic response': 1, 'psychotic symptoms': 1, 'Neurobehavioral Rating Scale': 1, 'Completion rates': 1, 'Side Effect Rating Scale': 1})
CD009990 Counter({'Healthy': 3, 'Smoking Effects Education': 3, 'Prevalence of smokers': 3})
CD005612 Counter({'Refractory Epilepsy': 3, 'Partial Epilepsy': 3, 'Epilepsy': 3, 'Pregabalin': 3, 'Clinical laboratory evaluation': 3, 'Physical examination': 3, 'seizure frequency': 3, 'adverse events': 3, 'Neurologic examination': 3})
CD004052 Counter({'Dementia': 3, 'Mania': 3, 'Divalproex Sodium': 3, 'psychiatric rating was primary outcome, signs and symptoms of mania, verbal agitation, adverse events': 3, 'Bech-Rafaelsen Mania Scale (BRMS)': 3, 'Cohen-Mansfield Agitation Inventory (CMAI)': 3, 'Brief Psychiatric Rating Scale (BPRS)': 3, 'Clinical Global Impressions (CGI)': 3})
CD010682 Counter({'Depression': 6, 'Epilepsy': 3, 'Nomifensine Oral Capsule': 3, 'Amitriptyline': 3})
CD009887 Counter({'Refractory Epilepsy': 3, 'Partial Epilepsy': 3, 'Epilepsy': 3, 'Stiripentol': 3, 'Carbamazepine': 3, 'Seizure frequency compared with baseline': 3, 'Unspecified': 3, 'Dropouts due to secures increased by at least 50% after randomisation compared with baseline': 3})
CD005562 Counter({"Dementia Due To Alzheimer's Disease": 18, 'Dementia': 15, 'Reality Orientation': 15, 'Cognitive Stimulation': 12, 'Cognitive function': 9, 'Cognitive Skills Training': 9, 'Living In Residential Institution': 9, 'Cognition: Mini-Mental State Examination': 6, 'Cognitive Rehabilitation Therapy': 6, 'Cognition': 6, 'Cognitive Impairment': 6, 'memory': 6, 'Old-age': 6, 'Caregiver': 6, 'Caregiver Support': 6, 'Reminiscence Therapy': 6, 'Quality of life': 3, "Alzheimer's Disease Assessment Scale - Cognition (ADAS-Cog)": 3, "Quality of Life - Alzheimer's Disease scales": 3, 'Behaviour': 3, 'Function': 3, 'tests of information and orientation': 3, 'motor speed': 3, 'Verbal Series Attention Test': 3, 'recall of personal information': 3, 'neuropsychologic measures of dementia severity': 3, 'visual memory': 3, 'face-name recall': 3, 'caregiver-assessed patient quality of life.': 3, 'word generation': 3, 'verbal memory': 3, 'Clifton Assessment Schedule': 3, 'Multidimensional Observation Scale for Elderly Subjects': 3, 'social feeling': 3, 'Verbal fluency': 3, "Consortium to establish a Registry for Alzheimer's Disease (CERAD) battery": 3, 'Word List Memory Test score': 3, 'composite sum of test scores': 3, 'Activities of Daily Living (ADL) scale': 3, "Alzheimer's Disease": 3, 'Rivastigmine': 3, 'Caregiver psychiatric symptoms': 3, 'neuropsychological battery': 3, "caregivers' depressive and anxiety symptoms": 3, 'Activities of Daily Living Scale': 3, 'Cognition: backward digit span scores': 3, 'Cognition:  mini-Mental State Examination': 3, 'Geriatric Depression Scale': 3, 'Mini Mental State Examination': 3, 'Orientation Scale for Geriatric Patients': 3, 'Amnestic Symptoms': 3, 'Mild Cognitive Impairment': 3, 'Change in global cognitive function (measured using the Mini Mental Status Examination (MMSE))': 3, "Change in global cognitive function (measured using the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog))": 3, 'Montgomery Asberg Depression Rating Scale (MADRS)': 3, 'Withdrawn': 3, 'Hospitalization': 3, 'Test scores: unspecified': 3, 'Donepezil': 3, 'Music Therapy': 3, "Alzheimer's Disease Assessment Scale (ADAS-cog)": 3, 'Geriatric Depression Scale (GDS) score': 3, 'Overall deterioration scale (measured using the FAST scale)': 3, 'Mini-Mental State Examination (MMSE)': 3, 'Day Care/respite Education, Guidance, And Counselling': 3, 'Family Counseling': 3, 'Caregiver: social support': 3, 'verbal fluency': 3, 'Caregiver: marital interaction': 3, 'hostility': 3, 'Caregiver: ability to cope': 3, 'Caregiver: stress': 3, 'cognitive outcomes': 3, 'Caregiver: physical health': 3, 'problem-solving ability': 3, 'Caregiver: emotional status': 3, 'Caregiver: depressive symptoms': 3, 'Anticholinesterases': 3, 'Cognitive evaluation': 3, 'Clinical evaluation': 3, 'Confusion': 3, '': 3})
CD001190 Counter({'Donepezil': 24, "Dementia Due To Alzheimer's Disease": 20, 'clinical laboratory testing (hematology, biochemistry, and urinalysis panels analyzed by a central laboratory)': 3, 'Severe Impairment Battery (SIB; cognition)': 3, 'physical examination': 3, '12-lead ECG': 3, "Clinician's Interview-Based Impression of Change Plus Caregiver Input scale": 3, 'Treatment-emergent adverse events (TEAEs)': 3, 'Global functioning': 3, 'vital sign measurements': 3, 'neurologic examinations': 3, 'cognition': 3, 'Severe Impairment Battery (SIB)': 3, "Clinician's Interview-Based Impression of Change-plus caregiver input (CIBIC-plus)": 3, 'Behavioural And Psychiatric Symptoms Of Dementia': 3, 'Agitation': 3, 'Cohen-Mansfield Agitation Inventory (CMAI)': 3, "Clinician's Global Impression of Change": 3, 'Neuropsychiatric Inventory Caregiver Distress Scale': 3, 'Neuropsychiatric Inventory': 3, 'Cognition: MMSE': 3, 'Cognition: CIBIC plus': 3, 'Cognition: ADAS-cog': 3, "Alzheimer's Disease": 3, 'Caregiver': 3, 'Activities of Daily Living': 3, 'Caregiver burden': 3, 'Haematology (measure not specified)': 3, 'Hepatotoxicity (measure not specified)': 3, 'Quality of Life scores (measure not specified)': 3, 'Treatment-emergent adverse events': 3, 'Clinical biochemistry test(s) (measure(s) not specified)': 3, "Alzheimer's Disease Assessment Scale-cognitive subscale score": 3, 'Vital signs (measures not specified)': 3, 'Mini-mental State Examination': 3, 'Elective Surgery': 3, 'Total Hip Replacement': 3, 'Length of postoperative hospital stay (days)': 3, 'Postoperative delirium (measured using the Delirium Symptom Interview)': 3, 'Memantine': 3, 'nursing home placement': 3, "Clinician's Interview-Based Impression of Change with caregiver input (CIBIC+)": 2, 'safe and well tolerated': 2, "Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog)": 2})
CD006220 Counter({'Memory Skills Training': 29, 'Healthy': 27, 'Well Elder': 24, 'Elderly': 12, 'Cognitive function': 12, 'Cognitive Skills Training': 9, 'Pramiracetam': 3, 'Memory': 3, 'Cognition': 3, 'Cognitive Therapy': 3, 'Behavioural - unspecified': 3, 'Logic memory': 3, 'Learning potential': 3, 'Cognitive - unspecified': 3, 'Working memory': 3, 'Quality of Life - unspecified': 3, 'Subjective memory': 3, 'Affective assessments - unspecified': 3, 'Biomedical - unspecified': 3, 'Immediate memory': 3, 'Every day function': 3, 'Anxiety and stress about memory functioning': 3, 'Cognition: Memory': 3, 'Recall': 3, 'Memory performance': 3, 'depressive symptoms': 3, 'self-reported memory function': 3, 'mood': 3, 'Mild Cognitive Impairment': 3, 'Old-age': 3, 'Relaxation Training Therapy': 3, 'Memory Loss Care Education': 3, 'Cognitive Restructuring': 3, 'memory performance': 3, 'neuropsychological measures of memory': 3, 'Impaired Cognition': 3, 'Information Processing Training': 3, 'Timed Instrumental Activities of Daily Living (Timed IADL)': 3, 'Processing speed (measured using the Usual Field of View test (UFOV))': 3, 'Relaxation Program': 3, 'Memory: recall': 3, 'Cognitive Stimulation': 3, 'Cognition: Benton visual retention test': 3, 'Cognition: free recall of words within the Buschke selective reminding paradigm': 3, 'Cognition: digit span': 3, 'Group Exercise': 3, 'Individual Exercises': 3, 'Perceived recall confidence': 3, 'Recall performance': 3, 'Cognitive Rehabilitation Therapy': 2, 'recognition memory (HVLT-R)': 2, 'Memory: Hopkins Verbal Learning Test - Revised': 2, 'Memory: Brown-Peterson': 2, 'Memory: Logical Stories': 2, 'Primary memory: Brown-Peterson, HVLT-R': 2, 'Working memory: Alpha span': 2, 'Memory: Alpha Span': 2})
CD008143 Counter({'Type 2 Diabetes Mellitus': 2, 'Atherosclerotic disease': 2, 'Cognitive impairment': 2, 'Instrumental activity of daily living': 2, 'Diabetic complications': 2, 'Glycemic control': 2, 'Obesity': 2, 'Depressive symptoms': 2, 'Dyslipidemia': 2, 'Hypertension': 2, 'Diabetes burden': 2})
CD005318 Counter({'Caregiver': 6, 'Anxiety': 3, 'Cognitive - Behavior Therapy': 3, 'Sleep: actigraph measurements': 3, 'anxiety: self-report': 3, 'anxiety: clinician-administered questionnaires': 3, 'Depression': 3, 'Group Cognitive Behavioural Therapy': 3, 'depressive symptomatology': 3, 'dysfunctional thoughts about caregiving': 3})
CD000269 Counter({'Citicoline': 6, 'Vascular Dementia': 3, 'neuropsychological performance': 3, 'Neuroimaging measures of total brain volume': 3, 'neurocognitive tests': 3, 'Neuroimaging measures of subcortical/periventricular hyperintensity (SH) volume': 3, 'Cerebrovascular Disease': 3, 'Cytidine Diphosphate Choline Injectable Solution': 3, 'motor functions': 3, 'common dementia symptoms': 3, 'Recall': 3, 'GBS rating scale': 3, 'Acquisition': 3, 'Cognitive Efficiency': 3, 'Attention Efficiency': 3, 'emotional functions': 3, 'cognitive functions': 3, 'mental functions': 3, 'Delayed Recall': 3, 'Randt Memory Test': 3, "Dementia Due To Alzheimer's Disease": 3, "Cognitive performance (measured by the Alzheimer's Disease Assessment Scale, and its cognition subscale)": 3, 'Diastolic velocity in the left middle cerebral artery': 3, 'Cerebral blood flow velocities (measured by transcranial Doppler recordings from both hemispheres)': 3, 'Hematological parameters - unspecified': 3, 'Adverse events': 3, 'brain bioelectrical activity': 3, 'Serum IL-1 beta level': 3, 'Blood histamine content': 3, 'Biological parameters - unspecified': 3})
CD006221 Counter({'No available term': 3, 'Testosterone': 3, 'bone mineral density (BMD)': 3, 'physical performance': 3, 'quality of life': 3, 'glucose tolerance': 3, 'body composition': 3, 'Elderly': 3, 'Androsterone': 3, 'Spatial declarative memory test': 3, 'Recall of visual material': 3, 'Visual-verbal declarative memory test': 3, 'Attention test': 3})
CD009537 Counter({'Delirium': 3, 'Quetiapine': 3, 'Delirium Rating Scale Revised 98': 3, 'Mini-Mental State Examination': 3, 'Clinical Global Improvement': 3, 'Brief Psychiatric Rating Scale': 3, 'Old-age': 2, 'Living In Nursing Home': 2, 'Potential delirium (measure not specified)': 2, 'Falls': 2, 'Hospitalisations potentially due to adverse drug events': 2, 'Mortality': 2})
CD003944 Counter({"Dementia Due To Alzheimer's Disease": 6, 'Depression': 6, 'Behavioural And Psychiatric Symptoms Of Dementia': 3, 'Sertraline': 3, "modified Alzheimer's Disease Cooperative Study Clinical Global Impression-Change (mADCS-CGIC)": 3, 'Cornell Scale for Depression in Dementia (CSDD)': 3, 'nonmood neuropsychiatric symptoms,': 3, 'quality of life': 3, 'global cognition': 3, 'function': 3, 'time to remission': 3, 'Dementia': 3, 'Maprotiline': 3, 'Cognition: Mini-Mental State Examination (MMS)': 3, 'Geriatric Depression Scale (GDS)': 3, 'Fluoxetine': 3, 'Rivastigmine': 3, 'Hamilton Depression Scale': 3, 'activities of daily living': 3, 'cognition': 3, 'global functioning': 3})
CD009126 Counter({'Caregiver': 18, 'Dementia': 15, 'Telephone Encounter': 9, 'Caregiver Education': 6, 'Cognitive - Behavior Therapy': 3, 'Coping strategies': 3, 'Depression': 3, 'Physical health': 3, 'Anxiety': 3, 'Perceptions of caregiver satisfaction': 3, 'Perceptions of caregiver burden': 3, 'Emotional health': 3, 'Relaxation Training Therapy': 3, 'Assertiveness Training': 3, 'Cognitive Therapy': 3, 'anger': 3, 'depression': 3, 'Self-efficacy': 3, 'Support': 3, 'Caregiver depression': 3, 'Caregiver personal gains': 3, 'caregiver burden': 3, 'psychosocial distress': 3, 'positive affect': 3, 'Caregiver self-efficacy': 3, "Dementia Due To Alzheimer's Disease": 3, 'caregiving burden': 3, 'distress': 3, 'Perceived reasons for perceived helpfulness of  telephone calls': 3, 'Perceived helpfulness of telephone calls': 3})
CD006489 Counter({'Physical Exercises': 17, "Dementia Due To Alzheimer's Disease": 15, 'Walking Practice': 11, 'Dementia': 9, 'Living In Residential Institution': 9, 'Depression': 6, 'cognition': 5, 'Hand Therapy': 3, 'Movement Therapy': 3, 'Cognition': 3, 'Anxiety': 3, 'Mood (symptoms of depression and anxiety)': 3, 'Rest-activity (actigraphy)': 3, 'muscle strength and flexibility': 3, 'Agility and dynamic balance (measured using the Senior Fitness Test)': 3, 'Activities of Daily Living (Katz and Bartel Scores)': 3, 'Gait and balance abilities (measured using the Tinetti scale)': 3, 'Endurance fitness (measured using the Senior Fitness Test)': 3, '6-minute walking test': 3, 'Barthel Index of Activities of Daily Living': 3, 'Cognition: Mini-Mental State Examination': 3, 'Active Exercise': 3, 'functional performance': 3, 'lower extremity strength': 3, 'caregiver burden': 3, 'neuropsychiatric symptoms,': 3, 'quality of life': 3, 'hand function': 3, 'walking analysis': 3, 'Rapid Evaluation of Cognitive Functions test (ERFC French version)': 3, 'Observed Affect Scale': 3, 'Dementia Mood Assessment Scale': 3, 'Cornell Scale for Depression in Dementia': 3, "Alzheimer's Mood Scale": 3, 'Cognition: the clock drawing test': 3, 'Disability: Revised Elderly Persons Disabilities Scale (REPDS)': 3, "Alzheimer's Disease": 3, 'Usual Care': 3, 'improved cognition': 3, 'Activities of Daily Living (measured using the Instrumental Activities of Daily Living score)': 3, 'Physical function (measured using the Timed Up and Go instrument)': 3, 'Cognitive function: Mini-Mental State Examination score': 3, 'Caregiver': 3, 'Light Therapy': 3, 'Total sleep time (measured using actigraphy)': 3, 'Number of awakenings (measured using actigraphy)': 3, 'Sleep quality (measured using caregiver ratings on the Sleep Disorders Inventory (SDI))': 3, 'Participant total wake time (measured using actigraphy)': 3, 'Sleep percentage (measured using actigraphy)': 3, 'Philadelphia Geriatric Center Morale Scale (PGCMS)': 2, 'depressive symptoms': 2, 'psychological well-being': 2, 'Geriatric Depression Scale (GDS-15)': 2})
CD009008 Counter({'Type 2 Diabetes Mellitus': 3, 'repaglinide': 3, 'Fasting plasma glucose (FPG)': 3, 'Composite score of executive and attention functioning': 3, 'Coefficient of variation of postprandial plasma glucose': 3, 'Cognition: Mini-mental state examination': 3, 'Hemoglobin A1c (HbA1c)': 3})
CD006929 Counter({'Dementia': 9, 'Behaviour': 5, 'Caregiver': 3, 'Cognitive Therapy': 3, 'Caregiver burden': 3, 'Carer depression': 3, 'Carer distress': 3, 'Hospitalization': 3, 'Music Therapy': 3, 'Active Exercise': 3, 'Music Exercise': 3, 'Cognition: Mini-Mental State Examination': 3, 'Cognition: Amsterdam Dementia Screening Test 6': 3, 'Behaviour: Stockton Geriatric Rating Scale': 3, 'Living In Residential Institution': 3, "Dementia Due To Alzheimer's Disease": 3, 'Physical Exercises': 3, 'nutritional status': 3, 'Behavioral disturbance': 3, 'activities of daily living': 3, 'Physical performance: get-up-and-go test': 3, 'Montgomery and Asberg Depression Rating Scale': 3, 'Mini-Nutritional Assessment': 3, 'Physical performance': 3, 'Physical performance: one-leg-balance test': 3, 'Physical performance: 6-meter walking speed': 3, 'depression': 3, 'Neuropsychiatric Inventory': 3, 'Memory Skills Training': 3, 'perceived memory function': 3, 'cognitive tests': 3, 'memory': 3, 'mood': 3, 'Multisensory Play': 3, 'Sensory Stimulation': 3, 'Mood': 3, 'cognition': 3, 'Donepezil': 2, 'Reality Orientation': 2, "Alzheimer's Disease Assessment Scale-Cognition": 2, 'Cognition: Mini-mental state examination': 2, 'Function': 2})
CD003002 Counter({'Obstructive Sleep Apnea Syndrome': 11, "Alzheimer's Disease": 3, "Dementia Due To Alzheimer's Disease": 3, 'Donepezil': 3, 'Polysomnography and cognitive evaluation using Alzheimer disease assessment scale-cognitive (ADAS-cog) subscale': 3, 'Apnea-hypopnea index (AHI) score': 3, 'Alzheimer disease and apnea-hypopnea index (AHI)': 3, 'Cognitive function (measured using the Alzheimer Disease Assessment Scale, Cognitive subscale (ADAS-cog) score': 3, 'Rapid eye movement (REM) sleep duration': 3, 'Oxygen saturation (measured using polysomnography)': 3, 'Oxygen saturation': 3, 'Rapid eye movement (REM) sleep duration (measured using polysomnography)': 3, 'Sleep Apnea': 3, 'Aminophylline': 3, 'Mixed apnea': 3, 'Sleep architecture': 3, 'Obstructive apnea': 3, 'sleep fragmentation': 3, 'arterial oxygen saturation': 3, 'sleep efficiency': 3, 'Central apnea': 3, 'sleep architecture': 3, 'Snoring': 3, 'Rhinitis': 3, 'Fluticasone': 3, 'Fluticasone Nasal Inhaler': 3, 'Fluticasone propionate': 3, 'Nasal congestion (measured using daily diary record)': 3, 'Daytime alertness (measured using daily diary record)': 3, 'Snoring noise (measure(s) not specified)': 3, 'Apnoea-hypopnoea frequency (AHI) (measured using polysomnography)': 3, 'nasal congestion': 3, 'nasal airflow resistance': 3, 'Sleep quality (measure(s) not specified)': 3, 'snoring noise': 3, 'apnoea-hypopnoea index': 3, 'daytime alertness': 3, 'polysomnography': 3, 'Nasal airflow resistance (NAR) (measure(s) not specified)': 3, 'Sleep Apnoeas': 3, 'Almitrine': 3, 'Duration of respiratory events during sleep (minutes)': 3, 'Respiratory events per hour of sleep': 3, 'No available term': 3, 'Acetazolamide': 3, 'Protriptyline': 3, 'frequency of desaturation': 3, 'apnea frequency': 3, 'Sleep': 2, 'Plasma Concentration of Sabeluzole': 2, 'Obstructive Sleep Apnea Daytime Symptoms': 2, 'Oxygen Desaturation During Sleep (Oxygen Desaturation Index (ODI))': 2, 'Breathing': 2})
CD006104 Counter({'Mild Cognitive Impairment': 3, 'Donepezil': 3, 'Rivastigmine': 3, '': 3, 'Cerebral blood flow (measured using [(15)O]water positron emission tomography (PET))': 3})
CD003260 Counter({"Dementia Due To Alzheimer's Disease": 9, 'Cognitive Skills Training': 3, 'Social Support': 3, 'Pyritinol': 3, 'Phosphatidyl Serine': 3, 'regional cerebral metabolic rate for glucose': 3, 'cognitive functioning': 3, 'neuropsychological testing': 3, 'Memory Skills Training': 3, 'neuropsychological tests': 3, 'everyday memory questionnaires': 3, 'activities of daily living (ADLs)': 3, 'Mixed Dementia': 3, 'Cognitive Rehabilitation Therapy': 3, 'Anticholinesterases': 3, 'Canadian Occupational Performance Measure': 3, 'career strain': 3, 'brief neuropsychological test battery': 3, 'functional magnetic resonance imaging (fMRI)': 3, 'quality of life': 3})
CD011971 Counter({'Mild Cognitive Impairment': 3, 'Hypertensive': 3, 'Old-age': 3, 'Recommendation To Stop Treatment': 3, 'Cantril Ladder': 3, 'Overall cognition compound score': 3, 'Psychomotor speed (cognitive domain) score': 3, 'Apathy Scale': 3, 'Adverse events': 3, 'Systolic Blood Pressure': 3, 'Diastolic Blood Pressure': 3, 'Groningen Activity Restriction Scale': 3, 'Geriatric Depression Scale-15': 3, 'Executive function (cognitive domain) score': 3, 'Memory (cognitive domain) score': 3})
CD003153 Counter({"Dementia Due To Alzheimer's Disease": 7, 'Cycloserine': 5, 'Cognitive function: implicit memory test': 3, 'Cognitive Drug Research (CDR) efficacy assessments': 3, 'adverse events': 3, "cognitive subscale of the Alzheimer's Disease Assessment Scale": 2})
CD003804 Counter({'Type 2 Diabetes Mellitus': 6, 'metformin': 6, 'Cognitive Impairment': 3, 'Depression': 3, 'depressive behaviour': 3, 'diabetes improvement': 3, 'Cognitive function': 3, 'Wechsler Memory Scale-Revised': 3, 'Old-age': 3, 'Rosiglitazone': 3, 'Glyburide': 3, 'Cognitive function: Cambridge Neuropsychological Test Automated Battery': 3, 'Cognitive function: Rey Auditory Verbal Learning Test': 3, 'Cognitive function: Digit Symbol Substitution Test': 3, 'Glycemic control (measured using fasting plasma glucose (FPG))': 3, 'Paired Associates Learning Test': 3})
CD009727 Counter({'Well Elder': 3, 'Healthy': 3, 'Old-age': 3, 'Goal Directed Therapy': 3, 'Self-rated executive deficits': 3, 'Tabletop simulated real-life tasks (SRLTs)': 3})
CD003120 Counter({"Dementia Due To Alzheimer's Disease": 2, 'Ginkgo Biloba Extract': 2})
CD010321 Counter({'Caregiver': 9, 'Dementia': 9, 'Cognitive - Behavior Therapy': 3, 'Behavior Management': 3, 'Depressive symptoms': 3, 'overall perceived stress': 3, 'caregiving-specific stress': 3, 'Psychoeducation': 3, 'burden': 3, 'depression': 3, 'Depression Management Program': 3, 'Anger Management Training': 3, 'anger': 3, 'perceived caregiving self-efficacy': 3, 'frequency of use of positive and negative coping strategies': 3, 'hostile mood': 3, 'depressed mood': 3})
CD008754 Counter({"Alzheimer's Disease": 3, 'Mild Cognitive Impairment': 3, 'Cognitive Rehabilitation Therapy': 3, 'Cognition:  memory': 3, 'Functional performance': 3})
CD006379 Counter({'Hospitalization': 3, 'Delirium': 3, 'Acquired Immune Deficiency Syndrome': 3, 'Chlorpromazine': 3, 'Haloperidol': 3, 'Lorazepam': 3, 'adverse effects': 3, 'Extrapyramidal Symptom Rating Scale': 3, 'Cognition:  Mini-Mental State': 3, 'Delirium Rating Scale': 3})
CD010569 Counter({'Hip Fracture': 6, 'Cognitive Impairment': 3, 'Functional Rehabilitation': 3, 'Death': 3, 'Function': 3, 'Surgery': 3, 'Old-age': 3, 'Haloperidol': 3, 'Length of postoperative hospital stay (days)': 3, 'Postoperative delirium (measured using the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, and Confusion Assessment Method criteria)': 3, 'Duration of postoperative delirium (days)': 3, 'Severity of postoperative delirium (measured using the Delirium Rating Scale, revised version-98 (DRS-R-98))': 3})
CD011066 Counter({'Postmenopause': 2, 'Healthy': 2, 'quality of life (QOL)': 2, 'serum hormone and lipid levels': 2, 'sleep': 2, 'muscle endurance': 2, 'sexual function': 2, 'lower extremity muscle (calf) mass': 2, 'muscle strength': 2, 'feelings of well-being': 2})
CD004395 Counter({'Vascular Dementia': 3, 'Donepezil': 3, "Cognitive function: Alzheimer's Disease Assessment Scale-cognitive subscale": 3, "Clinician's Interview-Based Impression of Change-plus": 3})
CD005594 Counter({'Hyperactivity': 3, 'Delirium': 3, 'Postoperative State': 3, 'Morphine sulfate': 3, 'Morphine': 3, 'Richmond Agitation Scale score': 3, 'Therapeutic response time': 3, 'Richmond Sedation Scale score': 3, 'Number of patients requiring additive sedatives': 3})
CD000147 Counter({'Nimodipine': 18, 'Dementia': 6, 'Vascular Dementia': 6, 'Global Deterioration Scale': 6, 'Cognitive Impairment': 6, "Dementia Due To Alzheimer's Disease": 3, 'eight measures': 3, 'disease progression': 3, 'Multi-infarct Dementia': 3, 'sequential NMR imaging': 3, 'Clinical ratings': 3, 'Cerebrovascular events': 3, 'Mini-Mental State Examination (MMSE) score': 3, 'Sandoz Clinical Assessment Geriatric scale 5-point variation': 3, 'Dropouts': 3, 'Cardiovascular events': 3, 'Deterioration (defined as a 3 or more point-drop versus baseline in the Mini-Mental State Examination (MMSE) score)': 3, 'Behavioural disturbances requiring intervention': 3, 'Lexical production': 3, 'Set Test score': 3, 'Fuld-Object-Memory Evaluation': 3, 'Instrumental Activities of Daily Living scale': 3, 'Zahlen-Verbindungs-Test': 3, 'Word Fluency': 3, 'Cognition: Mini Mental State Examination': 3, 'Severity of Illness and Global Improvement Scales of Clinical Global Impression': 3, 'Sandoz Clinical Assessment Geriatric Scale': 3, 'Hamilton Psychiatric Rating Scale for Depression': 3, 'Cognition: Wechsler Memory Scale': 3, 'Plutchik Geriatric Rating Scale': 3, 'general clinical conditions': 3, 'tolerability': 3})
CD011513 Counter({'Palliative Care': 6, 'Hospitalization': 3, 'Dementia': 3, 'End Of Life Care Planning': 3, 'Tube feeding': 3, 'hospitalizations': 3, 'Other invasive interventions': 3, 'Mortality': 3, 'hospitalization: length of stay': 3, "Dementia Due To Alzheimer's Disease": 3, 'Memantine': 3, "Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus)": 3, 'Neuropsychiatric Inventory (NPI) score': 3, "19-item Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL19) score": 3, 'Headache': 3, 'Severe Impairment Battery (SIB) score': 3, 'Diarrhea': 3, 'Verbal Fluency Test score': 3})
CD012345 Counter({'Docosahexaenoic Acid Supplementation': 9, "Dementia Due To Alzheimer's Disease": 6, 'N-3 Fatty Acid Supplementation': 6, 'Eicosapentanoic Acid Supplementation': 6, 'Cognition: mini-Mental State Examination (MMSE)': 3, 'peripheral F2-isoprostane levels (oxidative stress measure)': 3, 'Activities of Daily Living/Instrumental Activities of Daily Living (ADL/IADL)': 3, 'Cognition: Alzheimer Disease Assessment Scale-cognitive subscale (ADAS-cog)': 3, 'Coronary Heart Disease': 3, 'Myocardial Infarction': 3, 'Alpha-linolenic Acid Supplementation': 3, 'Cognitive function: Mini-Mental State Examination': 3, 'Clinical Dementia Rating (CDR) sum of boxes': 3, "cognitive subscale of the Alzheimer's Disease Assessment Scale": 3, 'Rate of brain atrophy (measured using volumetric magnetic resonance imaging)': 3, 'Healthy': 3, 'Cognition: battery of cognitive tests': 3, 'California Verbal Learning Test (CVLT)': 3})
CD003154 Counter({'Memantine': 51, "Dementia Due To Alzheimer's Disease": 30, 'Vascular Dementia': 9, "Alzheimer's Disease Assessment Scale, Cognitive subscale (ADAS-cog) score": 6, 'Mini-Mental State Examination (MMSE) score': 6, 'Neuropsychiatric Inventory (NPI)': 6, 'Dementia': 6, 'Cognition: ADAS-cog': 6, 'Unspecified': 6, "Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) score": 6, 'Cognition': 6, 'Clinical Global Impression of Change (CGI-C)': 3, "Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog)": 3, "Alzheimer's Disease": 3, 'Global N-acetylaspartate concentration (measured using chemical shift imaging)': 3, 'Regional N-acetylaspartate concentration (measured using chemical shift imaging)': 3, 'Regional glucose metabolism (measured using multimodal imaging)': 3, 'Global glucose metabolism (measured using multimodal imaging)': 3, 'Global myoinositol concentration (measured using chemical shift imaging)': 3, 'Hippocampal volume (measured using multimodal imaging)': 3, 'Regional myoinositol concentration (measured using chemical shift imaging)': 3, 'Total brain volume (measured using multimodal imaging)': 3, 'Treatment-related regional CMRgl effects (measured using an automated brain mapping algorithm and predefined regions of interest)': 3, "Alzheimer's Disease ssessment Scale, Cognitive subscale (ADAS-cog) score": 3, 'Cognition: Mini-Mental State Examination (MMSE) score': 3, 'Regional cerebral metabolic rate for glucose (CMRgl) (measured using fluorodeoxyglucose positron emission tomography (FDG-PET))': 3, 'Cognitive decline (measured using the Severe Impairment Battery)': 3, 'Cerebrospinal fluid amyloid β (Aβ) and tau assays': 3, 'Donepezil': 3, 'Treatment discontinuation due to adverse events': 3, "Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus)": 3, '19-item AD Cooperative Study-Activities of Daily Living Inventory': 3, 'Behavioral Rating Scale for Geriatric Patients (BGP Care Dependency Subscale)': 3, "Activities of dailyliving (measured using a modified 19-item Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL19))": 3, 'Cognitive function: Severe Impairment Battery (SIB)': 3, 'MRI scans': 3, 'behavioral scales': 3, 'cognitive scales': 3, 'Behavioural And Psychiatric Symptoms Of Dementia': 3, 'Frontotemporal Degeneration': 3, 'Semantic Dementia': 3, 'cognitive adverse events': 3, 'clinical global impression of change (CGIC)': 3, 'neuropsychiatric inventory (NPI)': 3, 'well tolerated': 3, 'D-alpha-tocopherol': 3, 'Caregiver Activity Survey': 3, "Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory score": 3, 'Dependence Scale': 3, "Nurses' Observation Scale for Geriatric Patients disturbing behavior dimension": 3, 'Mini-Mental State Examination (MMSE ) score': 3, 'Any adverse event': 3, 'Cognition (ADAS-cog)': 3, 'Cognition (MMSE)': 3, "Global Clinician's Interview Based Impression of Change (CIBIC-plus)": 3, 'Gottfries-Brane-Steen Scale intellectual function subscore': 3, "Parkinson's Disease": 3, 'Goal attainment scaling': 3, "Dementia Due To Parkinson's Disease": 3, 'Dementia With Lewy Bodies': 3, 'clinical global impression of change': 3, 'dementia-induced disturbances': 3, 'clinicochemical tests': 3, 'tolerability': 3, 'Clinical Assessment Geriatric Scale (SCAG)': 3, "global assessment of the change in the patient's condition": 3, 'activities of daily living (ADL)': 3, 'heart rate': 3, 'psychomotor tests': 3, 'blood pressure': 3, 'safety parameters': 3, 'Gottfries-Bräne-Steen Scale (GBS)': 3, "Clinician's Interview-Based Impression of Change with caregiver input (CIBIC-plus) score": 3, 'Cognition: ADAS-Cog': 3, '23-item Alzheimer Disease Cooperative Study-Activities of Daily Living Scale (ADCS-ADL(23))': 3, 'Any adverse events': 3, '': 3, 'Cognition: trail making tests': 3, 'Cognition: Rey-Osterrieth Complex Figure Test': 3, 'Cognition: FULD object memory evaluation': 3, "Global clinical status (measured using the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus))": 3, 'Treatment discontinuations due to adverse events': 3, "Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL(23))": 3, 'Behaviour (measured using the Neuropsychiatric Inventory (NPI))': 3, 'Sandoz Clinical Assessment Geriatric scale (SCAG), Cognitive disturbances subscale score': 3, "Physician's global impression (measure not specified)": 3, 'Sandoz Clinical Assessment Geriatric scale (SCAG), Social behaviour subscale score': 3, 'Sandoz Clinical Assessment Geriatric scale (SCAG), Lack of drive subscale score': 3, 'Syndrom-Kurz-Test (SKT) score': 3, 'Mini-Mental State Evaluation (MMSE) score': 3, 'Total time required in the subtests of Activity of Daily Living tests (ADL)': 3, 'Sandoz Clinical Assessment Geriatric scale (SCAG) score': 3, 'Total time required in the subtests of Activity of Daily Living tests (ADL) (minutes)': 3, 'Sandoz Clinical Assessment Geriatric scale (SCAG), Emotional disturbances subscale score': 3, 'Fine motor rating (measured using Tapping and Trace tests)': 3, 'Sandoz Clinical Assessment Geriatric scale (SCAG), Somatic disturbances subscale score': 3, 'Adverse drug effects': 3, 'Vitamin E': 3, 'Activities of daily living': 3, 'Caregiver measures': 3, 'slower functional decline': 3})
CD003477 Counter({'Music Therapy': 36, 'Dementia': 30, "Dementia Due To Alzheimer's Disease": 12, 'Behavioural And Psychiatric Symptoms Of Dementia': 9, 'Living In Residential Institution': 9, 'Activities of daily living (measure not specified)': 6, 'Depression': 6, 'Living In Nursing Home': 6, 'Quality of life (measure not specified)': 6, 'emotional response': 3, "BPSD changes using the behavioral pathology in alzheimer's disease (BEHAVE-AD) rating scale": 3, 'stress levels': 3, 'autonomic nerve index and the faces scale': 3, 'physically aggressive behavior': 3, 'agitated behavior': 3, 'verbally non-aggressive behavior': 3, 'verbally aggressive behavior': 3, 'emotional relaxation': 3, 'physically non-aggressive behavior': 3, 'inter-personal interactions': 3, 'immediate prose memory test': 3, 'Music Therapy Activity Scale (SVAM)': 3, 'deferred prose memory test': 3, 'attentional matrices': 3, 'Geriatric Music Therapy Profile (GMP)': 3, 'Agitation': 3, 'modified Cohen-Mansfield Agitation Inventory (CMAI)': 3, 'Global Deterioration Scale': 3, 'Brain Stimulation': 3, 'mood and mental state': 3, 'depressive symptoms': 3, 'belonging': 3, 'Dementia Quality of Life and Geriatric Depression Scale': 3, 'Anxiety': 3, 'Anxiety: Hamilton Scale': 3, 'Geriatric Depression Scale': 3, 'Cognitive Stimulation': 3, 'Cognitive function (measure not specified)': 3, 'Neuropsychiatric Inventory global score': 3, 'Agitation (measure not specified)': 3, 'Prescription of psychotropic medication': 3, 'ECG Holter recordings': 3, 'neuropsychological assessment': 3, 'Hospitalization': 3, 'agitation': 3, 'activity disturbances': 3, "behavior pathology in alzheimer's disease rating scale (BEHAVE-AD": 3, 'anxiety': 3, 'aggressiveness': 3, 'Singing': 3, 'orientation': 3, 'mood': 3, 'memory': 3, 'cognition': 3, 'QOL': 3})
CD002955 Counter({'Naftidrofuryl': 15, 'Dementia': 6, 'Vascular Dementia': 6, 'Hospitalization': 3, 'Behavioural rating score': 3, 'standard memory scales': 3, "Sperling's Perceptual Trace, SPT": 3, 'Clinical Global Impression (CGI) Item 2 scale': 3, 'NOSGER': 3, 'SCAG': 3, 'ADAS-cog': 3, 'Senile Dementia': 3, 'Concentration (measured using the Zazzo test)': 3, 'Numerical memory (measured using the digit-span test)': 3, 'Verbal memory (measured using the Rey test)': 3, 'Any adverse events': 3, 'Routine laboratory parameters': 3, 'Visual memory (measured using the Benton test)': 3, "Echelle d'Appréciation Clinique en Gériatrie": 3, 'Global symptoms of senile dementia (measured using the Stockton Geriatric Rating Scale (SGRS) score)': 3, 'Mixed Dementia': 3, 'Cognition: Mini-Mental State Examination': 3, 'Alzheimer Disease Assessment Scale cognitive subscale': 3, 'global function': 3})
CD009812 Counter({'Dementia': 14, 'Living In Residential Institution': 9, 'Living In Nursing Home': 4, 'Psychosocial Intervention Strategy': 3, 'Verbal behaviour (measure not specified)': 3, 'Positive affect': 3, 'Negative affect': 3, 'Non-verbal behaviour': 3, 'Social Interaction Encouragement': 3, 'Sleep: actigraph': 3, 'Occupational Therapy': 3, 'Quality of life (measured by self-rating)': 3, 'dependency': 3, 'challenging behaviour': 3, 'Number and type of medication': 3, 'Quality of life (measured by care home staff ratings)': 3, 'severity of dementia': 3, 'depression': 3, 'anxiety': 3, 'Behavioural And Psychiatric Symptoms Of Dementia': 3, 'Agitation': 3, 'Activity Therapy': 3, 'affect and engagement': 3, 'Physically aggressive behaviour': 3, 'Agitation (measured using the Agitated Behavior Mapping Instrument (ABMI))': 2, "Positive affect (measured using Lawton's Modified Behavior Stream)": 2, "Negative affect (measured using Lawton's Modified Behavior Stream)": 2, 'Cognitive Impairment': 2, 'Engagement (measured using video recordings and real-time observations)': 2, 'Passivity (measured using video recordings and real-time observations)': 2, 'Agitation (measured using video recordings and real-time observations)': 2, 'Pleasure (measured using video recordings and real-time observations)': 2, 'Affect (measured using video recordings and real-time observations)': 2, 'Mood (measured using video recordings and real-time observations)': 2, 'Alertness (measured using video recordings and real-time observations)': 2, 'Attention (measured using video recordings and real-time observations)': 2})
CD009178 Counter({'Melatonin': 12, "Dementia Due To Alzheimer's Disease": 9, 'Living In Residential Institution': 6, 'Dementia': 6, 'Behavioural And Psychiatric Symptoms Of Dementia': 3, 'Risperidone': 3, 'Haloperidol': 3, 'Olanzapine': 3, 'Recommendation To Discontinue A Therapy': 3, 'Sleep: actigraphy': 3, 'Behavioral rating using the Neuropsychiatric Inventory Questionnaire (NPI-Q)': 3, 'Old-age': 3, 'Continuous Bright Light': 3, 'Sleep duration (minutes, measure not specified)': 3, 'Nocturnal restlessness (minutes per hour per year, measure not specified)': 3, 'Sleep efficiency (%; measure not specified)': 3, 'Withdrawn behaviour (measured using the Multi Observational Scale for Elderly Subjects scale)': 3, 'Cohen-Mansfield Agitation Index': 3, 'Multi Observational Scale for Elderly Subjects scale': 3, 'Sleep efficiency (percent, measure not specified)': 3, 'Postive affect (measured using the Philadelphia Geriatric Centre Affect Rating Scale)': 3, 'Functional limitations in activities of daily living (measured using a nurse-informant activities of daily living scale)': 3, 'Negative affect (measured using the Philadelphia Geriatric Centre Affect Rating Scale)': 3, 'Sleep onset latency (minutes, measure not specified)': 3, 'Cognition': 3, 'Depressive symptoms (measured using the Cornell Scale for Depression in Dementia)': 3, 'Aggressive behaviour (measured using the Cohen-Mansfield Agitation Index)': 3, 'Psychosocial': 3, 'Positive affect (measured using the Philadelphia Geriatric Centre Affect Rating Scale)': 3, 'Nocturnal restlessness (minutes per hour per year)': 3, 'Sleep onset latency (minutes)': 3, 'Activities of daily living (measured using a nurse-informant activities of daily living scale)': 3, 'Sleep duration (minutes)': 3, 'Daytime sleep duration (minutes, measured using actigraphy)': 3, "Alzheimer's Disease Assessment Scale, Non-cognitive subscale (ADAS-noncog) score": 3, 'Mini Mental State Examination (MMSE) score': 3, 'Nighttime sleep duration (minutes, measured using actigraphy)': 3, 'Clinical Dementia Rating Scale (CDR)': 3, 'Daytime activity count (measured using actigraphy)': 3, 'Nighttime activity count (measured using actigraphy)': 3, "Alzheimer's Disease Assessment Scale, Cognitive subscale (ADAS-cog) score": 3, 'Activity count (measured using actigraphy)': 3, 'Sleep duration (minutes, measured using actigraphy)': 3, 'sleep and agitation': 3, 'Sleep Disturbance': 3, 'nocturnal total sleep time': 3, 'day-night sleep ratio': 3, 'wrist actigraphy': 3, 'wake-time after sleep onset': 3, 'sleep efficiency': 3})
CD005380 Counter({"Dementia Due To Alzheimer's Disease": 2, 'Plasma Abeta42 levels': 2, "cognitive subscale score of the Alzheimer's Disease Assessment Scale": 2, 'Plasma zinc levels': 2})
CD006496 Counter({'Hiv Infection': 3, 'Cognitive Impairment': 3, 'Dementia Associated With Aids': 3, 'Memantine': 3, 'Changes in cognitive performance: NPZ-8': 3, 'Brain metabolism (measured using magnetic resonance spectroscopy)': 3})
CD011542 Counter({'Dementia': 3, 'Provision Of Patient Decision Aid': 3, 'decision-making for feeding options': 3, "Alzheimer's Disease": 3, 'Living In Residential Institution': 3, 'Mixed Dementia': 3, 'Music Therapy': 3, 'Severity of behavioural disorders (measure not specified)': 3, 'Professional caregiver distress (measure not specified)': 3, 'Emotional state (measure not specified)': 3, 'Cognitive status (measure not specified)': 3, "Dementia Due To Alzheimer's Disease": 3, 'Organic Brain Syndrome': 3, 'Therapeutic Touch': 3, 'nutrition': 3})
CD005379 Counter({'Elderly': 3, 'Old-age': 3, 'Docosahexaenoic Acid Supplementation': 3, 'Eicosapentanoic Acid Supplementation': 3, 'Memory (measured using an unspecified neuropsychological test battery)': 3, 'Sensorimotor speed (measured using an unspecified neuropsychological test battery)': 3, 'Attention (measured using an unspecified neuropsychological test battery)': 3, 'Executive function (measured using an unspecified neuropsychological test battery)': 3})
CD002222 Counter({'Glaucoma': 1})
CD009002 Counter({"Dementia Due To Alzheimer's Disease": 3, 'Docosahexaenoic Acid Supplementation': 3, 'Anticholinesterases': 3, 'Eicosapentanoic Acid Supplementation': 3, 'safe and well tolerated': 3, 'Cognition: cognitive portion of the Alzheimer Disease Assessment Scale': 3, 'Cognition: Mini-Mental State Examination (MMSE)': 3})
CD001749 Counter({"Dementia Due To Alzheimer's Disease": 3, 'Nicotine Transdermal Patch': 3, "Attentional performance: Conners' continuous performance test (CPT)": 3, 'Motor function': 3, 'Memory': 3})
CD003155 Counter({'Metrifonate': 6, "Dementia Due To Alzheimer's Disease": 3, 'Adverse effects': 3, 'Cognition: Mini-Mental State Examination': 3, 'Alzheimer Disease Assessment Scale cognitive subscale': 3, "Alzheimer's Disease": 3, 'Psychiatric and behavioural symptoms (measured using the Neuropsychiatric Inventory (NPI))': 3, "Psychiatric and behavioural symptoms (measured using the Alzheimer's Disease Assessment Scale, Non-cognitive subscale (ADAS-noncog))": 3, "Cognition (measured using the Alzheimer's Disease Assessment Scale, Cognitive subscale (ADAS-cog))": 3, 'Global functioning (measured using the Global Depression Scale (GDS))': 3, 'Cognition Cognition (measured using the Mini Mental State Examination (MMSE) score)': 3, 'Instrumental and basic activities of daily living (measured using the Disability Assessment in Dementia (DAD) scale)': 3, "Global functioning (measured using the Clinician's Interview-Based Impression of Severity plus caregiver input (CIBIS-plus) scale)": 3, "Global functioning (measured using the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC- Plus))": 3})
CD005563 Counter({'Surgery': 17, 'Old-age': 11, 'Postoperative delirium (measure not specified)': 8, 'Intravenous Infusion': 6, 'Elective Surgery': 6, 'Hip Fracture': 6, 'Hospitalization': 5, 'Cardiopulmonary Bypass': 3, 'Methylprednisolone': 3, 'Composite of mortality and major morbidity (myocardial injury, stroke, renal failure, or respiratory failure) (measured at 30 days)': 3, 'Any type of infection': 3, 'Surgical site infection': 3, 'Mortality (measured at 30 days)': 3, 'Pain': 3, 'Medication Administration: Intrathecal': 3, 'Morphine': 3, 'Patient Controlled Analgesia': 3, 'Rate of awakening (measure not specified)': 3, 'Length of hospital stay (days)': 3, 'Pain intensity (measure not specified)': 3, 'Daily intravenous morphine consumption (measure not specified)': 3, 'Time to ambulation without assistance (days, measure not specified)': 3, 'Postoperative delirium or confusion (measure not specified)': 3, 'Time to awakening from anaesthesia (minutes)': 3, 'Mental function (measured using the Digit Symbol substitution Test)': 3, 'Mental function (measured using the Mini Mental State Examination (MMSE))': 3, 'Use of sedation (measure not specified)': 3, 'Time to ileus resolution (days, measure not specified)': 3, 'Gastric Cancer': 3, 'Colon Cancer': 3, 'Gastrointestinal Surgery': 3, 'Pethidine': 3, 'Flunitrazepam Injectable Solution': 3, 'Intramuscular Injection': 3, 'Diazepam': 3, 'Morning lethargy': 3, 'Postoperative delirium (POD)': 3, 'Xenon': 3, 'General Anesthesia': 3, 'Respiratory profile': 3, 'Any adverse event(s)': 3, 'Systemic haemodynamics (assessed by the use of a pulmonary artery catheter)': 3, 'Pulmonary haemodynamics (assessed by the use of a pulmonary artery catheter)': 3, 'Renal function (safety)': 3, 'Intraoperative blood loss (safety)': 3, 'Dosage of study treatments (safety)': 3, 'Perioperative haemodynamic profile': 3, 'Regional cerebral tissue oxygenation (safety)': 3, 'Bispectral index': 3, 'Need for inotropic support (safety)': 3, 'Serious Physical Health Problem': 3, 'Ramelteon Oral Tablet': 3, 'Time to development of delirium (measured using Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) diagnostic criteria and days)': 3, 'Delirium (measured using Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) diagnostic criteria)': 3, 'Local Anesthetic Fascia Iliac Block': 3, 'Postoperative delirium (measured using the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) and Confusion Assessment Method (CAM) criteria)': 3, 'Duration of postoperative delirium (days)': 3, 'Severity of postoperative delirium (measured using the Delirium rating scale-revised-98 (DRSR-98))': 3, 'Gabapentin': 3, 'Joint Replacement': 3, 'Olanzapine': 3, 'Severity of postoperative delirium (measured using DSM-III-R diagnostic criteria)': 3, 'Duration of postoperative delirium (measured using DSM-III-R diagnostic criteria)': 3, 'Postoperative delirium (measured using DSM-III-R diagnostic criteria)': 3, 'Spinal Anaesthesia': 3, 'Sedation': 3, 'Mortality (at 1 year)': 3, 'No available term': 3, 'Epidural Anesthesia': 3, 'postoperative confusion': 3, 'Delirium (measured using the confusion assessment method screening instrument)': 2, 'Colorectal Cancer': 2, 'Heart failure': 2, 'Serum interleukin-6 (IL-6) levels (measured by laboratory test)': 2, 'Pulmonary infection': 2, 'Recovery of bowel movement (measured by the time to pass flatus)': 2, 'Urinary infection': 2, 'Length of postoperative hospital stay (days)': 2})
CD012485 Counter({'Surgery': 4, 'Length of postoperative hospital stay (days)': 4, 'Hip Fracture': 2, 'Delirium (measured using the Confusion Assessment Method (CAM))': 2, 'Delirium Symptom Interview (DSI)': 2, 'Mini-Mental State Examination (MMSE) score': 2, 'Memorial Delirium Assessment Scale (MDAS)': 2, 'Cancer': 2, 'Elective Surgery': 2, 'Old-age': 2, 'Postoperative delirium (measure not specified)': 2, 'Mortality': 2, 'Care dependency (measure not specified)': 2, 'Return to an independent preoperative living situation': 2, 'Quality of life (measure not specified)': 2, 'Severity of postoperative delirium (measure not specified)': 2, 'Length of hospital stay (days)': 2, 'Postoperative complications (not specified)': 2, 'Additional care at home': 2, 'Hospitalization': 2, 'Fracture Of Neck Of Femur': 2, 'Nutritional complications': 2, 'Postoperative delirium (measured using DSM-IV diagnostic criteria)': 2, 'Number of days of postoperative delirium (measured using DSM-IV diagnostic criteria)': 2, 'Sleeping problems': 2, 'Urinary tract infections': 2, 'Decubitus ulcers': 2, 'Falls': 2})
CD009374 Counter({'No available term': 3, 'Lecithin': 3, 'Glucose': 3, 'Carnitine': 3, 'Memory (measure not specified)': 3, 'Mood (measure not specified)': 3, 'Ability to sustain attention (measure not specified)': 3, 'Reaction time (measure not specified)': 3})
CD009699 Counter({'Hip Fracture': 2, 'Surgery': 2, 'Presence or absence of delirium (defined according to the Confusion Assessment Method (CAM))': 2, 'Severity of delirium (measured using the Memorial Delirium Assessment Scale (MDAS))': 2})
CD008307 Counter({'Surgery': 3, 'Old-age': 3, 'Pregabalin': 3, 'Agitation (measured using the Richmond Agitation Sedation score)': 3, 'Postoperative pain (measured by telephone interview)': 3, 'Postoperative confusion (measured using Confusion Assessment Method for the intesnive care unit (CAM-ICU) instrument)': 3, 'Cumulative consumption of parenteral oxycodone during 16 h after extubation': 3, 'Total oxycodone consumption from extubation to the end of the fifth postoperative day': 3, 'Time to extubation (minutes)': 3, 'Pain intensity (measured using the Verbal Rating Scale (VRS))': 3, 'Mini-Mental State Examination (MMSE) score': 3})
CD003946 Counter({'Light Therapy': 18, 'Dementia': 9, "Dementia Due To Alzheimer's Disease": 9, 'Vascular Dementia': 6, 'Living In Residential Institution': 3, 'Agitation': 3, 'Behavioral Pathology in Alzheimer Disease scale (Behave-AD)': 3, 'Nocturnal sleep duration (hours)': 3, 'Cornell Scale for Depression in Dementia': 3, 'Nighttime activity (measured by continuous rest activity (R-A) monitoring, using an actigraph)': 3, 'Nighttime activity as a percentage of total activity (measured by continuous rest activity (R-A) monitoring, using an actigraph)': 3, 'Sleep quality (measure not specified)': 3, 'Agitation (measure not specified)': 3, 'Cognitive function (measured using Mini-Mental State Examination (MMSE) score)': 3, 'Body temperature rhythm (minutes, measure not specified)': 3, "Dementia In Alzheimer's Disease": 3, 'Agitation (measured using caregiver ratings)': 3, 'Agitation (measured using research staff observation and ratings)': 3, 'Timing of the acrophase of the agitation rhythm': 3, 'Melatonin': 3, 'Day:night sleep ratio (measured using actigraphy)': 3, 'Rest-activity parameters (measured using actigraphy)': 3, 'Nighttime sleep variables (measured using actigraphy)': 3, 'Duration of day activity (measured using actigraphy)': 3, 'Duration of day sleep time (measured using actigraphy)': 3})
CD006211 Counter({'Frail Elderly': 3, 'Elderly': 3, 'Co-morbid Conditions': 3, 'Assessment Using Assessment Scale': 3, 'Comprehensive Consultation': 3, 'instrumental activities of daily living (IADL)': 3, 'nutrition assessment (MNA)': 3, 'Tinetti gait scale (TGS)': 3, 'arsons insomnia scale (AIS)': 3, 'activities of daily living (ADL)': 3, 'mini-mental state examination (MMSE)': 3, 'Tinetti balance scale (TBS)': 3, 'Hamilton anxiety (HAMA)': 3, 'self-rating depression scale (SDS)': 3, 'Hospitalization': 2, 'Cognitive Impairment': 2, 'Old-age': 2, 'Use of anticholinergic drugs': 2, 'Discontinuation order for Foley catheterization': 2, 'Geriatric consult order': 2, 'Use of physical restraints': 2})
CD011283 Counter({'Surgery': 2, 'Old-age': 2, 'Volatile anaesthetics delivery': 2, 'Propofol delivery': 2, 'Postoperative delirium (measured using Confusion Assessment Method criteria)': 2})
CD004034 Counter({'Hypertensive': 3, 'Antihypertensives': 3, 'Candesartan': 3, 'blood pressure': 3, 'EuroQoL Health Utility Index (EuroQoL)': 3, 'Psychological General Well-being (PGWB) Index': 3, 'Subjective Symptoms Assessment Profile (SSA-P)': 3})
CD001499 Counter({"Dementia Due To Alzheimer's Disease": 21, 'Physostigmine': 21, 'Clinical Global Impression of Change (CGIC)': 6, 'selective reminding task': 3, 'Family members reported improvement': 3, 'nonmemory tasks': 3, 'memory': 3, 'verbal memory': 3, 'Liver function (measure not specified)': 3, 'Cognitive function (measured using the Alzheimer Disease Assessment Scale, Cognitive subscale (ADAS-cog) score)': 3, 'Vomiting': 3, 'Nausea': 3, 'Anorexia': 3, 'Activities of daily living (measures not specified)': 3, 'Diarrhea': 3, 'Mini-Mental State Examination (MMSE) score': 3, "Clinician's Interview-Based Impression of Change-Plus with caregiver input (CIBIC+)": 3, 'gastrointestinal side effects including nausea, vomiting, diarrhea, anorexia, dyspepsia, and abdominal pain': 3, 'Geriatric Evaluation by Relatives Rating Instrument': 3, 'cardiac rhythm disturbance': 3, 'liver function abnormalities': 3, 'dropout rate': 3, 'Agitation': 3, 'Instrumental Activities of Daily Living Scale': 3, "Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog)": 3, 'Recognition memory (measured using a recognition memory task)': 3, 'Psychomotor performance (measure not specified)': 3, 'Electrical activity of the brain (measured using Electroencephalography (EEG))': 3, 'Regional cerebral blood flow (measure not specified)': 3, 'Cognitive function (measure not specified)': 3, 'Physostigmine Oral Tablet': 3, 'Memory': 3, 'Communication (measure not specified)': 3, 'Cardiac side effects': 3, 'Memory complaint (measure not specified)': 3, 'Other systemic adverse effects (unspecified)': 3, 'Transdermal Patch': 3, 'efficacy': 3, 'safety': 3, 'Plasma cholinesterase activity': 3, 'well tolerated': 3})
CD004989 Counter({'Dementia': 3, 'Living In Nursing Home': 3, 'Music Therapy': 3, 'Verbally agitated behaviours (measured using the Cohen-Mansfield Agitation Inventory)': 3, 'Physically aggressive behaviours (measured using the Cohen-Mansfield Agitation Inventory)': 3, 'Physically nonaggressive behaviours (measured using the Cohen-Mansfield Agitation Inventory)': 3, 'Agitation (measured using the Cohen-Mansfield Agitation Inventory)': 3})
CD008276 Counter({'Hypertensive': 3, 'Perindopril': 3, 'Indapamide': 3, 'Heart failure': 3, 'Blood pressure': 3, 'Adverse events': 3, 'stroke': 3, 'Death from cardiovascular causes': 3})
CD009221 Counter({'Traumatic Brain Injury': 8, 'Modafinil': 3, 'fatigue': 3, 'Cognitive Deficit In Attention': 3, 'Atomoxetine': 3, 'Neurobehavioural Functioning Inventory (NFI)': 3, 'Computerized Cognitive Assessment System': 3, 'Stroop Color and Word Test': 3, 'cognitive Drug Research (CDR)': 3, 'Adult ADHD Self-Report Scale (ASRS-v1.1)': 3, 'Stroke': 2, 'attenuated appetite': 2, 'nausea': 2, 'mental stamina': 2, 'attention': 2, 'Adverse reactions': 2, 'processing speed': 2})
CD011745 Counter({'Systolic Hypertension': 3, 'Enalapril': 3, 'Hydrochlorothiazide': 3, 'systolic &amp;amp; diastolic blood pressures': 3})
CD008634 Counter({'Dementia': 6, 'Depression': 6, 'Living In Nursing Home': 3, 'Education': 3, 'Reduction in antipsychotic dose by 50% or more': 3, 'Withdrawal from antipsychotics': 3, 'Change in days of antipsychotic use per 100 days of nursing home residence (days)': 3, 'Psychotic Disorder': 3, 'Prescription': 3, 'psychotropic prescribing': 3, 'Behavioural And Psychiatric Symptoms Of Dementia': 3, 'Living In Residential Institution': 3, 'Socialization Enhancement': 3, 'Validation Therapy': 3, 'Physical restraint': 3, 'Psychotropic medication': 3, 'Aggression': 3})
CD001120 Counter({'Reminiscence Therapy': 18, 'Dementia': 14, 'Depression': 7, 'Cognition': 6, "Dementia Due To Alzheimer's Disease": 6, 'quality of life': 5, 'behavioral functioning': 3, 'Vascular Dementia': 3, 'Improvement in cognitive function and behavioral activities (measure(s) not specified)': 3, 'Cognitive Rehabilitation Therapy': 3, 'Cognitive Skills Training': 3, 'Depression (measure not specified)': 3, 'Apathy (measure not specified)': 3, 'Functional disability (measure not specified)': 3, 'Survival without moderately severe to severe dementia (at 2 years)': 3, 'Caregiver burden (measure not specified)': 3, 'Resource utilisation (unspecified)': 3, 'Behavioural disturbance (measure not specified)': 3, 'Quality of life (measure not specified)': 3, 'Cognition (measure not specified)': 3, 'Living In Residential Institution': 3, "Quality of life (measured using the Quality of Life-Alzheimer's Disease instrument, self-report)": 3, 'Psychotherapy - Cognitive': 3, 'Caregiver': 3, 'psychological distress': 3, 'Apathy': 1})
CD002853 Counter({'Propentofylline': 9, 'Vascular Dementia': 3, 'regional cerebral glucose metabolism (rCMRGl)': 3, "Dementia Due To Alzheimer's Disease": 3, 'cerebral metabolic response to a memory task': 3, 'Dementia': 3, 'Gottfries-Brane-Steen': 3, 'mini mental state examination': 3, 'psychometric assessments': 3, 'Cognitive improvement': 3})
CD001011 Counter({'Piracetam': 24, 'Cognitive Impairment': 9, 'Mild Cognitive Impairment': 9, 'Dementia': 6, 'Cognition': 6, "Parkinson's Disease": 3, "Dementia Due To Parkinson's Disease": 3, 'Neurological, psychological, and functional measures': 3, 'Uncomplicated Arteriosclerotic Dementia': 3, 'Senile Dementia': 3, "Memory (measured using Wechsler's memory test)": 3, 'Clinical improvement in short term memory (measure not specified/ unclear)': 3, 'Clinical improvement in thought (measure not specified/ unclear)': 3, 'Psychological condition (measured using a Q scale)': 3, 'Clinical improvement in motor hypoactivity (measure not specified/ unclear)': 3, 'Clinical improvement in fatigue (measure not specified/ unclear)': 3, 'Share of synchronous slow activity (measured using Electroencephalogram (EEG))': 3, 'No available term': 3, 'perception in real driving conditions': 3, 'orientation in real driving conditions': 3, 'Pentoxifylline': 3, 'Psycho-intellectual performance (measure not specified)': 3, 'Elderly': 3, 'RBC choline levels': 3, 'Moderate Cognitive Impairment': 3, 'Behavioral-personality changes': 3, 'Memory functions': 3, 'Attention': 3, 'Alcohol-induced Organic Mental Disorder': 3, 'Cognitive function': 3})
CD009125 Counter({'Dementia': 8, "Dementia Due To Alzheimer's Disease": 6, 'Agitation': 6, 'Cognitive - Behavior Therapy': 3, 'cost': 3, 'behavioural disturbance': 3, 'depression': 3, 'quality of life': 3, 'anxiety': 3, 'cognition': 3, 'mood': 3, 'Counseling': 3, "Montgomery-Asberg Depression Rating Scale and the Sadness and Apathy subscales of the Alzheimer's Disease and Related Disorders Mood Scale": 3, 'Cognition: Mini-Mental State Examination': 3, 'Interpersonal Psychotherapy': 3, 'Psychodynamic-interpersonal Psychotherapy': 3, 'Carer ability to cope': 3, 'activities of daily living': 3, 'carer stress': 3, 'cognitive function': 3, 'global measure of change': 3, 'Behavioural And Psychiatric Symptoms Of Dementia': 3, 'Living In Residential Institution': 3, 'Psychosocial Care': 3, 'Antipsychotic Drug Therapy': 3, 'proportion of residents taking neuroleptics': 3, 'disruptive behaviour': 3, '': 2, 'Cognition': 2})
CD005993 Counter({'Elderly': 3, 'Old-age': 3, 'Hematoporphyrin / Procaine Oral Capsule': 3, 'Consolidation of new learning (measure not specified)': 3, 'Incontinence': 3, 'Grip strength (measure not specified)': 3, 'Adverse reactions (unspecified)': 3})
CD001191 Counter({"Dementia Due To Alzheimer's Disease": 11, 'Rivastigmine': 11, 'Cognition: ADAS-cog': 6, 'Dementia': 3, "Clinicians' Interview-Based Impression of Change-Plus (CIBIC-Plus)": 3, 'BEHAVE-AD': 3, 'adverse events (AEs)': 3, 'Cognition: MMSE': 3, 'Progressive Deterioration Scale (PDS)': 3, 'Mini-Mental State Examination (MMSE)': 3, 'Gastrointestinal adverse events': 3, 'Clinician Interview Based Impression of Change incorporating caregiver information (CIBIC-Plus)': 3, 'Withdrawal due to adverse events': 3, 'Progressive Deterioration Scale': 3, 'Global Deterioration Scale': 3, "Alzheimer's Disease Assessment Scale, Cognitive subscale (ADAS-cog) score": 3, 'Transdermal Patch': 2})
CD009095 Counter({'No available term': 2, 'discontinuation of long-acting benzodiazepines': 2, 'Depression': 2, 'Cognition': 2})
CD010509 Counter({'Chronic Obstructive Pulmonary Disease': 20, 'Aclidinium Bromide': 9, 'Tiotropium': 9, 'Aclidinium': 6, 'Formoterol And Aclidinium Bromide': 6, 'Moderate Chronic Obstructive Pulmonary Disease': 3, 'Severe Chronic Obstructive Pulmonary Disease': 3, 'Dyspnea - Focal score (measured using the Transition Dyspnea Index (TDI))': 3, 'Dyspnea (measured using the Transition Dyspnea Index (TDI))': 3, 'Lung function: morning trough forced expiratory volume in 1 s (FEV(1))': 3, 'Lung function - Morning trough forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, "Health status (measured using the St. George's Respiratory Questionnaire (SGRQ))": 3, 'other lung function outcomes': 3, 'Anticholinergic-related adverse events': 3, 'safety: Anticholinergic-related adverse events (e.g., dry mouth)': 3, "health status [measured by the St. George's Respiratory Questionnaire (SGRQ)]": 3, 'dyspnea [measured using the Transition Dyspnea Index (TDI)]': 3, 'FEV1 AUC': 3, 'Relief medication use': 3, 'symptoms': 3, 'COPD symptoms (measured using the EXACT-Respiratory Symptoms (E-RS) questionnaire)': 3, 'COPD symptoms (measured using the COPD additional symptoms questionnaire)': 3, 'Use of relief medication - relief medication-free days (days)': 3, 'change from baseline in forced expiratory volume in 1 second': 3, 'Trough (pre-dose) forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Post-dose forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Serious adverse event(s) (unspecified)': 3, 'Nasopharyngitis': 3, 'Cough': 3, 'Treatment-emergent adverse events - Nasopharyngitis': 3, 'Brochodilation - Trough forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Any treatment-emergent adverse event(s)': 3, 'Brochodilation - Post-dose forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Treatment-emergent adverse events - Back pain': 3, 'Exercise tolerance (exercise endurance time, measure not specified)': 2, 'Stopping exercise due to breathing discomfort': 2, 'IC/total lung capacity (IC/TLC)': 2, 'Safety outcomes (unspecified)': 2, 'Inspiratory capacity (IC)': 2, 'Trough forced expiratory volume in one second (FEV1) (measured using spirometry)': 2, 'Locus of symptom limitation (measure(s) not specified)': 2, 'Exertional dyspnea (measured using the Borg Dyspnea Scale score)': 2, 'Functional residual capacity (FRC)': 2})
CD005580 Counter({'Elderly': 3, 'Schizophrenia': 3, 'Psychiatric Disorders': 3, 'Piracetam': 3, 'Behavioural scales': 3, 'Cognition: Wechsler Adult Intelligence and Memory scales': 3, 'Cognition: IQ': 3})
CD004396 Counter({'Stress': 4, 'Depression': 2, 'Quality of life': 2, 'Sleep quality': 2, 'Physical health': 2, 'Worry': 2})
CD011802 Counter({'Asthma': 6, 'Budesonide': 6, 'Salbutamol': 3, 'Formoterol': 3, 'Terbutaline': 3, 'Reliever medication usage (unspecified)': 3, 'Odds of achieving a well-controlled asthma week (WCAW) (measure not specified)': 3, 'Asthma exacerbation': 3, '': 3, 'Airway responsiveness': 3, 'bronchodilator requirements': 3, 'symptoms': 3, 'spirometry': 3})
CD003564 Counter({'Asthma': 10, 'Exercise Induced Bronchospasm': 9, 'Albuterol Metered Dose Inhaler': 6, 'Albuterol Inhalant Solution': 6, 'Bronchospasm': 6, 'Albuterol Inhalant Powder': 3, 'physical examination': 3, 'laboratory tests': 3, 'change in FEV1': 3, 'Pulmonary function - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'electrocardiogram and rhythm strips': 3, 'vital signs,': 3, 'Prevention of exercise-induced bronchospasm (assessed using Forced expiratory volume in one second (FEV1) and % of patients protected by treatment)': 3, 'pulmonary auscultation': 3, 'clinical adverse events': 3, 'postexercise change in FEV1': 3, 'Drug-related adverse events': 3, 'postexercise minimum FEV1': 3, 'exercise-induced bronchospasm': 3, 'Metered Dose Inhaler': 3, 'Albuterol Inhalant Solution [ventolin Hfa]': 3, 'Unspecified': 3, 'Maximum percentage fall in serial forced expiratory volume in 1 second (FEV1) during 60 minutes after exercise (measured using serial spirometry)': 3, 'Cromolyn Nasal Inhaler': 3, 'prophylaxis for exercise-induced bronchospasm': 3, 'Forced expiratory volume in one second (FEV1)  (measured using spirometry)': 3, 'Rimiterol': 3, 'Exercise-induced asthma (measure not specified)': 3, 'Lung function - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Cromoglycate': 2, 'Reproterol': 2, 'Spirometry, heart rate and blood pressure, and ECG': 2})
CD001186 Counter({'Immunological Therapy': 9, 'Asthma': 8, 'Allergic Asthma': 6, 'Cat Hair Extract': 3, 'Systemic reaction(s) (unspecified)': 3, 'Methacholine provocative concentration causing a 20% fall in forced expiratory volume in one second (FEV1) (PC20) (measured using a methacholine challenge test)': 3, 'Cat extract in vitro leukocyte histamine release (LHR) (measured by laboratory test)': 3, 'Serum immunoglobulin E (IgE) antibodies to cat extract level (measured by laboratory test)': 3, 'Serum immunoglobulin G (IgG) antibodies to cat extract level (measured by laboratory test)': 3, 'Cat albumin level (measured by laboratory test)': 3, 'Cat extract producing a 20% fall in FEV1 (PD20) (measured using a cat hair and dander extract bronchoprovocation test)': 3, 'Cat extract required for end point reaction in intradermal skin test end point titration (STEPT)': 3, 'Seasonal Asthma': 3, 'Grass Pollen': 3, 'HRF production': 3, 'Perennial Allergic Rhinitis': 3, 'Respiratory parameters': 3, 'Immunological parameters': 3, 'Childhood Asthma': 3, 'Hyposensitization To Allergens': 3, 'number of days on which oral corticosteroids were used': 3, 'Partial or complete remission of asthma': 3, 'daily medication score': 3, 'decrease in the forced expiratory volume in one second': 3, 'Rhinitis': 3, 'Allergic Contact Dermatitis Caused By Latex': 3, 'Conjunctival provocation tests': 3, 'symptom and medication scores recorded on diary cards': 3, 'Allergy To Pollen': 2, '': 2, 'Immunologic agent': 2, 'Allergy To Tree Pollen': 1})
CD001287 Counter({'Acetylcysteine': 21, 'Chronic Obstructive Pulmonary Disease': 18, 'Chronic Bronchitis': 12, 'Ambroxol': 6, 'exacerbations': 6, 'Acute Exacerbation Of Chronic Bronchitis': 3, 'Bronchitis': 3, 'Exacerbation of chronic bronchitis': 3, 'Number of days lost through illness (days)': 3, 'preventing exacerbations': 3, 'Symptoms - Difficulty in expectoration (measure not specified)': 3, 'Symptoms - Coughing (measure not specified)': 3, 'Clinical signs - Auscultatory signs (measure not specified)': 3, 'days of antibiotic therapy': 3, 'Number of days when antibiotic therapy needed (days)': 3, 'Symptoms - Dyspnea (measure not specified)': 3, 'symptom improvement': 3, 'reduction of exacerbations': 3, 'yearly exacerbation rate': 3, 'exacerbation rate': 3, 'quality of life': 3, 'pulmonary function': 3, 'Letosteine': 3, 'sputum, expectoration, cough, dyspnea': 3, 'VC, FEVsub 1': 3, 'Acute exacerbation(s) of chronic bronchitis': 3, 'Number of days on which patient was incapacitated (days)': 3, 'Days of absenteeism from work (days)': 3, 'Days with exacerbation(s) of chronic bronchitis (days)': 3, 'Exacerbation(s) of chronic bronchitis': 3, 'Days of absenteeism from work caused by exacerbation(s) of chronic bronchitis (days)': 3, 'COPD Exacerbation': 3, 'Serious adverse event(s)': 3, 'Any adverse event(s)': 3, 'COPD exacerbation(s)': 3, 'glutathione': 3, 'airway geometry, inflammation and oxidative stress': 3, 'Inhaled Bronchodilator Therapy': 3, 'cough': 3, 'expectoration': 3, 'ease of breathing': 3})
CD002168 Counter({'Hospitalization': 3, 'COPD Exacerbation': 3, 'Acute Exacerbation Of Chronic Obstructive Airways Disease': 3, 'Chronic Obstructive Pulmonary Disease': 3, 'Aminophylline': 3, 'Side effects of treatment - Tremor': 3, 'Arterial blood gases - Partial pressure of oxygen (PO2) (kPa)': 3, 'Side effects of treatment - Palpitations': 3, 'forced expiratory volume': 3, 'Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'side effects': 3, 'Arterial blood gases - Partial pressure of carbon dioxide (PCO2) (kPa)': 3, 'forced vital capacity': 3, 'Forced vital capacity (FVC) (measured using spirometry)': 3, 'Dyspnea (measured using a verbal dyspnea index with a scale of 1 to 10)': 3, 'Arterial blood gas measurements': 3, 'Side effects of treatment - Nausea': 3, 'Side effects of treatment - Vomiting': 3})
CD010844 Counter({'Chronic Obstructive Pulmonary Disease': 121, 'Tiotropium': 36, 'Salmeterol': 30, 'Fluticasone propionate': 24, 'Fluticasone': 21, 'COPD Exacerbation': 19, 'Formoterol': 18, 'Budesonide': 18, 'Salmeterol And Fluticasone': 18, 'COPD exacerbation(s)': 15, 'Forced expiratory volume in one second (FEV1) (measured using spirometry)': 15, 'Indacaterol': 12, 'FEV1': 12, 'exacerbations': 9, 'forced expiratory volume': 9, 'Formoterol And Budesonide': 9, 'COPD exacerbations': 9, 'Dyspnea': 9, 'Adverse events': 6, 'Nasopharyngitis': 6, 'Smoker': 6, 'Lung function - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 6, 'FEV(1)': 6, 'frequency of exacerbations': 6, 'Pneumonia': 6, 'Lung function': 6, 'Death': 6, 'Ipratropium Bromide': 6, 'Quality of life (measure(s) not specified)': 6, 'Trough forced expiratory volume in one second (FEV1)  (measured using spirometry)': 6, 'Health status (measure(s) not specified)': 6, 'Copd': 6, 'spirometry': 6, 'Chronic Obstructive Lung Disease': 6, 'Acute Exacerbation Of Chronic Obstructive Airways Disease': 3, 'Lung function - Pre-dose forced expiratory volume in one second (FEV1)  (measured using spirometry)': 3, 'Time to first COPD exacerbation (days)': 3, 'Lung Density (derived from a pixel-density histogram of the whole lung as the 15th percentile density (PD15))': 3, 'Lung density (LD) (defined as 15th percentile density (PD15), volume-adjusted to predicted total lung capacity; measured using a pixel-density histogram of the whole lung)': 3, 'Relative area of emphysema (at a threshold of -910 Hounsfield units (RA-910), adjusted to predicted total lung capacity; measured using a CT scan)': 3, 'Lung density (derived from the relative area of emphysema at a threshold of -910 Hounsfield units (RA-910))': 3, 'CD8+ cells': 3, 'airway anti-inflammatory effects': 3, 'nighttime awakenings': 3, 'Lung function - Peak (post-dose) forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Quality of Life (measured using the St. George’s Respiratory Questionnaire (SGRQ), Total score)': 3, 'Lung function - Trough (pre-dose) forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'safety measures': 3, 'Use of relief bronchodilator medication': 3, 'Response to treatment (undefined)': 3, 'Nighttime awakening(s)': 3, 'Budesonide / Formoterol Inhalant Solution': 3, "Health status (measured using the St George's Respiratory Questionnaire (SGRQ)": 3, "Dyspnoea (measured using the St George's Respiratory Questionnaire (SGRQ))": 3, 'Pulmonary function - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, "Health status (measured using the St George's Respiratory Questionnaire)": 3, "Dyspnoea (measured using the St George's Respiratory Questionnaire)": 3, 'All cause death': 3, 'Health status': 3, 'Exacerbations of COPD': 3, 'Ex-smoker': 3, 'Vilanterol': 3, 'Vilanterol (GW642444)': 3, 'Vilanterol And Fluticasone Furoate': 3, 'Bone fracture': 3, 'Moderate and severe COPD exacerbations': 3, 'Death from pneumonia': 3, 'Moderate and severe COPD exacerbation(s)': 3, 'Death due to pneumonia': 3, 'Fracture(s)': 3, 'Fatal lower respiratory adverse event': 3, 'Adverse events - Fatal cardiac event': 3, 'Adverse events - Fatal lower respiratory event': 3, 'Premature stopping of trial medication': 3, 'All-cause fatal adverse event': 3, 'Fatal cardiac adverse event': 3, 'Adverse events - Fatal event': 3, 'decline in health status': 3, 'respiratory withdrawals': 3, 'decline in FEV(1)': 3, 'Time to the first severe COPD exacerbation (days)': 3, 'discontinuation of treatment': 3, 'Serious adverse event(s)': 3, 'Severe COPD exacerbation(s)': 3, 'Moderate to severe COPD exacerbation(s)': 3, 'Adverse event': 3, 'Time to the first COPD exacerbation (days)': 3, 'time to first exacerbation': 3, 'Adverse event(s) leading to the discontinuation of treatment': 3, "St. George's respiratory questionnaire total score": 3, 'Beclometasone': 3, 'Dry Powder Inhaler': 3, 'Metered Dose Inhaler': 3, 'COPD exacerbations (number per patient per year)': 3, 'COPD symptoms (measure(s) not specified)': 3, 'Pulmonary function - Pre-dose morning forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Salbutamol': 3, 'Lung function - Forced expiratory volume in one second (FEV1) responsiveness (defined as &gt;or=12% increase over baseline and &gt;or=200 mL in FEV1, measured using spirometry)': 3, 'Lung function - Forced vital capacity (FVC) (measured using spirometry)': 3, 'Lung function - Forced expiratory volume in one second (FEV1) responsiveness (defined as &gt;or=15% increase over baseline in FEV1, measured using spirometry)': 3, 'Lung function - Forced expiratory volume in one second (FEV1) responsiveness (defined as &gt;or=10% absolute increase in % of predicted FEV1, measured using spirometry)': 3, 'Glycopyrronium Bromide': 3, 'Rescue medication use (unspecified)': 3, 'Dyspnoea (measure(s) not specified)': 3, 'Arformoterol': 3, 'Forced expiratory volume in one second (FEV1) - Peak percent change from predose (measured using spirometry)': 3, 'Forced expiratory volume in one second (FEV1) - Average area under the curve AUC (measured using spirometry)': 3, 'Mortality - Respiratory-related': 3, 'Mortality - Other cancer-related': 3, 'Mortality - Cardiac-related': 3, 'Mortality - Other causes': 3, 'Mortality - Lung cancer-related': 3, 'All cause mortality': 3, 'COPD exacerbation(s) (measured using daily record cards)': 3, 'pneumonia': 3, 'Pneumonia (measured using daily record cards)': 3, 'exacerbations  of COPD': 3, 'EQ 5D': 3, 'holter monitoring': 3, 'electrocardiography': 3, 'Health related QoL': 3, 'Chronic Bronchitis': 3, 'Emphysema': 3, 'Sputum myeloperoxidase concentration (measure not specified)': 3, 'Sputum albumin concentration (measure not specified)': 3, 'Neutrophil elastase inhibitory capacity of the sputum sol phase (measure not specified)': 3, 'Chemotactic activity of the sputum sol phase (measure not specified)': 3, 'Peripheral neutrophil functions (measure(s) not specified)': 3, 'FEV(1)/FVC': 3, 'bronchial hyperresponsiveness': 3, 'maximal expiratory flows at 50% and 25% FVC': 3, 'indices of inflammation': 3, 'Forced expiratory volume': 3, 'CD8+': 3, 'Symptoms': 3, 'CD8:CD4 ratio': 3, 'neutrophils': 3, 'CD68+ cells': 3, 'CD4+ cells': 3, 'Beta 2-agonist use (inhalations/ day)': 3, 'Asthma symptoms (measured using a self-report diary)': 3, 'COPD symptoms (measured using a diary card)': 3, 'Any adverse event(s)': 3, 'Dyspnea (measure(s) not specified)': 3, 'Lung function (measure(s) not specified)': 3, 'Asthma': 3, 'forced vital capacity': 3, 'puffs of prn salbutamol': 3, 'forced expiratory volume in 1 s': 3, "St George's respiratory questionnaire SGRQ": 3, 'FVC': 3, 'adverse events': 3, 'Corticosteroids': 3, 'Inflammatory biomarkers': 3, 'pulmonary function and quality of life': 3, 'Moderate Chronic Obstructive Pulmonary Disease': 3, 'Severe Chronic Obstructive Pulmonary Disease': 3, 'biopsy CD4+ cells': 3, 'biopsy CD68+': 3, 'IFN-gamma': 3, 'sputum total eosinophils': 3, 'sputum neutrophils': 3, 'biopsy CD8+': 3, 'cells expressing genes for tumor necrosis factor-alpha': 3, 'biopsy CD45+ cells': 3, 'forced expiratory volume in 1 s (FEV(1))': 3, 'Forced Vital capacity (FVC)': 3, 'd': 3, 'Nebulizer Therapy': 3, 'Safety, CVAEs, serum potassium, vital signs and physical': 3, 'hyperresponsiveness': 3, 'QoL': 3, 'CD3+, CD4+ and CD8+ counts': 3, '% intact epithelium': 3, 'Mast cell,  neutrophil, macrophage and lymphocyte counts': 3, '': 3, "Assessment Using Saint George's Respiratory Questionnaire": 3, 'Prednisolone': 3, 'peak expiratory flow': 3, 'bone mineral density (BMD)': 3, 'tidal volume': 3, 'postdose FRC': 3, 'inspiratory capacity': 3, 'minute ventilation': 3, 'exercise endurance time': 3, 'likelihood of having at least 1 exacerbation': 3, 'hospitalization days': 3, 'the number of antibiotic days': 3, 'hospitalizations for exacerbations': 3, 'unscheduled clinic visits': 3, 'forced expiratory volume in 1 second': 3, 'reduction of at least 4 units in the SGRQ total score': 3, 'reduced exacerbations': 3, 'risks of exacerbations and hospitalizations': 3, 'smaller pre-bronchodilator and post-bronchodilator FEV(1)': 3, 'more severe COPD': 3, 'Premature discontinuation': 3, 'worse SGRQ scores': 3, 'Aclidinium Bromide': 3, 'plasma glucose levels': 3, 'health status (St. George Respiratory Questionnaire )': 3, 'ECG findings (corrected QT interval)': 3, 'serum potassium': 3, 'trough (24 h postdose) FEV(1)': 3, 'Inhalation Therapy Procedure': 3, 'lung function, 6 minute walk distance, scores of clinical symptoms and times of exacerbation': 3, 'Budesonide Inhalant Powder': 3, 'Peak expiratory flow rate (PEFR)': 3, 'Citric acid cough threshold': 3, 'Spirometry': 3, 'PC20 histamine': 3})
CD010346 Counter({'Asthma': 3, 'Yoga': 3, 'Day time symptoms (measure not specified)': 3, 'Pulmonary functions - Eosinophils level': 3, 'Pulmonary functions - Monocytes level': 3, 'Asthma Quality of Life (AQOL), Emotional function subdomain score': 3, 'Rescue medication use (inhalation therapy)': 3, 'Pulmonary functions - Super oxide dismutase level': 3, 'Asthma Quality of Life (AQOL), Overall score': 3, 'Pulmonary functions - haemoglobin level': 3, 'Asthma Quality of Life (AQOL), Activity limitation subdomain score': 3, 'Asthma symptom score (measure not specified)': 3, 'Pulmonary functions - total lung capacity (TLC)': 3, 'Mild Asthma': 3, 'Exerciser': 3, '': 3})
CD006429 Counter({'Chronic Obstructive Pulmonary Disease': 20, 'Oxygen': 18, 'Dyspnoea': 6, 'COPD Exacerbation': 6, 'Oxygen Therapy': 6, 'breathlessness': 5, 'Oxygen Tension': 3, 'Distance walked in 6 minutes (measured using the 6-minute walk test (6MWT))': 3, 'distance walked': 3, 'dysnpnea': 3, 'Degree of dyspnea during exercise (measured using a questionnaire that had eight descriptors of dyspnea sensations)': 3, 'Degree of dyspnea during exercise (measured using a visual analog scale (VAS))': 3, 'dyspnea': 3, 'Dyspnea On Exertion': 3, 'Intranasal Oxygen Therapy': 3, 'Medical Air': 3, 'Health-related quality of life (measure(s) not specified)': 3, 'Forced expiratory volume in one second (FEV1)  (measured using spirometry)': 3, 'Functional status (measure(s) not specified)': 3, 'Health-related quality of life (measure not specified)': 3, 'Depression (measure(s) not specified)': 3, 'Mood disturbance (measure not specified)': 3, 'Arterial oxygen partial pressure (PaO2)': 3, 'Cylinder utilisation (measure not specified)': 3, 'Dyspnoea (measure(s) not specified)': 3, 'Cylinder utilisation': 3, 'Functional status  (measure not specified)': 3, 'Time of ascent of stairs (seconds)': 3, 'Desaturation (measure not specified)': 3, 'Maximal dyspnoea (measured using a 100mm visual analogue scale (VAS))': 3, 'Airways Obstruction': 3, 'Hypoxemia': 3, 'Peak inspiratory gastric (Pga) pressure (measure not specified)': 3, 'Peak inspiratory pleural (Ppl) pressure (measure not specified)': 3, 'Gastric (Pga) contraction (measure not specified)': 3, 'Exercise endurance (seconds, measure(s) not specified)': 3, 'Peak expiratory gastric (Pga) pressure (measure not specified)': 3, 'Pleural (Ppl) contraction (measure not specified)': 3, 'Transdiaphragmatic pressure (Pdi) (measure not specified)': 3, 'Maximal transdiaphragmatic pressure (Pdi) (measure not specified)': 3, 'No available term': 3, 'ventilatory response to exercise,  maximal ventilation, PaCO2': 3, 'exercise tolerance': 3, 'Questionaire, anxiety, depression and SF36': 3, 'Salbutamol And Ipratropium Bromide': 3, 'Endurance time': 3, 'Inspiratory Capacity': 3, 'Oxygen saturation': 3, 'Dyspnoea Score': 3, '6 Minute Walk Test': 3, 'Resting SpO2': 3, 'Active SpO2': 3, 'Ambulatory Oxygen Therapy': 3, 'distance': 3, 'Helium': 3, 'walking distance, oxygen saturation, dyspnea': 3, 'Chronic Obstructive Lung Disease': 2, 'exterional dyspnoea': 2, '': 2, 'notanswered': 1})
CD000052 Counter({'Asthma': 15, 'Nebulizer (physical Object)': 6, 'Spacer (physical Object)': 6, 'Emergency Care': 6, 'Salbutamol': 6, 'Fenoterol': 3, 'Nebulizer Therapy': 3, 'Peak expiratory flow (PEF) (measured using spirometry)': 3, 'Bronchiodilation - Peak expiratory flow (PEF) (measured using spirometry)': 3, 'Exacerbation Of Asthma': 3, 'Metered Dose Inhaler': 3, 'Bronchodilation - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Days of absenteeism from school (days, children)': 3, 'Days of absenteeism from work (days, parents)': 3, 'Total cost of treatment (per patient, children, currency and price year not reported)': 3, 'Salbutamol use': 3, 'Costs of treatment - Costs of new emergency room visit(s) (per patient, children, currency and price year not reported)': 3, 'Costs of treatment - Inhaler device cost (per patient, children, currency and price year not reported)': 3, 'Costs of treatment - Sterilisation process costs (per patient, children, currency and price year not reported)': 3, 'Costs of treatment - Labour costs (per patient, children, currency and price year not reported)': 3, 'Costs of treatment - Costs of hospitalisation(s) (per patient, children, currency and price year not reported)': 3, 'Costs of treatment - Electricity cost (per patient, children, currency and price year not reported)': 3, 'Days with asthma symptoms (days, children)': 3, 'Costs of treatment - Salbutamol cost (per patient, children, currency and price year not reported)': 3, 'Metaproterenol': 3, 'FVC and FEV1': 3, 'Acute Asthma': 3, 'Albuterol Metered Dose Inhaler': 3, 'Albuterol Inhalant Solution [respirol]': 3, 'Efficiency of delivery': 3, 'Dry Powder Inhaler': 3, 'clinical response, hospitalisation, asthma revisit, corticosteroids, adverse events.': 3})
CD010283 Counter({'Ipratropium Bromide': 15, 'Asthma': 15, 'Fenoterol': 12, 'Wheezing': 6, 'Acute Wheezy Bronchitis': 3, 'bronchial obstruction': 3, 'Diurnal variation in airway calibre (measured using peak expiratory flow rate recorded before salbutamol)': 3, 'Diurnal variation in bronchodilator responsiveness (measured using peak expiratory flow rate recorded after salbutamol)': 3, 'Forced expiratory volume in one second (FEV1)  (measured by spirometry)': 3, 'Histamine provocative concentration causing a 20% drop in FEV1 (PD20) (measured using a bronchial histamine challenge test)': 3, 'Diurnal variation in bronchodilator responsiveness (defined as the increase in peak expiratory flow rate (PEFR) after salbutamol)': 3, 'Diurnal variation in airway calibre (defined as peak expiratory flow rate (PEFR) recorded before salbutamol)': 3, 'Childhood Asthma': 3, 'Ipratropium': 3, 'Salbutamol': 3, 'hospitalization': 3, 'frequency of hospitalization': 3, 'oxygenation': 3, 'lung function': 3, 'Eformoterol': 3, 'Forced expiratory volume in 1 second (FEV1)': 3, 'peak expiratory flow rate': 3, 'Dose-response curves for systemic beta 2 responses': 3, 'Dose-response curves for airways': 3, 'Medication Administration: Oral': 3, 'Aminophylline': 3, 'Fenoterol / Ipratropium Inhalant Solution': 3, 'Anabolic Steroids': 3, 'Nebulizer Therapy': 3, 'Normal Saline': 3, 'Administration Of Steroid': 3, 'Intravenous Infusion': 3, '': 3, 'nebulized bronchodilators': 3, 'Symptom scoring': 3, 'number of days in the hospital': 3, 'Exacerbation Of Asthma': 3, 'Salbutamol And Ipratropium Bromide': 3, 'Asthma clinical score (measure not specified)': 3, 'Peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Airways Obstruction': 3, 'Allergic Asthma': 3, 'Budesonide': 3, 'Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Evening peak expiratory flow (PEF) (measured using spirometry)': 3, 'Methacholine provocative concentration causing a 20% fall in forced expiratory volume in one second (FEV1) (PC20) (measured using a methacholine challenge test)': 3, 'Morning peak expiratory flow (PEF) (measured using spirometry)': 3, 'peak flows and nocturnal asthma': 3, 'Mild Asthma': 3, 'BHR': 3, 'Peak expiration flow': 3, 'FEV1': 3, 'Severe Asthma': 3, 'use of a rescue inhaler': 3, 'asthma symptoms': 3, 'peak expiratory flow rate (PEFR)': 3, 'Asthma With Status Asthmaticus': 3, 'Wheeze': 3, 'Oxygenation': 3, 'Accessory muscle use': 3, 'Air exchange': 3, 'Respiratory rate': 3})
CD009611 Counter({'Asthma': 37, 'Salmeterol': 12, 'Formoterol': 6, 'Budesonide': 6, 'Asthma symptoms (measure(s) not specified)': 6, 'asthma symptoms': 6, 'Supplemental albuterol use': 6, 'Fluticasone': 6, 'Exacerbation Of Asthma': 3, 'Formoterol And Budesonide': 3, 'Budesonide / Formoterol Inhalant Solution': 3, '': 3, 'Lung function': 3, 'Time to first severe asthma exacerbation': 3, 'Lung function (measure(s) not specified)': 3, 'exacerbation': 3, 'Asthma exacerbation(s) - Exacerbations requiring hospitalisation or emergency room treatment': 3, 'Asthma exacerbation(s) - Total exacerbations': 3, 'Nonsmoker': 3, 'Asthma symptoms - Nighttime symptoms (measure not specified)': 3, 'Pulmonary function (measured using unspecified pulmonary function tests)': 3, 'Vital signs': 3, 'Safety - physical examination results (unspecified)': 3, 'Asthma-specific quality of life (measured using the Asthma Quality of Life Questionnaire (AQLQ))': 3, 'Physical examination findings (unspecified)': 3, 'Asthma-related quality of life - specific subdomains (unspecified, measured using the Asthma Quality of Life Questionnaire (AQLQ) subdomain scores)': 3, 'Daily peak expiratory flow (PEF) rate (measured using spirometry)': 3, 'Pulmonary function - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Safety - vital signs (unspecified)': 3, 'Clinical adverse events (unspecified)': 3, 'Asthma symptoms - Daytime symptoms (measure not specified)': 3, 'Nighttime asthma symptoms (measured by patient daily record)': 3, 'Forced expiratory volume in one second (FEV1)  (measured using spirometry)': 3, 'Supplemental albuterol use (measured by patient daily record)': 3, 'Daytime asthma symptoms (measured by patient daily record)': 3, 'Asthma-related quality of life (measured using the Asthma Quality of Life Questionnaire (AQLQ) global score)': 3, 'Peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Asthma symptom-free days (days)': 3, 'Pulmonary function - Forced expiratory volume in one second (FEV1)  (measured using spirometry)': 3, 'asthma control': 3, 'Pulmonary function - Morning peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'pulmonary-function measurements': 3, 'Asthma control (measure not specified)': 3, 'nights without awakenings': 3, 'Nights without awakenings (nights)': 3, 'bronchodilation, as measured by FEV1': 3, 'Pulmonary function - Evening peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Systolic blood pressure': 3, 'Frequency of supraventricular ectopic beats (measured by 24-hr Holter monitoring)': 3, 'Clinical laboratory values (unspecified)': 3, 'Frequency of ventricular ectopic beats (measured by 24-hr Holter monitoring)': 3, 'Asthma exacerbation(s)': 3, 'Pulse rate': 3, 'Diastolic blood pressure': 3, 'Heart rate (measured by 24-hr Holter monitoring)': 3, 'Drug-related adverse events': 3, 'Death': 3, 'Metered Dose Inhaler': 3, 'Trough (pre-dose) forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Any adverse event(s)': 3, 'Evening peak expiratory flow (PEF) (measured using spirometry)': 3, '24-hour urine cortisol excretion (measured by laboratory test)': 3, 'Morning peak expiratory flow (PEF) (measured using spirometry)': 3, 'Fluticasone propionate': 3, 'Pulmonary function - Forced expiratory volume in one second/ Forced vital capacity (FEV1/FVC) (measured using spirometry)': 3, 'Pulmonary function - Peak expiratory flow (PEF) variability (measured using spirometry)': 3, 'Pulmonary function - Morning peak expiratory flow (PEF) (measured using spirometry)': 3, 'Exhaled nitric oxide level (measure not specified)': 3, 'Albuterol use': 3, 'Asthma control (measured using the Asthma Control Questionnaire (ACQ) score)': 3, 'Impedence (measure(s) not specified)': 3, 'Asthma control - Asthma control days (days, not defined)': 3, 'Exercise Induced Bronchospasm': 3, 'Tachyphylaxis': 3, 'Bronchoprotection (measure not specified)': 3, 'Beclometasone': 3, 'serum eosinophil cationic protein. (sECP)': 3, 'safety variables': 3, 'pulmonary function': 3, 'Montelukast': 3, 'Asthma-free days, FEV': 3, 'Long-Acting Beta-Agonists': 3, 'Corticosteroids': 3, 'Bronchial Hyperresponsiveness': 3, 'Asthma Control': 3, 'Albuterol / Beclomethasone Inhalant Solution': 3, 'peak expiratory air flow': 3, 'improvement in FEV1': 3, 'percentage of days with no symptoms': 3, 'percentage of nights with no awakenings': 3, 'improvement in morning peak expiratory flow': 3, 'Adverse events were similar': 3, 'Salmeterol Dry Powder Inhaler': 3, 'Use of emergency prednisolone': 3, 'Admission to hospital': 3, 'Serious asthma exacerbations': 3, 'Moderate Persistent Asthma': 2, 'emergency room visits': 2, 'hospitalisations': 2, 'total inhaled corticosteroid dose': 2, 'airway inflamation: Mean sputum eosinophil cell counts': 2, 'Severe asthma exacerbations': 2, 'asthma medication costs': 2, 'total annual costs per patient': 2, 'reliever medication use': 2})
CD002207 Counter({'Opioid Dependence': 3, 'Buprenorphine': 3, 'Global functioning (measured using the DSM-IV Global Assessment of Functioning (DSM-IV-GAF) scale)': 3, 'Psychosocial adjustment (measured using the Symptom Checklist-90-R (SCL-90-R))': 3, 'psychosocial adjustment and global functioning,': 3, 'Negative for opioid use (assessed by urinalysis)': 3, 'Dropouts from study (reason(s) not specified)': 3})
CD005989 Counter({'Asthma': 15, 'Ginger': 3, 'Forced expiratory flow at 25-75% of the pulmonary volume (FEF25-75) (measured using spirometry)': 3, 'Asthma stage (higher or lower stage)': 3, 'coughing attacks': 3, 'Clinical symptoms - Wheezing': 3, 'Clinical symptoms - Nocturnal cough(s)': 3, 'Clinical symptoms - Dyspnea': 3, 'Clinical symptoms - Dyspneic attack(s)': 3, 'chest tightness relief': 3, 'dyspneic attacks': 3, 'Forced vital capacity (FVC) (measured using spirometry)': 3, 'asthmatic symptoms': 3, 'Dyspnea': 3, 'stage change': 3, 'nocturnal cough': 3, 'spray usage': 3, 'Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Clinical symptoms - Chest tightness': 3, 'Clinical symptoms - Coughing attack(s)': 3, 'Spray usage (unspecified)': 3, 'wheezing relief': 3, 'Chinese Herbal Medicine': 3, 'Peak Expiratory Flow Rate (PEFR)': 3, 'Lung Function': 3, 'Serum Inflammatory Markers': 3, 'Asthma Monitoring Using Asthma Symptom Diary': 3, 'Pulmonary Methacholine Challenge Test': 3, 'Medication Score': 3, 'Atopic Dermatitis': 3, 'Evening Primrose Oil': 3, 'plasma concentrations of essential fatty acids': 3, 'Peak expiratory flow': 3, 'improvements of the eczema symptoms': 3, 'fidget': 3, 'asthma symptoms': 3, 'Allergic Asthma': 2, 'Adenosine monophosphate (AMP) bronchoprovocation': 2, 'Peripheral blood eosinophil count': 2, 'add on therapy herbal remedy': 2, 'Serum eosinophil cationic protein': 2, 'Exhaled nitric oxide': 2, 'Residual bronchial hyperreactivity (assessed six hours after inhaled house dust mite or pollen allergen challenge using a provocation test to acetylcholine)': 2, 'Bronchoconstriction (assessed immediately following inhaled house dust mite or pollen allergen challenge)': 2, 'Any side effect(s)': 2, 'Asthma symptoms (measure(s) not specified)': 2, 'Methacholine provocative concentration causing a 20% fall in forced expiratory volume in one second (FEV1) (PC20) (measured using a methacholine challenge test)': 2, 'Eosinophils count in peripheral blood (measured by laboratory test)': 2, 'Serum eosinophil cationic protein (ECP) level (measured by laboratory test)': 2, 'Sputum eosinophil cationic protein (ECP) level (measured by laboratory test)': 2, 'Sputum eosinophils count (measured by laboratory test)': 2})
CD009019 Counter({'Asthma': 6, 'Formoterol': 6, 'Budesonide': 6, 'Salbutamol': 3, 'Formoterol And Budesonide': 3, 'Overall rate of exacerbations': 3, 'Total costs (mean cost per patient year, 2005 Canadian Dollars (CAN))': 3, 'Cost-effectiveness (planned measure(s) not specified)': 3, 'Total direct medical costs (mean cost per patient year, 2005 Canadian Dollars (CAN))': 3, 'Direct medical costs - Physician and emergency room visits (mean cost per patient year, 2005 Canadian Dollars (CAN))': 3, 'Use of as-needed salbutamol': 3, 'Direct medical costs - Hospitalisations (mean cost per patient year, 2005 Canadian Dollars (CAN))': 3, 'Cost of lost productivity (due to absenteeism) (mean cost per patient year, 2005 Canadian Dollars (CAN))': 3, 'Time to the first severe asthma exacerbation (days)': 3, 'Asthma exacerbation(s)': 3, 'Cost per patient year - societal perspective (measured in Canadian Dollars (CAN), 2005 price year)': 3, 'Time to the first severe exacerbation (metric not specified)': 3, 'Use of as-needed reliever medication (unspecified)': 3, 'Direct medical costs - Asthma drugs (mean cost per patient year, 2005 Canadian Dollars (CAN))': 3, 'Cost per patient year - health care perspective (measured in Canadian Dollars (CAN), 2005 price year)': 3, 'Exacerbation of Asthma': 3, 'Incremental Cost Effectiveness Ratio (ICER) - Cost per Exacerbation of Asthma Avoided (Societal perspective; 2009 Euros (EUR))': 3, 'Total Societal Costs (Per patient; 2009 Euros (EUR))': 3, 'Total Direct Healthcare Costs (Per patient; 2009 Euros (EUR))': 3, 'Cost of Drugs (Per patient; 2009 Euros (EUR))': 3, 'Hospitalization': 3, 'Emergency Department Patient Visit': 3, 'Use of Oral Corticosteroids': 3, 'Incremental Cost Effectiveness Ratio (ICER) - Cost per Exacerbation of Asthma Avoided (Health care system perspective; 2009 Euros (EUR))': 3})
CD003135 Counter({'Asthma': 11, 'Fluticasone': 8, 'Fluticasone propionate': 8, 'parent global evaluation': 3, 'Pulmonary function - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Symptom-free days (days)': 3, 'Pulmonary function - Evening peak expiratory flow (PEF) (measured using spirometry)': 3, 'Symptom scores (measure(s) not specified)': 3, 'Bronchial responsiveness - Provocation dose of methacholine causing a 20% fall in FEV1 (PD20) (measured using spirometry)': 3, 'Pulmonary function - Morning peak expiratory flow (PEF) (measured using spirometry)': 3, 'use of rescue medication': 3, 'pulmonary function tests': 3, 'Parent global evaluation (measure not specified)': 3, 'Use of rescue medication - Beta2-mimetics': 3, 'Wheezing (measure not specified)': 3, 'Wheezing': 3, 'Chronic Obstructive Pulmonary Disease': 3, 'Dry Powder Inhaler': 3, 'perceived side effects': 3, 'Perceived side-effects of fluticasone propionate (FP) (measured using a questionnaire)': 3, 'Compliance with treatment (measured by counts of Rotadisks returned)': 3, 'Rotadisks returned': 3, 'Perceived effectiveness': 3, 'Perceived effectiveness of fluticasone propionate (FP) (measured using a questionnaire)': 3, '': 2, 'Safety': 2})
CD012331 Counter({'Asthma': 9, 'Education': 6, 'No available term': 3, 'Adolescence': 3, 'Asthma Education': 3, 'Smoking Effects Education': 3, 'Smoking-related knowledge and perception (measured using a self-administered questionnaire)': 3, 'Nicotine dependence (measured using a self-administered questionnaire)': 3, 'Smoking-related knowledge and perception (measured using self-administered questionnaire)': 3, 'Asthma control (measured using self-administered questionnaire)': 3, 'Asthma control (measured using a self-administered questionnaire)': 3, 'Nicotine dependence (measured using self-administered questionnaire)': 3, 'Diabetes Mellitus': 3, 'Sickle Cell Anaemia': 3, 'Cystic Fibrosis': 3, 'Family Support': 3, "Children's Depression Inventory": 3, 'Adjustment (measured using the Personal Adjustment and Role Skills Scale III, Adjustment score)': 3, 'Self-Perception Profile for Children': 3, 'Maladjustment (measured using the Personal Adjustment and Role Skills Scale III, Adjustment score)': 3, "Revised Children's Manifest Anxiety Scale": 3, 'Reinforcement Of Adherence To Treatment Regimen': 3, 'Encounter By Short Message Service Text Messaging': 3, 'Referral To Support Group': 3, 'Adherence to inhaled corticosteroids (ICS) (measured by self-report)': 3, 'Adherence to inhaled corticosteroids (ICS) (measured using a Doser CT device)': 3, 'school absenteeism': 3, 'asthma attacks': 3, 'lung function': 3, 'improvement in quality of life': 3})
CD002158 Counter({'Asthma': 31, 'Salbutamol': 18, 'Metered Dose Inhaler': 12, 'Dry Powder Inhaler': 12, 'Heart rate': 9, 'Adverse events (unspecified)': 6, 'Forced expiratory volume in one second (FEV1) (measured using spirometry)': 6, 'Asthma symptom score(s) (measure(s) not specified)': 6, 'Any adverse event(s)': 6, 'Terbutaline': 6, 'Blood pressure': 3, 'Clinical laboratory tests (unspecified)': 3, 'Physical examinations (outcome(s) not specified)': 3, 'Electrocardiograms (outcome(s) not specified)': 3, 'bronchodilation': 3, 'Safety parameters': 3, 'Severe Asthma': 3, 'Salmeterol Inhalant Powder': 3, 'ventilatory function': 3, 'Lung function - Morning peak expiratory flow (PEF) (measured using spirometry)': 3, 'Daily use of inhaled study medication (measured by patient-completed daily record)': 3, 'Lung function - Evening peak expiratory flow (PEF) (measured using spirometry)': 3, 'Trough (pre-dose) forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Evening peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Post-dose forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Trough (pre-dose) forced vital capacity (FVC) (measured using spirometry)': 3, 'Trough (pre-dose) morning peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Post-dose morning peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Use of rescue medication (unspecified)': 3, 'Post-dose forced vital capacity (FVC) (measured using spirometry)': 3, 'Acceptability of device - Ease of use (measured by patient rating)': 3, 'Forced expiratory flow at 25-75% of the pulmonary volume (FEF25-75) (measured using spirometry)': 3, '12-lead electrocardiogram (ECG) parameters (unspecified, measured using electrocardiogram (ECG))': 3, 'Serum potassium level (measured by laboratory test)': 3, 'Heart rate and rhythm (measured using Holter monitor recordings)': 3, 'Diastolic blood pressure': 3, 'Forced vital capacity (FVC) (measured using spirometry)': 3, 'Systolic blood pressure': 3, 'Bronchodilation - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Placebo': 3, 'Bronchodilator response (measure(s) not specified)': 3, 'Any side effects (not specified)': 3, 'Lung function - Forced vital capacity (FVC) (measured using spirometry)': 3, 'Lung function - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Taste sensation': 3, 'Muscle tremor': 3, 'Factitious Asthma': 3, 'Albuterol Inhalant Solution': 3, 'tremors': 3, 'effectiveness': 3, 'patient preference': 3, 'cardiovascular effects': 3, 'pulmonary function, expiratory volume FEV1 and forced vital capacity FVC': 3, 'Peak Expiratory Flow Rate (PEFR)': 3, 'Forced Vital Capacity (FVC)': 3, 'Forced Expiratory Volume in One Second (FEV1)': 3, 'Adverse Event': 3, 'Forced Expiratory Flow at 25-75% of the Pulmonary Volume (FEF25-75)': 3, 'Airways Obstruction Reversible': 3, 'Albuterol Metered Dose Inhaler': 3, 'forced expiratory volume in one second (FEV1)': 3, 'Morning and evening peak expiratory flow (PEF)': 3, 'adverse events': 3, 'use of rescue beta 2-agonist': 3, 'Compliance with study drug': 3, 'daily PEF measurements': 2, 'use of additional bronchodilator': 2, 'change in heart rate': 2, 'paradoxical bronchospasm': 2, 'Symptom scores': 2, 'incidence of adverse events': 2, 'bronchodilating effect': 2, 'pulmonary deposition': 2, 'FEV1': 2})
CD003558 Counter({'Asthma': 6, 'Budesonide': 6, 'Cromoglycate': 3, 'Salbutamol': 3, 'Cromoglycate Nasal Solution': 3, 'efficacy and tolerability': 3, 'Morning peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Evening peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Daytime symptom score (measure(s) not specified)': 3, 'monitoring of adverse effects of both drugs used': 3, 'Nighttime symptom score (measure(s) not specified)': 3, 'Patient’s assessment of medication (measured during clinic visit)': 3, 'Adverse events (unspecified)': 3, 'Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Use of rescue salbutamol': 3, 'Forced vital capacity (FVC) (measured using spirometry)': 3, 'Global opinion of efficacy (measured during clinic visit)': 3, 'Physician’s assessment of medication (measured during clinic visit)': 3, 'asthma symptom scores': 3, 'health care resource use': 3, 'Asthma exacerbation, asthma related health outcomes': 3, 'rescue medication use': 3, 'Moderate Persistent Asthma': 3, 'Mild Persistent Asthma': 3, '': 3, 'Forced expiratory volume in one second (FEV1)': 1, 'symptom-free days and nights': 1, 'Relief medication use': 1, 'Peak Flow measurements': 1, 'Withdrawals due to adverse events': 1})
CD003530 Counter({'Asthma': 12, 'Steroid Prophylaxis': 3, '': 3, 'symptom free days': 3, 'symptom scores': 3, 'lung function tests': 3, 'additional use of salbutamol': 3, 'Beclomethasone Inhalant Solution': 3, 'Budesonide': 3, 'Beclomethasone Nasal Inhaler': 3, 'Morning peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Evening peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'eosinophilia counts': 3, 'Forced expiratory volume in one second (FEV1)  (measured using spirometry)': 3, 'FEV1': 3, 'Other adverse effects (unspecified)': 3, 'Peak flow measurements': 3, 'Candida': 3, 'Administration(s) of concomitant anti-asthmatic therapy (number)': 3, 'Plasma cortisol': 3, 'White blood cell counts': 3, 'Plasma cortisol (measure(s) not specified)': 3, 'White blood cell (WBC) count (measured by laboratory test)': 3, 'Blood eosinophil count (measured by laboratory test)': 3, 'Blood differential count (measured by blood differential test)': 3, 'adverse effects': 3, 'Budesonide Dry Powder Inhaler': 3, 'Lung function': 3, 'Airway responsiveness': 3, 'Patient preference': 3, 'Beclometasone': 3, 'Asthma symptoms - Cough (measured by patient-reported measure)': 3, 'Asthma symptoms - Dyspnea at rest (measured by patient-reported measure)': 3, 'Use of prednisone (measure not specified)': 3, 'Asthma symptoms - Thoracic noises (measured by patient-reported measure)': 3, 'Asthma symptoms - Exercise-induced dyspnea (measured by patient-reported measure)': 3, 'Use of rescue salbutamol (number of inhalations/day)': 3, 'Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Bronchial reactivity - Methacholine provocative concentration causing a 20% fall in FEV1 (PC20) (measured using methacholine challenge test)': 3, 'Sputum eosinophil count (measured by laboratory test)': 3, 'Asthma symptoms - Expectoration (measured by patient-reported measure)': 3})
CD002310 Counter({'Asthma': 12, 'Fluticasone': 9, 'Fluticasone propionate': 3, 'oral corticosteroid sparing': 3, 'Acute asthma exacerbation(s)': 3, 'Hypothalamic-pituitary-adrenal (HPA) axis suppression (assessed by morning serum cortisol excretion)': 3, 'Hypothalamic-pituitary-adrenal (HPA) axis suppression (assessed by 12-h nocturnal urinary cortisol excretion)': 3, 'Metered Dose Inhaler': 3, 'Any adverse event(s)': 3, "Physician rating of treatment - 'Very effective' (measured by physician rating)": 3, 'Evening peak expiratory flow (PEF) (measured using spirometry)': 3, 'Asthma symptom-free days (% of days)': 3, 'Treatment-related adverse event(s)': 3, 'Morning peak expiratory flow (PEF) (measured using spirometry)': 3, 'Peak Expiratory Flow Rate (PEFR)': 3, 'Forced Vital Capacity (FVC)': 3, 'Serology Test': 3, 'Forced Expiratory Volume in One Second (FEV1)': 3, 'Adverse Event': 3})
CD003269 Counter({'Asthma': 6, 'Chronic Bronchitis': 3, 'Bronchitis': 3, 'Ipratropium Bromide': 3, 'Salbutamol': 3, 'Morning peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Week-to-week variation in peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'lung function': 3, 'Exacerbation(s)': 3, 'Bronchial hyperresponsiveness (measured using a bronchial challenge test)': 3, 'Respiratory symptoms (measure(s) not specified)': 3, 'exacerbation rate': 3, 'reported health': 3, 'peak flow rate': 3, 'Diurnal variation in peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'bronchial hyper-responsiveness': 3, 'Patient-reported health (measure(s) not specified)': 3, 'Lung function (measure not specified)': 3, 'respiratory symptoms': 3, 'Atropine': 3, '': 3})
CD001115 Counter({'Asthma': 9, 'Emergency Care': 6, 'Albuterol Inhalant Solution': 6, 'Non-smoker': 3, 'Prednisolone': 3, 'Nebulizer (physical Object)': 3, 'Electrocardiograms': 3, 'Spirometric values (unspecified, measured using spirometry)': 3, 'Vital signs (unspecified)': 3, 'Spirometry': 3, 'vital signs': 3, 'Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'continuous cardiac monitoring': 3, 'Acute Asthma': 3, 'Salbutamol': 3, 'Hemodynamic Test': 3, 'Forced Expiratory Volume in One Second (FEV1)': 3, 'Vital Signs Finding': 3, 'Hand Tremor': 3, 'Drug Tolerance': 3, '': 3, 'Respiration therapy time': 3})
CD002178 Counter({'Acute Asthma': 3, 'Asthma': 3, 'Hydrocortisone Injectable Solution [a-hydrocort]': 3, 'Isoproterenol': 3, 'Hydrocortisone': 3, 'plethysmography': 3, 'plethysmography, spirometry, lung volumes, subjective complaints and physical findings': 3, 'clinical variables': 3, 'Lung volume (measure not specified)': 3, 'Subjective complaints (measure not specified)': 3, 'physical findings': 3, 'spirometry': 3})
CD010673 Counter({'Anxiety': 3, 'Chronic Obstructive Pulmonary Disease': 3, 'Depression': 3, 'Group Cognitive Behavioural Therapy': 3, '6-minute walk distance (metres, measured using the six-minute walk test (6MWT))': 3, 'Generic quality of life (measured using the Medical Outcomes Survey Short Form-36 (SF-36))': 3, 'Walk distance (measured using the 6-minute walk test (6MWT))': 3, 'Use of health services (unspecified, measure not specified)': 3, 'Use of health services (unspecified)': 3, 'depressive symptoms [Beck Depression Inventory-II (BDI-II)': 3, 'Health-related quality of life (measured using the 36-Item Short Form Health Survey questionnaire (SF-36))': 3, 'anxiety [Beck Anxiety Inventory (BAI)': 3, 'Depressive symptoms (measured using the Beck Depression Inventory-II (BDI-II))': 3, 'Anxiety (measured using the Beck Anxiety Inventory (BAI))': 3, 'Disease-specific quality of life (measured using the Chronic Respiratory Questionnaire (CRQ))': 3})
CD006480 Counter({'Atopic Disorders': 3, 'Dietary Regime': 3, 'serum IgE level': 3, 'atopic disease': 3, 'atopic dermatitis': 3, 'lung function': 3, 'food or aeroallergen sensitization': 3, 'milk sensitization': 3, 'reduction in food allergy': 3, 'allergic rhinitis': 3, 'presence of nasal eosinophils or nasal basophilic cells': 3, 'asthma': 3, 'Atopy': 3, 'Recommendation To Avoid Behavior': 3, 'Serum immunoglobulin G (IgG) beta-lactoglobulin (BLG) level (measured by laboratory test)': 3, 'Allergic rhinitis': 3, 'Asthma': 3, 'Serum immunoglobulin F (IgF) level (measured by laboratory test)': 3, 'Serum immunoglobulin G (IgG) ovalbumen/ ovomucoid (OVA) level (measured by laboratory test)': 3, 'Food sensitisation (measure not specified)': 3, 'Positive inhalant skin test': 3, 'Food allergy (measure not specified)': 3, 'Childhood': 3, 'Environmental Intervention': 3, 'Lung Function': 3, 'Allergen Sensitivity (Skin Tests)': 3, 'Specific Airway Resistance (sRaw)': 3, 'Maximal Flow at Functional Residual Capacity': 3, 'IgE': 3, 'development of asthma and atopy': 1})
CD003902 Counter({'Theophylline': 15, 'Chronic Bronchitis': 6, 'Abnormal Breathing': 3, 'Salbutamol': 3, 'clinical symptoms of dyspnea': 3, 'emotional function': 3, 'distance patients could walk in 6 min': 3, 'peak flow rates': 3, 'fatigue': 3, 'spirometry': 3, 'Chronic bronchitis symptoms (unspecified)': 3, 'Serum concentration of theophylline (measured by laboratory test)': 3, 'Symptoms': 3, 'Forced expiratory volume in 1 second': 3, 'Pulmonary function - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Forced vital capacity': 3, 'Side-effects (unspecified)': 3, 'Pulmonary function measurements': 3, 'Pulmonary function - Forced vital capacity (FVC) (measured using spirometry)': 3, 'Withdrawal from study due to side effects (unspecified)': 3, 'Peak expiratory flow rate': 3, 'Pulmonary function - Peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Airways Obstruction': 3, 'Cardiac ectopy (measured using Holter monitor recordings)': 3, 'Serum theophylline concentration (measured by laboratory test)': 3, 'Symptoms (measure(s) not specified)': 3, 'Any drug side effect(s)': 3, 'Withdrawal from study due to increasing symptom severity': 3, 'Use of metered-dose inhalers': 3, 'Peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Circadian variation in peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Chronic Obstructive Airway Disease With Asthma': 3, 'Dyspnea (measure not specified)': 3, 'Lung function - Forced vital capacity (FVC) (measured using spirometry)': 3, 'Exercise performance (measured using a visual analogue scale (VAS)': 3, 'Exercise performance - 6-minute walk distance (metres, measured using the six-minute walk test (6MWT))': 3, 'Lung function - Peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Trapped gas volume (derived from static lung volumes using helium dilution and body plethysmography)': 3, 'Any side effect(s)': 3, 'Lung function - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Lung function - Slow vital capacity (SVC) (measured using spirometry)': 3, 'Chronic Obstructive Pulmonary Disease': 3, 'Frequency of adverse events': 3, 'Pre-bronchodilator FEV1': 3, 'Frequency of clinical visits': 3, 'Satisfaction with treatment': 3, 'notanswered': 1})
CD009437 Counter({'Chronic Obstructive Pulmonary Disease': 15, 'Pulmonary Rehabilitation': 12, 'Hospitalization': 3, 'COPD Exacerbation': 3, 'dyspnoea': 3, 'exercise capacity index': 3, 'Any adverse effect(s)': 3, 'Hospital readmission (at 3 months)': 3, 'Cumulative length of hospital stay for COPD-related readmissions (days)': 3, 'BMI': 3, 'Airflow obstruction (measure(s) not specified)': 3, 'airflow obstruction': 3, 'readmission days': 3, 'Dyspnoea (measure(s) not specified)': 3, 'adverse effects': 3, 'Exercise capacity (measured using an exercise capacity index)': 3, 'Body mass index (BMI)': 3, 'Physiotherapy Of Chest': 3, 'Lung function - Inspiratory vital capacity (IVC) (measured using spirometry)': 3, 'Lung function - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Exercise tolerance - 6-minute walk distance (metres, measured using the six-minute walk test (6MWT))': 3, 'Quality of life (measured using the Chronic Respiratory Questionnaire (CRQ))': 3, 'Well-being (measure(s) not specified)': 3, 'Arterial oxygen saturation during exercise (measure(s) not specified)': 3, 'Dyspnea during exercise (measured using the Borg Dyspnea Scale score during a cycle ergometer test)': 3, 'Exercise performance (measured using a cycle ergometer test)': 3, 'Heart rate during exercise': 3, 'Leg effort during exercise (measured using the Borg Leg Effort Scale score during a cycle ergometer test)': 3, 'Exercise performance - 4-minute walk distance (metres, measured using a four-minute walking test (4MWT))': 3, 'Lung function during exercise (measure(s) not specified)': 3, 'Assessment Using Chronic Respiratory Disease Questionnaire': 3, 'Assessment Using Millon Behavior Health Inventory (MBHI)': 3, 'Walking Distance Test': 3, 'Assessment Using Revised Symptom Checklist (SCL-90-R)': 3, 'Asthma': 3, 'Exercises': 3, 'Patient Education': 3, 'Relaxation Training Therapy': 3, 'Recreational Therapy': 3, 'Breathing Exercises': 3, 'cycle ergometer tests and 6 min walking tests': 3, 'Chronic Respiratory Disease Questionnaire': 3})
CD003271 Counter({'Asthma': 9, 'Budesonide': 6, 'Allergic Asthma': 3, 'bronchial hyperreactivity': 3, 'methacholine provocation': 3, 'forced expiratory volume in one second (FEV1)': 3, 'Beclomethasone Inhalant Solution': 3, 'Subjective score for sputum production (measure not specified)': 3, 'Any adverse event(s)': 3, 'Need for concomitant beta 2-agonist therapy': 3, 'Plasma cortisol levels': 3, 'Subjective score for cough (measure not specified)': 3, 'Airway functions (measure(s) not specified)': 3, 'Subjective score for dyspnoea (measure not specified)': 3, 'Budesonide Inhalant Powder': 3, 'Inhaled bronchodilator use': 3, 'Number of asthma exacerbations': 3, 'Asthma severity': 3, 'Methacholine challenge': 3})
CD004109 Counter({'Asthma': 18, 'Budesonide': 9, 'Fluticasone propionate': 8, 'Fluticasone': 3, 'Standardized dry air treadmill exercise testing': 3, 'Exercise-induced bronchoconstriction (EIB) (defined as &amp;gt;/=20% fall from baseline in forced expiratory volume in one second (FEV1), measured using spirometry during standardized dry air treadmill exercise testing)': 3, 'Provocation dose of methacholine causing a 20% decline in forced expiratory volume in one second (FEV1) (PD(20)) (measured using a methacholine challenge test using a dosimetric technique)': 3, 'methacholine challenge using a dosimetric technique': 3, 'Exercise induced bronchoconstriction': 3, 'Beclometasone': 3, 'Pulmonary function - Morning peak expiratory flow (PEF) (measured using spirometry)': 3, 'Pulmonary function - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Asthma symptoms (measure(s) not specified)': 3, 'Low Dose': 3, 'High Dose': 3, 'Lung function - Histamine provocative concentration causing a 20% drop in FEV1 (PC20) (measured using a bronchial histamine challenge test)': 3, 'Lung function - Forced expiratory volume in one second (FEV1) (% of predicted, measured using spirometry)': 3, 'Serum eosinophil protein x/eosinophil derived neurotoxin (EPX/EDN) (measured by laboratory test)': 3, 'Serum neutrophil myeloperoxidase (MPO) (measured by laboratory test)': 3, 'Serum eosinophil cationic protein (ECP) level (measured by laboratory test)': 3, 'Serum neutrophil lactoferrin (LF) (measured by laboratory test)': 3, 'use of rescue albuterol': 3, 'night awakenings': 3, 'pulmonary function': 3, 'Symptom control': 3, 'Asthma Finding': 3, 'Length of Hospital Stay (Days)': 3, 'Lost Productivity (Days)': 3, 'Costs of Lost Productivity (Per patient; Japanese Yen (JPY), Price Year Not Reported)': 3, 'Emergency Department Patient Visit': 3, 'Total Direct Healthcare Costs (Per patient; Japanese Yen (JPY), Price Year Not Reported)': 3, 'drug-related adverse events': 2, 'FEV(1)': 2, 'morning peak expiratory flow': 2, 'albuterol use': 2, 'asthma symptom scores': 2, 'withdrawal due to lack of efficacy': 2})
CD007524 Counter({'Asthma': 12, 'High Dose': 9, 'Fluticasone': 9, 'Corticosteroids': 6, 'Exacerbation Of Asthma': 6, 'Started oral prednisolone (at 12 months)': 3, 'number of individuals starting oral prednisolone': 3, 'Forced expiratory volume in one second (FEV1)  (measured using spirometry)': 3, 'Hospitalisation(s)': 3, 'Budesonide': 3, 'Treatment failure -  Unscheduled physician visit': 3, 'Treatment failure - Asthma not returning to baseline severity': 3, 'Treatment failure - Any cause': 3, 'Treatment failure - Requirement for systemic steroids': 3, 'Dyspnea': 3, 'Acute Exacerbation Of Chronic Obstructive Airways Disease': 3, 'Emergency Care': 3, 'Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Discharged from hospital (at 2 weeks)': 3, 'Peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Relapse - Return to emergency department with exacerbation (at 2 weeks)': 3, 'Side-effects - Mood changes': 3, 'Treatment failure (not defined)': 3, 'Peak expiratory flow (PEF) (measured using spirometry)': 3, 'Side-effects - Sleep disturbance': 3, 'Side-effects - Changes in appetite': 3, 'Acute Asthma': 3, 'Peak Expiratory Flow Rate': 3})
CD010942 Counter({'Intensive Care': 3, 'Sedation': 3, 'Critical Illness': 3, 'Mechanical Ventilation': 3, 'Physical Rehabilitation Therapy Procedure': 3, 'Occupational Therapy': 3, 'Mobilizing Exercises': 3, 'ability to walk independently': 3, 'ventilator-free days': 3, 'six activities of daily living and the ability to walk independently': 3, 'serious adverse event': 3, 'Discontinuation of therapy': 3, 'duration of delirium': 3, 'ventilator-free days during the first 28 days of hospital stay': 3, 'activities of daily living': 3, 'Return to independent functional status': 3})
CD005305 Counter({'Chronic Disease Of Respiratory System': 3, 'Pulmonary Rehabilitation': 3, 'Endurance shuttle walk test distance (metres, measured using an endurance shuttle walk test (ESWT))': 3, 'quadriceps muscle strength (QMVC)': 3, 'endurance shuttle walk test (ESWT)': 3, 'incremental shuttle walk test (ISWT)': 3, 'Quadriceps maximal voluntary contraction (QMVC)': 3, 'Incremental shuttle walk test distance (metres, measured using an incremental shuttle walk test (ISWT))': 3, 'COPD Exacerbation': 3, 'Chronic Obstructive Pulmonary Disease': 3, 'Home Exercise Program': 3, 'Dyspnea level (measure not specified)': 3, 'Exercise capacity (measured by distance walked in a shuttle walk test)': 3, 'Isometric muscle strength - knee extensor muscle (measure not specified)': 3, 'COPD exacerbations': 3, 'Exercise capacity (measured using a three minute step test)': 3, 'Quality of life (measure not specified)': 3})
CD001936 Counter({'Immunological Therapy': 15, 'Allergy To Tree Pollen': 6, '': 6, 'Allergy To Wall Pellitory Pollen': 6, 'Parietaria Officinalis Extract': 6, 'Asthma': 6, 'Rhinitis': 6, 'Allergy To Grass Pollen': 6, 'Allergic Reaction To Pollen': 3, 'use of rescue medication': 3, 'Clinical symptom score from the upper airway (measure not specified)': 3, 'Clinical symptom score from the lower airway (measure not specified)': 3, 'No available term': 3, 'Pollen Extracts': 3, 'Allergic rhinitis symptoms - Nasal block (measured using diary symptom scores)': 3, 'Allergic rhinitis symptoms - Rhinorrhoea (measured using diary symptom scores)': 3, 'Skin reactions - Systemic reaction (measure unclear)': 3, 'Allergic rhinitis symptoms - Sneezing (measured using diary symptom scores)': 3, 'Skin reactions - Local reaction (measure unclear)': 3, 'Diary symptom scores': 3, 'Nasal provocation test (outcome unclear)': 3, 'Skin reactivity': 3, 'Skin reactivity - Skin test suppression (measure unclear)': 3, 'Visual analogue scores': 3, 'Allergic Rhinoconjunctivitis': 3, 'Subcutaneous Immunotherapy': 3, 'Serum grass pollen allergen-specific Immunoglobulin G1 (IgG1)  antibody concentration (measured by laboratory test)': 3, 'Allergen tolerance (measured using a conjunctival provocation test)': 3, 'Serum grass pollen allergen-specific Immunoglobulin G4 (IgG4)  antibody concentration (measured by laboratory test)': 3, 'Combined symptom and medication score': 3, 'Quality of life (measured using an unspecified standardised questionnaire)': 3, 'Allergic Rhinitis': 3, 'Mild systemic reaction (unspecified)': 3, 'Rhinitis severity (measured using an unspecified scale)': 3, 'Immediate cutaneous response (measure not specified)': 3, 'Asthma severity (measured using an unspecified scale)': 3, 'Clinical efficacy (based on asthma symptoms and medication scores, measure(s) not specified)': 3, 'Asthma medication score (measure not specified)': 3, 'Quality of life (measure(s) not specified)': 3, 'Healthy days (% of days without asthma symptoms or medication)': 3, "Clinical efficacy (based on patient's self-evaluation)": 3, 'Clinical efficacy (based on blinded clinical evaluation by physician)': 3, 'Late-phase/ delayed cutaneous response (measure not specified)': 3, 'Asthma symptom score (measure not specified)': 3, 'Allergy': 3, 'Specific Immunoglobulins': 3, 'allergic symptoms': 3, 'Conjunctivitis': 3, 'Allergic Asthma': 3, 'Allergic Reaction': 3, 'Efficacy (unspecified)': 3, 'Specific cutaneous reactivity': 3, 'Tolerance to allergen': 3, 'Nasal inspiratory peak flow': 3, 'Nasal inflammation': 3, 'Symptom recording': 3, 'Phleum Pratense Top Extract': 3, 'symptom': 3, 'Hypersensitivity': 3, 'Allergen Extracts': 3, 'Ocular allergy symptoms': 3, 'Bronchial asthma': 3, 'Specific IgE antibodies': 3, 'Medication intake': 3, 'Nasal allergy symptoms': 3})
CD009764 Counter({'Chronic Obstructive Pulmonary Disease': 9, 'COPD exacerbations': 6, 'Erythromycin': 3, 'Total cells in the sputum (measured by laboratory test)': 3, 'Neutrophil elastase in sputum supernatant (measured by laboratory test)': 3, 'Neutrophil number in sputum (measured by laboratory test)': 3, 'Time to first COPD exacerbation (days)': 3, 'COPD Exacerbation': 3, 'Trimethoprim': 3, 'Respiratory functions (unspecified)': 3, 'Haematological parameters (unspecified)': 3, 'Blood counts of folate levels (measured by laboratory test)': 3, 'Blood counts of folate levels (measured using laboratory test)': 3, 'COPD exacerbation(s)': 3, 'Azithromycin': 3, 'Hearing decrements': 3, 'median time to the first exacerbation': 3, "St. George's Respiratory Questionnaire": 3, 'hazard ratio': 3, 'frequency of exacerbations': 3})
CD001106 Counter({'Obstructive Sleep Apnea Syndrome': 24, 'Continuous Positive Airway Pressure Ventilation Treatment': 24, 'Stroke': 6, 'Sleep Apnea': 6, 'Profile of Mood States (POMS), Fatigue subscale score': 3, 'Profile of Mood States (POMS), Total score': 3, 'Profile of Mood States (POMS), Tension subscale score': 3, 'Profile of Mood States (POMS), Confusion subscale score': 3, 'Hypertensive': 3, 'Diastolic blood pressure': 3, 'Systolic blood pressure': 3, 'reduction in the frequency of prehypertension': 3, 'reduction in the frequency of masked hypertension': 3, 'Sleepiness (measured using the Epworth Sleepiness Scale (ESS) score)': 3, 'Fatigue (measured using the Profile of Mood States-Short Form (POMS), Fatigue subscale)': 3, 'Vigor (measured using the Profile of Mood States-Short Form (POMS), Vigor subscale)': 3, 'Fatigue/vigor (measured using the Multidimensional Fatigue Symptom Inventory-Short Form (MSFI-SF))': 3, 'Home Continuous Positive Airway Pressure Unit': 3, 'Apnoea hypopnoea index': 3, 'Visceral abdominal fat': 3, 'Total fat': 3, 'Liver fat': 3, 'Insulin sensitivity': 3, 'Blood adiponectin': 3, 'Disposition index': 3, 'Blood leptin': 3, 'Radiofrequency Ablation Device': 3, 'Daytime sleepiness (measure not specified)': 3, 'Reaction times - Median reaction time (measure not specified)': 3, 'Sleep disordered breathing-specific quality of life (measured using the Symptoms of Nocturnal Obstruction and Related Events (SNORE25) instrument)': 3, 'Reaction times - Fastest reaction time (measure not specified)': 3, 'Obstructive sleep apnoea-specific quality of life (measured using the Functional Outcomes of Sleep Questionnaire (FOSQ))': 3, 'Reaction times - Slowest reaction time (measure not specified)': 3, 'Nighttime systolic blood pressure': 3, 'Daytime mean arterial blood pressure': 3, 'Daytime diastolic blood pressure': 3, 'Nighttime mean arterial blood pressure': 3, 'Nighttime diastolic blood pressure': 3, 'Blood oxygen saturation (measure not specified)': 3, 'Daytime systolic blood pressure': 3, 'Obstructive Sleep Apnea Of Adult': 3, 'Continuous Positive Airway Pressure Titration': 3, '6-minute walk test distance': 3, 'Functional Independence measure': 3, 'neurocognitive function': 3, 'Beck depression inventory': 3, 'Stanford Sleepiness scale': 3, 'Epworth Sleepiness scale': 3, 'digit or spatial span-backward': 3, 'sustained attention response test': 3, 'Canadian Neurological scale': 3, 'Chedoke McMaster Stroke assessment': 3, 'Chronic Heart Failure': 3, 'daytime sleepiness and other not specified': 3, 'plasma neurohormonal markers': 3, 'peak VO(2),changes in left ventricular ejection fraction': 3, 'Health-Related Quality of Life (36-Item Short Form Health Survey (SF-36))': 3, 'Cardiovascular Event-Free Survival': 3, 'Time to Event - Cardiovascular Event (Months)': 3, 'Neurological Status (Canadian Neurological Scale)': 3, 'Death - Cardiovascular': 3, 'Activities Of Daily Living Assessment': 3, 'Digit Span Test Forward and Backward': 3, 'Geriatric Depression Scale': 3, 'Complex Figure Recall': 3, 'SteerClear': 3, 'Epworth Sleepiness Scale': 3, 'Controlled Oral Word Association': 3, 'Digit Symbol': 3, 'Trail Making A and B': 3, 'Functional Outcomes of Sleep Questionnaire': 3, 'Epworth Sleepiness Score': 3, 'blood pressure': 3})
CD003274 Counter({'Budesonide': 27, 'Asthma': 24, 'Wheezing': 3, 'Number of episodes': 3, 'daily total symptom score': 3, 'Salmeterol And Budesonide': 3, 'Salbutamol': 3, 'Allergen PC15': 3, 'Methacholine airway responsiveness (methacholine PC20)': 3, 'Methacholine dose shift': 3, 'Corticosteroids': 3, 'Salmeterol': 3, 'Asthma symptoms (measure(s) not specified)': 3, 'Airway calibre - Forced expiratory volume in one second (FEV1) before bronchodilation (measured using spirometry)': 3, 'Withdrawals': 3, 'Airway calibre - Peak expiratory flow (PEF) before bronchodilation (measured using spirometry)': 3, 'Airway calibre - Forced expiratory volume in one second (FEV1) after bronchodilation (measured using spirometry)': 3, 'Relapse (/remission) during treatment': 3, 'Airway responsiveness - PD20 histamine': 3, 'Airway calibre - Peak expiratory flow (PEF) after bronchodilation (measured using spirometry)': 3, 'Asthma control - Morning peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Withdrawal from study for reasons unrelated to budesonide treatment': 3, 'Asthma control - Evening peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Supplementary bronchodilator use (measured by patient-report using a daily diary)': 3, 'Asthma symptoms (measured by patient-report using a daily diary)': 3, 'Withdrawal from study due to acute asthma attacks requiring treatment with systemic steroids': 3, 'Functional residual capacity of the lungs (measured using the helium dilution technique)': 3, 'Bronchodilator responsiveness (measure(s) not specified)': 3, 'Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Exhaled nitric oxide (parts per billion)': 3, 'Airway responsiveness to methacholine (measure not specified)': 3, 'the carboxy-terminal propeptide of type I procollagen and the carboxy terminal pyridinoline cross-linked telopeptide of type I procollagen (ICTP)': 3, 'insulin-like growth factor-binding protein-3': 3, 'the urinary concentrations of the type I collagen degradation products pyridinoline (PYD) and deoxypyridinoline (DPD) cross-links': 3, 'lower leg growth velocity': 3, 'the serum marker of type III collagen formation': 3, 'the amino-terminal propeptide of type III procollagen (PIIINP)': 3, 'Serum markers of type I collagen formation and degradation': 3, 'Serum levels of insulin-like growth factor-I': 3, 'time to relapse': 3, 'Mild Asthma': 3, 'maximal response plateau of the dose-response curve to inhaled methacholine': 3, 'forced expiratory flow': 3, 'expression of HLA-DR antigens on infammatory cells': 3, 'activated eosinophils': 3, 'morning peak expiratory flow rate (PEFR)': 3, 'numbers of mast cells': 3})
CD009585 Counter({'Montelukast': 17, 'Asthma': 15, 'Salmeterol': 6, 'Fluticasone propionate': 6, 'Exercise Induced Bronchospasm': 3, 'Budesonide': 3, 'Formoterol And Budesonide': 3, 'Exercise-induced bronchoconstriction (defined as maximum percent fall in forced expiratory volume in one second (FEV1), measured after a standardised exercise challenge test)': 3, 'Exercise-induced bronchoconstriction (defined as area under the curve for forced expiratory volume in one second (FEV1), measured during a standardised exercise challenge test)': 3, 'Pulmonary Function Studies Abnormal': 3, 'Placebo': 3, 'Fluticasone': 3, 'Overnight asthma symptoms (measured using patient diary cards)': 3, 'Healthcare utilisation (unspecified)': 3, 'Lung function - Morning peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Quality of life (measured using an unspecified asthma-specific quality-of life questionnaire)': 3, 'Asthma attacks (measured using patient diary cards)': 3, 'Eosinophil levels (measure not specified)': 3, 'House Dust Mite Allergy': 3, 'Formoterol': 3, 'Triamcinolone': 3, 'Asthma symptoms (measure not specified)': 3, 'Eosinophils count in peripheral blood (measured by laboratory test)': 3, 'Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Serum interleukin 10 (IL-10) level (measured by laboratory test)': 3, 'Eosinophil cationic protein (ECP) level (measured by laboratory test)': 3, 'Histamine provocative concentration causing a 20% drop in FEV1 (PD20) (measured using a bronchial histamine challenge test)': 3, 'Usual Care': 3, 'Respiratory-related mortality': 3, 'Asthma-related mortality': 3, 'Combined respiratory-related death or life-threatening experience(s)': 3, 'Combined asthma-related death or life-threatening experience(s)': 3, 'Mild Persistent Asthma': 3, 'Beclomethasone Inhalant Solution [becotide]': 3, 'percentage of days with beta-agonist use': 3, 'used oral corticosteroid rescue': 3, 'Linear growth rates': 3, 'imbalance in bone marker levels': 3, 'Adverse event profiles': 3, 'forced expiratory volume in 1 second': 3, 'chest tightness, wheeze, and overall symptom scores': 3, 'morning peak expiratory flow': 3, 'shortness of breath symptom score': 3, 'Asthma exacerbation rates': 3, 'evening peak expiratory flow': 3, 'percentage of days with no albuterol use': 3, 'Moderate Persistent Asthma': 3, 'Childhood Asthma': 3, 'exhaled nitric oxide': 3, 'Evening (PM) asthma score': 3, 'Post-bronchodilator forced expiratory volume in 1 sec': 3, 'Acute exacerbations': 2, 'Lung function (FEV1)': 2, 'Lung function (Peak flow)': 2, 'Quality of sleep': 2, 'Asthma specific Quality of LIfe': 2, 'Eosinophil count': 2})
CD006322 Counter({'Idiopathic Pulmonary Fibrosis': 3, 'Pulmonary Rehabilitation': 3, 'cardiopulmonary exercise test': 3, 'Pulmonary function': 3, 'dyspnea': 3, 'Six minute walking test (6MWT)': 3, 'QOL': 3})
CD008290 Counter({'Chronic Obstructive Pulmonary Disease': 6, 'Cardiovascular Exercises In Water': 3, 'Pulmonary Rehabilitation': 3, 'dyspnoea': 3, 'QoL': 3, 'Six minute walking test (6-MWT)': 3, 'emotional function': 3, "patients' feeling of control over the disease": 3, 'exercise capacity': 3, 'depression': 3, 'anxiety': 3, 'pulmonary function': 3, 'Group Exercise Program': 3, 'Physical Exercises': 3, 'Workload during cycle (measured using a cycle ergometer test)': 3, 'Health-related quality of life - Overall (measured using the St. Georges Respiratory Questionnaire (SGRQ), Total score)': 3, 'Distance walked in shuttle walking test (measured using the Incremental Shuttle Walk Test (ISWT)': 3, 'Time cycled (measured using a cycle ergometer test)': 3, 'Health-related quality of life - Physical health (measured using the 36-Item Short Form Health Survey (SF-36), Physical health subdomain score)': 3, 'Health-related quality of life - Activity (measured using the St. Georges Respiratory Questionnaire (SGRQ), Activity subdomain score)': 3, 'Distance walked in shuttle walking test (measured using the Endurance Shuttle Walk Test (ESWT))': 3, 'Health-related quality of life - Overall (measured using the 36-Item Short Form Health Survey (SF-36), Total score)': 3})
CD008328 Counter({'Chronic Obstructive Pulmonary Disease': 6, 'Hospitalization': 3, 'COPD Exacerbation': 3, 'Postural Drainage Therapy': 3, 'Physiotherapy Of Chest': 3, 'length of hospitalization': 3, 'Dyspnea (measured using the Borg Dyspnea Scale score)': 3, 'sputum volume': 3, 'quality of life': 3, 'Sputum volume': 3, 'COPD exacerbation(s)': 3, 'dyspnoea (Borg score)': 3, 'Length of hospital stay (days)': 3, 'Quality of life (measured using the St George Respiratory Questionnaire (SGRQ))': 3, 'incidence of COPD exacerbations': 3, 'Chronic Bronchitis': 3, 'Positive Expiratory Pressure Mask Physiotherapy': 3, 'Breathing Exercises': 3, 'Deep Breathing And Coughing Exercises': 3, 'Tracheobronchial clearance (measured using a radio-aerosol technique)': 3, 'Sputum production (measured by laboratory test)': 3, 'Hypercapnic Respiratory Failure': 3, 'Active Cycle Of Breathing Technique': 3, 'time requiring non-invasive ventilation': 3, 'acute physiology score': 3, 'length stay in intensive care unit': 3, 'arterial blood gas values': 3, 'Tracheobronchitis': 3, 'Physiotherapy Manipulation': 3, 'dyspnoea': 3, 'Controls of lung function': 3, 'cough': 3, 'acceptance of the physiotherapy': 3, 'sputum': 3, 'Severe Chronic Obstructive Pulmonary Disease': 1})
CD002994 Counter({'Pulmonary Arterial Hypertension': 5, 'Beraprost': 3, 'change in exercise capacity assessed by the 6-min walk test': 3, 'chances in cardiopulmonary hemodynamics': 3, 'changes in Borg dyspnea index': 3, 'Chances in NYHA functional class': 3, 'Dyspnea (measured using the Borg Dyspnea Index)': 3, 'New York Heart Association (NYHA) functional class': 3, 'Cardiopulmonary hemodynamics (unspecified)': 3, 'Drug-related adverse events': 3, 'Exercise capacity (measured using the 6-minute walk test (6MWT))': 3, 'Lung Disease Due To Connective Tissue Disorder': 2, '': 2})
CD007891 Counter({'Chronic Obstructive Pulmonary Disease': 6, 'Tiotropium': 6, 'Drug Combinations or Combinations of Drugs': 3, 'Fluticasone propionate': 3, 'Salmeterol': 3, 'Pulmonary function': 3, 'Airway dimensions': 3, 'Salmeterol And Fluticasone': 3, 'Pulmonary function - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Pulmonary function - Forced vital capacity (FVC) (measured using spirometry)': 3, 'Airway dimensions - Airway wall area corrected for body surface area (WA/BSA) (measured using a validated CT technique)': 3, 'Airway dimensions - Airway wall thickness (T) (measured using a validated CT technique)': 3, 'Airway dimensions - Luminal area (Ai)/BSA at the right apical segmental bronchus (measured using a validated CT technique)': 3, "Quality of life - Overall (measured using the St George's Respiratory Questionnaire (SGRQ) total score)": 3, 'Airway dimensions - Percentage wall area (WA%) (measured using a validated CT technique)': 3, 'Pulmonary function - Ratio of residual volume (RV) to total lung capacity (TLC) (RV/TLC)': 3})
CD000313 Counter({'COPD Exacerbation': 3, 'Chronic Obstructive Pulmonary Disease': 3, 'Discharge Planning': 3, 'COPD hospitalisations': 3})
CD009878 Counter({'Asthma': 12, 'Fluticasone propionate': 6, 'Wheezing': 3, 'Low Dose': 3, 'Fluticasone': 3, 'number of wheezing episodes': 3, 'Height standard deviation score': 3, 'Days of albuterol use (days)': 3, 'serum levels of cortisol (SC)': 3, 'Wheezing episode(s)': 3, 'height': 3, 'days on albuterol': 3, 'bone alkaline phosphatase fraction (AKP)': 3, 'insulin-like growth factor-binding protein 3 (IGFBP-3)': 3, 'Insulin-like growth factor-binding protein 3 (IGFBP-3) level': 3, 'osteocalcin (OC)': 3, 'Bone alkaline phosphatase fraction (AKP)': 3, 'Osteocalcin (OC) (also known as bone γ-carboxyglutamic acid protein (BGP)) level': 3, 'Serum levels of cortisol (measured by laboratory test)': 3, 'Budesonide': 3, 'serum concentrations of PIIINP': 3, 'synthesis of type III collagen': 3, 'Ciclesonide': 3, 'Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Daily albuterol use': 3, 'Asthma symptoms score(s) (measure(s) not specified)': 3, 'Hypothalamic-pituitary-adrenal (HPA) axis function (measure not specified)': 3, 'bone mineral density, HPA axis function and eyes': 3, 'Fluticasone, Combinations': 3, 'Salmeterol': 3, 'Peak expiratory flow (PEF) and exacerbations': 3})
CD008250 Counter({'Chronic Obstructive Pulmonary Disease': 15, 'Respiratory Muscle Function Training': 9, 'Severe Chronic Obstructive Pulmonary Disease': 6, 'Exercises': 6, 'Medical research council scale': 3, 'Six-minute walking distance (measured using the 6-minute walk test (6MWT))': 3, 'Maximal inspiratory pressure (measured using spirometry)': 3, 'Maximal expiratory pressure (measured using spirometry)': 3, 'Medical Research Council scale grade (outcome not specified)': 3, 'quality of life': 3, 'Quality of life (measure not specified)': 3, '6-minute walking distance': 3, 'maximal expiratory pressure': 3, 'activities of daily living': 3, 'Activities of daily living (measure not specified)': 3, 'maximal inspiratory pressure': 3, 'Breathing Exercises': 3, 'Pulmonary function test(s) (measure(s) not specified)': 3, "St George's Respiratory Questionnaire (SGRQ) total score": 3, 'Forced vital capacity (FVC) (measured using spirometry)': 3, 'Spirometry, ABG, 6MWT was done and SGRQ': 3, '6-Minute Walk Test (6MWT)': 3, 'Peak expiratory flow (PEF) (measured using spirometry)': 3, 'Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Arterial blood gas (ABT) (measure not specified)': 3, "St George's Respiratory Questionnaire (SGRQ), Impact domain score": 3, "St George's Respiratory Questionnaire (SGRQ), Symptoms domain score": 3, "St George's Respiratory Questionnaire (SGRQ), Activity domain score": 3, 'Exercise-induced dynamic hyperinflation (measure not specified)': 3, 'Expiratory time (measure(s) not specified)': 3, 'Exercise duration (minutes, measured as duration of constant work rate exercise)': 3, 'Respiratory System Device (physical Object)': 3, 'Inspiratory Muscle Training': 3, 'Inspiratory muscle endurance (defined as highest tolerated resistance for 10 minutes on a P Flex device)': 3, 'Exercise performance (measured using a cycle endurance test on a cycle ergometer)': 3, 'Exercise performance (measured using a twelve-minute walking test (12MWT))': 3, 'Lung function (measure(s) not specified)': 3, 'Exercise performance (measured using an incremental progressive exercise test on a cycle ergometer)': 3, 'Breathing frequency': 3, 'Breathlessness (measured by patient rating)': 3, 'Tidal volume': 3, 'Respiratory minute volume': 3, 'Perceived exertion (measured by patient rating)': 3, 'Expiratory time': 3, 'Exercise duration (minutes, measured using a constant work-rate leg-cycle ergometer test at 85 percent of maximal power output)': 3})
CD002992 Counter({'Asthma': 15, 'Atenolol': 9, 'Metoprolol': 9, 'Terbutaline': 6, 'forced vital capacity': 6, 'Oxygen': 3, 'Helium': 3, 'maximal expiratory flow-volume': 3, 'Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Dose response to infused terbutaline': 3, 'Resting heart rate': 3, 'Pindolol': 3, 'Propranolol': 3, 'Bronchodilation - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Heart rate': 3, 'Resting pulse rate': 3, 'No significant bronchoconstrictor response (assessed using forced expiratory volume in one second (FEV1), measured using spirometry)': 3, 'Hypertensive': 3, 'Celiprolol': 3, 'Bronchoconstriction (measure(s) not specified)': 3, 'Responsiveness to beta-2 agonist therapy (measure not specified)': 3, 'Day-to-day asthma control (assessed using patient recordings of peak flow, inhaler use and symptom scores, measures not specified)': 3, 'Isoproterenol': 3, 'maximal midexpiratory flow': 3, 'FEV1': 3, 'Airways Obstruction Reversible': 3, 'forced expiratory volume in 1 second': 3, 'airway conductance': 3, 'peak plasma drug level': 3, 'heart rate': 3, 'blood pressure': 3, 'cardioselectivity': 3, 'peak expiratory flow': 3})
CD011715 Counter({'Asthma': 16, 'Asthma Management': 6, 'asthma': 3, 'Telemedicine': 3, 'Asthma Education': 3, 'Asthma Monitoring': 3, 'Telehealth Monitoring': 3, 'Inhaler technique scores (assessed by digital videos of patients using their controller medication inhaler)': 3, 'Hospital admission(s) for asthma': 3, 'Rescue-therapy use (unspecified)': 3, 'Inhaler technique scores': 3, 'Quality of life score (caregiver reported, measure(s) not specified)': 3, 'Retention of asthma knowledge (measure(s) not specified)': 3, 'Emergency department visit(s) for asthma': 3, 'Emergency department visits and hospital admissions for asthma were avoided': 3, 'Peak expiratory flow (PEF) (measured using spirometry)': 3, 'Satisfaction with home telemonitoring': 3, 'quality-of-life survey scores': 3, 'Symptom control (measure(s) not specified)': 3, 'Quality of life (patient reported, measure(s) not specified)': 3, 'being woken by asthma': 3, 'hospital re-admissions': 3, 'Telephone Consultation': 3, 'Asthma control (measured using the Asthma Control Questionnaire (ACQ))': 3, 'Direct healthcare costs (per patient per annum, UK Pounds (GBP), price year not reported)': 3, 'Health status (measure(s) not specified)': 3, 'Healthcare resource utilisation (unspecified)': 3, 'Mobile Phone Application': 3, 'short form-12 physical component score': 3, 'expiratory flow rate': 3, 'Chronic Obstructive Pulmonary Disease': 3, 'Therapeutic Drug Monitoring Assay (regime/therapy)': 3, 'Pulmonary function tests': 3, 'serum theophylline level': 3, 'dyspnea index scores': 3, 'questionnaires, visual analog scales, and other psychosocial measures': 3, 'Asthma symptom-free days (days, measured using a 4-week web-based diary)': 2, 'Daily inhaled corticosteroids (ICS) dose (measured using a 4-week web-based diary)': 2, 'Symptom-free days (SFD)': 2, 'Daily inhaled corticosteroid (ICS) dose': 2, 'patient and family costs': 2, 'SF-6D': 2, 'productivity losses': 2, 'EQ-5D': 2, 'one year health care costs': 2})
CD010744 Counter({'Chronic Obstructive Pulmonary Disease': 25, 'Smoker': 22, 'Smoking Cessation Assistance': 6, 'Smoking Cessation Therapy': 6, 'Brief Intervention For Smoking Cessation': 6, 'Cessation of Smoking': 6, 'Varenicline': 3, 'Carbon monoxide-confirmed continuous abstinence rate (CAR)': 3, 'Abnormal dreams': 3, 'Nausea': 3, 'Serious adverse events': 3, 'carbon monoxide-confirmed continuous abstinence rate (CAR) for weeks 9 to 12': 3, 'Insomnia': 3, 'Death': 3, 'upper-respiratory tract infection': 3, 'Psychiatric adverse events (unspecified)': 3, 'Lung function - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Cost-effectiveness - Cost per successful quitter (UK Pounds (GBP), price year not reported)': 3, 'New diagnosis of chronic obstructive lung disease (COLD)': 3, 'Smoking cessation (measured using salivary cotinine test)': 3, 'Number of cigarettes consumed per day (measured by self-report)': 3, 'Counseling': 3, 'sel-rreported': 3, 'biochemically verified point': 3, 'Nicotine Replacement Therapy Using Nicotine Patch': 3, 'Smoking cessation (validated using measurement of carbon monoxide in exhaled air)': 3, 'Withdrawal or dropout from study': 3, 'Nurse Contact': 3, 'Dyspnea (measure not specified)': 3, 'Nicotine addiction (measure not specified)': 3, 'Motivation to stop smoking (measure not specified)': 3, 'Stage of change (measure not specified)': 3, 'Smoking cessation (measured using biochemical validation)': 3, 'Intensive Support': 3, 'Telephone Encounter': 3, 'Nicotine Sublingual Tablet': 3, 'Home Care By Visiting Nurse': 3, "Assessment Using Saint George's Respiratory Questionnaire": 3, 'Abstinence': 3, '24-h abstentions from smoking (measured by daily self-report)': 2, 'Breath carbon monoxide (CO) level': 2, 'Sustained abstinence from smoking  (measured by daily self-report)': 2, 'Smoking abstinence (measure(s) not specified)': 2})
CD007949 Counter({'Asthma': 39, 'Salmeterol': 15, 'Formoterol': 12, 'Exercise-induced Asthma': 6, 'Fluticasone propionate': 6, 'Asthma symptom-free days (days)': 6, 'Metered Dose Inhaler': 6, 'Formoterol And Budesonide': 6, 'Dry Powder Inhaler': 6, 'safety': 6, 'FEV1': 6, 'Morning peak expiratory flow rate (PEFR) (measured using spirometry)': 6, 'Pulse rate': 6, '': 6, 'Salmeterol And Fluticasone': 5, 'Fluticasone': 3, 'Propionate': 3, 'Maximal fall in forced expiratory volume in one second (FEV1)  (measured using spirometry)': 3, 'Asthma rescue medication-free days (days)': 3, 'Asthma symptom-free days (days, measure(s) not specified)': 3, 'Maximal fall in forced expiratory volume in one second (FEV1) following exercise (measured using spirometry)': 3, 'Bronchospasm': 3, 'Budesonide': 3, 'lung function parameters': 3, 'Lung function - Morning peak expiratory flow (PEF) (measured using spirometry)': 3, 'Morning peak expiratory flow (PEF)': 3, 'sleep quality': 3, 'pef': 3, 'Pre-dose forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Use of nighttime relief medication (unspecified)': 3, 'Nighttime awakenings due to asthma': 3, 'Use of daytime relief medication (unspecified)': 3, 'medication use': 3, 'Morning peak expiratory flow (PEF) (measured using spirometry)': 3, 'Evening peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Quality-of-life scores (measure(s) not specified)': 3, 'Quality-of-life score (measure not specified)': 3, 'Symptom scores (measure(s) not specified)': 3, 'Symptom score (measure not specified)': 3, 'Evening peak expiratory flow (PEF) rate (measured using spirometry)': 3, 'Morning peak expiratory flow (PEF) rate (measured using spirometry)': 3, 'Medication-related adverse event(s)': 3, 'Medication-related adverse events': 3, 'Blood pressure': 3, 'Time to event - Onset of effect (measure not specified)': 3, 'Adverse events (unspecified)': 3, 'Lung function - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Urine formoterol level (measured by laboratory test)': 3, 'incidence of severe exacerbations': 3, 'asthma symptom score': 3, 'expiratory volume in 1 sec (FEV(1))': 3, 'tolerance': 3, 'Lung-function': 3, 'serial PEF measured over 12 hr': 3, 'quality of life': 3, 'morning peak expiratory flow (PEF)': 3, 'evening PEF': 3, 'Eformoterol': 3, 'lung function': 3, 'change in rescue medication use': 3, 'symptom scores': 3, 'carer quality of life': 3, 'patient quality of life': 3, 'symptom measures': 3, 'peak expiratory flow': 3, 'PC20': 3, 'High Dose': 3, 'Corticosteroids': 3, 'Use of asthma relief medication (measured using patient- or parent-reported daily record)': 3, 'Minor adverse event(s) (unspecified)': 3, 'Morning peak expiratory flow (PEF) (% of predicted, measured using spirometry)': 3, 'Nightime asthma symptoms (measured using patient- or parent-reported daily record)': 3, 'Evening peak expiratory flow (PEF) (% of predicted, measured using spirometry)': 3, 'Daytime asthma symptoms (measured using patient- or parent-reported daily record)': 3, 'Asthma symptoms (measure(s) not specified)': 3, 'Patient regarded study drug(s) as superior to their previous asthma medication': 3, 'Any adverse event(s)': 3, 'Asthma symptom-free days (% of days)': 3, 'Use of rescue medication (unspecified)': 3, 'Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Quality of life (measure(s) not specified)': 3, 'peak expiratory flow (PEF)': 3, 'Budesonide / Formoterol Inhalant Powder': 3, 'improvements in lung function for 24h': 3, 'maximum decrease in percent predicted FEV1 postexercise': 3, 'Asthma control': 2, 'Mean pre-bronchodilator maximal-expiratory flow at 50% vital capacity': 2, 'percentage rescue-free days': 2, 'mean morning peak expiratory flow': 2})
CD011293 Counter({'Asthma': 36, 'Immunological Therapy': 30, 'Sublingual Tablet': 24, 'Allergic Rhinoconjunctivitis': 13, 'Allergic Asthma': 12, 'Subcutaneous Immunotherapy': 11, 'House Dust Mite Allergy': 10, 'Rhinitis': 9, 'Corticosteroids': 6, '': 6, 'Allergic Rhinitis': 6, 'Pollen Extracts': 6, 'Mild Asthma': 5, 'lung function parameters (FEV<sub>1</sub> and PEF)': 3, 'Any adverse event(s)': 3, 'Serious treatment-related adverse event(s) - Migraine': 3, 'reduction in ICS dose': 3, 'asthma control questionnaire score (ACQ)': 3, 'Asthma-specific quality of life (measured using the Asthma Quality of Life Questionnaire (AQLQ))': 3, 'dizziness': 3, 'Discontinuation of of inhaled corticosteroid (ICS)': 3, 'Withdrawal from study due to adverse event(s)': 3, 'asthma exacerbation frequency': 3, 'Dose of inhaled corticosteroid (ICS)': 3, 'Lung function - Peak expiratory flow (PEF) (measured using spirometry)': 3, 'oral pruritus': 3, 'Asthma exacerbation(s)': 3, 'Treatment-emergent adverse events - oral pruritus': 3, 'Lung function - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Asthma control (measured using the Asthma Control Questionnaire (ACQ) score)': 3, 'asthma quality of life (AQLQ)': 3, 'migraine': 3, 'Serious treatment-related adverse event(s) - Dizziness': 3, 'throat irritation': 3, 'tolerability': 3, 'adverse events (AEs)': 3, 'Seasonal Asthma': 3, 'Fluticasone': 3, 'Late skin response to the allergen (measure not specified)': 3, 'Symptom score - Chest symptoms (measure not specified)': 3, 'Symptom score - Nose symptoms (measure not specified)': 3, 'Parietaria pollen count': 3, 'Drug score (measure not specified)': 3, 'Symptom score - Eye symptoms (measure not specified)': 3, 'Early skin response to the allergen (measure not specified)': 3, 'Dropouts': 3, 'Visual analogue scores (VASs) (outcome/ outcome type not specified)': 3, 'House Dust Mite Desensitization Therapy': 3, 'physical examination': 3, 'ECG': 3, 'Treatment-related asthma exacerbation': 3, 'laboratory tests': 3, 'Adverse events': 3, 'Serious adverse events': 3, 'vital signs': 3, 'Anaphylaxis': 3, 'mild oropharyngeal reactions': 3, 'Epinephrine use': 3, 'Death': 3, 'Mild oropharyngeal reactions': 3, 'spirometry': 3, 'Serum house dust mite-specific immunglobulin E (HDM-sIgE) level  (measured by laboratory test)': 3, 'Titrated skin prick test results': 3, 'Bronchial allergen provocation dose': 3, 'Symptom score for rhinitis (measure not specified)': 3, 'Bronchial allergen provocation doses': 3, 'Titrated skin prick test': 3, 'Serum house dust mite-specific immunglobulin E (HDM-sIgE) level': 3, 'Serum interferon (IFN)-gamma level': 3, 'Serum Interleukin 10 (IL-10) level': 3, 'Nasal allergen provocation doses': 3, 'Serum sIgG4 level': 3, 'Serum interleukin 10 (IL-10) level (measured by laboratory test)': 3, 'Nasal allergen provocation dose': 3, 'Symptom score for asthma (measure not specified)': 3, 'Aerum immunoglobulin G4 (sIgG4) level (measured by laboratory test)': 3, 'Serum interferon-gamma (IFN-gamma) level (measured by laboratory test)': 3, 'Drug usage (unspecified)': 3, 'House mite allergy vaccine': 3, 'medication intake': 3, 'frequency of local and systemic reactions': 3, 'symptoms, peak expiratory flow, skin sensitivity to mites': 3, "Total combined rhinitis score (TCRS) (bespoke measure combining 'rhinoconjunctivitis symptoms' and 'medication score')": 3, 'Rhinitis-specific quality of life - Non-nose symptoms (measured using the Rhinitis Quality of Life Questionnaire with Standardized Activities RQLQ(S), Non-nose symptoms domain score)': 3, 'Rhinitis-specific quality of life - Activities (measured using the Rhinitis Quality of Life Questionnaire with Standardized Activities RQLQ(S), Activities domain score)': 3, 'Rhinitis-specific quality of life - Non-eye symptoms (measured using the Rhinitis Quality of Life Questionnaire with Standardized Activities RQLQ(S), Non-eye symptoms domain score)': 3, 'Rhinitis-specific quality of life - Nasal symptoms (measured using the Rhinitis Quality of Life Questionnaire with Standardized Activities RQLQ(S), Nasal symptoms domain score)': 3, 'Rhinitis-specific quality of life - Sleep (measured using the Rhinitis Quality of Life Questionnaire with Standardized Activities RQLQ(S), Sleep domain score)': 3, 'Rhinitis-specific quality of life - Overall (measured using the Rhinitis Quality of Life Questionnaire with Standardized Activities RQLQ(S), Total score)': 3, 'Allergic Rhinitis Caused By Insects': 3, 'Serum cockroach-specific Immunoglobulin G4 (IgG4) level (measured by laboratory test)': 3, 'Serum cockroach-specific Immunoglobulin E (IgE) level (measured by laboratory test)': 3, 'Functional blocking antibody response (measure not specified)': 3, 'Serious adverse drug reaction(s)': 3, 'Combined symptom-medication score (measure not specified)': 3, 'Allergen-specific immunoglobulin G1 (IgG1) level (measured by laboratory test)': 3, 'Allergen-specific immunoglobulin E (IgE) level (measured by laboratory test)': 3, 'Allergen-specific immunoglobulin G4 (IgG4) level (measured by laboratory test)': 3, 'Intermittent Asthma Co-occurrent With Allergic Rhinitis': 3, 'symptoms and other clinical indicators': 3, 'symptoms, VAS, AEs': 3, 'bronchial sensitivity': 3, 'serum-specific IgE antibodies': 3, 'Exacerbation of Asthma': 3, 'Need of Albuterol': 3, 'Forced Expiratory Volume in One Second (FEV1)': 3, 'Prophylactic Immunotherapy': 3, 'reduction in medication': 3, 'mean difference in asthma medication score': 3, 'Well days increased': 3, 'reduction in rhinoconjunctivitis symptom': 3, 'Tablet': 3, 'asthma exacerbation': 3, 'Mild Persistent Asthma Co-occurrent With Allergic Rhinitis': 3, 'Allergic Rhinitis Due To Pollen': 3, 'Seasonal Allergic Rhinitis': 3, 'Conjunctivitis': 3, 'Skin reactivity': 3, 'Symptom/Medication score': 3, 'Allergic Reaction To Grass Pollen': 3, 'Allergens': 3, 'Immunotherapy was well tolerated and compliance was good': 3, 'Symptoms and medications were scored': 3, 'reduction of total symptoms': 3, 'bronchial symptoms': 3, 'Nasal eosinophil cationic protein levels': 3, 'Childhood Asthma': 3, 'use of urgency service': 3, 'use of steroids': 3, 'Drug consumption': 3, 'Diary card': 3, 'skin test reactivity': 2, 'FEV(1)': 2, 'intake of drugs': 2, 'Asthma symptoms': 2, 'safety': 2, 'asthma control questionnaire': 2, 'inhaled corticosteroid': 2, 'quality of life': 2, 'Moderate Asthma': 2, 'Asthma control parameters': 2, 'Immunological parameters': 2, 'Placebo': 2})
CD010834 Counter({'Asthma': 18, 'Allergic Asthma': 15, 'Omalizumab': 12, 'Eosinophilic Asthma': 8, 'Mepolizumab': 8, 'Asthma exacerbation(s)': 6, 'Immunological Therapy': 6, 'Benralizumab': 6, 'Asthma exacerbation-related resource utilisation (not specified)': 3, 'Healthcare resource use': 3, 'Asthma exacerbation-related inpatient resource utilisation (not specified)': 3, 'Cat Hair Extract': 3, 'Cat Skin Extract': 3, 'Sensitivity of circulating basophils (measure not specified)': 3, 'Serum immunoglobulin (IgG) antibody to CAT allergen 1': 3, 'Time to onset of pulmonary symptoms (metric not specified)': 3, 'sSensitivity of circulating basophils (measure(s) not specified)': 3, 'Bronchial sensitivity (measure not specified)': 3, 'Time to onset of ocular symptoms (metric not specified)': 3, 'Antibody to cat allergen 1 level in serum immunoglobulin G (IgG)': 3, 'Bronchial reactivity to methacholine (measure(s) not specified)': 3, 'Bronchial reactivity to methacholine (measure not specified)': 3, 'Prick test titer': 3, 'Serum immunoglobulin (IgG) antibody to CAT albumin': 3, 'Time to onset of pulmonary symptoms on exposure to living cats (minutes)': 3, 'Time to onset of ocular symptoms on exposure to living cats (minutes)': 3, 'Antibody to cat albumin level in serum immunoglobulin G (IgG)': 3, 'Bronchial sensitivity (measure(s) not specified)': 3, 'Eosinophils': 3, 'asthma exacerbation at 52 weeks': 3, 'Forced expiratory volume in one second (FEV1)  (measured using spirometry)': 3, 'Asthma exacerbation': 3, 'Symptom-free days (% days, defined as total symptom score = 0)': 3, 'Asthma-related quality of life (measured using the Asthma Quality of Life Questionnaire (AQLQ))': 3, 'Symptom-controlled days (% days, defined as total symptom score /=90% of baseline, daytime asthma score': 3, 'House Dust Mite Allergy': 3, 'House Dust Mite Desensitization Therapy': 3, 'Leukocyte sensitivity - Leukocyte histamine release (measured by laboratory test)': 3, 'Clinical response - Medication scores (measured using diary cards, patient-reported)': 3, 'Lung function - Peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Clinical response - Symptoms scores (measured using diary cards, patient-reported)': 3, 'Serum dermatophagoides pteronyssinus-specific immunoglobulin E (Dpt-specific IgE) (measured by laboratory test; double antibody antigen-binding assay by use of the purified fraction of mite extract F4P1)': 3, 'Serum total immunoglobulin E (IgE) (measured by laboratory test)': 3, 'Exacerbation Of Asthma': 3, 'Asthma control (measure(s) not specified)': 3, 'Quality of life (measure(s) not specified)': 3, 'Airway responsiveness - Methacholine provocative concentration causing a 20% fall in forced expiratory volume in one second (FEV1) (PC20) (measured using a methacholine challenge test)': 3, "Airway responsiveness - Adenosine 5'-monophosphate (AMP) provocative concentration causing a 20% fall in forced expiratory volume in one second (FEV1) (PC20) (measured using an AMP challenge test)": 3, 'reduced rescue medication requirements': 3, 'reducing inhaled corticosteroid requirements': 3, 'improved asthma symptoms': 3, 'asthma-related quality of life': 3, 'Allergic Rhinitis': 3, 'reduced Wasserfallen symptom scores': 3, 'asthma exacerbations': 3, 'improvement in both Asthma Quality of Life Questionnaire and Rhinitis Quality of Life Questionnaire': 3, 'adverse events were observed': 3, 'decreases in the annual exacerbation rate': 3, 'Adverse events': 3, 'lung function and asthma symptom improvement': 3})
CD003137 Counter({'Asthma': 6, 'Fluticasone propionate': 3, 'Patient satisfaction with therapy (measure not specified)': 3, 'Rescue albuterol use': 3, 'Asthma-related quality-of-life (measure not specified)': 3, 'Pulmonary function (measure not specified)': 3, 'Physician assessment/rating of efficacy': 3, 'Asthma exacerbation': 3, 'Withdrawals from study due to asthma exacerbations': 3, 'Percentage of symptom-free days': 3, 'Nighttime awakenings (number)': 3, 'Asthma symptom score (measure not specified)': 3, 'Fluticasone': 3, 'Albuterol use - rescue medication-free days (% of days)': 3, 'Pulmonary function - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Asthma exacerbation(s)': 3, 'Asthma symptom-free days (% of days)': 3, 'Pulmonary function - Evening peak expiratory flow (PEF) (measured using spirometry)': 3, 'Pulmonary function - Morning peak expiratory flow (PEF) (measured using spirometry)': 3, 'Withdrawal from study due to lack of treatment efficacy': 3, 'Nights with uninterrupted sleep (% of nights)': 3})
CD012226 Counter({'Asthma': 35, 'Budesonide': 8, 'Reinforcement Of Adherence To Treatment Regimen': 6, 'Education': 6, 'Monitoring Adherence To Medication Regime (regime/therapy)': 3, 'adherence medication': 3, 'adherence': 3, 'Pulmonary function (measure(s) not specified)': 3, 'Adherence to inhaled corticosteroids (measure not specified)': 3, 'pulmonary function': 3, 'Flunisolide': 3, 'Compliance': 3, 'Emergency Care': 3, 'Exacerbation Of Asthma': 3, 'Inhaler (physical Object)': 3, 'Reminding About Taking Drug': 3, 'Adherence to preventive inhaled corticosteroids': 3, 'Absence from school for any reason (% days)': 3, 'Asthma control - Asthma morbidity score (measure not specified)': 3, 'Reminding': 3, 'Nasal Inhaler': 3, 'ACT scores': 3, 'severe exacerbations': 3, 'Formoterol': 3, 'Withdrawal from the study (reason(s) not specified)': 3, 'Inhaled corticosteroid (budesonide) dose (microg/day)': 3, 'Nebulizer (physical Object)': 3, 'Drug delivery - Delivered dose of budesonide (measured using a datalogger incorporated into the device)': 3, 'Acceptability of device shape, size and weight (measure not specified)': 3, 'True adherence (measured using a datalogger incorporated into the device)': 3, 'Adherence to treatment (measured using a datalogger incorporated into the device)': 3, 'Compliance with device (measured using a datalogger incorporated into the device)': 3, 'Asthma Education': 3, 'One or more asthma exacerbation each month': 3, 'Telephone Call By Physician To Patient Or For Consultation': 3, 'adherence to drug regime': 3, 'Chronic Obstructive Pulmonary Disease': 3, 'Group Education': 3, 'absenteeism from work': 3, 'GP consultations': 3, "St George's Respiratory Questionnaire": 3, 'Reinforcement Of Adherence To Physical Therapy Regimen': 3, 'adherence and asthma control': 3, 'missing data': 2, 'drug adherence': 2})
CD012158 Counter({'Emphysema': 11, 'Endobronchial Valve': 6, "St George's Respiratory Questionnaire (SGRQ)": 3, 'Dyspnea': 3, 'Non-smoker': 3, 'Plastic Stent (physical Object)': 3, 'Bronchoscopy': 3, 'Pulmonary function - Forced vital capacity (FVC) (measured using spirometry)': 3, 'Dyspnea (measured using the modified Medical Research Council Dyspnea Scale)': 3, 'Lung Hyperinflation': 3, 'Composite of body mass index, airflow obstruction, dyspnoea and exercise capacity (measured using the BODE index)': 3, 'Air Trapping': 2, 'major complications (including pneumonia requiring hospitalization and other potentially life-threatening or fatal events)': 2, '6-minute-walk distance': 2, 'forced expiratory volume in the first second': 2, "St George's Respiratory Questionnaire": 2, 'Other serious adverse events including pneumonia (20% coil vs 4.5% usual care) and pneumothorax': 2})
CD005623 Counter({'Chronic Obstructive Pulmonary Disease': 6, 'Music Therapy': 3, 'anxiety (State-Trait Anxiety Inventory-State)': 3, 'perceived dyspnea (modified Borg scale)': 3, 'dyspnea (modified Borg scale': 3, '6-minute Walk Test': 3, 'Walker (physical Object)': 3, '6-minute walk distance (metres, measured using the six-minute walk test (6MWT))': 3, 'Duration of rest during six-minute walk test (6MWT) (seconds, measured during the six-minute walk test (6MWT))': 3, 'Gait (measure(s) not specified, measured during the six-minute walk test (6MWT))': 3, 'Dyspnea during six-minute walk test (measure not specified, measured during the six-minute walk test (6MWT))': 3, 'Cardiorespiratory function (measure(s) not specified, measured during the six-minute walk test (6MWT))': 3, 'Preference for the rollator (walker) device versus walking unaided (patient-reported)': 3})
CD010398 Counter({'Asthma': 6, 'Medication Action/side Effects Education, Guidance, And Counselling': 3, 'Dispensing Medication Management': 3, 'Referral To Pharmacist': 3, 'Management Of Drug Regimen': 3, 'patient knowledge': 3, 'inhalation technique': 3, 'use of inhaled beta2 agonists': 3, 'days of sickness per week': 3, 'nocturnal asthma symptoms': 3, 'asthma attacks': 3, 'Education': 3, 'quality of life, function': 3})
CD011859 Counter({'Asthma': 12, 'utilization of services': 6, 'Asthma Self Management': 6, 'Education About Asthma Self Management': 3, 'daily functioning': 3, 'medical condition': 3, "patients' knowledge": 3, 'self-management practices': 3, 'Referral To Practice Nurse': 3, 'Liaison With Gp (general Practitioner)': 3, 'Asthma symptoms (measure(s) not specified)': 3, 'Disturbance of daily activities (measure(s) not specified)': 3, 'Intervention felt to be useful by doctor/ practice nurse (%)': 3, 'Prescribing costs (unspecified, currency and price year not reported)': 3, 'Lung function (measure(s) not specified)': 3, 'Quality of life (measure(s) not specified)': 3, 'Intervention felt to be useful by patient (%)': 3, 'Referral To Clinical Nurse Specialist': 3, 'patient reported self-management of asthma exacerbations': 3, 'home peak flow and symptom diaries': 3, 'self-management-plans': 3, 'how to recognize and manage uncontrolled asthma and when to seek medical assistance': 3, 'Incremental Cost Effectiveness Ratio (ICER) - Cost per Quality-Adjusted Life Year (QALY) (Healthcare provider perspective; Euros, Price Year Not Reported)': 3, 'Costs of Lost Productivity (Per patient; Euros, Price Year Not Reported)': 3, 'Health State Utility Values (HSUVs)': 3, 'Incremental Cost Effectiveness Ratio (ICER) - Cost per Successfully Treated Week Gained (Societal perspective; Euros, Price Year Not Reported)': 3, 'Quality-Adjusted Life Years (QALYs)': 3, 'Use of Rescue Medication': 3, 'Treatment Success': 3, 'Incremental Cost Effectiveness Ratio (ICER) - Cost per Successfully Treated Week Gained (Healthcare provider perspective; Euros, Price Year Not Reported)': 3, 'Incremental Cost Effectiveness Ratio (ICER) - Cost per Quality-Adjusted Life Year (QALY) (Societal perspective; Euros, Price Year Not Reported)': 3, 'Total Costs (Total Direct Healthcare Costs + Costs of Lost Productivity) (Per patient; Euros, Price Year Not Reported)': 3, 'Total Direct Healthcare Costs (Per patient; Euros, Price Year Not Reported)': 3, 'Asthma Action Care Planning': 2, 'remembered significantly more asthma educational messages': 2, 'asthma quality of life (QOL)': 2, 'unscheduled visits': 2, 'days with symptoms': 2, 'emergency deparatment visits': 2, 'nocturnal symptoms': 2, 'beta-agonist use': 2, 'days of activity limitation': 2})
CD003531 Counter({'Obstructive Sleep Apnea Syndrome': 27, 'Continuous Positive Airway Pressure Ventilation Treatment': 18, 'Home Continuous Positive Airway Pressure Unit': 9, 'compliance': 6, '': 6, 'Sleep apnea severity (measured using the Apnea–Hypopnea Index (AHI))': 6, 'Sleepiness (measured using the Epworth Sleepiness Scale)': 6, 'Sleep Apnea': 5, 'Compliance with continuous positive airway pressure (CPAP) treatment (assessed by homecare technicians during follow-up clinical visits)': 3, 'CPAP use (hours per night, assessed by homecare technicians during follow-up clinical visits)': 3, 'Health-related quality of life (measured using the 36-item short-form health survey (SF-36) score)': 3, 'Clinical symptom scores (assessed by homecare technicians during follow-up clinical visits, measure(s) not specified)': 3, 'Polysomnography (PSG)': 3, '24-hour systolic blood pressure': 3, 'Compliance with prescribed use of continuous positive airway pressure device (measured as number of hours of use per night)': 3, 'Office systolic blood pressure': 3, '24-hour diastolic blood pressure': 3, 'daytime sleepiness, health status': 3, 'Daytime vigilance (measured using an unspecified standardised questionnaire)': 3, 'Apnea/Hypopnea Index (AHI) score (measured during a controlled sleep study)': 3, 'Concentration (measured using Trailmaking Tests (TMT))': 3, 'Daytime vigilance (measured using the maintenance of wakefulness test (MWT))': 3, 'Amount of continuous positive airway pressure (CPAP) device home use (estimated by the number of sleeping hours with a positive pressure applied)': 3, 'Continuous positive airway pressure (CPAP) home treatment time spent at a pressure &lt; or = effective pressure level (Peff) (% time)': 3, 'Any side effect(s) of treatment (unspecified)': 3, 'Obstructive sleep apnea syndrome symptoms (measure(s) not specified)': 3, 'Compliance with treatment (measure not specified)': 3, 'Satisfaction with/ preference for each device': 3, 'Leakage time (minutes per night, measured using the software LOGSoft of the Magellan iPAP device)': 3, 'Preference for the automatic mode of continuous positive airway pressure ventilation treatment (APAP)': 3, 'Compliance (minutes of use per night, measured using the software LOGSoft of the Magellan iPAP device)': 3, 'Positive End Expiratory Pressure Reduced': 3, 'Patient preference for continuous positive airway pressure (CPAP) device': 3, 'Discontinuation of continuous positive airway pressure (CPAP) ventilation therapy': 3, 'Slow-wave sleep (SWS) duration (minutes per night (measured by polysomnography)': 3, 'Arousal(s) during sleep (measured using the Arousal Index, by polysomnography)': 3, 'Respiratory event(s) during sleep (measured by polysomnography)': 3, 'Nocturnal use of continuous positive airway pressure (CPAP) device (hours per night)': 3, 'Sleep Apnoeas': 3, 'Heated Respiratory Humidifier (physical Object)': 3, 'adherence': 3, 'nasal symptoms': 3, 'Fluticasone': 3, 'Blocked nose': 3, 'Runny nose': 3, 'Headache': 3, 'SF-36': 3, 'Epworth Sleepiness Scale score': 3, 'Dry nose': 3, 'Sneezing': 3})
CD011818 Counter({'Asthma': 9, 'Cognitive - Behavior Therapy': 6, 'Severe Asthma': 3, 'Asthma Quality of Life Questionnaire': 3, 'Hospital Anxiety and Depression (HAD) score': 3, 'Asthma Control Questionnaire': 3, 'Asthma Quality of Life questionnaire': 3, 'Self-monitoring': 3, 'adherence': 3, 'functional status': 3, 'Asthma Education': 3, 'Depression (measure not specified)': 3, 'External control (measure not specified)': 3, 'Psychophysiological disorder (measure not specified)': 3, 'Anxiety (measure not specified)': 3, 'Emotional reactions to asthma attacks (measure not specified)': 3, 'Internal beliefs (measure not specified)': 3, 'External chance (measure not specified)': 3, 'Psychological stigma (measure not specified)': 3})
CD009471 Counter({'Asthma': 12, 'Budesonide': 9, 'Beclometasone': 6, 'Childhood Asthma': 6, 'Beclomethasone Inhalant Solution': 3, 'Height (centimetres and millimetres)': 3, 'Adrenal function (measured/ assessed by overnight urinary cortisol production)': 3, 'Spacer (physical Object)': 3, 'Metered Dose Inhaler': 3, 'Fasting morning blood': 3, 'Bone mineral density': 3, 'Bone mineral density (BMD)': 3, 'Asthma control': 3, 'overnight urine samples': 3, 'serum cortisol': 3, 'urine deoxypyridinoline (DPD)': 3, 'serum osteocalcin': 3, 'growth rates': 3, 'serum 1-carboxyterminal telopeptide (ICTP)': 3, 'Wheezing': 3, 'Fluticasone': 3, 'Adverse events - Symptom worsening': 3, 'Drug-related adverse events - Cough': 3, 'Drug-related adverse events -  Hoarseness': 3, 'Exacerbation(s)': 3, 'Symptom-free days (days)': 3, 'Adverse events - Cataract': 3, 'Days without use of rescue treatment (days)': 3, 'Requirement(s) for oral steroid treatment': 3, 'Growth (measured using height, cm and mm)': 3, 'Urinary cortisol concentration (measured by laboratory test)': 3, 'Growth (measured using length, cm and mm)': 3, 'Serum cortisol concentration (measured by laboratory test)': 3, 'Moderate Asthma': 3, 'Mild Asthma': 3, 'Nedocromil': 3, 'FEV1': 3, 'lung function': 3, 'FEV1 to FVC ratio': 3, 'airway responsiveness': 3, 'forced expiratory volume in one second': 3, 'hospitalization': 3, 'urgent care': 3, 'medication use': 3, 'growth reduction': 3, 'Montelukast': 3, 'Lower leg and height growth': 3, 'Fluticasone propionate': 3, 'Side-effects of the treatment were evaluated': 3, 'use of bronchodilators': 3, 'forced expiratory volume in 1 second (FEV1)': 3})
CD009296 Counter({'Asthma': 3, 'Outpatient Care Management': 3, 'cost': 3, 'resource utilisation': 3})
CD007736 Counter({'Obstructive Sleep Apnea Syndrome': 15, 'Support': 6, 'adherence': 6, 'Sleep Apnea': 6, 'Continuous Positive Airway Pressure Ventilation Treatment': 3, 'Group Cognitive Behavioural Therapy': 3, 'Expectancy (measured by unspecified questionnaire)': 3, 'Adherence to continuous positive airway pressure (CPAP) treatment (defined as usage of at least 4 hours per night)': 3, 'Hours of continuous positive airway pressure (CPAP) usage (hours per night)': 3, 'Social support (measured by unspecified questionnaire)': 3, 'Self-efficacy (measured by unspecified questionnaire)': 3, 'Reinforcement Of Adherence To Treatment Regimen': 3, 'Weekly adherence to continuous positive airway pressure (CPAP) treatment': 3, 'Excessive sleepiness disorder-specific quality of life - Overall (measured using the Functional Outcomes of Sleep Questionnaire (FOSQ), Total score)': 3, 'Patient activation (measure(s) not specified)': 3, 'Self-efficacy (measure(s) not specified)': 3, 'Patient satisfaction with treatment (measure(s) not specified)': 3, 'Excessive sleepiness disorder-specific quality of life - Vigilance (measured using the Functional Outcomes of Sleep Questionnaire (FOSQ), Vigilance domain score)': 3, 'Obstructive Sleep Apnea Of Adult': 3, 'Shared Decision Making': 3, 'Identifying Problems': 3, '': 3, 'Motivation Therapy': 3, 'Education': 3, 'Telehealth Monitoring For Chronic Disease': 3, 'side-effects scores': 3, 'Attendance rates, CPAP use,': 3, 'Telemedicine': 3, 'differences in nasal CPAP use': 3, 'client satisfaction': 3, 'general perceived self-efficacy': 3, 'functional status': 3})
CD012195 Counter({'Asthma': 3, 'Prednisone': 3, 'Asthma attacks - number for which medicine was used (measured by patient interview, certified by computerised patient records and chart reviews)': 3, 'Asthma attack(s) for which medicine was used': 3, 'Asthma attacks - total number (measured by patient interview, certified by computerised patient records and chart reviews)': 3, 'Asthma attack(s)': 3, 'Cumulative length of hospital stay(s) for treatment of acute asthma (days, measured by patient interview, certified by computerised patient records and chart reviews)': 3, 'Asthma attack(s) requiring an outpatient visit': 3, 'Outpatient visits for treatment of acute asthma - total number (measured by patient interview, certified by computerised patient records and chart reviews': 3, 'Hospitalisations for treatment of acute asthma (measured by patient interview, certified by computerised patient records and chart reviews)': 3, 'Length of hospital stay (days)': 3, 'Asthma attack(s) requiring hospitalisation': 3})
CD001001 Counter({'Lung Volume Reduction Surgery': 23, 'Emphysema': 21, 'Chronic Obstructive Pulmonary Disease': 9, 'Pulmonary Rehabilitation': 6, 'Forced expiratory volume in one second (FEV1) (measured using spirometry)': 6, 'Length of hospital stay (days)': 6, 'Severe Chronic Obstructive Pulmonary Disease': 3, 'tidal volume': 3, 'Minute ventilation (measured using unspecified exercise test)': 3, 'Tidal volume (measured using unspecified exercise test)': 3, 'minute ventilation': 3, 'Endurance time (measured using an unspecified endurance test)': 3, 'endurance': 3, "Peak oxygen uptake (V'O2,pk) (measured using unspecified exercise test)": 3, 'peak oxygen uptake': 3, 'exercise capacity': 3, 'Smoking Cessation Therapy': 3, 'Quality of life (measured using an unspecified quality of life scale)': 3, 'Distance walked on shuttle walking test (metres, measured using a shuttle walking test (SWT))': 3, 'All cause mortality': 3, "Time to event (years) - Occurrence of death, or a clinically meaningful decline in Quality of Life (the latter defined as an increase of at least eight points in the St. George's Respiratory Questionnaire (SGRQ) total score) (composite endpoint)": 3, "Occurrence of death, or a clinically meaningful decline in Quality of Life (the latter defined as an increase of at least eight points in the St. George's Respiratory Questionnaire (SGRQ) total score) (composite endpoint)": 3, "Quality of Life decline (defined as an increase of at least eight points in the St. George's Respiratory Questionnaire (SGRQ) total score)": 3, 'probability of death': 3, 'Quality of life': 3, 'Time to event - First COPD exacerbation': 3, 'COPD exacerbation(s)': 3, 'Excision Of Bulla Of Lung': 3, 'Thoracoscopy': 3, 'Laser Surgery': 3, 'Elimination of dependency on supplemental oxygen': 3, 'Operating time (minutes)': 3, 'Delayed pneumothorax': 3, 'Operative mortality': 3, 'Air leakage for more than 7 days': 3, 'Median Sternotomy': 3, 'Living independently (measure not specified)': 3, 'Direct healthcare costs - Total costs in the 6-moths after surgery (unspecified, per patient, currency and price year not reported)': 3, 'Mortality': 3, 'Direct healthcare costs - Total costs of the operation and the postoperative hospital stay (per patient, currency and price year not reported)': 3, 'Complication(s) of treatment (unspecified)': 3, 'Usual Care': 3, 'Incremental Cost Effectiveness Ratio (ICER) - Cost per Quality-Adjusted Life Year (QALY) (Healthcare provider perspective; Canadian Dollars (CAD), Price Year Not Reported)': 3, 'Health State Utility Values (HSUVs)': 3, 'Forced Expiratory Volume in One Second (FEV1)': 3, 'Costs of Surgery (Per Patient; Canadian Dollars (CAD), Price Year Not Reported)': 3, 'Residual Volume (RV)': 3, 'Quality-Adjusted Life Years (QALYs)': 3, 'Walking Distance Test': 3, 'Death': 3})
CD001496 Counter({'Asthma': 9, 'Gastroesophageal Reflux Disease': 9, 'Omeprazole': 6, 'Gastroesophageal Reflux': 3, 'Pantoprazole': 3, 'improvement in the scores for respiratory symptoms': 3, 'quality of life': 3, 'Lung function (FEV1)': 3, 'Lung function (Peak flow)': 3, 'Asthma control': 3, 'Histamine bronchial responsiveness': 3, 'Lung function (FVC)': 3, 'Asthma symptoms': 3, 'Esomeprazole': 3, 'peak expiratory flow (PEF)': 3, 'PEV and FEV1 dynamics': 3, 'pulmonary (CIEI I) and gastric (CIEI II) symptoms': 3})
CD000364 Counter({'Asthma': 9, 'Influenza Vaccination': 6, 'No available term': 3, 'Influenza Virus Vaccine': 3, 'respiratory function': 3, 'Duration of influenza-related asthma exacerbation(s) (days, measured by pharyngeal swab)': 3, 'asthma exacerbations': 3, 'Influenza-related asthma exacerbation(s) (measured by pharyngeal swab)': 3, 'Rise in serum hemagglutination inhibition antibody titer for vaccine antigens (measured by laboratory test)': 3, 'Serum hemagglutination inhibition antibody titer for vaccine antigens &gt; or =1:32 (measured by laboratory test)': 3, 'Serological response (assessed using serum hemagglutination inhibition antibody titer for vaccine antigens, measured by laboratory test)': 3, 'Vaccines': 3, 'antibody titres': 3, 'diarrhoea': 3, 'erythema': 3, 'SER, IgG, IgM': 3, 'platelets': 3, 'pulmonary function': 3})
CD001114 Counter({'Sarcoidosis': 6, 'Pulmonary Sarcoidosis': 3, 'Lung Function Testing Abnormal': 3, 'Budesonide': 3, 'Predicted or transfer factor of the lungs for carbon monoxide (TL,CO)': 3, 'Lung function (inspiratory vital capacity (IVC))': 3, "Patient's Global Clinical Impression (GCI) score": 3, 'Angiotensin-converting enzyme (ACE) in serum (measured by laboratory test)': 3, 'Chest radiographic appearance (measured using chest radiography)': 3, 'Prednisolone': 3, 'Radiological (unspecified)': 3, 'Unspecified': 3, 'Vital capacity (measured using spirometry)': 3, 'Diffusing capacity of the lungs for carbon monoxide (DLCO)': 3, 'Vital capacity (VC) of the lungs (measure(s) not specified)': 3, 'Diffusing capacity of the lung for carbon monoxide (DLCO)': 3, 'Corticosteroids': 3, 'Roentgenography': 3, 'Pulmonary function testing': 3, 'No available term': 3, 'Fluticasone': 3, 'Cough': 3})
CD005535 Counter({'Asthma': 12, 'Salmeterol': 6, 'Albuterol Inhalant Powder': 3, 'Salmeterol Inhalant Powder': 3, 'Nightime asthma symptoms (measure(s) not specified)': 3, 'Use of rescue albuterol': 3, 'Serum concentration of eosinophil cationic protein (ECP) (measured using laboratory test)': 3, 'Serum inflammatory markers - Serum eosinophil cationic protein (ECP) concentration (measured by laboratory test)': 3, 'Evening peak expiratory flow (PEF) (measured using spirometry)': 3, 'Mean (all day) peak expiratory flow (PEF) (measured using spirometry)': 3, 'Efficacy (measured by patient rating)': 3, 'Nocturnal symptoms (unspecified, measure not specified)': 3, 'Serum inflammatory markers - Serum tryptase concentration (measured by laboratory test)': 3, 'Daytime symptoms (unspecified, measure not specified)': 3, 'Morning peak expiratory flow (PEF) (measured using spirometry)': 3, 'Efficacy rating (patient subjective report)': 3, 'Daytime asthma symptoms (measure(s) not specified)': 3, 'Serum concentration of soluble interleukin 2R (sIL-2R) (measured using laboratory test)': 3, 'Serum inflammatory markers - Serum soluble interleukin 2R (sIL-2R) concentration (measured by laboratory test)': 3, 'Serum concentration of tryptase (measured using laboratory test)': 3, 'Magnesium Sulfate': 3, 'forced expiratory volume in 1 second': 3, 'pulse oximetry': 3, 'vital signs': 3, 'serum magnesium': 3, 'Safety': 3, 'Low Dose': 3, 'Beclometasone': 3, 'Asthma problems (unspecified, measured using a daily diary)': 3, 'Asthma symptoms (unspecified, measured using a daily diary)': 3, 'Peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Asthma-specific quality of life (measured using the Living with Asthma Questionnaire)': 3, 'Salmeterol And Fluticasone': 3, 'Peak flow expiratory rate': 3, 'Asthma Control': 3})
CD010909 Counter({'Magnesium Sulfate': 11, 'Asthma': 9, 'Emergency Care': 6, 'Exacerbation Of Asthma': 3, 'Intravenous Steroid Injection': 3, 'FEV1': 3, 'Pulmonary function - Forced expiratory volume in one second (FEV1) (% of predicted FEV1, measured using spirometry)': 3, 'Hospital admission(s)': 3, 'Hospital admission': 3, 'proportion of patients admitted to hospital within 7 days': 3, 'breathlessness measured on a 100 mm visual analogue scale (VAS) in the 2 h after initiation of treatment': 3, 'PEF': 3, 'hospital admission rates': 3, 'Intravenous Therapy': 2, 'pulmonary function': 2, 'forced expiratory volume': 2, 'lung function': 2})
CD010256 Counter({'Asthma': 12, 'Terbutaline Injectable Solution': 3, 'Terbutaline': 3, 'Blood pressure': 3, 'Arterial blood gases - Partial pressure of oxygen (PaO2)': 3, 'Peak expiratory flow (PEF) rate (percentage of expected value, measured using spirometry)': 3, 'Arterial partial pressure of oxygen (PaO2) (measured by laboratory test)': 3, 'Pulse rate': 3, 'Peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Acute Asthma': 3, 'Severe Asthma': 3, 'Intravenous Infusion': 3, 'tachycardia': 3, 'lung function': 3, 'non-response': 3, 'cardiovascular effects': 3, 'adverse events': 3, 'peak expiratory flow rate': 3, 'Aminophylline': 3, 'Salbutamol': 3, 'FEV': 3, 'FVC and PEFR': 3, 'Nebulizer Therapy': 3, 'Intravenous Injection': 3, 'Oxygen': 3, 'time until discharge': 3, 'needed oxygen': 3, 'recovery time': 3, 'significant side-effects': 3})
CD002066 Counter({'Chronic Obstructive Pulmonary Disease': 3, 'Morphine': 3, 'exercise endurance': 3, 'gas exchange at rest or at any time during exercise': 3, 'breathlessness': 3, 'ventilation': 3})
CD000211 Counter({'Cerebral Infarction': 2, 'mortality': 2, 'neurological assessments': 2})
CD010347 Counter({'Asthma': 17, 'Budesonide': 9, 'Montelukast': 9, 'Forced Expiratory Volume in One Second (FEV1)': 6, 'Leukotriene Receptor Antagonists': 3, 'Long-Acting Beta-Agonists': 3, 'Glucocorticoids - Inhaled': 3, 'Mini Asthma Quality of Life Questionnaire': 3, 'Exacerbation rates': 3, 'Asthma Control Questionnaire': 3, 'Formoterol': 3, 'Peak Expiratory Flow Rate (PEFR)': 3, 'Current Symptom Scale': 3, 'Pulmonary Methacholine Challenge Test': 3, 'Sputum Finding': 3, 'Theophylline': 3, 'Peak Expiratory Flow Rate': 3, 'Pranlukast': 3, 'PEF': 3, 'serum eosinophil cationic protein': 3, 'FEV1': 3, 'use of beta2-agonist': 3, 'exhaled nitric oxide': 3, 'asthma symptoms': 3, 'blood eosinophil counts': 3, 'use of short-acting beta2 agonist': 3, 'lung function': 3, 'symptom scores': 3, 'adverse events': 3, 'asthma exacerbations': 3, 'Moderate Asthma': 2, 'Severe Asthma': 2, '': 2})
CD002885 Counter({'Asthma': 3, 'Theophylline': 3, 'Lung function - Peak expiratory flow (PEF) (measured using spirometry)': 3, 'Serum eosinophil cationic protein (sECP) level (measured by laboratory test)': 3, 'Asthma symptoms (measure not specified)': 3, 'Use of rescue medication (unspecified)': 3, 'Peripheral blood lymphocyte subpopulations (measured by laboratory test)': 3, 'clinical and immunomodulatory effect': 3})
CD001740 Counter({'Asthma': 6, 'Methylprednisolone Pulse Therapy': 6, 'Exacerbation Of Asthma': 3, 'Placebo': 3, 'effect of MPPT': 3, 'patient preference': 3, 'Acute Asthma': 3, 'Methylprednisolone': 3, 'Forced Expiratory Volume in One Second (FEV1)': 3, 'Therapeutic Response': 3, 'Use of Supplementary Prednisolone': 3, 'Death': 3, 'Assisted Ventilation': 3})
CD004979 Counter({'Acute Lower Respiratory Tract Infection': 3, 'Lower Respiratory Tract Infection': 3, 'Cefpodoxime': 3, 'Cefazedone': 3, 'Satisfactory clinical response (defined as cured or improved)': 3, 'clinical response (cured or improved)': 3})
CD004104 Counter({'Chronic Obstructive Pulmonary Disease': 15, 'COPD Exacerbation': 12, 'Noninvasive Positive Pressure Ventilation': 9, 'Chronic Obstructive Lung Disease': 6, 'Noninvasive Ventilation': 6, 'Heart rate': 6, 'In-hospital mortality': 6, 'Respiratory rate': 6, 'Arterial blood gases - Partial pressure of oxygen (PaO2)': 6, 'Respiratory Failure': 6, 'Hypercapnia': 3, 'Oxygen Therapy': 3, 'Overnight partial pressure of carbon dioxide in arterial blood (PaCO2)': 3, 'Sleep efficiency (measure not specified)': 3, 'Daytime partial pressure of carbon dioxide in arterial blood (PaCO2)': 3, 'Quality of life (measure not specified)': 3, 'Daytime arterial partial pressure of oxygen (PaO2)': 3, 'Total sleep time (measure not specified)': 3, 'in-hospital mortality rate': 3, 'frequency of complications': 3, 'mean hospital stay': 3, 'length of the hospital stay': 3, 'need for endotracheal intubation': 3, 'Arterial blood pH (pHa)': 3, 'Endotracheal intubation': 3, 'Scale for accessory muscle use': 3, 'Partial pressure of carbon dioxide in artery (PaCO(2)': 3, 'Intubation': 3, 'Arterial blood gases - Acid-base (pH) level': 3, 'Use of accessory muscles (measured using an unspecified scale)': 3, 'Respiratory Acidosis': 3, 'Intensive Care': 3, 'Hospitalization': 3, 'Inhaled Bronchodilator Therapy': 3, 'Oxygen': 3, 'Corticosteroids': 3, 'Arterial blood gases - Partial pressure of carbon dioxide (PaCO2)': 3, 'Breathing frequency': 3, 'Endo-Tracheal Intubation (ETI)': 3, 'Arterial blood gases - pH level': 3, 'Serum lactate level (measured by laboratory test)': 3, 'Lung function (measure(s) not specified)': 3, 'Dyspnea symptom score (measure not specified)': 3, 'All-cause mortality': 3, 'Length of intensive care unit (ICU) stay (days)': 3, 'Long-term Oxygen Therapy': 3, '': 3, 'Intermittent Positive Pressure Ventilation': 3, 'Paco2': 3, 'arterial PaO2': 3})
CD011721 Counter({'Asthma': 24, 'Tiotropium': 21, 'Salmeterol': 6, '': 6, 'Smoker': 3, 'Ex-smoker': 3, 'first episode of asthma worsening': 3, 'peak forced expiratory volume in 1 second': 3, 'FEV1': 3, 'ACQ-7 response': 3, 'Time to first severe asthma exacerbation': 3, 'exacerbation': 3, 'Steroid Therapy': 3, 'Metered Dose Inhaler': 3, 'Forced vital capacity (FVC) area under the curve (AUC) (measured using spirometry)': 3, 'FEV response': 3, 'rescue medication use': 3, 'Forced vital capacity (FVC) peak response (measured using spirometry)': 3, 'Rescue medication use': 3, 'Forced expiratory volume in one second (FEV1) peak response (measured using spirometry)': 3, 'Forced expiratory volume in one second (FEV1) trough response (measured using spirometry)': 3, 'Forced expiratory volume in one second (FEV1) area under the curve (AUC) (measured using spirometry)': 3, 'Time to first exacerbation': 3, 'time to first exacerbation': 3, 'Asthma Control Questionnaire (ACQ) score': 3, 'ACQ': 3, 'Long-Acting Beta-Agonists': 3, 'Corticosteroids': 3, 'Lung function - Peak forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Primary lung function endpoints were peak FEV&lt;sub&gt;1&lt;/sub&gt; (0-3h) and trough FEV&lt;sub&gt;1&lt;/sub&gt; response': 3, 'Lung function - Trough forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'FEV1 AUC response': 3, 'Beclomethasone Metered Dose Inhaler': 3, 'validated asthma questionnaires': 3, 'asthma control days': 3, 'rescue bronchodilator use': 3, 'forced expiratory volume in one second': 3, 'exacerbations': 3, 'peak expiratory flow rate': 3, 'peak expiratory flow': 3, 'Formoterol': 3, 'Budesonide': 3, 'improvement in FEV1': 3, 'reductions in rescue medication use': 3, 'FEV1 response': 3, 'responder rate assessed by ACQ': 3, 'peak FEV1(0-3 h) response': 3})
CD004878 Counter({'Viral Respiratory Infection': 3, 'Emergency Care': 3, 'Respiratory Distress': 3, 'Prednisolone': 3, 'Use of additional asthma medication': 3, 'need for additional asthma medication': 3, 'median duration of symptoms of respiratory distress': 3, 'Hospitalization': 3, 'requiring &amp;gt;or=3 days of hospitalization': 3, '&gt;or=3 days of hospitalisation': 3, 'Duration of symptoms of respiratory distress (days)': 3, 'Hospitalisation': 3, 'Length of hospital stay (days)': 3, 'median lenght of stay': 3})
CD003134 Counter({'Idiopathic Pulmonary Fibrosis': 6, 'Interferon Gamma': 3, 'Treatment adherence': 3, 'QoL': 3, 'Pneumonia': 3, 'Progression free survival': 3, 'Acute respiratory infection': 3, 'Lung function': 3, 'Premature discontinuation': 3, 'Death': 3, 'Gas exchange': 3, 'Interferon Gamma-1b': 3, 'Constitutional signs and symptoms (influenza-like illness, fatigue, fever, and chills)': 3, 'Serious adverse event(s)': 3, 'Any adverse event(s)': 3, 'Mortality': 3, 'Treatment adherence (measure(s) not specified)': 3, 'Premature discontinuation of treatment': 3, 'Pulmonary Fibrosis': 3, 'Acetylcysteine': 3, 'composite physiologic index (CPI)': 3, 'vital capacity (VC)': 3, 'diffusing capacity (DLco': 3})
CD000245 Counter({'Healthy': 3, 'Cough': 3, 'Erythromycin': 3, 'Sputum production': 3, 'Symptoms': 3, 'Congestion': 3, 'Abnormal lung examination': 3, 'Required cough or cold medication': 3, 'General health': 3})
CD003232 Counter({"Wegener's Granulomatosis": 5, 'Cyclophosphamide': 5, 'Prednisolone': 5, 'Renal Vasculitis': 3, 'Cyclosporine': 3, 'Plasma Exchange': 3, 'Immunosuppressants': 3, 'Relapses': 3, 'Renal survival (various follow-up time points)': 3, 'Patient survival (various follow-up time points)': 3, 'Mortality': 3, 'Morbidity': 3, 'Dialysis dependence (at 5 years)': 3, 'Relapse': 3, 'Renal survival': 3, 'Plasma creatinine levels': 3, 'Morbidity (unspecified)': 3, 'Death': 3, 'Time to relapse': 3})
CD001390 Counter({'Chronic Obstructive Pulmonary Disease': 6, 'Pneumococcal Vaccine': 6, 'Incidence of pneumonia': 3, 'Antibody titers': 3, 'flora of the sputum': 3, 'deaths': 3, 'respiratory infections or pneumonias': 3, 'Death': 3, 'Pneumococcal Polysaccharides (23)': 3, 'Community acquired pneumonia (CAP) of pneumococcal or unknown aetiology (confirmed by radiology)': 3, 'Non-bacteraemic pneumococcal community acquired pneumonia (CAP)': 3, 'Time to event - Community acquired pneumonia (CAP) of pneumococcal or unknown aetiology (days, confirmed by radiology)': 3})
CD007498 Counter({'Idiopathic Pulmonary Fibrosis': 3, 'Antibiotic Therapy': 3, 'Use of ventilation therapy': 3, 'mortality rate': 3, 'Mortality (at 30 days)': 3, 'Antibiotic treatment duration (days)': 3, 'days of hospitalization': 3, 'Days of hospitalization (days)': 3, 'ventilation therapy': 3, 'reduced exposure to antibiotics': 3, 'Treatment success (measure/ criteria not specified)': 3, 'Use of antibiotics treatment (at 30 days)': 3})
CD011434 Counter({'Chronic Obstructive Pulmonary Disease': 10, 'Exercises': 9, '': 3, 'Dyspnea during activity of daily living (ADL) (measured using the Chronic Respiratory Disease Questionnaire (CRDQ))': 3, 'Health-related quality of life (HRQL) (measured using the Chronic Respiratory Disease Questionnaire (CRDQ))': 3, 'Muscle strength - Triceps (measured using an isometric dynamometer)': 3, 'Arm function - Shoulder flexion force (measured using the 6-min pegboard and ring test (6PBRT))': 3, 'Arm function - Shoulder abduction force (measured using the 6-min pegboard and ring test (6PBRT))': 3, 'Exercise capacity (measured using the unsupported upper limb exercise test (UULEX))': 3, 'Muscle strength - Middle deltoids (measured using an isometric dynamometer)': 3, 'Arm function - Elbow flexion force (measured using the 6-min pegboard and ring test (6PBRT))': 3, 'Muscle strength - Anterior deltoids (measured using an isometric dynamometer)': 3, 'Arm function - Elbow extension force (measured using the 6-min pegboard and ring test (6PBRT))': 3, 'Muscle strength - Biceps (measured using an isometric dynamometer)': 3, 'Resistive Exercise': 3, 'Exercise Test Finding': 3, 'Finding Of Power Of Skeletal Muscle': 3, 'Chronic Obstructive Lung Disease': 3, 'exercise performance': 3, 'well-being': 3, 'pulmonary function': 3, 'lung function': 3, 'V02 max': 3, 'muscle endurance': 3, 'whole body endurance': 3, 'muscle strength': 3})
CD002179 Counter({'Seasonal Asthma': 3, 'Asthma': 3, 'Oxatomide': 3, 'Wheezing  (measured using an unspecified scale)': 3, 'Dyspnea at rest  (measured using an unspecified scale)': 3, 'Cough (measured using an unspecified scale)': 3, 'Dyspnea following exercise  (measured using an unspecified scale)': 3, 'Drowsiness requiring a reduction in oxatomide dosage': 3, 'Sleep disorders  (measured using an unspecified scale)': 3})
CD011699 Counter({'Bronchiectasis': 5, 'Oscillating Positive Expiratory Pressure (flutter) Physiotherapy': 3, 'Sputum weight (measured buy laboratory test)': 3, 'Acceptability (measured using a patient questionnaire)': 3, 'Health status (Chronic Respiratory Disease Questionnaire)': 3, 'Dyspnea (measured using the Borg Dyspnea Scale score)': 3, 'patient acceptability': 3, 'sputum weights': 3, 'ventilatory function': 3, 'Health status (measured using the Chronic Respiratory Disease Questionnaire)': 3, 'Peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Ventilatory function (measure(s) not specified)': 3, 'Chronic Lung Disease': 3, 'Pneumococcal Vaccine': 3, 'Influenza Virus Vaccine': 3, 'patients with CLD experiencing infectious acute exacerbation (P=0.022), but not pneumonia': 3, 'FEV1': 2, 'effectiveness of clearing secretions': 2, 'forced vital capacity': 2, 'sputum production': 2, 'peak expiratory flow rate': 2, 'ease of use': 2})
CD010908 Counter({'Cyclophosphamide': 12, 'Interstitial Lung Disease': 9, 'Mycophenolate Mofetil': 6, 'Systemic Sclerosis': 6, 'Chronic Lung Disease': 3, 'lung function': 3, 'forced vital capacity': 3, 'Lung Disease With Systemic Sclerosis': 3, 'Cyclophosphamide Oral Tablet': 3, 'Mycophenolate': 3, 'Reached required dose': 3, 'Discontinued drug': 3, 'treatment responsiveness': 3, 'Deaths': 3, 'Time to reach maximum targeted dose': 3, 'Drug-related adverse events': 3, 'drug related serious side effects': 3, 'pulmonary function': 3, 'Scleroderma And Associated Disorders': 3, 'Dyspnea': 3, 'Simple Pulmonary Alveolitis': 3, 'Any serious adverse event(s)': 3, 'Health-related quality of life (measure(s) not specified)': 3, 'Dyspnea (measure not specified)': 3, 'Any adverse event(s)': 3, 'Thickening of the skin (measure not specified)': 3, 'Lung function - Forced vital capacity (FVC) (% of predicted, measured using spirometry)': 3, 'Cyclophosphamide Oral Capsule': 3, 'extent of fibrotic reticulation': 3, 'ground glass and honeycomb patterns': 3, 'quantitative ILD': 3})
CD001187 Counter({'Asthma': 18, 'House Dust Mite Allergy': 12, 'medication use': 6, 'Allergic Asthma': 6, 'Childhood Asthma': 6, 'House Dust Mite Barrier Duvet Cover': 3, 'Serum immunoglobulin E (IgE) to mite allergen level (measured by laboratory test)': 3, 'Asthma symptoms (measure(s) not specified)': 3, 'Allergen content of mattress dust samples (measured by laboratory test)': 3, 'Peak expiratory flow (PEF) (measured using spirometry)': 3, 'Medication use (unspecified)': 3, 'allergic symptoms': 3, '': 3, 'Laminar Airflow Unit (physical Object)': 3, 'Air Cleaner (physical Object)': 3, 'Air Filter': 3, 'histamine airway responsiveness': 3, 'symptom control': 3, 'Counseling': 3, 'Provision Of Written Information': 3, 'Symptom scores': 3, 'ug/g of mite allergen': 3, 'Recorded mite allergen': 3, 'Benzyl Benzoate': 3, 'House Dust Mite Barrier Pillowcase': 3, 'House Dust Mite Barrier Bed Mattress Cover': 3, 'Lung Function': 3, 'Bronchial Hyperresponsiveness': 3, 'Asthma Monitoring Using Asthma Symptom Diary': 3, 'Peak Expiratory Flow Rate': 3, 'Mite Allergen Level Measurement Finding': 3, 'Covering Device': 3, 'eosinophil cationic protein (ECP), eosinophil protein X (EPX), eosinophil peroxidase (EPO), and soluble interleukin-2 receptor': 3, 'treatment schedule': 3, 'daily symptom scores': 3, 'peak expiratory flow rate': 3, 'histamine challenge': 3, 'Bedding Set (physical Object)': 3, 'Mite counts': 3, 'asthma symptom scores': 3, 'Morning and evening peak expiratory flow': 3, 'Provocative concentration (PC) of histamine (measure(s) not specified)': 2, 'House dust mite numbers (measure(s) not specified)': 2, 'Evening peak expiratory flow (PEF) rate (measured using spirometry)': 2, 'Number of hours each day spent wheezing (hours)': 2, 'Symptom scores (measured using a linear analogue scale)': 2, 'Histamine airway responsiveness (measure(s) not specified)': 2, 'Morning peak expiratory flow (PEF) rate (measured using spirometry)': 2, 'Allergy': 2, 'Rhinitis': 2, 'global assessment of the clinical state': 2, 'measurement of the peak flow rate morning and evening': 2, 'observations related to ORL and bronchial symptoms': 2, 'antigenicity of the house dust': 2, 'hyperreactivity to chemical challenge': 1, 'lung function': 1, 'symptoms': 1, 'reduction in medication use': 1})
CD002996 Counter({'Bronchiectasis': 6, '24-hour sputum volume (measured by laboratory test)': 6, 'Quality of Life (measured using the St. George’s Respiratory Questionnaire (SGRQ))': 6, 'Gentamicin': 3, 'Cough (measured using the Leicester Cough Questionnaire)': 3, 'Exacerbation(s)': 3, 'Sputum bacterial density (measured by sputum bacteriology)': 3, 'FEV(1)': 3, "St. George's Respiratory Questionnaire": 3, 'reduced sputum bacterial density': 3, 'Forced vital capacity (FVC) (measured using spirometry)': 3, 'greater exercise capacity': 3, 'improvements in Leicester Cough Questionnaire': 3, 'Time to event - First exacerbation': 3, 'forced expiratory flow, midexpiratory phase': 3, 'Sputum purulence (measured by laboratory test)': 3, 'Exercise capacity (measure(s) not specified)': 3, 'FVC': 3, 'Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'less sputum purulence': 3, 'Mid-expiratory phase (measured using spirometry)': 3, 'fewer exacerbations': 3, 'Mannitol': 3, 'Time to event - First pulmonary exacerbation (days)': 3, 'Sputum microbiology (outcome(s) not specified)': 3, 'Epworth Sleepiness Scale (outcome not specified)': 3, 'Antibiotics prescribed for pulmonary exacerbation(s)': 3, 'Adverse events (unspecified)': 3, 'Lung function (measure(s) not specified)': 3, 'Airway reactivity (measure(s) not specified)': 3, 'Pulmonary exacerbation(s)': 3})
CD002314 Counter({'Asthma': 6, 'Montelukast': 6, 'Beclometasone': 3, 'Loratadine': 3, 'asthma-specific quality of life': 3, 'FEV(1)': 3, 'nocturnal awakenings': 3, 'evening peak expiratory flow': 3, 'nocturnal asthma symptom score': 3, 'Days of absenteeism from school (days, children)': 3, 'Days of absenteeism from work (days, parents)': 3, 'Asthma-related medical resource utilisation (unspecified)': 3, 'Overall satisfaction with treatment (patient- and parent-reported, measure not specified)': 3, 'Use of treatment as instructed (parent-reported, measure not specified)': 3, 'Difficulty of use of treatment (parent-reported, measure not specified)': 3, 'Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Adherence to treatment regimen (measure not specified)': 3, 'Convenience of treatment (parent-reported, measure not specified)': 3, 'Oral corticosteroid use': 3})
CD003123 Counter({'Acute Bronchiolitis': 3, 'Emergency Care': 3, 'Epinephrine': 3, 'Salbutamol': 3, 'Oxygen saturation (% at 60 minutes)': 3, 'admitted to the hospital': 3, 'Hospitalisation(s)': 3})
CD012393 Counter({'Asthma': 3, 'Omalizumab': 3, 'reduced number of days with asthma': 3})
CD001746 Counter({'Asthma': 14, 'Passive Smoker': 6, 'Counseling': 6, 'symptom free days': 6, 'Motivational Interviewing Technique': 5, 'Asthma Education': 3, 'cotinine to creatinine ratio (lnCCR)': 3, 'asthma-related medical visit': 3, 'reduction in tobacco smoke exposure': 3, 'natural logarithm of the cotinine to creatinine ratio (lnCCR)': 3, 'use of health-care services': 3, 'use of health-care service': 3, 'Preventive Procedure': 3, 'Cessation Of Smoking': 3, 'Home Visit': 3, 'smoking cessation': 3, 'Childhood Asthma': 3, 'Self-monitoring': 3, 'decreased exposure': 3, 'Significantly greater change': 3, 'Health Promotion': 3, 'Air Cleaner (physical Object)': 3, 'urine contine concentration': 3, 'particulate matter': 3, 'air nicotine': 3, 'Dosage': 2})
CD005351 Counter({'Acute Respiratory Failure': 4, 'Chronic Obstructive Pulmonary Disease': 3, 'Noninvasive Positive Pressure Ventilation': 3, 'Arterial blood gases - Partial pressure of oxygen (PaO2)': 3, 'amounts of time nurses and therapists spend at the bedside': 3, 'respiratory rate': 3, 'Heart rate': 3, 'Maximal inspiratory pressure (measure not specified)': 3, 'Dyspnea scores': 3, 'Need for intubation': 3, 'Dyspnea scores (measure(s) not specified)': 3, 'PaO2': 3, 'maximal inspiratory pressures': 3, 'need for intubation': 3, 'Time spent at the bedside by nurses and therapists (minutes)': 3, 'Respiratory rate': 3})
CD009660 Counter({'Asthma': 14, 'Exposed To Tobacco Smoke At Home': 3, 'Counseling': 3, "Exposure to the parent's cigarettes in the home": 3, 'Asthma Education': 3, 'Number of symptom-free nights (nights)': 3, 'Caregiver feelings of frustration (measure not specified)': 3, 'Hospitalisation(s)': 3, "Caregiver feelings of confidence to manage their child's asthma (measure not specified)": 3, 'Number of symptom-free days (days)': 3, "Caregiver feelings of upset due to their child's asthma (measure not specified)": 3, 'Emergency department visit(s)': 3, 'Asthma under control (measure not specified)': 3, 'Caregiver feelings of helplessness (measure not specified)': 3, 'Asthma Self Management': 3, 'knowledge': 3, 'morbidity index': 3, 'self-management': 3, 'Family Therapy': 3, 'Education About Asthma Self Management': 3, 'Health-related quality of life (measured using the 12-Item Short Form Health Survey (SF-12))': 3, 'Anxiety (parent(s), measured using the Hospital Anxiety and Depression Scale, Anxiety subscale)': 3, 'Withdrawal or dropout from study': 3, 'Perceived efficacy in asthma management (parent(s), measure not specified)': 3, 'Emotional well-being (parent(s), measured using the Body Mind Spirit Well-being Inventory, Emotion subscale)': 3, 'Exhaled nitric oxide level (child, measure not specified)': 3, 'Spirometry (child, outcome(s) not specified)': 3, 'Adjustment to asthma (child, measure not specified)': 3, 'emergency department or inpatient services for asthma': 2, 'change in asthma symptoms': 2, 'asthma-related quality of life': 2, 'health care utilisation': 2})
CD001495 Counter({'Chronic Obstructive Lung Disease': 3, 'Isoproterenol': 3, 'SGaw': 3, 'FEV1': 3, 'Pulmonary function - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Pulmonary function - Specific airway conductance (sGaw) (measured using spirometry)': 3, 'Symptom scores (measure(s) not specified)': 3, 'FVC': 3, 'Pulmonary function - Forced vital capacity (FVC) (measured using spirometry)': 3, 'Arterial blood gases (measured by laboratory test)': 3, 'Airways Obstruction Reversible': 3, 'Theophylline': 3, 'Terbutaline': 3, '': 3, 'Abnormal Airflow': 2, 'changes in dyspnea score': 2, 'forced expiratory volume in 1 second': 2, 'maximum expiratory pressures': 2})
CD004435 Counter({'Obstructive Sleep Apnea Syndrome': 10, 'side effects': 4, 'Sleep Apnea Palate Implant (physical Object)': 3, 'Insertion Of Implant Into Soft Palate': 3, 'Apnea/ hypopnea (measured using the Apnea/Hypopnea Index (AHI))': 3, 'Daytime sleepiness (measured using the Epworth Sleepiness Scale (ESS))': 3, 'Snoring intensity (measured using a visual analogue scale (VAS))': 3, 'Health-related quality of life (measured using the 36-Item Short Form Health Survey questionnaire (SF-36))': 3, 'Intraoral Device (physical Object)': 3, 'Apnea/hypopnea index (AHI) score': 3, 'Utilisation of the device (measure not specified)': 3, 'Ease of use of device (measured using a 6-point scale)': 3, 'Breathing-related arousal(s) (measure not specified)': 3, 'treatment failures (failure to reduce AHI to &lt;10/hour and/or failure to relieve symptoms)': 2, 'apnoea/hypopnoea index (AHI)': 2, 'compliance failure (unable or unwilling to use the treatment)': 2, 'patient satisfaction': 2, 'efficacy': 2, 'compliance': 2, 'patient preference': 2})
CD000008 Counter({'Asthma': 6, 'Acupuncture': 6, 'Bronchial hyperreactivity - Methacholine provocative concentration causing a 20% fall in FEV1 (PC20) (measured using methacholine challenge test)': 3, 'methacholine challenge': 3, 'FEV(1)': 3, 'daily peak flow (PF) variability': 3, 'Peak expiratory flow (PEF) variability (measured using spirometry)': 3, 'Lung function - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Asthma symptoms score (measured using an asthma diary)': 3, 'total airway resistance at 5Hz (R5) as measured by impulse oscillometry (IOS)': 3})
CD004434 Counter({'Pulmonary Arterial Hypertension': 6, 'Sitaxentan': 6, '6-minute walk distance (metres, measured using the six-minute walk test (6MWT))': 6, 'Connective Tissue Disorder': 3, 'Congenital Heart Disease': 3, 'Pulmonary vascular resistance (measure(s) not specified)': 3, 'Quality of life (measure(s) not specified)': 3, 'Maximum rate of oxygen consumption measured during incremental exercise (VO2 max) at anaerobic threshold (measured using cardiopulmonary exercise testing)': 3, '6-minute walk': 3, 'VO(2) at anaerobic threshold': 3, 'hemodynamics': 3, 'Maximum rate of oxygen consumption during incremental exercise (VO2 max) (measured using cardiopulmonary exercise testing)': 3, 'VE per carbon dioxide production at anaerobic threshold': 3, 'Hemodynamics (unspecified)': 3, 'quality of life': 3, 'New York Heart Association functional class': 3, 'Aminotransferase values (measure(s) not specified)': 3, 'Cardiac index (unspecified)': 3, 'Time to clinical worsening (days)': 3, 'New York Heart Association class': 3, 'change in peak VO(2) at Week 12': 3, 'time to clinical worsening': 3, 'Ventilation (VE) per carbon dioxide production at anaerobic threshold (measured using cardiopulmonary exercise testing)': 3, 'Pulmonary hypertension severity (measured using the World Health Organisation functional classification of pulmonary hypertension)': 3, 'Elevated liver transaminase level (measured by laboratory test)': 3, 'Dyspnea (measured using the Borg Dyspnea Scale score)': 3, 'Time to event - Clinical worsening (measure not specified)': 3, "Eisenmenger's Syndrome": 3, 'Bosentan': 3, 'pulmonary vascular resistance index': 3, '6-minute walk distance': 3, 'mean pulmonary arterial pressure': 3, 'additional hemodynamic parameters': 3, 'adverse events': 3, 'right- and left-heart catheterization': 3, 'functional capacity': 3, 'systemic pulse oximetry': 3})
CD012315 Counter({'Asthma': 9, 'Referral To Asthma Clinic': 3, 'Asthma Management': 3, 'Unscheduled care for acute asthma': 3, 'Ambulatory Care': 3, 'Airway function': 3, 'Clinical Support': 3, 'asthma severity index': 3, 'visits to the ED': 3, 'Admissions': 3})
CD006924 Counter({'Asthma': 21, 'Formoterol': 21, 'Budesonide': 15, 'Formoterol And Budesonide': 6, 'Mometasone furoate': 6, 'Vital signs (measured using physical examinations)': 3, '24-hour Holter monitor assessments': 3, '12 hour mean forced expiratory volume in 1 second (FEV(1)) (measured using serial spirometry)': 3, 'Electrocardiography': 3, 'Withdrawals due to worsening asthma': 3, 'Routine laboratory assessments (unspecified)': 3, 'Serious adverse events (unspecified)': 3, 'Morning predose forced expiratory volume in 1 second (FEV(1)) (measured using serial spirometry)': 3, 'Metered Dose Inhaler': 3, 'Dry Powder Inhaler': 3, 'Peak expiratory flow (PEF)': 3, 'Morning peak expiratory flow (PEF) (measured using spirometry)': 3, 'Serious adverse events - Asthma exacerbation(s)': 3, 'Mild-moderate adverse events - Headache(s)': 3, 'Sitting systolic blood pressure': 3, 'Mild-moderate adverse events - Upper respiratory infection(s)': 3, 'Treatment discontinuation due to adverse event(s)': 3, 'Any adverse event(s)': 3, 'Treatment-related adverse events (unspecified)': 3, 'Pulse rate': 3, 'Sitting diastolic blood pressure': 3, 'Mild-moderate adverse events - Nasopharyngitis': 3, 'Serious adverse events - Ruptured ovarian cyst': 3, 'Serious adverse events - Pyrexia': 3, 'Patient Satisfaction with Asthma Medication PSAM': 3, 'AQLQ questionnaire': 3, 'Medical Outcomes Study MOS Sleep Scale': 3, 'nocturnal awakenings': 3, 'safety': 3, 'asthma control': 3, 'Forced expiratory volume in 1 second': 3, 'Moderate Persistent Asthma Uncontrolled': 3, 'Formoterol And Mometasone': 3, 'Asthma exacerbations and deteriorations in control': 3, 'Lung function': 3, 'Peak Expiratory Flow Rate (PEFR)': 3, 'Exacerbation of Asthma': 3, 'Plasma Cortisol Level': 3, 'Serum Potassium Level': 3, 'Adverse Event': 3, 'Asthma Quality of Life Questionnaire (AQLQ)': 3})
CD008774 Counter({'Atopic Dermatitis': 3, 'Sublingual Tablet': 3, 'Prophylactic Immunotherapy': 3, 'House Dust Mite Desensitization Therapy': 3, 'Respiratory symptoms': 3, 'Asthma': 3, 'Rhinitis': 3})
CD002884 Counter({'Exacerbation Of Asthma': 6, 'Asthma': 6, 'Oxygen': 6, 'Helium': 6, 'Forced expiratory volume in one second (FEV1) (measured using spirometry)': 6, 'Emergency Care': 3, 'Albuterol Inhalant Solution': 3, 'Nebulizer Therapy': 3, 'Heart rate': 3, 'Forced expiratory volume in one second (FEV1)  (measured using spirometry)': 3, 'spirometry': 3, 'Hospitalization': 3, 'Forced expiratory flow at 25-75% of the pulmonary volume (FEF25-75) (measured using spirometry)': 3, 'Dyspnea (measure not specified)': 3, 'Oxygen saturation': 3, 'Clinical score (measure not specified)': 3, 'Forced vital capacity (FVC) (measured using spirometry)': 3, 'Respiratory rate': 3, 'Peak expiratory flow rate (PEFR) (measured using spirometry)': 3})
CD006135 Counter({'Atopic Dermatitis': 3, 'Respiratory Symptom': 3, 'Bifidobacterium Bifidum Preparation': 3, 'Fructooligosaccharide': 3, 'Infant Formula': 3, 'frequent wheezing': 3, 'specific IgE against aeroallergens': 3, 'asthma medication use': 3, 'total serum IgE': 3, 'wheezing and/or noisy breathing apart from colds': 3, 'respiratory symptoms': 3})
CD001285 Counter({'Asthma': 17, 'FEV1': 5, 'Nedocromil': 3, 'Albuterol Oral Tablet': 3, 'Mast cell numbers': 3, 'Evening peak flow': 3, 'Total and activated eosinophils in bronchial biopsy tissue.': 3, 'Lymphocyte numbers': 3, 'Clinical findings': 3, 'Allergic Asthma': 3, 'Albuterol Inhalant Solution': 3, 'Airway responsiveness': 3, 'Allergen-induced early asthmatic response (defined as fall in forced expiratory volume in one second (FEV1) (measured using spirometry))': 3, 'Allergen-induced asthmatic response': 3, 'Methacholine provocative concentration causing a 20% fall in FEV1 (PC20) (measured using methacholine challenge test)': 3, 'Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Allergen-induced late asthmatic response (defined as fall in forced expiratory volume in one second (FEV1) (measured using spirometry))': 3, 'Allergen-induced increase in airway responsiveness (defined as change in log methacholine provocative concentration causing a 20% fall in FEV1 (PC20) (measured using methacholine challenge test))': 3, 'forced expiratory volume in 1 second (FEV1)': 3, 'Salbutamol': 3, 'Placebo': 3, 'Steroid Dose Inhaled Daily': 3, 'exacerbations of asthma': 3, 'Fenoterol': 3, 'adverse effect': 3, 'airway responsiveness to methacholine': 3, 'control of asthma': 3, 'Budesonide': 3, 'Terbutaline': 3, 'dose of histamine or adenosine monophosphate (AMP)': 3, 'daily morning and evening peak expiratory flow': 3, 'PD20-FEV1 methacholine': 2, 'morning and evening PEF': 2, 'FVC': 2, 'PEF amplitude % mean': 2})
CD012290 Counter({'Chronic Obstructive Pulmonary Disease': 9, 'Participation In Tai Chi': 9, 'Education About Breathing Technique': 3, 'Physical Exercises': 3, '6-minute walk distance (metres, measured using the six-minute walk test (6MWT))': 3, 'Lung function - Forced vital capacity (FVC) (measured using spirometry)': 3, 'Lung function - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'COPD exacerbations': 3, 'disease progression': 3, 'Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Forced vital capacity (FVC) (measured using spirometry)': 3, 'Walking distance (measured using the 6-minute walk test (6MWT))': 3, 'COPD exacerbation(s)': 3, "Quality of life - Overall (measured using the St George's Respiratory Questionnaire (SGRQ) total score)": 3, 'Perceived social support (measured using the Multidimensional Scale of Perceived Social Support)': 3, "Quality of life - Symptoms (measured using the St George's Respiratory Questionnaire (SGRQ) symptoms domain score)": 3, "Quality of life - Activity (measured using the St George's Respiratory Questionnaire (SGRQ) activity domain score)": 3, 'Perceived social support from friends (measured using the Multidimensional Scale of Perceived Social Support (MSPSS))': 3, "Quality of life (measured using the St George's Respiratory Questionnaire (SGRQ), Total score)": 3})
CD011801 Counter({'Hospitalization': 3, 'Asthma': 3, 'Medication Dosage Tapering': 3, 'Corticosteroids': 3, 'readmission': 3, 'reexacerbation': 3, 'exacerbation of asthma': 3, 'relapse rate': 3, 'spirometry': 3, 'Severe Asthma': 3, 'Prednisolone': 3, 'control of asthma': 3})
CD004108 Counter({'Asthma': 19, 'Nedocromil': 15, '': 8, 'Montelukast': 3, 'Formoterol': 3, 'Triamcinolone acetonide': 3, 'Triamcinolone': 3, 'hyperresponsiveness': 3, 'allergic inflammation': 3, 'Forced expiratory volume in 1 second FEV1': 3, 'clinical parameters': 3, 'sIL-2R and sICAM-1 serum level': 3, 'Need for rescue inhaled beta 2-agonist': 3, 'Daytime asthma (measure not specified)': 3, 'Asthma symptoms - Overall (measure not specified)': 3, 'Asthma symptom-free days (% of days)': 3, 'Asthma symptoms - Cough (measure not specified)': 3, 'Peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'House Dust Mite Allergy': 3, 'Allergic Asthma': 3, 'Serum interleukin 4 (IL-4) level (measured by laboratory test)': 3, 'Serum immunoglobulin E (IgE) level (measured by laboratory test)': 3, 'Bronchial hyperreactivity (measure(s) not specified)': 3, 'Clinical symptoms (measure(s) not specified)': 3, 'Budesonide': 3, 'hypothalamic-pituitary-adrenal (HPA) axis function': 3, 'Beclometasone': 3, 'hyperresponsiveness to methacholine (PC20)': 3, 'flow ratio (M/P ratio)': 3, 'postbronchodilator FEV1': 3, 'Seasonal Asthma': 3, 'Nedocromil Metered Dose Inhaler': 3, 'Methacholine': 2, 'Antiinflammatory Agents': 2})
CD010130 Counter({'Lower Respiratory Tract Infection': 2, 'Prescription of antibiotics (measured by review of patient records)': 2, 'Prescription of antibiotics': 2})
CD005604 Counter({'Allergic Rhinitis': 3, 'Fexofenadine': 3, 'physical examination': 3, 'laboratory testing (blood chemistry and hematology profiles)': 3, '12-lead electrocardiography': 3, 'vital signs': 3, 'digestive': 3, 'treatment-emergent AEs': 3, 'vital signs (oral temperature, blood pressure, heart rate, and respiratory rate)': 3, 'physical examinations': 3, 'laboratory measures': 3})
CD001108 Counter({'Mycetoma': 3, 'Allergic Bronchopulmonary Aspergillosis': 3, 'Ketoconazole': 3, 'Serum immunoglobulin (IgG) concentration (measured using a laboratory test)': 3, 'Any adverse effect': 3, 'Symptom score (measure not specified)': 3, 'adverse effects': 3, 'lower symptom scores': 3, 'serum IgG concentration': 3})
CD011032 Counter({'Asthma': 3, 'Beclometasone': 3, 'Albuterol Inhalant Solution': 3, 'severe adverse events': 3, 'Linear growth (measured using height, cm)': 3, 'bronchitis.': 3, 'Asthma exacerbation(s)': 3, 'Frequency of treatment failure': 3, 'Time to first asthma exacerbation requiring oral corticosteroids (days)': 3, 'Severe adverse events - Viral meningitis': 3, 'Treatment failure': 3, 'viral meningitis': 3, 'Growth': 3, 'Frequency of exacerbations': 3, 'Severe adverse events - Bronchitis': 3})
CD000442 Counter({'Selegiline': 33, "Dementia Due To Alzheimer's Disease": 30, 'cognitive function': 6, 'Neuropsychological tests (unspecified)': 6, 'Clinical rating scales (unspecified)': 6, 'behavior': 6, 'Behaviour': 6, 'Cognitive function': 6, 'memory': 6, 'Concentration of tryptophan': 3, 'concentrations of NA': 3, 'concentrations of homovanillic acid (HVA)': 3, 'Concentrations of NA metabolites, 3,4-dihydroxyphenylglycol (DHPG), and 3-methoxy-4-hydroxyphenyl glycol (MHPG)': 3, 'concentrations of the dopamine metabolite, 3,4-dihydroxyphenylacetic acid (DOPAC)': 3, 'Concentration of  5-hydroxyindoleacetic acid (5-HIAA)': 3, 'Severity of dementia': 3, 'Controlled Oral Word Association Test': 3, "Alzheimer's Disease Assessment Scale , Non-cognitive subscale (ADAS-noncog) score": 3, 'Mini-Mental State Examination (MMSE)': 3, 'Brief Psychiatric Rating Scale (BPRS), Total and subdomain scores': 3, 'Buschke Selective Reminding Test (BSRT)': 3, 'Cornell Scale for Depression in Dementia': 3, 'Global Deterioration Scale': 3, 'Modified Continuous Performance Test': 3, "Relative's Assessment of Global Symptomatology-Elderly (RAGS-E)": 3, 'Behavioural And Psychiatric Symptoms Of Dementia': 3, 'Dementia Mood Assessment Scale': 3, 'Alzheimer Disease Assessment Scale (Cognitive) (ADAS-COG)': 3, 'Brief Psychiatric Rating Scale': 3, 'daily functioning': 3, 'dementia severity': 3, 'cognition': 3, 'behavior,': 3, 'Verbal memory (measured using the Rey-Auditory-Verbal Learning Test)': 3, 'memory parameters': 3, 'Brief Psychiatric Rating Scale (BPRS), Subdomain scores': 3, 'Brief Psychiatric Rating Scale (BPRS), Total score': 3, 'side effects': 3, 'Verbal memory: Rey Auditory Verbal Learning Test': 3, 'long-term memory skills': 3, 'cognitive functions': 3, 'behaviour': 3, 'learning': 3, 'Dementia': 3, 'Primary Degenerative Dementia': 3, 'clinical evaluation': 3, 'Attention': 3})
CD011882 Counter({'Living In Residential Institution': 2, "Dementia Due To Alzheimer's Disease": 2, 'Dementia': 2, 'Withdrawal: visual analog scale': 2, 'ADL Self-Performance Scale': 2, 'Mood: Positive Affect Rating Scale': 2, 'Affect: Positive Affect Rating Scale': 2, 'Agitation: Scale for the Observation of Agitation in Persons with Dementia': 2, 'Severity of dementia': 2})
CD004744 Counter({'Vascular Dementia': 6, 'Rivastigmine': 6, 'Subcortical Vascular Dementia': 3, 'Activities of Daily Living': 3, 'clinical dementia rating scale': 3, 'Cognition': 3, 'adverse events': 3, 'Neuropsychiatric Inventory': 3, 'neuropsychiatric symptoms': 3, 'cerebrovascular accidents': 3, 'Global performance': 3, 'Adverse events': 3, 'Cognitive function': 3, 'blood pressure': 3, 'mortality': 3, 'activities of daily living': 3})
CD003119 Counter({'Dementia': 6, 'Vinpocetine': 6, 'performance capability': 3, 'life satisfaction': 3, 'mood': 3, 'Cognition': 3, 'Global Improvement': 3})
CD004033 Counter({'Wernicke-korsakoff Syndrome': 3, 'Alcohol Dependence': 3, 'Thiamine': 3, 'Cognition: working memory': 3, 'Cognition: Mini-Mental State Examination': 3, 'Cognition: delayed alternation task': 3, 'neurological signs': 3})
CD004393 Counter({'Elderly': 3, 'Well Elder': 3, 'Healthy': 3, 'Pyridoxine': 3, 'Cognition: memory': 3, 'performance': 3, 'vitamin B-6 status': 3, 'Cognition: long-term memory': 3, 'mood': 3})
CD004394 Counter({'Hospitalization': 3, 'Vitamin B12 Decreased': 3, 'Vitamin B12 Deficiency Screening': 3, 'Cyanocobalamin': 3, 'Vitamin B12 status': 3, 'Homocyteine levels': 3, 'Red cell parameters': 3, 'Cognitive function: MMSE': 3, 'Folate levels': 3})
CD000464 Counter({'Behavioural And Psychiatric Symptoms Of Dementia': 6, 'Dementia': 6, 'Thioridazine': 6, 'Anxiety': 3, 'Agitation': 3, 'Anxiety: Hamilton Anxiety Rating Scale': 3, "Clinical symptoms: Modified Nurses' Observation Scale for Inpatient Evaluation (NOSIE)": 3, 'Clinical symptoms: global rating of degree of illness': 3, 'Clinical symptoms: global rating of degree of overall change': 3, 'Hospitalization': 3, 'Cognitive function: intellect': 3, 'agitation': 3, 'global change': 3, 'behavior at interviews': 3, "Clinical symptoms: Nurses' Observation Scale for Inpatient Evaluation (NOSIE)": 3, 'Clinical symptoms': 3, 'insomnia': 3, 'depressed mood': 3, 'tension': 3, 'modified Hamilton Anxiety Scale for specific psychiatric symptoms': 3, 'anxiety': 3, 'fears': 3, 'Elderly': 3, 'Aggression': 3, 'Zuclopenthixol': 3, 'restlessness': 3, 'side effects': 3, 'sleep': 3, 'hostility': 3})
CD007514 Counter({"Dementia Due To Alzheimer's Disease": 8, 'Simvastatin': 6, 'behaviour': 3, 'clinical global change': 3, 'function': 3, 'Cognition': 3, '24S-hydroxycholesterol': 3, 'cerebrospinal fluid levels of Abeta40 and Abeta42 and': 3, 'Neuropsychiatric Inventory Scale': 2, "Clincial symptoms: Alzheimer's Disease Assessment Scale": 2, "Cognitive function: Alzheimer's Disease Assessment Scale-cognitive subscale": 2, 'Clinical symptoms: Clinical Global Impression of Change Scale': 2, "Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory": 2, 'Cognitive function: Mini-Mental State Examination': 2, 'Mood: Geriatric Depression Scale': 2})
CD001498 Counter({"Dementia Due To Alzheimer's Disease": 3, 'Thiamine': 3, 'Mini-Mental State Examination (MMSE) score': 3, 'Naming score (measure not specified)': 3, 'Verbal learning score (measure not specified)': 3})
CD002854 Counter({"Dementia Due To Alzheimer's Disease": 3, 'Vitamin E': 3, 'Cognitive function (measured using the Mini-Mental State Examination)': 3, 'Cognition': 3, 'Cognitive function (measured using the Clock Drawing Test)': 3, 'Cognitive function (measured using the Blessed-Dementia Scale)': 3, 'Blood oxidized glutathione (GSSG)': 3})
CD001394 Counter({'Living In Residential Institution': 3, 'Elderly': 3, 'Validation Therapy': 3, 'Cognition': 3, 'global functioning': 3})
CD002308 Counter({'Methylprednisolone': 9, 'Asthma': 6, 'Salbutamol': 6, 'Budesonide': 3, 'Pulmonary index score': 3, 'Peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Bronchospasm': 3, 'High Dose': 3, 'Hospitalisation(s)': 3, 'Acute Asthma': 3, 'Emergency Department Patient Visit': 3, 'Hospitalization': 3, 'Duration of Emergency Department Treatment (Hours)': 3, 'Childhood Asthma': 3, 'statistically significant reduced admission rates in patients': 3})
CD007639 Counter({'Chronic Lung Disease': 3, 'Cystic Fibrosis': 3, 'Nebulizer (physical Object)': 3, 'Dornase Alfa (desoxyribonuclease)': 3, 'Pulmonary function (measure(s) not specified)': 3})
CD006363 Counter({'Salmeterol': 9, 'Asthma': 6, 'Moderate Asthma': 3, 'Inhaled Bronchodilator Therapy': 3, 'PEF': 3, 'percentage of days and nights when no additional inhaled bronchodilator was needed': 3, 'ercentage of symptom-free days and nights': 3, 'use of additional inhaled bronchodilator': 3, 'asthma score': 3, 'Asthma symptom-free nights (% of nights)': 3, 'Evening peak expiratory flow (PEF) (measured using spirometry)': 3, 'Any drug side effect(s)': 3, 'Morning peak expiratory flow (PEF) (measured using spirometry)': 3, 'Daily use of relief medication': 3, 'Peak Expiratory Flow Rate (PEFR)': 3, 'Daytime Use of Rescue Medication': 3, 'Night-time Use of Rescue Medication': 3, 'Adverse Event': 3, 'Asthma Daytime Symptoms': 3, 'Asthma Night-time Symptoms': 3, 'Drug Tolerance': 3})
CD007168 Counter({'Cystic Fibrosis': 3, 'Primary Ciliary Dyskinesia': 3, 'Acetylcysteine': 3, 'Ciliary function (measure not specified)': 3, 'Titres of specific antimicrobial antibodies (unspecified)': 3, 'Sputum bacteriology': 3, 'Sedimentation rate': 3, 'Lung function (measure(s) not specified)': 3, 'Subjective clinical score (measure not specified)': 3, 'Weight': 3, 'Blood leucocyte count': 3})
CD006922 Counter({'Asthma': 21, 'Salmeterol And Fluticasone': 12, 'Pulmonary function - Morning peak expiratory flow (PEF) (measured using spirometry)': 6, 'adverse events': 6, 'Salmeterol': 6, 'Asthma exacerbation(s)': 6, 'Corticosteroids': 3, 'Pulmonary function - Area under the 12-h serial forced expiratory volume in one second (FEV1) curve': 3, 'Pulmonary function - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Remained in study without being withdrawn because of worsening asthma': 3, 'Asthma symptom score(s) (measure(s) not specified)': 3, 'Supplemental albuterol use': 3, 'Salmeterol Xinafoate': 3, 'Zafirlukast': 3, 'asthma quality of life scores': 3, 'asthma symptoms': 3, 'supplemental albuterol use': 3, 'pulmonary function': 3, 'Fluticasone': 3, 'Pulmonary function - Evening peak expiratory flow (PEF) (measured using spirometry)': 3, 'Symptom scores (measure(s) not specified)': 3, 'Pulmonary function - Mean peak expiratory flow (PEF) (measured using spirometry)': 3, 'Use of rescue medication': 3, 'Episode-free days (days, defined as a day without the need for rescue medication, no nocturnal awakening or adverse events)': 3, 'Incremental cost effectiveness ratio (ICER) - Incremental cost per symptom-free day (Swedish Kroner (SEK), 1998 price year)': 3, 'Successfully-treated weeks (weeks, defined as a &gt; or =5% improvement in morning peak expiratory flow (PEF), measured using spirometry)': 3, 'Symptom-free days (days)': 3, 'Cost-effectiveness - Cost per episode-free day(Swedish Kroner (SEK), 1998 price year)': 3, 'Cost-effectiveness - Cost per symptom-free day (Swedish Kroner (SEK), 1998 price year)': 3, 'Cost-effectiveness - Cost per successfully-treated week (Swedish Kroner (SEK), 1998 price year)': 3, 'Incremental cost effectiveness ratio (ICER) - Incremental cost per episode-free day(Swedish Kroner (SEK), 1998 price year)': 3, 'Incremental cost effectiveness ratio (ICER) - Incremental cost per successfully-treated week (Swedish Kroner (SEK), 1998 price year)': 3, 'Direct asthma management (healthcare and drug) costs (Swedish Kroner (SEK), 1998 price year)': 3, 'Days with no symptoms (% days)': 3, 'Withdrawal from study due to worsening asthma': 3, 'Nights with no awakenings (% nights)': 3, 'Albuterol use': 3, 'Symptom score(s) (measure(s) not specified)': 3, 'Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Morning peak expiratory flow (PEF) (measured using spirometry)': 3, 'Evening peak expiratory flow (PEF) (measured using spirometry': 3, 'Beclometasone': 3, 'Asthma rescue medication-free days (% of days)': 3, 'Asthma sympom-free nights (% of nights)': 3, 'Lung function - Evening peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Asthma symptom-free days (% of days)': 3, 'Lung function - Morning peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Asthma rescue medication-free nights (% of nights)': 3, 'Histamine provocative concentration causing a 20% drop in FEV1 (PD20) (measured using a bronchial histamine challenge test)': 3, 'fev': 3, 'symptom free nights': 3, 'Mean morning PEV': 3, 'serum cortisol levels': 3, 'Moderate Asthma': 1, 'Severe Asthma': 1})
CD005307 Counter({'Asthma': 3, 'Salmeterol And Fluticasone': 3, 'Fluticasone': 3, 'Lung function - Evening trough (pre-dose) peak expiratory flow (PEF) (measured using spirometry)': 3, 'Use of rescue medication - rescue medication-free days (% days)': 3, 'Asthma symptom scores (measure(s) not specified)': 3, 'Asthma exacerbation(s) - Severe exacerbation(s)': 3, 'Lung function - Morning trough (pre-dose) peak expiratory flow (PEF) (measured using spirometry)': 3, 'Adverse events (unspecified)': 3, 'Asthma symptom-free days (% days)': 3, 'Lung function - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Lung function - Forced expiratory flow at 25-75% of the pulmonary volume (FEF25-75) (measured using spirometry)': 3})
CD003900 Counter({'Chronic Obstructive Pulmonary Disease': 12, 'COPD Exacerbation': 6, 'Hospitalization': 3, 'Salbutamol And Ipratropium Bromide': 3, 'Spirometric values (unspecified)': 3, 'Symptom score (unspecified subjective measure)': 3, 'Length of hospital stay (days)': 3, 'Selective Beta-2-adrenoreceptor Agonists- Inhaled': 3, 'Anticholinergics': 3, 'Xanthines': 3, 'Dose of inhaled ipratropium bromide producing maximal bronchodilatation (measured by dose-response curve)': 3, 'Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Dose of inhaled salbutamol producing maximal bronchodilatation (measured by dose-response curve)': 3, 'Forced vital capacity (FVC) (measured using spirometry)': 3, 'Asthma': 3, 'Ipratropium': 3, 'Aminophylline': 3, 'Methylprednisolone': 3, 'Antibiotic Therapy': 3, 'Salbutamol': 3, 'FEV1, FVC, and PaCO2': 3, 'Ipratropium Bromide': 3, 'Arterial blood gas samples': 3, 'Pulmonary function (FEV1 and FVC)': 3})
CD004359 Counter({'Chronic Lung Disease': 3, 'Home Care By Visiting Nurse': 3, 'survival': 3, 'pulmonary function': 3, 'everyday functioning': 3, 'average annual health care costs': 3, 'Average annual cost of care': 3})
CD007491 Counter({'Copd': 2, 'Home Support': 2})
CD007695 Counter({'Asthma': 3, 'Formoterol': 3, 'Direct medical costs - Cost of medications (mean cost per patient, 1995 US Dollars (USD))': 3, 'Clinically relevant improvement in quality of life (measured using the St. Georges Respiratory Questionnaire)': 3, 'Contacts with nurses': 3, 'Direct medical costs - Cost of lung function and other tests (mean cost per patient, 1995 US Dollars (USD))': 3, 'Hospital admissions': 3, 'Cost effectiveness (measured by Incremental cost-effectiveness ratio(s) (ICERs)': 3, 'Total cost per episode free day (mean cost per patient, 1995 US Dollars (USD))': 3, 'Costs of lost production (mean cost per patient, 1995 US Dollars (USD))': 3, 'Episode free days (days)': 3, 'Contacts with specialists': 3, 'Direct medical costs - Cost of hospital admissions (mean cost per patient, 1995 US Dollars (USD))': 3, 'Total costs (mean cost per patient, 1995 US Dollars (USD))': 3, 'Direct medical costs - Total direct medical costs (mean cost per patient, 1995 US Dollars (USD))': 3, 'Travel costs (mean cost per patient, 1995 US Dollars (USD))': 3, 'Emergency room visits': 3, 'Direct medical costs - Cost of emergency room visits (mean cost per patient, 1995 US Dollars (USD))': 3, 'Contacts with general practitioners (GPs)': 3, 'Direct medical costs - Cost of physician services (mean cost per patient, 1995 US Dollars (USD))': 3, 'Total cost per patient reaching a clinically relevant improvement in quality of life (mean cost per patient, 1995 US Dollars (USD))': 3})
CD002731 Counter({'Asthma': 3, 'Nedocromil': 3, 'Cromolyn sodium': 3, 'Standard exercise test(s) results (measure(s) not specified)': 3})
CD012286 Counter({'Asthma': 12, 'Inhalation technique (measure(s) not specified)': 6, 'Asthma control (measured using the Asthma Control Test (ACT) score)': 6, 'asthma control': 6, 'Prescribed Medication Education': 3, 'Education About Asthma Self Management': 3, 'Reliever medication use (unspecified)': 3, 'Adherence to controller medication': 3, 'Night-time awakenings due to asthma': 3, 'Medication Regimen Compliance Education': 3, 'Reliever medication use': 3, 'Nighttime awakening(s) due to asthma': 3, 'Adherence to controller medication (measure not specified)': 3, 'Severe Persistent Asthma': 3, 'Moderate Persistent Asthma': 3, 'Mild Persistent Asthma': 3, 'Inhalation Therapy Education': 3, 'MDI technique': 3, 'inhaler technique checklist to record which steps children performed correctly': 3, 'inhaler self-efficacy': 3, 'Asthma Education': 3, 'Inhalation Therapy Assessment': 3, 'Assessment Using Asthma Control Test': 3, 'Uses Inhaler Device': 3, 'Giving Self-help Leaflet': 3, 'Verbal Communication Interventions': 3, 'Interpreter/translator Services Case Management': 3, 'technique': 3, 'method of using the inhaler': 3, 'Childhood Asthma': 3, 'Interaction Education, Guidance, And Counselling': 3, 'adherence compared with children receiving usual care': 3, 'inhaler technique': 3, 'action plan ownership': 3, 'pediatric asthma caregiver quality of life': 3, 'goal achievement': 3, 'asthma knowledge': 3})
CD005536 Counter({'Asthma': 3, 'Nebulizer (physical Object)': 3, 'Metered Dose Inhaler': 3, 'Spacer (physical Object)': 3, 'Dry Powder Inhaler': 3, 'Salbutamol': 3, 'Forced expiratory volume in one second (FEV1)  (measured using spirometry)': 3, 'Clinical score (measure not specified)': 3, 'Side effects - Tremor': 3, 'Heart rate response': 3, 'Direct medical costs of treatment (incorporating costs of medication and spacer devices, Currency and price year not specified)': 3})
CD001283 Counter({'Eicosapentaenoic Acid': 5, 'Docosahexaenoic Acid Supplementation': 5, 'Asthma': 3, 'Diurnal peak expiratory flow (PEF) (measured using spirometry)': 3, 'Eicosapentaenoic acid content of neutrophil phospholipids (measured by gas chromatography)': 3, 'Neutrophil chemotactic response to formyl-methionyl-leucyl-phenylalanine (FMLP) (measured using a microchemotaxis technique)': 3, 'Total calcium ionophore induced neutrophil leukotriene LTB4 and LTB5 generation (measured using reverse phase high performance liquid chromatography and radioimmunoassay)': 3, 'Neutrophil chemotactic response to LTB4 (measured using a microchemotaxis technique)': 3, 'Symptom scores (measure(s) not specified)': 3, 'Bronchodilator use': 3, 'Airways responsiveness to histamine (measure(s) not specified)': 3, 'Airways responsiveness to exercise (measure(s) not specified)': 3, 'Asthma symptom scores': 2, 'No significant side-effects': 2, 'responsiveness to acetylcholine': 2, 'plasma EPA levels': 2})
CD001183 Counter({'Asthma': 12, 'Nedocromil': 12, 'Pulmonary function - Forced expiratory volume in one second (FEV1)  (measured using spirometry)': 3, 'Exercise-induced bronchoconstriction (EIB) (measure(s) not specified)': 3, 'Unusual symptom(s)': 3, 'Lung function - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Adverse reaction(s)': 3, 'Lung function - Peak expiratory flow (PEF) (measured using spirometry)': 3, 'Response to exercise challenge (measure(s) not reported)': 3, 'Any unusual symptom(s)': 3, 'Peak expiratory flow (PEF) (measured using spirometry)': 3, 'Side effects (not specified)': 3})
CD011090 Counter({'Obstructive Sleep Apnea Of Adult': 6, 'Insomnia': 6, 'Sleep Apnea': 6, 'Zolpidem': 6, 'Ramelteon': 3, 'sleep onset latency': 3, 'Snoring': 3, 'Obstructive Sleep Apnea Syndrome': 3, 'Brotizolam': 3, 'Nighttime wakefulness after sleep onset (measured using polysomnography)': 3, 'Nighttime arterial oxygen saturation (SaO2) (measured using polysomnography)': 3, 'Nighttime awakening(s) (measured using polysomnography)': 3, 'Nighttime respiratory disturbances (defined as number of events with O2 desaturation of more than 4% per hour of sleep, measured using the Respiratory Disturbances Index (RDI))': 3, 'Nighttime total sleep time (measured using polysomnography)': 3, 'Behavioral Therapy': 3, 'Temazepam': 3, 'Respiratory disturbance (measured using the Respiratory Disturbances Index (RDI))': 3, 'Nocturnal breathing (measure(s) not specified)': 3, 'arterial oxygen saturation': 3, 'Sleep architecture': 3, 'apnea + hypopnea index': 3})
CD001116 Counter({'Asthma': 6, 'Asthma Education': 3, 'Breathing Exercises': 3, 'Asthma symptom-free days (days)': 3, 'Lower asthma exacerbation(s)': 3, 'Total cell counts in induced sputum (measured by laboratory test)': 3, 'Eosinophil cell counts in induced sputum (measured by laboratory test)': 3, 'Fractional exhaled nitric oxide (FeNO) count': 3, 'Maximum rate of oxygen consumption measured during incremental exercise (VO(2max)) (measured using cardiopulmonary exercise testing)': 3, 'Physical Exercises': 3, 'carbon dioxide output': 3, 'provocative concentration of histamine causing a 20% fall in FEV1': 3, 'anthropometric characteristics': 3, 'breathlessness scores': 3, 'blood lactate': 3, 'minute ventilation': 3, 'oxygen pulse': 3, 'anaerobic threshold': 3, 'mean maximal oxygen uptake': 3, 'blood lipid profiles': 3})
CD001563 Counter({'Asthma': 6, 'House Dust Mite Allergy': 6, 'Rhinitis': 6, 'Allergic Asthma': 6, 'House Dust Mite Barrier Bed Mattress Cover': 3, 'Medication intake score (measure not specified)': 3, 'Clinical complaints - Asthma (measured using an unspecified standardised questionnaire)': 3, 'Serum eosinophil cationic protein (measured by laboratory test)': 3, 'Clinical complaints - Rhinoconjunctivitis (measured using an unspecified standardised questionnaire)': 3, 'Allergen content of house dust sample (measured using an immunodot assay with monoclonal antibodies against the house dust mite allergen der p 1, der f 1 and mite group 2; Sum of the three allergens)': 3, 'Asthma symptoms (measure not specified)': 3, 'Relative humidity in the air (%)': 3, 'General sleeping comfort (measure not specified)': 3, 'House Dust Mite Barrier Spray (physical Object)': 3, "Patient's opinion of clinical symptoms (measured using a 0-3 scale)": 3, "H.D.M. antigen content of child's bedroom (measured from dust samples)": 3, 'Asthma symptoms (measured using daily scorecard, 0-3 scale)': 3, 'Total immunoglobulin E (IgE) (measured by laboratory test)': 3, 'Forced expiratory volume in one second (FEV1)  (measured using spirometry)': 3, 'Dust mite-specific immunoglobulin E (IgE) (measured by laboratory test)': 3, "Doctor's opinion of spray efficacy (measured using a 0-3 scale)": 3, "Patient's opinion of spray efficacy (measured using a 0-3 scale)": 3, 'Asthma/ rhinitis symptoms - sneezing and lacrimation (measured using daily scorecard, 0-3 scale)': 3, 'Asthma/ rhinitis symptoms - nasal secretion (measured using daily scorecard, 0-3 scale)': 3, 'Peak expiratory flow (PEF) (measured using spirometry)': 3, 'Additional symptoms (any - unspecified, measured using daily scorecard, 0-3 scale)': 3, 'Use of concurrent medication (unspecified)': 3, 'Medication taken (measured using daily scorecard)': 3, 'Rhinitis symptoms (measured using daily scorecard, 0-3 scale)': 3, "Doctor's opinion of clinical symptoms (measured using a 0-3 scale)": 3, 'Allergic Conjunctivitis': 3, 'Atopic Dermatitis': 3, 'Allergic Rhinitis': 3, 'Benzyl Benzoate': 3, 'Guanine exposure': 3, 'Total serum IgE': 3, 'Daily symptoms': 3, 'Dust exposure': 3, 'Nasal smear eosinophilia': 3, 'Specific serum IgE (mite)': 3, 'Medication score': 3, 'Blood eosinophilia': 3})
CD001954 Counter({'Azithromycin': 6, 'Chronic Bronchitis': 3, 'Treatment failure (measure(s) not specified)': 3, 'Dropouts from study due to side effects (unspecified)': 3, 'Dropouts from study due to no follow-up': 3, 'Treatment efficacy (measure(s) not specified)': 3, 'Renal function (measured by gastralgia and laboratory test)': 3, 'Diahorrea': 3, 'Acute Exacerbation Of Chronic Bronchitis': 3, 'Tracheobronchitis': 3, 'Time to Event - Therapeutic Response or Treatment Success': 3, 'Assessment Of Compliance With Medication Regimen': 3, 'Treatment Failure': 3, 'Discontinuation of Treatment': 3, 'Therapeutic Response': 3, 'Adverse Event': 3, 'Relapse': 3, 'Treatment Success': 3})
CD010758 Counter({'Asthma': 9, 'Vilanterol And Fluticasone Furoate': 9, 'Serious adverse event(s)': 6, 'Any adverse event(s)': 6, 'Treatment-related adverse event(s)': 6, 'Asthma-specific quality of life (measured using the Asthma Quality of Life Questionnaire, Overall score)': 3, 'Symptom-free 24-h periods (% days)': 3, 'Rescue medication-free 24-h periods (% days)': 3, 'Evening peak expiratory flow (PEF) (measured using spirometry)': 3, 'Morning peak expiratory flow (PEF) (measured using spirometry)': 3, 'Death': 3, 'Time to event - First severe asthma exacerbation': 3, 'Lung function - Evening trough (pre-dose) forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Severe asthma exacerbation(s)': 3, 'Asthma rescue medication-free days (% of days)': 3, '24-hour urinary cortisol excretion (measured by laboratory test)': 3, 'Electrocardiogram (ECG)': 3, 'Asthma symptom-free days (% of days)': 3, 'Lung function - Weighted mean 0-24 hrs serial forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Lung function - Trough (pre-dose) forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Vital signs': 3, 'Asthma-specific quality of life (measured using the Asthma Quality of Life Questionnaire (AQLQ))': 3, 'Childhood Asthma': 3, 'Fluticasone / Vilanterol Dry Powder Inhaler': 3, '': 3, 'peak expiratory flow, maximum heart rate, blood pressure, and electrocardiographic parameters': 3, 'FF AUC0-4, FF cmax, serum glucose,': 3, 'serum potassium , serum cortisol [0-12 hours], and glucose': 3})
CD003534 Counter({'Asthma': 15, 'Fluticasone': 9, 'Fluticasone propionate': 5, 'Patient-rated asthma symptoms (measure(s) not specified)': 3, 'Pulmonary function - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Health-related quality of life (measured using an unspecified standard patient survey)': 3, 'No prednisone use': 3, 'Symptomatic albuterol use': 3, 'Nighttime awakening(s)': 3, 'Pulmonary function - Peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Fluticasone Metered Dose Inhaler': 3, '24-hour urinary cortisol excretion (measured by laboratory test)': 3, 'Asthma symptoms (measure(s) not specified)': 3, 'Pulmonary function - Trough (pre-dose) forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Withdrawal from study due to lack of treatment efficacy': 3, 'forced expiratory volume in  1 second FEV1': 3, 'Medical Outcomes Study Short Form': 3, 'FEV1': 3, 'signs of exacerbating asthma': 3, 'Asthma symptom scores': 3, 'nighttime awakenings due to asthma': 3, 'adverse events': 3, 'Fluticasone Inhalant Powder': 3, 'patient satisifaction': 3, 'Budesonide': 2, 'Placebo': 2, 'morning serum cortisol concentrations': 2, 'morning serum osteocalcin concentrations': 2, 'urinary levels of total cortisol metabolites': 2, 'hypothalamic-pituitary-adrenal axis': 2})
CD002873 Counter({'Wheezing': 11, 'Salbutamol': 5, 'Spacer (physical Object)': 3, 'Albuterol Inhalant Solution': 3, 'Blood oxygen saturation (measured using pulse oximetry)': 3, 'Hospitalisation(s)': 3, 'Acceptability (measured by parent-completed questionnaire)': 3, 'Pulmonary index (measure not specified)': 3, 'Ease of use (measured by parent-completed questionnaire)': 3, 'Prednisolone': 3, 'Placebo': 3, 'Treatment Failure': 3, 'Diary Card Measure of Symptoms': 3, 'Albuterol Metered Dose Inhaler': 3, 'Thoracic Gas Volume (TGV)': 3, 'Change in degree of pulmonary hyperinflation': 3, 'Degree of bronchial obstruction': 3, 'Airway conductance': 3})
CD007130 Counter({'Heart Disease': 3, 'Cardiac Rehabilitation': 3, 'LDL cholesterol': 3, 'HDL cholesterol': 3, 'systolic blood pressure': 3, 'health-related quality of life': 3, 'proportion of smokers': 3, 'Exercise capacity': 3, 'body composition': 3})
CD003941 Counter({'Not reported': 3, 'Reminding About Keeping Appointment': 3, 'Office visit for vaccination': 3, 'Influenza vaccination': 3, 'Missed opportunity to immunise': 3})
CD009552 Counter({'Tiotropium': 6, 'Chronic Obstructive Pulmonary Disease': 3, 'Time to event - First hospitalisation': 3, 'Rescue salbutamol use': 3, "Quality of life (measured using the St George's Respiratory Questionnaire, Total and impact domain scores)": 3, 'Lung function - Trough forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Lung function - Peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Dry mouth': 3, 'Time to event - First COPD exacerbation': 3, 'Dyspnoea (measured using the Transition Dyspnea Index, Total and domain scores)': 3, 'COPD exacerbation(s)': 3, 'COPD Exacerbation': 3, 'Health economics, excacerbations,': 3})
CD002733 Counter({'COPD': 3, 'Viral Vaccines': 3, 'Vaccines': 3, '': 3, 'Severity of total acute respiratory illness': 3, 'episodes of acute respiratory illness': 3, 'requirement of mechanical ventilation': 3, 'Frail Elderly': 2, 'Influenza Virus Vaccine': 2})
CD003795 Counter({'Neonate': 3, 'Whey-based Baby Milk': 3, 'Colic of allergic origin': 3, 'Eczema': 3, 'Diarrhoea of non-infectious origin': 3, "Cow's milk protein (CMP) sensitivity (measure not specified)": 3, 'Atopic disease manifestation(s)': 3, 'Allergic Disposition': 2, 'oral thrush': 2, 'diarrhoea': 2, 'wheezing': 2, 'rash': 2, 'eczema': 2, 'Infant': 1})
CD001384 Counter({'Ketotifen': 11, 'Asthma': 6, 'average duration for regular antiasthma drugs, average symptom scores, symptom free days, peak expiratory flow rate, FEV1, and need for emergency room visits.': 3, 'Clinician-Reported Outcome': 3, 'Use of Anti-asthmatic Drugs': 3, 'Childhood Asthma': 3, 'Lung function': 3, 'methacholine sensitivity': 3, 'diurnal variability in peak flow rates': 3, 'ICS dosage': 3, 'Nifedipine': 2, 'intensity, frequency and the time the crisis': 2, 'beneficial effects': 2, 'bronchodilator consumption': 2, 'improvement evaluated by the doctor': 2, 'cardiovascular parameters': 2, 'pulmonary function test': 2, 'Side effects': 2})
CD010177 Counter({'Chronic Obstructive Pulmonary Disease': 3, 'Ipratropium Bromide': 3, 'Salmeterol': 3, 'Bronchodilator response (measure(s) not specified)': 3, 'Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Use of rescue salbutamol': 3, 'Morning peak expiratory flow (PEF) (measured using spirometry)': 3, 'Daytime symptom score(s) (measure(s) not specified)': 3, 'Specific airway conductance (sGaw)': 3, 'COPD exacerbation(s)': 3, 'Airways Obstruction Reversible': 3, 'Formoterol': 3, 'Morning asthma symptoms (measure(s) not specified)': 3, 'Bronchodilation - Trough (pre-dose) peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Use of rescue medication (unspecified)': 3, 'Tachyphylaxis': 3, 'Sleep disturbance(s) (measure not specified)': 3, 'Evening asthma symptoms (measure(s) not specified)': 3})
CD000391 Counter({'Asthma': 9, 'Methotrexate': 9, "patients' subjective assessment of breathing ability": 3, 'mean dosage of prednisone': 3, 'forced expiratory volume in one second': 3, 'forced vital capacity': 3, 'adverse effects': 3, 'daily diary card variables and measurements of lung function': 3, 'Steroid Dependent Asthma': 3, 'Severe Asthma': 3, 'airway reactivity': 3, 'steroid dose': 3, 'Pulmonary function': 3, 'symptom scores': 3})
CD010085 Counter({'Pregnancy': 9, 'Polyunsaturated Fatty Acid Supplementation': 3, 'Promoter methylation level in LINE1 repetitive elements (measured using quantitative profiling of DNA methylation state in LINE1 repetitive elements of cord blood mononuclear cells)': 3, 'Promoter methylation level of Th1 (measured using quantitative profiling of DNA methylation state in Th1)': 3, 'Promoter methylation level of IL13 (measured using quantitative profiling of DNA methylation state in regulatory T-relevant genes)': 3, 'Promoter methylation level of Th17 (measured using quantitative profiling of DNA methylation state in Th17)': 3, 'Promoter methylation level of Th2 (measured using quantitative profiling of DNA methylation state in Th2)': 3, 'Promoter methylation level of IFNγ (measured using quantitative profiling of DNA methylation state in regulatory T-relevant genes)': 3, 'Atopy': 3, 'Fish Oil': 3, 'IL-10': 3, 'allergic response': 3, 'frequency of atopic dermatitis at 1 year of age': 3, 'IL-3': 3, 'positive skin prick test to egg at 1 year of age': 3, 'IL-5': 3, 'IFN-G': 3, 'n-3 polyunsaturated fatty acids': 3, 'Docosahexaenoic Acid Supplementation': 3, 'protective effect of DHA treatment': 3})
CD000500 Counter({'Meconium Stain': 3, 'Neonate': 3, 'Tracheobronchial Suctioning': 3, 'Oropharyngeal Suctioning': 3, 'Laryngeal disorder(s) (unspecified)': 3, 'Pulmonary disorder(s) (unspecified)': 3, 'Mortality': 3})
CD011285 Counter({'Exercises': 9, 'Pulmonary Arterial Hypertension': 9, 'Pulmonary Hypertension': 3, 'mean walking distance': 3, 'blood flow': 3, 'Self-care Patient Education': 3, 'Aerobic Exercises': 3, 'Physical activity level (self-reported, measure not specified)': 3, 'Fatigue severity (self-reported, measure not specified)': 3, 'Chronic Thromboembolic Pulmonary Hypertension': 3, 'Respiratory Muscle Function Training': 3, 'achieved workload': 3, 'oxygen consumption at the anaerobic threshold': 3, 'quality-of-life questionnaire': 3, 'distance walked in 6 minutes': 3, 'Systolic pulmonary artery pressure values at rest': 3, 'peak oxygen consumption': 3, 'exercise capacity': 3, 'trial will determine whether an exercise training program, is safe': 3, 'quality of life': 3})
CD004476 Counter({'Coronary Artery Bypass Graft': 3, 'Sotalol': 3, 'Supraventricular tachyarrhythmia (SVT)': 3, 'Treatment discontinuation for cardiac reasons': 3, 'Treatment discontinuation due to asthma': 3, 'Number of ventricular events (measured using Holter electrocardiographic analysis)': 3})
CD008351 Counter({'Bronchiectasis': 5, 'Mannitol': 3, 'Antibiotic use': 3, '24 hour sputum weight (measured by laboratory test)': 3, 'Adverse events (unspecified)': 3, 'Compliance with treatment (measure(s) not specified)': 3, "Quality of life (measured using the St. George's Respiratory Questionnaire (SGRQ) total score)": 3, 'Small airway mucus plugging (assessed by High Resolution Computed Tomography (HRCT) scan)': 3, 'Asthma': 2, 'bodyplethysmography': 2, 'FRC (Helium-dilution)': 2, 'Spirometry': 2, 'feeled to improve': 2})
CD002982 Counter({'Asthma': 3, 'Hypnosis For Therapy': 3, 'Asthma Symptom Checklist': 3, 'the State-Trait Anxiety Inventory': 3, 'the Dysfunctional Cognition Inventory (catastrophizing scale)': 3, 'Psychometric testing included the Eysenck Personality Inventory': 3})
CD002742 Counter({'Asthma': 9, 'Aminophylline': 6, 'Salbutamol': 3, 'Hydrocortisone': 3, "Clinical response (measured using Wood's asthma score)": 3, 'Objective response (assessed by Peak Expiratory Flow Rate (PEFR), measured using spirometry)': 3, "Wood's Clinical Asthma Score (M-WCAS)": 3, 'Serum theophylline concentration (measured by laboratory test)': 3, 'Adverse drug reactions': 3, 'Aminophylline level - Serum theophylline concentration (measured by laboratory test)': 3, 'Adverse drug reaction(s)': 3, 'Peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Aminophylline Injectable Solution': 3, 'other spirometric measurements': 3, 'Forced expiratory volume in 1 s (FEV1)': 3, 'Subjective patient response': 3, 'duration of hospitalization': 3, 'Chronic Obstructive Pulmonary Disease': 3, 'Hospital admission rate': 3, 'Peak Expiratory Flow Rate (PEFR)': 3, 'Forced Expiratory Volume at 1 second (FEV1)': 3, 'Forced Vital Capacity (FVC)': 3, 'Frequency of side effects': 3, 'Physician assessment of response to therapy': 3, 'Patient satisfaction': 3})
CD011050 Counter({'Magnesium Sulfate': 6, 'Asthma': 3, 'nausea and/or vomiting': 3, 'Wheeze (measure not specified)': 3, 'Dyspnea (measure not specified)': 3, 'Side effects - Nausea and/or vomiting': 3, 'Oxygen saturation in room air': 3, 'Retraction(s)': 3, 'Trend in Clinical Asthma Severity Scores (CASS) over 12 hours': 3, 'Clinical Asthma Severity Scores': 3, 'Side effects - Hypokalemia with ECG changes': 3, 'Respiratory rate': 3, 'Treatment success (defined as improvement in Clinical Asthma Severity Scores (CASS) of &gt;=4 at 1 hour)': 3, 'ECG changes': 3, 'Acute Exacerbation Of Asthma': 3, 'physical examination': 3, 'forced vital capacity': 3, 'Vital signs': 3, 'forced expiratory volume at 1 second': 3, 'peak expiratory flow rate (PEFR)': 3})
CD010660 Counter({'Pregnancy': 6, 'Asthma': 3, 'Beclometasone': 3, 'proportion of asthma exacerbations': 3, 'compliance': 3, 'treatment failure': 3, 'proportion of peak expiratory flow rate less than 80% predicted': 3, 'proportion of study visits with forced expiratory volume expired in 1 second': 3, 'incidences of discontinuing study medications caused by side effects': 3, 'maternal or perinatal outcomes': 3, 'Acute Asthma': 3, 'Salbutamol': 3, 'Asthma Exacerbation': 3, 'Oxygen Saturation': 3, 'Arterial Oxygen Tension': 3, 'pulse rate': 3})
CD008657 Counter({'Respiratory Distress': 2, 'Health (unspecified subjective measure)': 2, 'Household energy usage (unspecified objective measure)': 2, 'Household speciation mould (unspecified objective measure)': 2, 'Household beta glucans (unspecified objective measure)': 2, 'Comfort (unspecified subjective measure)': 2, 'Household general practitioner visits (unspecified objective measure)': 2, 'Household condition (unspecified objective measure)': 2, 'Household fuel usage (unspecified objective measure)': 2, 'Household hospital visits (unspecified objective measure)': 2, 'Household endotoxin (unspecified objective measure)': 2, 'Household house dust mite allergens (unspecified objective measure)': 2, 'Household temperature (unspecified objective measure)': 2, 'Household mass mould (unspecified objective measure)': 2, 'Well-being (unspecified subjective measure)': 2, 'Household relative humidity (unspecified objective measure)': 2})
CD002309 Counter({'Chronic Obstructive Pulmonary Disease': 12, 'Roflumilast': 9, 'Trough (pre-dose) forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Peak (post-dose) forced vital capacity (FVC) (measured using spirometry)': 3, 'Trough (pre-dose) forced vital capacity (FVC) (measured using spirometry)': 3, 'Peak (post-dose) forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Treatment-related adverse event(s) - Diarrhoea': 3, 'Cilomilast (SB207499)': 3, "St. George's Respiratory Questionnaire": 3, 'incidence rate of COPD exacerbations': 3, 'Adverse events': 3, 'FEV1': 3, 'Exacerbation frequency': 3, 'severe exacerbations leading to hospitalization/death': 3, '': 3})
CD009992 Counter({'Tinea Cruris': 3, 'Tinea Corporis': 3, 'Terbinafine': 3, 'Side effects (unspecified)': 3, 'Complete mycological and clinical cure of tinea cruris/corporis': 3})
CD004823 Counter({'Postnasal Drip': 3, 'Rabeprazole': 3, 'Reflux finding score (RFS) (measured using a Visual Analogue Scale (VAS))': 3, 'Postnasal drainage (PND) symptoms - PND frequency (measured using a Visual Analogue Scale (VAS))': 3, 'Extra-esophageal reflux (EER) (measured using 24-hour pharyngeal pH probe monitoring)': 3, 'Postnasal drainage (PND) symptoms - Chronic cough (measured using a Visual Analogue Scale (VAS))': 3, 'Postnasal drainage (PND) symptoms - Hoarseness (measured using a Visual Analogue Scale (VAS))': 3, 'Reflux symptom index (measured using a Visual Analogue Scale (VAS))': 3, 'Laryngitis Due To Gastroesophageal Reflux': 3, 'Esomeprazole': 3, 'Primary chronic posterior laryngitis symptom resolved (throat clearing. cough. globes. she throat, or hoarseness)': 3, 'Chronic Posterior Laryngitis Index (CPLI), Total score (based on laryngospopic examination)': 3})
CD007893 Counter({'Asthma': 6, 'Cyclosporine': 6, 'Medication Dosage Tapering': 3, 'Pulmonary function - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Biochemical profile (measure(s) not specified)': 3, 'Pulmonary function - Peak expiratory flow (PEF) (measured using spirometry)': 3, 'Blood cyclosporin levels (measured by laboratory test)': 3, 'Pulmonary function - Maximal mid-expiratory flow (MEF50) (measured using spirometry)': 3, 'Requirement for systemic corticosteroid - Daily prednisone dose': 3, 'Pulmonary function - Forced vital capacity (FVC) (measured using spirometry)': 3, 'Asthma symptoms score (measure not specified)': 3, 'Paresthesia': 3, 'Blood pressure': 3, 'Morning peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Hypertrichosis': 3, 'Renal function (measure(s) not specified)': 3, 'Withdrawal from study (reason(s) not specified)': 3, 'Daily prednisolone dosage': 3})
CD011897 Counter({'COPD Exacerbation': 3, 'Umeclidinium': 3, 'Vilanterol': 3, 'clinical chemistry and haematology, vital signs and lung function': 3, 'adverse events': 3, 'Copd': 2, '': 2})
CD010115 Counter({'Chronic Obstructive Pulmonary Disease': 3, 'Reduction Of Corticosteroid Dosage': 3, 'Fluticasone': 3, 'Health-related quality of life (measure(s) not specified)': 3, 'Return to usual inhaled corticosteroid (ICS) following COPD exacerbation(s)': 3, 'Clinical symptoms - Wheezing': 3, 'Lung function (measure(s) not specified)': 3, 'Time to event - First COPD exacerbation': 3, 'Peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Reliever inhaler use (unspecified)': 3, 'COPD exacerbation(s)': 3})
CD010257 Counter({'Chronic Obstructive Pulmonary Disease': 3, 'Antibiotic Therapy': 3, 'length of hospitalization': 3, 'symptoms': 3, 'treatment success rate on day 10 after admission': 3, 'mortality': 3, 'Acute Bronchitis': 3, 'Erythromycin': 3, 'M pneumoniae test positive': 3, 'feeling of well-being': 3, 'days lost from work': 3, 'coug, chest congestion': 3, 'use of cough medicine': 3})
CD007313 Counter({'Asthma': 3, 'Formoterol': 3, 'Budesonide': 3, 'Hospitalization': 3, 'PEF': 3})
CD006826 Counter({'Chronic Obstructive Pulmonary Disease': 3, 'Fluticasone': 3, 'c-RP, cytokines': 3, 'quality of life': 3, 'lung function': 3})
CD009769 Counter({'Chronic Bronchitis': 3, 'Beclomethasone Metered Dose Inhaler': 3, 'arterial blood gases': 3, 'change in the prebronchodilator FEV1': 3, 'postbronchodilator FEV1': 3, 'dyspnea': 3, 'adverse effects of beclomethasone': 3, 'courses of antibiotics and/or oral steroids': 3})
CD003562 Counter({'Pulmonary Hypertension': 6, 'Sildenafil': 6, 'Pulmonary artery systolic pressure (assessed by doppler echocardiography)': 3, 'Quality of life - Dyspnea component (measure not specified)': 3, 'Exercise time on treadmill (seconds, assessed using the Naughton Protocol)': 3, 'Syncope (fainting)': 3, 'Cardiac index (assessed by doppler echocardiography)': 3, 'Quality of life (measure not specified)': 3, 'Quality of life - Fatigue component (measure not specified)': 3, 'Death': 3, 'Fibrosis Of Lung': 3, 'Epoprostenol': 3, 'pulmonary vascular resistance index': 3})
CD008469 Counter({'Asthma': 19, 'Education About Asthma Self Management': 6, 'Family Education': 3, 'Asthma knowledge (parent(s), measure not specified)': 3, 'Emergency care visit(s) (child)': 3, 'Asthma management level (child, measure not specified)': 3, 'Asthma Management Plan Given': 3, 'Nighttime awakening(s) (nights)': 3, 'Asthma exacerbation(s)': 3, 'Asthma symptom score (measure not specified)': 3, 'Days of absenteeism from school (days)': 3, 'Asthma Self Management': 3, 'Acute asthma attack(s)': 3, 'Pulmonary function - Peak expiratory flow (PEF) (measured using spirometry)': 3, 'A/n Care Management': 3, 'quality of life, symptom free days etc': 3, '': 3, 'Asthma Action Care Planning': 3, 'IgE': 3, 'blood count': 3, 'urinary continine': 3, 'use of drug': 2, 'use of educational material': 2, 'perceptions of disability': 2, 'knowledge of drugs': 2})
CD003797 Counter({'Asthma': 3, 'Fenoterol': 3, 'Ipratropium Bromide': 3, 'Flow at mid and low lung volumes (measure not specified)': 3, 'Oxygen saturation (measure not specified)': 3, 'Heart rate': 3, 'Diastolic blood pressure': 3, 'Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Clinical score (measure not specified)': 3, 'Any adverse reaction(s)': 3, 'Systolic blood pressure': 3})
CD006923 Counter({'Formoterol': 21, 'Asthma': 18, 'Forced expiratory volume in one second (FEV1) (measured using spirometry)': 6, 'Supplemental terbutalin use': 3, 'Side effects requiring discontinuation of drug treatment': 3, 'Daytime asthma symptoms (measure not specified)': 3, 'Overall asthma control (measure not specified)': 3, 'Asthma exacerbation(s)': 3, 'Peak expiratory flow (PEF) (measured using spirometry)': 3, 'Any side effect(s) of drug treatment': 3, 'Nightime asthma symptoms (measure not specified)': 3, 'High Dose': 3, 'Trough (pre-dose) forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Post-dose forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Serious adverse event(s)': 3, 'Significant asthma exacerbation(s) (defined as requiring systemic corticosteroids)': 3, 'Any asthma exacerbation(s)': 3, 'Serious asthma exacerbation(s) (defined as life threatening or requiring hospitalisation)': 3, 'Nighttime use of asthma rescue medication (unspecified)': 3, 'Morning trough (pre-dose) peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Nighttime asthma symptoms score (measure not specified)': 3, 'Evening trough (pre-dose) peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Salbutamol': 3, 'Protection Against Exercise-Induced Asthma': 3, 'Forced Expiratory Volume in One Second (FEV1)': 3, 'Adverse Event': 3, 's.s. less rescue medication': 3, 'peak expiratory flow (PEF)': 3, 'adverse reactions': 3, 's.s. less asthma attacks': 3, 'global assessment of efficacy': 3, 'Airways Obstruction Reversible': 3, 'sleep disturbances': 3, 'morning and evening asthma symptoms': 3, 'need for rescue medication': 3, 'nocturnal awakenings': 3, 'asthma symptoms': 3, 'rescue medication': 3, 'lung function': 3, 'Exercise-induced Asthma': 3, 'Formoterol Inhalant Powder': 3, 'Salmeterol Dry Powder Inhaler': 3, 'Exercise tests': 3})
CD003974 Counter({'Airways Obstruction': 3, 'Terbutaline': 3, 'Lung function - Forced vital capacity (FVC) (measured using spirometry)': 3, 'Lung function - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3})
CD007031 Counter({'Asthma': 6, 'Ciclesonide': 6, 'asthma symptoms': 6, 'Pulmonary function - Peak expiratory flow (PEF) (measured using patient-reported diary assessment)': 3, 'Any adverse event(s)': 3, 'Pulmonary function - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Rescue medication use': 3, 'Pulmonary function - Peak expiratory flow (PEF) (measured using spirometry)': 3, 'Asthma symptoms score (measured using patient-reported diary assessment)': 3, 'Drug-related adverse event(s)': 3, 'Pulmonary function - Forced vital capacity (FVC) (measured using spirometry)': 3, 'ciclesonide': 3, 'rescue medication use': 3, 'forced expiratory volume in 1s': 3, 'morning peak expiratory flow': 3, 'forced vital capacity': 3, 'Childhood Asthma': 3, 'asthma symptom-free days': 3, 'morning and evening peak expiratory flow': 3, 'forced expiratory volume': 3, 'use of rescue medication': 3})
CD001735 Counter({'Intensive Care': 3, 'Transfer/turning Assistive Device (physical Object)': 3, 'Turning Patient In Bed': 3, 'Acute Physiologic Assessment and Chronic Health Evaluation (APACHE II) score': 3, 'Length of intensive care unit stay (days)': 3, 'Intensive care unit (ICU) mortality': 3, 'Nosocomial pneumonia': 3, 'Duration of mechanical ventilatory management (days)': 3})
CD005108 Counter({'Asthma': 3, 'Asthma Self Management': 3, 'Asthma symptoms severity (measure(s) not specified)': 3, 'Attitudes about asthma (measure(s) not specified)': 3, 'Health-care utilisation (measure(s) not specified)': 3, 'Acute asthma attack(s)': 3, 'Self-efficacy (measure(s) not specified)': 3, 'Knowledge about asthma (measure not specified)': 3})
CD003793 Counter({'Chronic Obstructive Pulmonary Disease': 3, 'Tiotropium': 3, 'Pulmonary Rehabilitation': 3, '': 3, 'No available term': 1})
CD001284 Counter({'Asthma': 9, 'Acute Asthma': 6, 'Ipratropium Bromide': 6, 'Salbutamol And Ipratropium Bromide': 3, 'Brochodilation - Peak expiratory flow (PEF) (measured using spirometry)': 3, 'Emergency Care': 3, 'Albuterol Inhalant Solution': 3, 'Forced Expiratory Volume in One Second (FEV1)': 3, 'Emergency Department Patient Visit or Hospitalization': 3, 'Therapeutic Response': 3, 'Adverse Event': 3, 'Nebulizer Therapy': 3, 'Atropine': 3, 'Metaproterenol': 3, 'Vital signs': 3, 'Side effects': 3, 'Spirometry': 3, 'Salbutamol': 3, '': 3})
CD007694 Counter({'Asthma': 6, 'Formoterol And Budesonide': 3, 'Use of as-needed medication (unspecified)': 3, 'Nighttime awakenings': 3, 'Severe asthma exacerbation(s)': 3, 'Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Peak expiratory flow (PEF) (measured using spirometry)': 3, 'Asthma control (assessed by "measures of exacerbations")': 3, 'asthma exacerbation': 2})
CD001112 Counter({'Caffeine': 6, 'Asthma': 3, 'Coffee': 3, 'Exhaled nitric oxide (FENO) level (measure not specified)': 3, 'Serum caffeine level (measured by laboratory test)': 3, 'Exercise Induced Bronchospasm': 3, '': 3})
CD009305 Counter({'Chronic Cough': 3, 'Fluticasone': 3, 'Exhaled carbon monoxide level (measure not specified)': 3, 'Sputum tumor necrosis factor alpha (TNF-alpha) concentration (measured by laboratory test)': 3, 'Sputum prostaglandin E2 (PGE(2)) concentration (measured by laboratory test)': 3, 'Sputum leukotriene E4 (LTE(4)) concentration (measured by laboratory test)': 3, 'Sputum leukotriene D4 (LTD(4)) concentration (measured by laboratory test)': 3, 'Exhaled nitric oxide level (measure not specified)': 3, 'Sputum cysteinyl leukotrienes concentration (measured by laboratory test)': 3, 'Sputum cell counts (measured by laboratory test)': 3, 'Sputum leukotriene B4 (LTB(4)) concentration (measured by laboratory test)': 3, 'Sputum myeloperoxidase concentration (measured by laboratory test)': 3, 'Sputum leukotriene C4 (LTC(4)) concentration (measured by laboratory test)': 3, 'Daily cough severity (measured using a visual analogue scale (VAS))': 3, 'Sputum interleukin 8 (IL-8) concentration (measured by laboratory test)': 3, 'Sputum eosinophilic cationic protein (ECP) concentration (measured by laboratory test)': 3})
CD010044 Counter({'Muscle Weakness': 3, 'Chronic Obstructive Pulmonary Disease': 3, 'Therapeutic Insufflation': 3, 'Peak cough expiratory flow rate (measured using spirometry)': 3, 'Cough expiratory volume (measure not specified)': 3})
CD003898 Counter({'Asthma': 9, 'Magnesium Sulfate': 6, 'Salbutamol': 6, 'Exacerbation Of Asthma': 3, 'Peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Pulmonary index (measure not specified)': 3, 'Acute Asthma': 3, 'Peak Expiratory Flow Rate (PEFR)': 3, 'Blood Gases': 3, 'Hemodynamic Test': 3, 'Serology Test': 3, 'Use of Additional Medication (Unspecified)': 3, 'Adverse Event': 3, 'Hospitalization': 3, 'Vital Signs Finding': 3, 'Nebulizer Therapy': 3, 'asthma severity score': 3})
CD010139 Counter({'Indacaterol': 6, 'Chronic Obstructive Pulmonary Disease': 3, "Quality of life (measured using the St George's Respiratory Questionnaire (SGRQ) total score)": 3, 'Bronchodilation - Trough (pre-dose) forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Any adverse event(s)': 3, 'Dyspnea (measured using the Transition Dyspnea Index (TDI))': 3, 'Moderate Chronic Obstructive Pulmonary Disease': 3, 'Severe Chronic Obstructive Pulmonary Disease': 3, 'rescue medication use': 3, 'transition dyspnoea index': 3, 'FEV(1) standardised area under curve (AUC) from 5 min to 11 h 45 min': 3, 'percentage of days with no rescue use': 3, 'FEV(1) easured over 24-h': 3, '24-h trough FEV(1)': 3, 'FVC measured over 24-h': 3})
CD003000 Counter({'Hospitalization': 3, 'Asthma': 3, 'Education About Asthma Self Management': 3, 'Asthma self-management skills - Knowledge of peak flow reading that warrants calling a physician (measure not specified)': 3, 'Functional status (measure(s) not specified)': 3, 'Use of health services (unspecified)': 3, 'Asthma self-management skills - Knowledge of correct inhalation technique (measure not specified)': 3, 'Asthma-related quality of life - Activity (measured using the Asthma Quality of Life Questionnaire, Activity domain score.': 3, 'Asthma self-management skills - Confidence in asthma treatment (measure not specified)': 3, 'Health status (measure(s) not specified)': 3})
CD005374 Counter({'Chronic Obstructive Pulmonary Disease': 3, 'Prednisolone': 3, 'Trough (pre-dose) forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Post-dose forced vital capacity (FVC) (measured using spirometry)': 3, 'Post-dose forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Trough (pre-dose) forced vital capacity (FVC) (measured using spirometry)': 3})
CD002160 Counter({'Asthma': 6, 'Prednisone': 6, 'Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Histamine provocative concentration causing a 20% drop in FEV1 (PD20) (measured using a bronchial histamine challenge test)': 3, 'Evening peak expiratory flow (PEF) (measured using spirometry)': 3, 'Morning peak expiratory flow (PEF) (measured using spirometry)': 3, 'Budesonide': 3, 'Symptom and FEV1': 3})
CD007685 Counter({'House Dust Mite Allergy': 3, 'Allergic Asthma': 3, 'Subcutaneous Immunotherapy': 3, 'House mite allergy vaccine': 3, 'Asthma symptoms (measure(s) not specified)': 3, 'Lung volumes (measure(s) not specified)': 3, 'Inhaled corticosteroids (ICS) use': 3, 'Required rescue bronchodilator(s)': 3, 'Bronchial response to methacholine (measure not specified)': 3, 'Evening peak expiratory flow (PEF) (measured using spirometry)': 3, 'Skin sensitivity to house dust mite extracts (measure not specified)': 3, 'Morning peak expiratory flow (PEF) (measured using spirometry)': 3})
CD011598 Counter({'Chronic Obstructive Pulmonary Disease': 6, 'Nutritional Supplement': 6, 'nutritional status': 6, 'Malnutrition (calorie)': 3, 'respiratory muscle and handgrip strength': 3, 'lung function': 3, 'sternomastoid muscle function': 3, '6-min walking distances': 3, 'general well-being and breathlessness scores': 3, 'arterial blood gas tensions': 3, 'Pulmonary Emphysema': 3, 'anthropometric, pulmonary function and Immunological status': 3, 'Feeding Tube': 3, 'Nasogastric Tube': 3, 'pulmonary function': 3, 'adductor pollicis function': 3, 'respiratory muscle strength and endurance,': 3})
CD002741 Counter({'Asthma': 3, 'Acute Exacerbation Of Asthma': 3, 'Telithromycin': 3, 'peak expiratory flow in the morning at home': 3, 'Nausea': 3, 'symptoms': 3})
CD003133 Counter({'Asthma': 2, 'Forced expiratory volume in one second (FEV1) (measured using spirometry)': 2, 'Eosinophils count in blood (measured by laboratory test)': 2, 'Serum eosinophil cation protein (ECP) level (measured by laboratory test)': 2})
CD012255 Counter({'Asthma': 6, 'Asthma Education': 3, 'symptom frequency': 3, 'days with activity limitations': 3, 'school absences': 3, 'quality of life': 3, 'self-management': 3, 'health care use': 3, 'Asthma Management': 3, 'Ensuring Good Communication': 3, '': 3, 'Activity limitations (Asthma-related)': 3})
CD007714 Counter({'Severe Chronic Obstructive Pulmonary Disease': 6, 'Chronic Obstructive Pulmonary Disease': 6, 'Noninvasive Positive Pressure Ventilation': 3, 'Helium/oxygen Breathing Gas Mixer': 3, 'maximum workload': 3, 'exercise time': 3, 'treadmill tests': 3, 'Copd': 3, 'Assisted Breathing': 3, 'dyspnoea': 3, 'HRQL score': 3, 'exercise tolerance': 3, 'leg fatigue': 3, 'Pressure Support Ventilator': 3, "Quality of life (measured using the St George's Respiratory Questionnaire (SGRQ))": 3, 'Distance walked on shuttle walking test (metres, measured using a shuttle walking test (SWT))': 3, 'Minute ventilation during exercise (measured during a constant-load cycle endurance test at 75% of peak work rate)': 3, 'COPD Exacerbation': 3, 'Noninvasive Ventilation': 3, 'heart rate, blood pressure and oxygen consumption': 3, 'Supervision While Exercising': 3, 'Exercises': 3, 'Heart rate': 3, 'Plasma lactate concentration': 3, 'Minute ventilation': 3, 'Constant work rate': 3, 'Peak work rate': 3})
CD002999 Counter({'Copd': 3, 'Airways Obstruction': 3, 'Chronic Obstructive Pulmonary Disease': 3, 'Inhaled Bronchodilator Therapy': 3, 'Smoking Cessation Therapy': 3, 'smoking cessation': 3, 'lung function': 3})
CD003537 Counter({'Asthma': 3, 'Beclometasone': 3, 'Fluticasone': 3, 'Bone resorption - Deoxypyridinoline crosslinks (measured by laboratory test)': 3, 'Bone formation - Osteocalcin level (measured by laboratory test)': 3, 'Morning cortisol level (measured by laboratory test)': 3, 'Peak expiratory flow (PEF) (measured using spirometry)': 3, 'Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Bone resorption - Type 1 collagen carboxyterminal telopeptide level (measured by laboratory test)': 3, 'Bone formation - Procollagen type 1 carboxyterminal propeptide level (measured by laboratory test)': 3})
CD003573 Counter({'Chronic Obstructive Pulmonary Disease': 6, 'Emergency Care': 3, 'COPD Exacerbation': 3, 'Home Care By Visiting Nurse': 3, 'Direct healthcare costs (per patient, Euros (EUR), Price year not reported)': 3, 'Inpatient Care': 3, 'Additional hospital days': 3, 'Readmission': 3, 'Deaths within 60 days of admission': 3})
CD000460 Counter({'Aspirin-induced Asthma': 2, 'Asthma': 2, 'Allergic Asthma': 2, 'adverse reactions': 2, 'allergic reaction': 2})
CD001276 Counter({'Childhood Asthma': 3, 'Asthma With Status Asthmaticus': 3, 'Asthma': 3, 'Theophylline': 3, 'Intravenous Therapy': 3, 'side-effects': 3, 'asthma score': 3, 'number of albuterol treatments required': 3, 'supplemental oxygen requirement': 3})
CD001217 Counter({'At Risk Of Deep Vein Thrombosis': 3, 'Surgical Procedure': 3, 'Compression Therapy': 3, 'Heparin': 3, 'DVT': 3, 'evaluation of bilateral lower extremity deep venous systems': 3, 'thromboembolism': 3})
CD009607 Counter({'Asthma With Irreversible Airway Obstruction': 3, 'Exercises': 3, '6-min walk distance': 3, 'Asthma QOL Questionnair': 3})
CD001941 Counter({'Sleep Hypoventilation': 3, 'Chronic Respiratory Failure': 3, 'Noninvasive Ventilation': 3, 'Sleep apnea severity (measured using the Apnea–Hypopnea Index (AHI))': 3, 'Sleep efficiency (not defined, measured using polysomnography)': 3, 'Arterial gas exchange during sleep - Minimum average arterial oxyhaemoglobin saturation total sleep time (measured using polysomnography)': 3, 'Delta transcutaneous carbon dioxide non-rapid eye movement sleep to rapid eye movement sleep (measured using polysomnography)': 3, 'Arousal indices (unspecified, outcome(s) not specified)': 3})
CD001387 Counter({'Chronic Obstructive Pulmonary Disease': 8, 'Ipratropium Bromide': 6, 'Peak (post-dose) forced expiratory volume in one second (FEV1) (measured using spirometry)': 5, "physician's global evaluation": 3, 'peak expiratory flow rates': 3, 'COPD symtom score': 3, 'quality of life': 3, 'use of concomitant medications': 3, 'pulmonary function': 3, 'Metaproterenol': 3, 'Peak (post-dose) forced vital capacity (FVC) (measured using spirometry)': 3, 'Duration of action (days, measure not specified)': 3, 'Morning peak expiratory flow rate (PEFR) (measured using spirometry)': 3, 'Any adverse event(s)': 3, 'Quality of life (measure(s) not specified)': 3, 'Disease-specific quality of life - Fatigue (measured using the Chronic Respiratory Question Disease (CRQD), Fatigue domain score)': 2, 'Disease-specific quality of life (measured using the Chronic Respiratory Question Disease (CRQD), Total score)': 2, 'Any drug side effect(s)': 2, 'Disease-specific quality of life - Emotional function (measured using the Chronic Respiratory Question Disease (CRQD), Emotional function domain score)': 2, 'Symptomatic benefit (not defined, measure not specified)': 2, 'Disease-specific quality of life - Dyspnea (measured using the Chronic Respiratory Question Disease (CRQD), Dyspnea domain score)': 2, 'Clinical improvement (not defined, measure not specified)': 2, 'Disease-specific quality of life - Mastery (measured using the Chronic Respiratory Question Disease (CRQD), Mastery domain score)': 2})
CD000060 Counter({'Exacerbation Of Asthma': 3, 'Asthma': 3, 'Salbutamol': 3, 'Peak expiratory flow rate (PEFR) (measured using spirometry)': 3})
CD001281 Counter({'Asthma': 3, 'Theophylline': 3, 'Total sleep time spent in stage 2 sleep (% of total sleep time, measured using electroencephalography (EEG))': 3, 'Total sleep time spent in stage 3/4 sleep (% of total sleep time, measured using electroencephalography (EEG))': 3, 'Plasma concentration on a wakening (measure not specified)': 3, 'Total sleep time (measured using electroencephalography (EEG))': 3, 'Total sleep time spent in stage 1 sleep (% of total sleep time, measured using electroencephalography (EEG))': 3, 'Total sleep time spent in REM sleep (% of total sleep time, measured using electroencephalography (EEG))': 3, 'Sleep onset latency (measured using electroencephalography (EEG))': 3})
CD006897 Counter({'COPD Exacerbation': 3, 'Chronic Obstructive Pulmonary Disease': 3, 'Prednisone': 3, 'Mechanical ventilation duration (days)': 3, 'Length of intensive care unit stay (days)': 3, 'Intensive care unit (ICU) mortality': 3, 'Hyperglycaemic episode(s) requiring initiation or alteration of current insulin doses': 3})
CD008930 Counter({'Vascular Disorder': 3, 'Continuing Positive Airway Pressure Unit': 3, 'length of intensive care surveillance': 3, 'cardiac and pulmonary complications': 3, 'length of total postoperative hospital stay': 3, 'oxygenation disturbances': 3})
CD009134 Counter({'Elective Surgery': 3, 'Continuous Positive Airway Pressure Ventilation Treatment': 3, 'Physiotherapy Of Chest': 3, 'Lung volume - Vital capacity (VC)': 3, 'Post-operative pulmonary complication(s)': 3, 'Blood oxygen saturation': 3, 'Lung volume - Functional residual capacity (FRC)': 3, 'Length of hospital stay (days)': 3})
CD001726 Counter({'Acute Cough': 3, 'Albuterol Oral Tablet': 3, 'Healthcare utilisation (unspecified)': 3, 'Sleepless nights (nights, measure not specified)': 3, 'Cough severity (measure not specified)': 3, 'Time to event - Return to full activity (days, measure not specified)': 3, 'Nervousness (self-reported)': 3, 'Shakiness (self-reported)': 3})
CD011094 Counter({'Moderate Asthma': 3, 'Mild Asthma': 3, 'Borage Oil': 3, 'generation of PMN-15-HETrE': 3, 'phospholipid fatty acids': 3, 'exhaled NO': 3, 'LTB4 generation': 3, 'daily asthma scores': 3, 'pulmonary function': 3})
CD003571 Counter({'Emergency Care': 3, 'COPD Exacerbation': 3, 'Chronic Obstructive Pulmonary Disease': 3, 'Oxygen': 3, 'Ipratropium Bromide': 3, 'Nebulizer Therapy': 3, 'Albuterol Inhalant Solution': 3, 'Helium': 3, 'Adverse outcome(s) (unspecified)': 3, 'Withdrawal from study (reason(s) not specified)': 3, 'Forced expiratory flow at 25-75% of the pulmonary volume (FEF25-75) (% of predicted, measured using spirometry)': 3, 'Forced expiratory volume in one second (FEV1) (% of predicted, measured using spirometry)': 3})
CD001385 Counter({'Asthma': 5, 'Formoterol': 3, 'Serum immunoglobulin E (IgE) level (measured by laboratory test)': 3, 'Asthma symptoms (measure(s) not specified)': 3, 'Serum interleukin 4 (IL-4) level (measured by laboratory test)': 3, 'Serum soluble receptor of interleukin 2 (sIL-2R) level (measured by laboratory test)': 3, 'Eosinophils count in peripheral blood (measured by laboratory test)': 3, 'Serum eosinophil cationic protein (ECP) level (measured by laboratory test)': 3, 'Pulmonary function - Forced expiratory volume in one second (FEV1) (% of predicted, measured using spirometry)': 3, 'Serum soluble intercellular adhesion molecule-1 (ICAM-1) level (measured by laboratory test)': 3, 'Pulmonary function - Histamine provocative concentration causing a 20% drop in FEV1 (PD20) (measured using a bronchial histamine challenge test)': 3, 'House Dust Mite Allergy': 2, 'Allergic Asthma': 2, 'allergen concentrations (Der p 1)': 2, 'FEV1': 2, 'bronchial hyperresponsiveness': 2, 'peak flow parameters': 2, 'asthma symptom scores': 2})
CD004417 Counter({'Rhinosinusitis': 2, 'Acute Exacerbation Of Chronic Bronchitis': 2, 'Acute Pharyngitis': 2, 'COPD Exacerbation': 2, 'Acute Bronchitis': 2, 'Antibiotic Therapy': 2, 'Prescription': 2})
CD012406 Counter({'Bronchiectasis': 3, 'Azithromycin': 3, 'Lung function - Forced vital capacity (FVC) (measured using spirometry)': 3, 'Exacerbation(s)': 3, 'Quality of life (measure(s) not specified)': 3, 'Lung function - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Pulmonary symptoms (measure(s) not specified)': 3, 'Cystic Fibrosis': 1})
CD002997 Counter({'Asthma': 9, 'Azithromycin': 3, 'Usual Care': 3, '': 3, 'Serum immunoglobulin A (IgA) antibodies to Chlamydia pneumoniae level (measured by laboratory test)': 3, 'Asthma symptoms (measure(s) not specified)': 3, 'Asthma-specific quality of life (measured using the Juniper Asthma Quality of Life Questionnaire (Juniper AQLQ), Total score)': 3, 'Rescue inhaler use (unspecified)': 3, 'Serum immunoglobulin G (IgG) antibodies to Chlamydia pneumoniae level (measured by laboratory test)': 3, 'Roxithromycin': 3, 'PEF peak expiratory flow': 3, 'Troleandomycin': 3, 'Methylprednisolone': 3, 'Prednisone': 3, 'Asthma Finding': 3, 'Pulmonary Methacholine Challenge Test': 3, 'Pulmonary Function Test Finding': 3})
CD011316 Counter({'Asthma': 6, 'Fluticasone / Salmeterol Dry Powder Inhaler': 3, '': 3, 'Fluticasone, Combinations': 3, 'asthma control': 3, 'clinical features': 3, 'lung function': 3})
CD007836 Counter({'Neonatal Respiratory Distress Syndrome': 2, 'pulmonary interstitial emphysema': 2, 'PaO2/FiO2 ratio': 2, 'bronchopulmonary dysplasia': 2, 'pneumothorax': 2, 'oxygenation': 2, 'neonatal mortality': 2})
CD003136 Counter({'Hospitalization': 2, 'Tonsillar Hypertrophy': 2, 'Obstructive Sleep Apnea Syndrome': 2, 'Adenoidal Hypertrophy': 2, 'Postoperative pain - Severe pain (patient-reported)': 2, 'Postoperative pain - No pain (patient-reported)': 2, 'Daytime sleepiness (measure not specified)': 2, 'Postoperative pain - Mild to moderate pain (patient-reported)': 2, 'Narcotic use (unspecified)': 2, 'Total volume reduction (measure not specified)': 2, 'Weight loss (kgs)': 2, 'Respiratory distress (measured using the Respiratory Distress Index (RDI))': 2, 'Snoring (measured using a Visual Analogue Scale (VAS))': 2, 'Return to normal diet (patient-reported)': 2})
CD005224 Counter({'Generalized Myasthenia': 3, 'Cyclophosphamide': 3, 'muscle strength': 3, 'ventilatory failure': 3, 'steroid and pyridostigmine requirements': 3, 'swallowing impairment': 3})
CD006980 Counter({'Low Birth Weight Infant': 3, 'Vitamin Supplementation': 3, 'Bcg Vaccination': 3, 'Vitamin A': 3, 'skin prick tests': 3, 'atopy': 3, 'food allergy': 3, 'asthma': 3, 'eczema': 3})
CD006343 Counter({'Invasive Pulmonary Aspergillosis': 3, 'Voriconazole': 3, 'Complete clinical response': 3, 'Severe drug-related adverse event(s) - Transient visual disturbance(s)': 3, 'Any severe drug-related adverse event(s)': 3, 'Treatment success (defined as complete or partial clinical response)': 3, 'Partial clinical response': 3, 'Survival': 3})
CD008989 Counter({'Chronic Obstructive Pulmonary Disease': 5, 'Indacaterol': 3, 'Tiotropium': 3, 'Airway dimensions - Percentage wall area (WA%) (measured using computed tomography; corrected for body surface area)': 3, "Quality of life (measured using the St George's Respiratory Questionnaire (SGRQ), Total score)": 3, 'Lung volume - Inspiratory capacity (IC) (measured using spirometry)': 3, 'Airway dimensions - Luminal area (Ai/BSA) (measured using computed tomography)': 3, 'Lung function - Forced expiratory volume in one second (FEV1) (measured using spirometry)': 3, 'Airway dimensions - Airway wall thickness (measured using computed tomography; corrected for body surface area)': 3, "St George's respiratory questionare": 2, 'forced expiratory volume in 1 second (FEV1)': 2})
CD008532 Counter({'Chronic Obstructive Pulmonary Disease': 3, 'Formoterol': 3, 'Budesonide': 3, 'Tiotropium': 3, 'Direct heathcare costs - Emergency room visit(s) (per patient; 2010 Danish Krone (DKK), 2010 Euros (EUR), 2010 Norwegian Krone (NOK), 2010 Swedish Krona (SEK))': 3, 'Resource use associated with a severe exacerbation - Systemic glucocorticosteroid use': 3, 'Direct heathcare costs - Hospitalisation(s) (per patient; 2010 Danish Krone (DKK), 2010 Euros (EUR), 2010 Norwegian Krone (NOK), 2010 Swedish Krona (SEK))': 3, 'Resource use associated with a severe exacerbation - Antibiotic use': 3, 'Resource use associated with a severe exacerbation - Hospitalisation(s)': 3, 'Total indirect costs (not specified; per patient; 2010 Danish Krone (DKK), 2010 Euros (EUR), 2010 Norwegian Krone (NOK), 2010 Swedish Krona (SEK))': 3, 'Severe exacerbation(s)': 3, 'Direct heathcare costs - Systemic glucocorticosteroids (per patient; 2010 Danish Krone (DKK), 2010 Euros (EUR), 2010 Norwegian Krone (NOK), 2010 Swedish Krona (SEK))': 3, 'Incremental cost-effectiveness ratios - Total direct healthcare costs per severe exacerbation avoided (healthcare perspective; 2010 Danish Krone (DKK), 2010 Euros (EUR), 2010 Norwegian Krone (NOK), 2010 Swedish Krona (SEK))': 3, 'Direct heathcare costs - Drug costs (per patient; 2010 Danish Krone (DKK), 2010 Euros (EUR), 2010 Norwegian Krone (NOK), 2010 Swedish Krona (SEK))': 3, 'Total direct healthcare costs (per patient; 2010 Danish Krone (DKK), 2010 Euros (EUR), 2010 Norwegian Krone (NOK), 2010 Swedish Krona (SEK))': 3, 'Resource use - Drugs (budesonide, formoterol and tiotropium)': 3, 'Resource use associated with a severe exacerbation - Emergency room visit(s)': 3, 'Incremental cost-effectiveness ratios - Total costs (direct healthcare costs + indirect costs) per severe exacerbation avoided (societal perspective; 2010 Danish Krone (DKK), 2010 Euros (EUR), 2010 Norwegian Krone (NOK), 2010 Swedish Krona (SEK))': 3, 'Direct heathcare costs - Antibiotics (cost per patient; 2010 Danish Krone (DKK), 2010 Euros (EUR), 2010 Norwegian Krone (NOK), 2010 Swedish Krona (SEK))': 3})
CD002752 Counter({'Diabetes Mellitus': 3, 'Hospitalization': 3, 'Congestive Heart Failure': 3, 'Chronic Obstructive Pulmonary Disease': 3, 'Referral To Nurse': 3, 'Referral To Gp': 3, 'Follow-up Consultation': 3, 'Patient satisfaction with care (measure not specified)': 3, 'Hospitalisation(s)': 3, 'Quality of life (measure(s) not specified)': 3, 'Emergency department visit(s)': 3, 'Length of hospital stay (days)': 3})
CD006153 Counter({'Amyotrophic Lateral Sclerosis': 3, 'Riluzole': 3, 'functional status': 3, 'stiffness': 3, 'respiratory function': 3, 'cramps': 3, 'adverse reactions': 3, "patient's assessments of fasciculation": 3, 'survival without a tracheostomy': 3, 'risk of death': 3, 'tiredness': 3, 'muscle strength': 3})
CD007354 Counter({'Chronic Obstructive Pulmonary Disease': 3, 'Prochlorperazine': 3, 'Morphine': 3, 'Promethazine': 3, 'maximum minute ventilation': 3, 'reaction time': 3, 'the workload': 3, 'adversely affected': 3, 'Vo2max': 3})
CD000436 Counter({'Asthma': 3, 'Sodium': 3, 'airway response to histamine': 3})
CD011440 Counter({'Asthma': 7, 'asthma exacerbations': 5, 'Pregnancy': 3, 'Diagnostic Procedure': 3, 'improved': 3, 'asthma events': 2, 'asthma control': 2, 'questionares on quality of life': 2, 'exacerbation rate': 2, 'corticosteroid use': 2, '': 2, 'doses of inhaled corticosteroids': 2, 'the number of days with asthma symptoms': 2, 'pulmonary function': 2})
CD004769 Counter({'Dyspnea': 3, 'Hospice Care': 3, 'Cancer': 3, 'Oxygen': 3, 'Dyspnea (measured using a visual analogue scale (VAS)]': 3, 'Lung function (measure(s) not specified)': 3, 'Arterial oxygen saturation (measured by laboratory test)': 3, 'Dyspnea (measured using the Borg Dyspnea Scale score)': 3})
CD003030 Counter({'Asthma': 3, 'Education': 3, 'Asthma Management': 3, "parent perceptions of physicians' communication: inquire about patients' concerns about asthma": 3, "patients' asthma health care utilization: emergency department asthma visits": 3, "the child's asthma symptoms: days limited by asthma symptoms": 3, "parent perceptions of physicians' communication: set goals for successful treatment": 3, "parent perceptions of physicians' communication: encourage patients to be physically active": 3})
CD010941 Counter({'Chronic Lung Disease': 3, 'Corticosteroids': 3, 'disability, cerebral palsy, cognitive ability, behavioural difficulty , growth and respiratory symptoms': 3})
CD003901 Counter({'Asthma': 3, 'Salmeterol': 3, 'Lung function, FEV1': 3})
CD000356 Counter({'Chronic Obstructive Pulmonary Disease': 2, 'Factors associated with patient preference': 2, 'patient satisfaction (overall and per item)': 2, 'Patient preference for treatment place': 2, 'resume normal daily activities': 2, 'Caregiver': 2, 'caregiver strain index': 2})
CD001288 Counter({'Chronic Obstructive Pulmonary Disease': 3, 'Methylprednisolone': 3, '': 3, 'COPD Exacerbation': 1})
CD009385 Counter({'Interstitial Lung Disease': 2, '6MWD,dyspnoea score and CRDQ': 2})
CD005189 Counter({'Bronchiolitis': 3, 'Azithromycin': 3, 'Length of hospital stay, duration of oxygen': 3})
CD005603 Counter({'Asthma': 5, 'Corticosteroids': 3, 'exacerbations': 3, 'Exacerbation of Asthma': 2, 'Use of Inhaled Corticosteroids': 2})
CD008524 Counter({'Bronchiolitis': 3, 'Vitamin Supplementation': 3, 'respiratory episodes': 3})
CD011129 Counter({'Palliative Care': 3, 'Chronic Obstructive Pulmonary Disease': 3, 'Advanced Cancer': 3, 'Congestive Heart Failure': 3, 'Coronary Heart Disease': 3, 'Specialist Palliative Care Treatment': 3, 'Clinical utilisation outcomes': 3})
CD007205 Counter({'Cardiac Valve Disorders Nec': 3, 'Bypass Surgery': 3, 'Positioning Patient': 3, 'Effect of position on oxygenation': 3})
CD002878 Counter({'Severe Chronic Obstructive Pulmonary Disease': 3, 'Hypercapnia': 3, 'Nasal Ventilation Therapy': 3, 'lung function': 3, 'bilevel PAP device': 3, 'substantial reduction in PaCO2': 3, 'nocturnal oxygen saturation': 3, 'sleep efficiency': 3})
CD012066 Counter({'Chronic Obstructive Pulmonary Disease': 6, 'Indacaterol': 3, 'Glycopyrronium Bromide': 3, 'Moderate to severe exacerbations': 3, 'Formoterol': 3, 'Tiotropium': 3, 'Forced Expiratory Volume in One Second (FEV1)': 3, 'Forced Vital Capacity (FVC)': 3, 'COPD Exacerbation': 1})
CD011421 Counter({'Acute Postoperative Pain': 3, 'Dipyrone': 3, 'Global efficacy was assessed by the patient and the investigator on a visual analogue scale(VAS)': 3, 'total pain relief (TOTPAR)': 3, 'serious adverse events': 3, 'Memorial Pain Assessment Card': 3, 'mood as part of the MPAC.': 3, 'SPID on the Tursky pain adjective scale': 3, 'Sum of Pain Intensity Differences (SPID) on a VAS': 3, 'Mild to moderate adverse events': 3})
CD011227 Counter({'Asthma': 2, 'FEV1, QOL': 2})
CD002104 Counter({'Asthma': 6, 'Audio Cassette Tape (physical Object)': 3, 'adherence': 3, 'Treatment Side Effects Education': 3, 'Side effects': 3, 'Blood drug level': 3})
CD010749 Counter({'Healthy': 3, 'Vitamin E': 3, 'Aspirin': 3, 'asthma': 3, 'Not reported': 3, 'Magnesium supplement': 3, 'Vitamin Supplementation': 3, 'reductions in inhaled corticosteroid dose': 3})
CD005590 Counter({"Wegener's Granulomatosis": 3, 'Co-trimoxazole': 3, 'signs of infection': 3, 'compliance with treatment': 3, 'side effects': 3, 'anitibody titers': 3, 'signs of disease activity': 3})
CD006217 Counter({'Asthma': 3, 'Ciclesonide': 3, 'bronchial challenge': 3})
CD010669 Counter({'Healthcare Professional': 2, 'sales of asthma medication': 2})
CD001002 Counter({'Asthma': 3, 'External Manipulation': 3, 'Lung function': 3})
CD000011 Counter({'Asthma': 3, 'Education': 3, 'Medication adherence': 3, 'Health-related quality of life': 3, 'Asthma knowledge': 3})
CD002988 Counter({'Acute Asthma': 3, 'Asthma': 3, 'Terbutaline': 3, 'Bronchodilatation': 3, 'Adverse Event': 3})
CD012629 Counter({'Asthma': 6, 'Acute Asthma': 3, 'Emergency Care': 3, 'Placebo': 3, 'Triamcinolone': 3, 'Diary Card Measure of Symptoms': 3, 'Withdrawn from Research Study': 3, 'Relapse': 3, 'Intramuscular Injection': 3, 'Methylprednisolone': 3, 'relapse rate': 3})
CD007451 Counter({'Pulmonary Hypertension': 3, 'Atenolol': 3, 'Nitrendipine': 3, 'Drug Tolerance': 3, 'Withdrawn from Research Study': 3, 'Adverse Event': 3, 'Hemodynamic Test': 3})
CD002894 Counter({'Emergency Care': 2, 'Aminophylline Maintenance Infusion (mg/kg/hour)': 2, 'Serology Test': 2, 'Peak Expiratory Flow Rate (PEFR)': 2})
CD011992 Counter({'Polyps Nasal': 1})
CD006580 Counter({'Asthma': 3, 'Asthma Education': 3, 'Environmental Intervention': 3, 'Asthma Finding': 3, 'Incremental Total Direct Social Care Costs (Per patient; US Dollars (USD), Price Year Not Reported)': 3, 'Incremental Cost Effectiveness Ratio (ICER) - Cost per Symptom-Free Day Gained (Social care provider perspective; US Dollars (USD), Price Year Not Reported)': 3})
CD001955 Counter({'Intubation': 9, 'Dexamethasone': 6, 'Intensive Care': 3, 'Mechanical Ventilation': 3, 'Hemodynamic Test': 3, 'Current Symptom Scale': 3, 'Use of Aerosolized Racemic Epinephrine': 3, 'Adverse Event': 3, 'Withdrawn from Research Study': 3, 'Wheezing': 3, 'Endotracheal Intubation': 3, 'postextubation stridor': 3})
CD001392 Counter({'Bronchiectasis': 6, 'Ciprofloxacin': 3, 'Time to Event - First Pulmonary Exacerbation': 3, 'Bacterial Load (Log10 Units)': 3, 'Initiation of Antibiotics': 3, 'Adverse Event': 3, 'Amoxicillin': 3, 'Adverse effects experienced were minor': 3, 'concentrations of Haemophilus spp. in sputum': 3, 'reduction in purulent sputum volume': 3, 'time confined to bed and away from work': 3, 'stool cultures': 3, 'frequency of exacerbations': 3})
CD004107 Counter({'Asthma': 6, 'Self-care Patient Education': 3, 'Provision Of Written Information': 3, 'Exacerbation of Asthma': 3, 'Total Societal Costs (Direct Healthcare Costs + Costs of Lost Productivity) (Per Patient; Currency and Price Year Not Reported)': 3, 'Morbidity Savings (Per Patient; Health Policy-Maker Perspective; Currency and Price Year Not Reported)': 3, 'Length of Hospital Stay (Days)': 3, 'Net benefits (Per Patient; Societal Perspective; Currency and Price Year Not Reported)': 3, 'Total Direct Healthcare Costs (Per Patient; Currency and Price Year Not Reported)': 3, 'Emergency Department Patient Visit': 3, 'Cost-Effectiveness Ratio - Cost per Day of Admission Prevented (Currency and Price Year Not Reported)': 3, 'Cost-Benefit Ratio (Per Patient; Societal Perspective; Currency and Price Year Not Reported)': 3, 'Morbidity Savings (Per Patient; Societal Perspective; Currency and Price Year Not Reported)': 3, 'Asthma Education': 3, 'correct inhaler use': 3, 'inhaler adherence': 3, 'medication adherence': 3, 'total adherence rating': 3, 'knowledge of the disease': 1})
CD005074 Counter({'Chronic Obstructive Pulmonary Disease': 3, 'Disease Management Program': 3, 'Total Direct Healthcare Costs (Per Patient; US Dollars (USD), Price Year Not Reported)': 3, 'Use of Respiratory Medications': 3, 'Cost of Disease Management Program (Overall and Per Patient; US Dollars (USD), Price Year Not Reported)': 3, 'Emergency Department Patient Visit': 3, 'Hospitalization': 3, 'ncremental Total Direct Healthcare Costs (Per Patient; US Dollars (USD), Price Year Not Reported)': 3, 'Hospitalization or Emergency Department Patient Visit (Composite Outcome)': 3, 'Cost of Hospitalization(s) (Per Patient; US Dollars (USD), Price Year Not Reported)': 3, 'Cost of Emergency Department Patient Visit(s) (Per Patient; US Dollars (USD), Price Year Not Reported)': 3, 'Cost of Respiratory Medications (Per Patient; US Dollars (USD), Price Year Not Reported)': 3})
CD011716 Counter({'Idiopathic Pulmonary Fibrosis': 6, 'Ambulatory Oxygen Therapy': 3, 'exertional dyspnoea': 3, 'Oxygen': 3, 'peak exercise SpO2': 3, 'endurance time': 3, 'maximal workload': 3, '6MWT nadir SpO2': 3, 'peak VO2': 3, 'DLco': 3, 'end tidal CO2': 3, 'endurance distance': 3, 'oxygen pulse': 3, 'mean FVC': 3, 'resting SpO2': 3})
CD011511 Counter({'Asthma': 5, 'Cholecalciferol': 3, 'severity': 3, 'NUMBER OF EXCERBATION': 3, 'number of emergency visits': 3, 'PEFR': 3, '': 2})
CD006904 Counter({'Emergency Care': 3, 'Mechanical Ventilation': 3, 'Respiratory Failure': 3, 'Monitoring Of Changes In Respiratory Status': 3, 'Trial For Spontaneous Breathing': 3, 'Weaning From Mechanically Assisted Ventilation': 3, 'Time to Event - Discontinuation of Mechanical Ventilation Treatment (Days)': 3, 'Total Intensive Care Unit (ICU) Costs (Per Patient; Currency and Price Year Not Reported)': 3, 'Total Hospital Costs (Per Patient; Currency and Price Year Not Reported)': 3, 'Length of Hospital Stay (Days)': 3, 'Adverse Event': 3, 'Length of Intensive Care Unit (ICU) Stay (Days)': 3, 'Duration of Mechanical Ventilation Treatment (Days)': 3, 'Endotracheal Reintubation': 3})
CD000998 Counter({'Chronic Obstructive Pulmonary Disease': 3, 'Malnutrition Nos': 3, 'Food': 3, 'anthropometry(BW, mid arm circumference)': 3, 'pulmonary functions(FVC, EFV1, FEV1/FVC ratio, PEFR)': 3, 'respiratory rate': 3})
CD005306 Counter({'Hospitalization': 6, 'Acute Asthma': 3, 'Asthma': 3, 'Nurse Contact': 3, 'Asthma Action Care Planning': 3, 'Asthma Education': 3, 'Administration Of Steroid': 3, 'Pfm - Peak Flow Metre': 3, 'Emergency Department Patient Visit': 3})
CD001000 Counter({'Intubation': 3, 'Emergency Care': 3, 'Hydrocortisone': 3, 'Endotracheal Reintubation': 3, 'Adverse Event': 3, 'Post-Extubation Stridor': 3, 'Placebo': 3, 'Dexamethasone': 3, 'stridor score': 3, 'failure of study extubation': 3})
CD010112 Counter({'Asthma': 3, 'House Dust Mites': 3, 'Fat - Dietary': 3, 'asthma, eczma, and atopy': 3})
CD010010 Counter({'Acute Bronchitis': 6, 'Bronchitis': 3, 'Immunological Therapy': 3, 'Acute Wheezy Bronchitis': 3, 'Use of Antibiotics': 3, 'Current Symptom Scale': 3})
CD001145 Counter({'Patient Ventilated': 3, 'Dexamethasone': 3, 'PCO2': 3, 'Serum pH': 3, "Postextubation Downes' score": 3, 'Oxygen requirement at time intervals': 3})
CD009238 Counter({'Allergic Rhinoconjunctivitis': 2, 'Skin Test Finding': 2, 'Current Symptom Scale': 2, 'Adverse Event': 2, 'Pulmonary Adenosine Monophosphate (AMP) Challenge Test': 2, 'Peak Expiratory Flow Rate': 2})
CD002738 Counter({'Beclometasone': 6, 'Asthma': 6, 'Mild Asthma': 3, 'Propranolol': 3, 'FEV1': 3, 'changes of clinical symptoms': 3, 'pathological changes of the mucosa': 3, 'sign of mucosal atrophy': 3, 'spirometric values': 3, 'Placebo': 3, 'Salbutamol': 3, 'provocative ventilation (in liters per minute) necessary to increase SRaw': 3, 'provocative concentration (in milligrams per milliliter) necessary to increase the specific airway resistance': 3})
CD008863 Counter({'Airways Obstruction': 3, 'Metered Dose Inhaler': 3, 'Pulmonary function': 3, 'Changes in passive expiratory flow': 3})
CD002886 Counter({'Asthma': 3, 'Prednisolone': 3, 'Hydrocortisone': 3, 'Heart rate': 3, 'Pulsus paradoxus': 3, 'Peak expiratory flow rate (PEFR)': 3, 'Respiratory rate': 3, 'Arterial oxygen saturation': 3})
CD011017 Counter({'Asthma': 2, '': 2, 'lung volume and flow rate': 2})
CD010651 Counter({'No available term': 3, 'Streptokinase': 3, 'total volume (mean +/- SD) of fluid drained after treatment': 3, 'total cost of the drug': 3, 'mean volume drained during the first 24 h': 3, 'instillations': 3, 'High fever': 3, 'Clinical and radiologic improvement': 3, 'mean total hospital stay': 3, 'Pleural Infections And Inflammations': 2, 'referral for surgery': 2, 'duration of hospital stay': 2, 'change in pleural opacity': 2, 'frequency of adverse events': 2})
CD001456 Counter({'Healthy': 3, 'Lung Surfactants': 3, 'incidence of pulmonary interstitial emphysema': 3, 'reduction in mean maximum fraction of inspired oxygen': 3, 'lowered mortality': 3, 'incidence of grade 3-4 RDS': 3})
CD011996 Counter({'Nasal Polyp': 3, 'Fluticasone Nasal Suspension': 3, 'Beclomethasone Nasal Spray': 3, 'Peak nasal inspiratory flow': 3, 'assessment of symptoms': 3, 'polyp score': 3})
CD005533 Counter({'Asthma': 3, 'Salmeterol Xinafoate': 3, 'Fluticasone, Combinations': 3, 'Fluticasone propionate': 3, 'bronchial hyperresponsiveness (BHR) to methacholine (MCh)': 3, 'circadian variation in PEF and FEV1': 3})
CD006632 Counter({'Hospitalization': 3, 'Asthma': 3, 'Following Clinical Pathway Protocol': 3, '': 3, 'acute care visits': 3, 'medication use': 3, 'length of stay': 3})
CD012597 Counter({'Paranasal Sinus Disorders (excl Infections And Neoplasms)': 3, 'isotonic Ems salt solution': 3, 'general discomfort': 3, 'duration of improved nasal resistance after each irrigation': 3, 'saccharin-clearance test': 3, 'Nasal endoscopy': 3, 'radiography of the paranasal sinuses': 3, 'amount of additional nasal spray': 3, 'olfactometry': 3, 'agreeableness of the irrigation': 3, 'nasal airway obstruction': 3, 'anterior rhinomanometry': 3})
CD003244 Counter({'Gastroesophageal Reflux Disease': 3, 'Rabeprazole': 3, 'reduction in symptoms': 3, 'improvements in quality-of-life scores': 3, 'oesophageal mucosal healing': 3})
CD007676 Counter({'Asthma': 3, 'Stress Management': 3, 'perceived stress': 3, 'lung function': 3})
CD002989 Counter({'Allergic Rhinitis Due To Animals': 3, 'Asthma': 3, 'High-efficiency Filter Air Cleaner, Mobile (physical Object)': 3, 'cat-allergen levels': 3, 'peak-flow rates': 3, 'methacholine (MCh) challenge testing': 3, 'medication scores': 3, 'daily morning, afternoon, and nighttime nasal- and chest-symptom scores': 3, 'spirometry': 3})
CD011047 Counter({'Idiopathic Pulmonary Fibrosis': 3, 'Interferon Gamma-1b': 3, 'transfer factor of the lung for carbon monoxide': 3, 'resting arterial oxygen tension': 3, 'death': 3, 'total lung capacity': 3, 'forced vital capacity': 3, 'high-resolution computed tomographic scoring': 3, "St George's Respiratory Questionnaire": 3})
CD003051 Counter({'Lung Cancer': 3, 'Chronic Obstructive Pulmonary Disease': 3, 'Non-small Cell Lung Cancer': 3, 'Stapling': 3, 'Fluid collected via chest-drain': 3, 'Hospital stay duration': 3, 'Air leak (post operative)': 3})
CD009910 Counter({'Severe Asthma': 3, 'Thermoplasty Of Bronchus': 3, 'difference in Asthma Quality of Life Questionnaire (AQLQ) scores': 3})
CD008165 Counter({'Diabetes Mellitus': 3, 'Coronary Arteritis': 3, 'Symptomatic Congestive Heart Failure': 3, 'Chronic Obstructive Pulmonary Disease': 3, 'Usual Care': 3, 'APTCare approach': 3, 'preventive care': 3})
CD001277 Counter({'Asthma': 3, 'Breathing Exercises': 3, 'SF-36v2': 3, 'breathlessness disability': 3, 'FEV1% predicted': 3, 'Nijmegen Hyperventilation Questionnaire': 3, 'Medical Research Council scale': 3, 'hypocapnia': 3, 'end-tidal carbon dioxide': 3, 'respiratory rate': 3, 'Asthma Control Test score': 3, 'spirometry': 3})
CD004437 Counter({'Pulmonary Hypertension': 3, 'Right Ventricular Dilatation': 3, 'Acute Pulmonary Embolism': 3, 'Dysfunction Of Right Cardiac Ventricle': 3, 'Streptokinase': 3, 'Enoxaparin': 3, 'Alteplase': 3, 'in-hospital death': 3, 'major bleeding, pulmonary hypertension, right ventricular dilatation at the end of the first week': 3, 'clinical deterioration': 3, 'exertional dyspnea at the end of the first month': 3})
CD011714 Counter({'Childhood Asthma': 3, 'Web-based Application Software (physical Object)': 3, 'Asthma Monitoring': 3, 'patient utilities': 3, 'healthcare costs': 3, 'incremental cost per quality adjusted life year(QALY)': 3, 'societal costs': 3})
CD007717 Counter({'Asthma': 3, 'Telephone Counseling': 3, 'Self efficacy': 3, 'number of readmissions': 3, 'quality of life': 3})
CD003559 Counter({'Allergic Asthma': 3, 'Omalizumab Injectable Solution': 3, 'Asthma-related Quality of Life': 3})
CD012489 Counter({'Childhood Asthma': 3, 'Asthma': 3, 'Electromyographic Biofeedback': 3, 'Self-rated asthma severity': 3, 'Medication usage': 3, 'Self-concept': 3, 'Lung function': 3, 'Chronic anxiety': 3, 'Attitudes toward asthma': 3, 'Frequency of asthma attacks': 3})
CD000437 Counter({'Perinatal Interstitial Emphysema': 3, 'High Frequency Jet Ventilation': 3, 'Incidence of patent ductus ateriosus': 3, 'Chronic lung disease': 3, 'Radiographic assessment of disease': 3, 'Airway pressures (peak and mean)': 3, 'Intraventricular hemorrhage': 3})
CD009524 Counter({'Antihistamine': 2, "Alzheimer's Disease Assessment Scale, Cognitive subscale (ADAS-cog) score": 2, 'Any adverse event': 2, 'Depressed mood or depression (measure not specified)': 2, 'Dry mouth': 2})
CD001015 Counter({'Lecithin': 2, 'Serum levels of lecithin (measured by laboratory test)': 2})
CD003428 Counter({'Ipratropium Bromide': 2, 'Salbutamol And Ipratropium Bromide': 2, 'Salbutamol': 2, 'Airway resistance (measure(s) not specified)': 2, 'Forced expiratory volume in one second (FEV1) (measured using spirometry)': 2, 'Static lung volumes (measure(s) not specified)': 2})
CD008426 Counter({'House Dust Mite Barrier Bed Mattress Cover': 2, '': 2})
CD001004 Counter({'Radiofrequency Ablation Of Soft Palate': 2, '': 2})
CD009574 Counter({'Morphine': 2, 'Tramadol': 2, 'postoperative pain': 2, 'Postoperative sedation, respiratory events, and vomiting': 2})
CD007988 Counter({'Education Programs Case Management': 2, 'Usual Care': 2, '': 2})
CD011899 Counter({'stress': 1, 'intention to seek help,': 1, 'Center for Epidemiologic Studies-Depression scale': 1, 'Positive Aspects of Caregiving instrument': 1, 'State-Trait Anxiety Inventory': 1, 'self-efficacy': 1, 'Caregiver Strain scale from Benjamin Rose': 1, 'caregiver strain': 1, 'depression': 1, 'anxiety': 1})
CD004072 Counter({'': 1})
